Substituted pyrazole compounds

Abstract

Compounds of formula (I) N-oxides, or their salts, are described, where G, A, R1, and R5 are defined herein. Methods for using these compounds as inhibitors of signaling through Toll-like receptors 7, 8, or 9, and pharmaceutical compositions containing them, are also described. These compounds are useful in the treatment of inflammatory and autoimmune diseases.

Description

Substituted pyrazole compounds Cross-reference This application claims priority over the U.S. provisional application serial no. 62 / 929299, filed on November 1, 2019. Description The present invention relates generally to substituted pyrazole compounds useful as inhibitors of signaling through Toll-like receptor 7, 8, or 9 (TLR7, TLR8, TLR9) or combinations thereof. Substituted indole compounds, compositions comprising such compounds, and methods of their use are provided herein. The invention also relates to pharmaceutical compositions containing at least one compound according to the invention that is useful for the treatment of conditions related to TLR modulation, such as inflammatory and autoimmune diseases, and methods for inhibiting TLR activity in a mammal. Members of the Toll-like receptor / IL-1 receptor family are important regulators of inflammation and host resistance. The Toll-like receptor family recognizes molecular patterns from infectious organisms, including bacteria, fungi, parasites, and viruses (reviewed in Kawai, T. et al., Nature Immunol., 11:373-384 (2010)). Ligand binding to the receptor induces dimerization and recruitment of adaptor molecules to a conserved cytoplasmic motif on the receptor called the Toll-like receptor / IL-1 (TIR) ​​domain. With the exception of TLR3, all TLRs recruit the adaptor molecule MyD88. The IL-1 receptor family also contains a cytoplasmic TIR motif and recruits MyD88 upon ligand binding (reviewed in Sims, JE et al., Nature Rev. Immunol., 10:89-102 (2010)). Toll-like receptors (TLRs) are a family of evolutionarily conserved transmembrane innate immune receptors involved in first-line defense. As pattern recognition receptors, TLRs protect against foreign molecules, activated by pathogen-associated molecular patterns (PAMPs), or damaged tissue, activated by hazard-associated molecular patterns (DAMPs). A total of 13 members of the TLR family have been identified, 10 of which are found in humans, spanning the cell surface or the endosomal compartment. TLR7 / 8 / 9 are among those located endosomally and respond to single-stranded RNA (TLR7 and TLR8) or unmethylated single-stranded DNA containing cytosine phosphate-guanine (CpG) motifs (TLR9). Activation of TLR7 / 8 / 9 can initiate a variety of inflammatory responses (cytokine production, B cell activation and IgG production, and type I interferon response). In autoimmune disorders, sustained aberrant activation of TLR7 / 8 / 9 leads to a worsening of disease states. While TLR7 overexpression in mice has been shown to exacerbate autoimmune disease, TLR7 inactivation in mice was found to be protective against disease in lupus-prone MRL / lpr mice. Dual inactivation of TLR7 and TLR9 showed even greater protection. Since numerous conditions can benefit from treatment involving modulation of cytokines, IFN production, and B-cell activity, it is immediately apparent that novel compounds capable of modulating TLR7 and / or TLR8 and / or TLR9 and methods of using these compounds could provide substantial therapeutic benefits to a wide variety of patients. Document WO 2010 / 045188 A1 discloses heteroaryl-substituted indole compounds that are MMP-13 inhibitors. Document WO 2009 / 146343 describes the use of amyloid-binding compounds as tracers in positron emission tomography. WO 2019 / 125977 and WO 2019 / 126081 describe compounds that act as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, which are useful in the treatment of inflammatory and autoimmune diseases. Document WO 2019 / 136147 describes compounds that have Toll-like receptor inhibitory activity, including TLR2, TLR4, TLR7 and / or TLR9. Summary of the invention The present invention relates to a novel class of substituted pyrazole compounds that have been found to be effective inhibitors of signaling through TLR7 / 8 / 9. These compounds are provided to be useful as pharmaceutical products with desirable values ​​of stability, bioavailability, therapeutic index, and toxicity, which are important for their suitability as drugs. The present invention provides compounds of formula (I) that are useful as inhibitors of signaling through Toll-like receptor 7, 8 or 9 and are useful for the treatment of proliferative diseases, allergic diseases, autoimmune diseases and inflammatory diseases, or stereoisomers, N-oxides, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof. The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts or solvates thereof. The compounds of the present invention can be used in a method for the inhibition of Toll-like receptor 7, 8 or 9 comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts or solvates thereof. The compounds of the present invention can also be used in a method for the treatment of proliferative, metabolic, allergic, autoimmune, and inflammatory diseases, comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or pharmaceutically acceptable stereoisomers, tautomers, salts, or solvates thereof. The compounds of the present invention can also be used in a method of treating a disease or disorder associated with the activity of Toll-like receptor 7, 8 or 9, the method comprising administering to a mammal in need at least one of the compounds of formula (I) or solvates thereof. This application also describes processes and intermediate products for making the compounds of formula (I) that include salts or solvates thereof. The present invention also provides at least one of the compounds of formula (I) or salts or solvates thereof, for use in therapy At least one of the compounds of formula (I) or salts or solvates thereof, may also be used for the manufacture of a drug for the prophylaxis treatment of conditions related to Toll receptor type 7, 8 or 9, such as allergic disease, autoimmune diseases, inflammatory diseases and proliferative diseases. The compound of formula (I) and the compositions comprising the compounds of formula (I) can be used in the treatment, prevention, or cure of various conditions related to Toll-like receptor 7, 8, or 9. Pharmaceutical compositions comprising these compounds are useful for treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as allergic diseases, autoimmune diseases, and proliferative diseases. These and other features of the invention will be set forth in expanded form as disclosure continues. Detailed description The first aspect of the present invention provides at least one compound of formula (I): N-oxide, or a salt thereof, wherein: G is: R1 is, -CH3, -CH2CH3, -CH(CH3)2, -CF3 or -CH2CF3; each R2 is independently -CN, -CH3 or -OCH3; R2a is C1-6 alkyl, C1-3 fluoroalkyl, C1-6 hydroxyalkyl, C1-3 aminoalkyl, -(CH2) 0-40 (C1-3 alkyl), C3-6 cycloalkyl, -(CH2) 1-3C (O) NRyRy, -CH2 (C3-6 cycloalkyl), -CH2 (phenyl), tetrahydrofuranyl, tetrahydropyranyl or phenyl; each R2b is independently hydrogen, halo, -CN, -NRXRX, C1-6 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 fluoroalkoxy, -(CH2)0-2(C1-3 alkyl), -(CH2)0-3C(O)NRxRx, -(CH2)1-3(C3-6), -C(O)O(C1-3 alkyl), -C(O)NRX(C1-3 alkyl), -CrX=CRXRX, or -Crx=CH(C3-6 cycloalkyl); A is: (i) -CH2N(CH3)RX, -C(O)NRXRX, -C(O)N(CH3)(CH2CH2CN), -C(O)N(CH2CH3)(CH2CH2CN), or -C(O)N(CH3)(CH2CH2CH2N(CH3)2); (ii) -C(O)A1, -C(0)NRX(CRXRX)0-2A1, -CH2 NHA1 or -C(O)C(O)NHA1; (iii) cyclohexyl substituted from zero to 1 R3b; (iv) zero-substituted piperidinyl to 1 R3c; (v) phenyl substituted with zero to 1 R3d and zero to 1 R3e; (vi) pyridinyl substituted with zero to 1 R3f and zero to 1 R3g; (vii) pyrazinyl or pyrimidinyl, each substituted with zero to 1 R3f; (viii) thiazolyl substituted with R2h and zero to 1 R3i; (ix) diazabicyclo[2.2.1]heptanyl or diazaspiro[3.3]heptanyl, each substituted with zero to 1 R3j; o (x) benzo[d]thiazolyl, dihydroisoquinolinyl, tetrahydronaphthyridinyl, tetrahydrobenzo[d]thiazolyl, tetrahydroimidazo[1, 2-a]pyrazinyl, tetrahydroisoquinolinonyl, tetrahydroisoquinolinyl, tetrahydronaphthalenyl, tetrahydropyrazolo[1,1]. 5-a]pyrazinyl, tetrahydropyrido[4, 3-d]pyrimidinyl, tetrahydrothiazolo[4, 5-C]pyridinyl or tetrahydrothiazolo[5, 4-C]pyridinyl, each substituted with zero to 1 R3k; A1 is azetidinyl, cyclohexyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, pyridinyl, diazepanyl, hexahydropyrrolo[3,4-C]pyrrolyl, each substituted with zero to 1 Ria) R3a es -OH, -CH3, -CH2CH3, -CH2CH2CH3, -CH (CH3) 2, -CH2CH (CH3) 2, -CH (CH3) (CH2CH3) , -CH2C (CH3) 3, -CH2CH2CH (CH3) 2, -CH (CH3) CH (CH3) 2, -CH2CH2C (CH3) 3, -CH2C (CH2CH3) 2, -CH2CF3, -CH2CH2CF3, -CH2CH 32CH2CF3, -CH2CH2CN, -CH2C (CH3) 2OH, -CH2CH2 OCH 3, -CH2CH2S (O) 2CH3, -CH (CH3) CH2S (O) 2CH3, -CH2NH2, -CH2CH2N (CH3) 2, -CH2C (O) NH (CH3) , -CH2C (O) N (CH3) 2, -NRyRy, -N (CH 3) (CH2CH2 OCH 3) , -NH (CH2CH2CH2CF3) , -NHCH (CH3) (CH2 OCH3) , -C (O) NH2, -C (O) OC (CH3) 3, -CH2 (ciclopropilo) , -CH2 (metiloxetanilo) , -CH2 (tetrahidrofuranilo) , -CH2 (tetrahidropiranilo) , -CH2 (dimetilisoxazolilo) , -CH2 (metiltriazolilo) , -CH2 (metoxipirimidinilo) , -NH (oxetanilo) , -NH (metiloxetanilo) , -NH (tetrahidropiranilo) , -NH (dimetiltetrahidropiranilo) , -N (ciclopropilo) 2, -NHCH2 (ciclopentilo) , -NHCH2 (dimetilisoxazolilo) , NHCH2 (metiloxetanilo) , -NHCH2 (piridinilo) , -NHCH2 (pirimidinilo) , -NHCH2 (metilpirimidinilo) , NHCH2 (methoxypyrimidinyl), -NHCH2 (tetrahydrofuranyl), NHCH2 (tetrahydropyranyl), cyclobutyl, oxetanyl, isopropylpiperidinyl, tetrahydropyranyl, dimethyltetrahydropyranyl or pyridinyl; R3b es -NH (CH3) , -NH (CH2CHF2) , -N (CH3) (CH2CH3) , -NH (CH2CH2N (CH3) 2) , -N (CH3) C (O) CH2N (CH3) 2, -N (CH3) CH2C (O) N (CH3) 2, -NH (isopropylpiperidinyl) , -N (CH3) C (O) (azetidinyl) , -N (CH3) C (O) (isopropylazetidinyl) , -N (CH3) C (O) (ethylazetidinyl) , -N (CH3) C (O) (methylazetidinyl) , -NH (CH2 (methyloxetanil) , morpholinyl, methylpiperazinyl or dimethylaminopiperidinyl; R3C is C1-3 alkyl, -CH2C(O)N(CH3)RX, -C(O)CH2N(CH3)2, -C(O)CH2CH2N(CH3)2 or -C(O)CH2CH2NH(CH(CH3)2); R3d es: (a) CRxRxNRxRx, -CrxRxNRx (alkyl C2-5) , -CH (CH3) N (CH3) (CH2CF3) , -CH2CH2S (O) 2CH3, -CH (CH3) N (CH 3) CH2C (O) N (CH3O (CH3) CH2 2X2 NRXC Crx R x NRxC (O) CHRxNRxRy, -CH (CH3) N (CH3) C (O) CH2NRX (FLUOROALKUILO C3-4) , -NRXRX, -NH (CH (CH3) 2) , -CQ1 (O) NHX2, -Xr.X-CRX CRXRXNRXCH2QI, -CrXRXNRXC (O) Q1.- CRXRXNRXC (O) CRXRXQI, -CrxRxNRxC (O) CRxRxNRxQi, o -CH (CH3) N (oxetanyl) (C (O) 1 -2N (C (b) zero to 1-substituted azetidinyl substituents selected between alkyl C1–3, −CH2C(CH3)2OH, −C(O)CH2N(CH3) (c) cyclopropyl or cyclohexyl, each substituted with -NRXRX, NRx (alkyl C2-4) , -NH (oxetanyl) , -N (CH3) CH2CH2 OCH, -N (CH3) CH2C (O) N (CH3) 2, CCH -N (O) (CH3) (CH3) CH2 (ethylhethanyl) ; the (d) morpholinyl, piperazinonyl, piperazinyl, piperidinyl or pyrrolidinyl, each substituted with zero to one substituent selected from C1-5 alkyl - CH2CF 3, -CH2C (CH3) 2OH, -CH2CH2 OCH 3, -CH2C (O) CRXRX, -C (O) CH2N (CH3) 2, oxetanyl, methyloxetanyl and tetrahydropyranyl; Q1 is azetidinyl, cyclopropyl, morpholinyl, oxetanyl, tetrahydropyranyl, triazolyl, oxaazaspiro[3.3]heptanyl, piperazinonyl, difluoropiperidinyl or pyrrolidinyl, each substituted with zero to 2 substituents independently selected from F, -CH3.- CH2CH3.- CH2OH and oxetanyl; R3e is F; R3f is: (a) -OH, -NH2, -N (CH3) 2, -NH (CH (CH3) 2), -NHCH2C (CH3) 2OCH3.- CH2NH (CH3) , -CH2N (CH3) 2.- CH2NH (CH (CH3) 2), -CH (CH3) N (CH3) 2, or -CH (CH3) N (CH3) C (O)CH2N(CH3)2; (b) cyclohexyl substituted with -NH2.- N (CH3) 2.- NRX (CH2CH2OCH3), -NH (cyclobutyl), -NH (methyloxetanyl), -NHCH2 (methylsulfonylcyclopropyl), morpholinyl, methoxyazetidinyl, piperazinonyl, difluoropiperidinyl, methoxypiperidinyl, oxaazaspiro [3.3]heptanyl or oxaazaspiro[3.5]nonanyl; (c) diazaspiro[3.3]heptanyl substituted with zero to one substituent selected from C1-4 alkyl.- CH2CH2OCH3.- CH2CH2S (O) 2CH3.- CH2 (C3-4 cycloalkyl) , -CH2 (tetrahydropyranyl) , cyclobutyl, oxethanyl and tetrahydropyranyl; (d) piperazinyl substituted with zero to one substituent selected from C1-6 alkyl, -CH2CH2CF3, -CH2CH2OCH3, -CH2CH2S(O)2CH3, -CH2(C3-4 cycloalkyl), -CH2(ethyloxethanyl), -CH2C(O)NH(CH3), -CH2C(O)N(CH3), -C(O)CH2N(CH3), -C(O)CH2N(CH2CH3), -CH2(tetrahydropyranyl), cyclobutyl, oxethanyl, tetrahydropyranyl, and dioxototetrahydropyranyl; or (e) piperidinyl substituted with zero to one substituent selected from C1-6 alkyl.- CH2CN, -CH2CH2F, -CH2CH2CH2F, -CH2CH2CF3.- CH2C (CH3) 2OH, -CH2CH2OCH3.- CH2CH2S (O) 2CH3.- CH2C (O) NRXRX, -C (O) CH2N (CH3) 2.- C (O) CH2N (CH2CH3) 2.- CH2 (CYCLOALKYL CS-4) , -CH2 (tetrahydrofuranyl) , -CH2 (tetrahydropyranyl) , -CH2 (methyltriazolyl) , cyclobutyl, ethoxycyclobutyl, oxethanyl, tetrahydrofuranyl and tetrahydropyranyl; R3g is F, -CH3 or -CF3; R311 is: (a) -CH (CH3) N (CH3) RX, -CH (CH3) N (CH3) (C2-3 alkyl), -CH (CH3) N (CH3) CH2C (O) N (CH3) 2, -CH (CH3) N (CH3) C (O) CH2N (CH3) 2 or -CH (CH3) N (CH3) (tetrahydropyranyl); (b) cyclohexyl substituted with -N (CH3) RX, -N (CH3) (CH (CH3) 3) , -N (CH3) (CH2CH2CF3) , -NRX (CH2CH2 OCH 3) , -NH (CH2C (CH3) 2 OCH (CH3) CH 3) -N -NH (cyclobutyl) , -NRx (oxetanyl) , -NH (methyl oxetanyl) , -NH (tetrahydropyranyl) , -NHCH2 (methylsulfonylcyclopropyl) , -NHCH2 (methyloxetanyl) , methoxyazetidinyl, (trifluoromethyl) hydroxyazethidinyl, morpholinel, pyrrolidinyl, piperazinonyl, methylsulfonylpiperazinyl, [oxane,azap3pyl], oxaazaspiro [3, 5]nonhanyl or dioxothiazaspiro[3, 3]heptanyl; (c) piperazinyl substituted with zero to two -CH3; and zero or one substituent selected from C1-5 alkyl.- CH2CN, -CH2CH2F, -CH2CH2CH2F, -CH2C (CH3) 2OH, -CH2CH2 OCH 3, -CH2CH2S (O) 2CH3, -CH2C (O) N (CH3) RX, -NHC (O) CH2N (CH3) 2, -NHC (O) CH2N (CH2CH3) 2, -C (O) CH2N (CH3) 2, -C (O) CH2N (CH2CH3) 2, -CH2 (C3-4 cycloalkyl), -CH2 (tetrahydropyranyl), -C (O) CH2 (morpholinyl), cyclobutyl, oxethanyl and tetrahydropyranyl; or (d) piperidinyl replaced with wax or a -CH3 and wax or 1 substitute selected between alquilo C1-6.- CH2CN, -CH2CH2F, -CH2 CH 2CH2 F, -CH 2 CH 2CH2 F, -CH2 CH 2 CF3, -CH 2 C (CH 3) 2 OH, -CH 2 CH 2 OCH 3, -CH 2 CH 2OC (CH3) 3, -CH2CH 2 S (O) 2 CH3, -CH2C (O) NH2, -CH2C (O) N (CH3) 2, -CH2C (O) N (CH3) (CH (CH3) 2) , -C (O) CH2N (CH3) 2, -C (O) CH2N (CH2CH3) 2, -C (O) CH2N (CH3) (CH2CH2 OCH 3) , -NH2, -NH(CH2CH2CH3) , -NH(CH(CH3)2) , -NHCH2CH(CH3)2, -N(CH3)2, -N(CH3)(CH2CH3) , -NH(CH2C(CH3)2OCH3) , -CH2(C3-6 cycloalkyl) , -CH2(methylsulfonylcyclopropyl) , -CH2(oxetanil) , -CH2(methyloxetanil) , -CH2(ethyloxetanil) , -CH2(tetrahydrofuranyl) , -CH2(tetrahydropyranyl) , -CH2(methyltriazolyl) , -CH2C(O)(oxetanil) , -CH2C(O)(morpholinil) , -CH2C(O)(oxaazaspiro [3.3]heptanilo) , -C (O) CH2 (methoxiazetidinilo) , -C (O) CH2 (morpholinilo) , -C (O) CH2 (oxaazaspiro [3.5]nonanilo) , -C (O) CH2 (piperidinonilo) , -N (CH 2 (cyclopropyl) ) 2, -N (CH 2 (tetrahydropyranilo) ) 2.- NH (methyloxetanilo) , -NH (tetrahydropyranilo) , -NHC (O) CH2 (morpholinio) , NHCH2 (cyclopropyl) , cyclobutyl, ethoxycyclobutyl, oxetanilo, tetrahydrofuranilo, tetrahydropyranilo, tetrahydroxytetrahydrothiophenyl y oxanilo;. R3j es -CH3 o -CF3; R3j is C1-6 alkyl.- CH2CH2 OCH 3, -CH2CH2S (O) 2CH3, -C (O) CH2N (CH3) 2, -CH2 (C3-4 cycloalkyl) , -CH2 (tetrahydropyranyl) , -CH (CH3) (cyclopropyl) , cyclobutyl, oxethanyl, tetrahydropyranyl or isopropylpiperidinyl; R3k is C1-4 alkyl.- CH2C (CH3) 2OH, -CH2CH2 OCH 3, -CH2C (O) NRXRX, -C (O) CH3, -C (O) CH2CH (CH3) OH, -C (O) CH2N (CH3) 2.- NRX (C1-3 ALKYL), -NRx (C3-4 fluoroalkyl), -NRX (CH2CH2 OCH 3) , -N (CH3) (CH2CH2S (O) 2CH3) , -N (CH3) (CH2C (O) N (CH3) 2) , -NRX (C (O) CH2N (CH3) 2) , -N (CH2CH2CH2CF3) 2.- NRx (oxetanyl) , -N (CH3) (methyloxetanyl), -N (CH3) (tetrahydropyranyl), -NH (ethoxycyclobutyl), oxetanyl or isopropylpiperidinyl; R5 is hydrogen. each Rx is independently H or -CH3; each Ry is independently H or C1-6 alkyl; and p is zero, 1 or 2. One embodiment provides a compound of formula (I), N-oxide or a salt thereof where G is: This embodiment includes compounds in which R2a is C1-4 alkyl, C1-2 fluoroalkyl, C1-4 hydroxyalkyl, -(CH2) 1-3 OCH3, C3-6 cycloalkyl, -CH2C (O) NRXRX, -CH2 (C3-6 cycloalkyl), -CH2 (phenyl), tetrahydrofuranyl or phenyl; each R2b is independently H, F, Cl, -CN, -NRXRX, C1-6 alkyl, C1-2 fluoroalkyl, C1-3 hydroxyalkyl, -(CH2) 0-20 (C1-2 ALKYL), -(CH2) 0-2C (O) NRXRX, -(CH2) 1-3 (cyclopropyl), -C (O) O (C1-2 alkyl) or -C (O) NRX (C1-3 ALKYL); yp is 1 or 2. One embodiment provides a compound of formula (I), N-oxide or a salt thereof where G is: One embodiment provides a compound of formula (I), N-oxide or a salt thereof where G is: One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein R1 is -CH(CH3)2. One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is -CH2N(CH3)RX, -C(O)NRXRX, -C(O)N(CH3)(CH2CH2CN), -C(O)N(CH2CH3)(CH2CH2CN) or -C(O)N(CH3)(CH2CH2CH2N(CH3)2) One embodiment provides a compound of formula (I) , N-oxide or a salt thereof wherein A is -C (O) A1.- C (0) NRx (CRxRx) 0-2Ai, -CH2NHA1 or -C (O) C (O) NHA1. One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is cyclohexyl substituted with R3b. Also included in this embodiment are compounds in which G is: One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is piperidinyl substituted with R3c. One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is piperidinyl substituted with zero to 1 R3c. Also included in this embodiment is R3c. are compounds in which G is: One embodiment provides a compound of formula (I), N-oxide, or a salt thereof, wherein A is phenyl substituted with zero to one R3a and zero to one R3e. This embodiment includes compounds in which A is phenyl substituted with R3a and zero to one R3e. This embodiment also includes compounds in which A is phenyl substituted with R3a. In addition, this embodiment includes compounds in which A is phenyl substituted with R3d and R3e. This realization also includes compounds in which G is: One embodiment provides a compound of formula (I), N-oxide, or a salt thereof, wherein A is pyridinyl substituted with zero to one R3r and zero to one R3g. This embodiment includes compounds wherein A is pyridinyl substituted with R3f and zero to one R3g. This embodiment also includes compounds wherein A is pyridinyl substituted with R3r. In addition, this embodiment includes compounds wherein A is pyridinyl substituted with both R3f and R3g. This realization also includes compounds in which G is: One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is pyrazinyl or pyrimidinyl, each substituted with zero to one R3f. This embodiment also includes compounds wherein A is pyrazinyl or pyrimidinyl, each substituted with R3f. In addition, this embodiment includes compounds wherein A is pyrimidinyl substituted with zero to one R3f. This realization also includes compounds in which G is: One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is a thiazolyl substituted with R3h and zero to 1 R3i. In addition, this embodiment includes compounds wherein A is a thiazolyl substituted with R3h. This realization also includes compounds in which G is: One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is diazabicyclo[2.2.1]heptanyl, diazaspiro[3.3]heptanyl or dioxidotiazaspiro[3.3]heptanyl, each substituted with zero to 1 R3j. This embodiment includes compounds in which A is diazabicyclo[2.2.1]heptanyl or diazaspiro[3.3]heptanyl, each substituted with zero to 1 R3j. One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is diazabicyclo[2.2.1]heptanyl or diazaspiro[3.3]heptanyl, each substituted with zero to 1 R3.j Also included in this realization, compounds in which G is: One embodiment provides a compound of formula (I), N-oxide, or a salt thereof wherein A is benzo[d]thiazolyl, dihydroisoquinolinyl, tetrahydronaphthiridinyl, tetrahydrobenzo[d]thiazolyl, tetrahydroimidazo[1, 2-a]pyrazinyl, tetrahydroisoquinolinonyl, tetrahydroisoquinolinyl, tetrahydronaphthalenyl, tetrahydropyrazolo[1, 5-a]pyrazinyl, tetrahydropyrido[4, 3-d]pyrimidinyl, tetrahydrothiazolo[4, 5-C]pyridinyl, or tetrahydrothiazolo[5, 4-C]pyridinyl, each substituted with zero to 1 R3k. This embodiment includes compounds in which A is benzo[d]thiazolyl, dihydroisoquinolinyl, tetrahydronaphthiridinyl, tetrahydrobenzo[d]thiazolyl, tetrahydroimidazo[1, 2-a]pyrazinyl, tetrahydroisoquinolinonyl, tetrahydroisoquinolinyl, tetrahydronaphthalenyl, tetrahydropyrazolo[1, 5-a]pyrazinyl, tetrahydropyrido[4, 3-d]pyrimidinyl, tetrahydrothiazolo[4, 5-C]pyridinyl or tetrahydrothiazolo[5, 4-C]pyridinyl, each substituted with R3k.This embodiment also includes compounds in which A is benzo[d]thiazolyl, dihydroisoquinolinyl, tetrahydronaphthiridinyl, tetrahydrobenzo[d]thiazolyl, tetrahydroimidazo[1,2-a]pyrazinyl, tetrahydroisoquinolinonyl, tetrahydroisoquinolinyl, tetrahydronaphthalenyl, tetrahydropyrazolo[1,5-a]pyrazinyl, tetrahydropyrido[4,3-d]pyrimidinyl, tetrahydrothiazolo[4,5-C]pyridinyl, or tetrahydrothiazolo[5,4-C]pyridinyl. Also. Included in this realization are compounds in which G is: One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is: (i) -CH2N(CH3)RX, -C(O)NRXRX, -C(O)N(CH3)(CH2CH2CN), -C(O)N(CH2CH3)(CH2CH2CN) or -C(O)N(CH3)(CH2CH2CH2N(CH3)2); or (ii) -C(O)A1, -C(O)NRX(CRXRX)O-2AI, -CH2NHA1 or -C(O)C(O)NHA1. This embodiment includes compounds wherein A is (i) -CH2N(CH3)RX or -C(O)NRXRX; or (ii) -C(O)A1, -C(O)NRX(CRXRX)O-2AI or -CH2NHA1. One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein A is: (i) cyclohexyl substituted from zero to 1 R3b; (ii) piperidinyl substituted with zero to 1 R3C; (iii) phenyl substituted with zero to 1 R3d and from zero to 1 R3e; (iv) pyridinyl substituted with zero to 1 R3f and from zero to 1 R3g; (v) pyrazinyl or pyrimidinyl, each substituted with zero to 1 R3f; (vi) thiazolyl substituted with R3h and from zero to 1 R3i; (vii) diazabicyclo[2.2.1]heptanyl or diazaspiro[3.3]heptanyl, each substituted with zero to 1 R3j; or (viii) benzo[d]thiazolyl, dihydroisoquinolinyl, tetrahydronaphthyridinyl, tetrahydrobenzo[d]thiazolyl, tetrahydroimidazo[1, 2-a]pyrazinyl, tetrahydroisoquinolinonyl, tetrahydroisoquinolinyl, tetrahydronaphthalenyl, tetrahydropyrazolo[1, 5-a]pyrazinyl, tetrahydropyrido[4, 3-d]pyrimidinyl, tetrahydrothiazolo[4,5]pyridinyl or tetrahydrothiazolo[5,4]pyridinyl, each substituted with 1 R3k. One embodiment provides a compound of formula (I) N-oxide or a salt thereof wherein A is: (i) cyclohexyl substituted with zero to 1 R3b; (ii) piperidinyl substituted with zero to 1 R3C; (iii) phenyl substituted with zero to 1 R3a and zero to 1 R3e; (iv) pyridinyl substituted with zero to 1 R3f and zero to 1 R3g; (v) pyrazinyl or pyrimidinyl, each substituted with zero to 1 R3f; or (vi) thiazolyl substituted with R3h and zero to 1 R3i. One embodiment provides a compound of formula (I) , N-oxide or a salt thereof wherein A is: (i) piperidinyl substituted with zero to 1 R3c; (ii) phenyl substituted with zero to 1 R3 a and zero to 1 R3e; (iii) pyridinyl substituted with zero to 1 R3f and zero to 1 R3g; or (iv) pyrazinyl or pyrimidinyl, each substituted with zero to 1 R3r or (vi) thiazolyl substituted with R3h and zero to 1 R3i. One embodiment provides a compound of formula (I) , N-oxide or a salt thereof wherein A is: (i) phenyl substituted with zero to 1 R3a and zero to 1 R3e; (ii) pyridinyl substituted with zero to 1 R3f and zero to 1 R3g; or (iii) pyrazinyl or pyrimidinyl, each substituted with zero to 1 R3r; or (vi) thiazolyl substituted with R3h and zero to 1 R3i. One embodiment provides a compound of formula (I), N-oxide or a salt thereof wherein: G is R1 is -CH (CH3) 2; each R2 is independently -CH3 or -OCH3; yp is 1 or 2. One embodiment provides a compound of formula (I), N-oxide or a salt thereof, wherein said compound is a compound of one of the examples described herein below. The invention encompasses all combinations of the aspects and / or embodiments of the invention described herein. It is understood that each and every embodiment of the present invention may be taken together with any other embodiment or embodiments to describe further embodiments. It is also understood that each individual element of the embodiments is intended to be combined with each and every other element of any embodiment to describe a further embodiment. Definitions Those skilled in the art can more easily understand the features and advantages of the invention after reading the detailed description below. It will be appreciated that certain features of the invention, which for the sake of clarity have been described above and below in the context of separate embodiments, can be combined to form a single embodiment. Conversely, several features of the invention, which for the sake of brevity are described in the context of a single embodiment, can also be combined to form subcombinations thereof. The embodiments identified herein as exemplary or preferred are illustrative and not limiting. Unless otherwise specified herein, references made in the singular may also include the plural. For example, "a" and "an" may refer to one, or to one or more. As used herein, the phrase "compounds" refers to at least one compound. For example, a compound of formula (I) includes one compound of formula (I) and two or more compounds of formula (I). Unless otherwise stated, any heteroatom with unsatisfied valencies is assumed to have enough hydrogen atoms to satisfy the valencies. The definitions set forth herein take precedence over the definitions set forth in any patent, patent application, and / or patent application publication cited herein. The definitions of various terms used to describe the present invention are listed below. These definitions apply to the terms used throughout the specification (unless otherwise limited in specific cases), whether individually or as part of a larger group. Throughout the descriptive memorandum, an expert in the technique can choose the groups and substituents of the same to provide stable residues and compounds. According to a convention used in the art, the term "halo" is used in structural formulas herein to represent the bond that is the point of attachment of the substituent to the nucleus or main structure. The terms "halo" and "halogen," as used herein, refer to F, Cl, Br, and I. The term "cyano" refers to the -CN group. The term "amino" refers to the -NH2 group. The term "oxo" refers to the group =0. The term "alkyl," as used herein, refers to saturated aliphatic hydrocarbon groups, both branched and straight-chain, containing, for example, 1 to 12 carbon atoms, 1 to 6 carbon atoms, and 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec-butyl, and β-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. When numbers appear in a subscript after the symbol "C", the subscript defines more specifically the number of carbon atoms a particular group may contain. For example, "C1-6 alkyl" represents linear or branched chain alkyl groups with one to six carbon atoms. The term "fluoroalkyl," as used herein, is intended to include saturated, straight-chain and branched aliphatic hydrocarbon groups substituted with one or more fluorine atoms. For example, "C1-4 fluoroalkyl" is intended to include C1, C2, C3, and C4 alkyl groups substituted with one or more fluorine atoms. Representative examples of fluoroalkyl groups include, but are not limited to, -CF3 and -CH2CF3. The term "cyanoalkyl" includes both branched and linear alkyl groups substituted by one or more cyano groups. For example, "cyanoalkyl" includes -CH2CN, -CH2CH2CN, and C1-4 cyanoalkyl. The term "aminoalkyl" includes both branched and linear alkyl groups substituted with one or more amine groups. For example, "aminoalkyl" includes -CH2NH2, -CH2CH2NH2, and C1-4 aminoalkyl. The term "hydroxyalkyl" includes both branched and linear alkyl groups substituted with one or more hydroxyl groups. For example, "hydroxyalkyl" includes -CH2OH, -CH2CH2OH, and C1-4 hydroxyalkyl. The term "hydroxyfluoroalkyl" includes both branched and linear alkyl groups substituted with one or more hydroxyl groups and one or more fluorine atoms. For example, "hydroxyfluoroalkyl" includes -CHFCH2OH, -CH2CHFC(CH3)2OH, and C1-4 hydroxyfluoroalkyl. The term "cycloalkyl," as used herein, refers to a group obtained from a non-aromatic, monocyclic or polycyclic hydrocarbon molecule by the removal of a hydrogen atom from a carbon atom of the saturated ring. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When numbers appear in a subscript after the symbol "C," the subscript more specifically defines the number of carbon atoms a particular cycloalkyl group may contain. For example, "C3-C6 cycloalkyl" represents cycloalkyl groups with three to six carbon atoms. The term "alkoxy", as used herein, refers to an alkyl group attached to the precursor molecular moiety through an oxygen atom, for example, the methoxy group (-OCH3). For example, "C1-3 alkoxy" represents alkoxy groups with one to three carbon atoms. The term "alkoxyalkyl", as used herein, refers to an alkoxy group attached through its oxygen atom to an alkyl group, which is attached to the precursor molecular moiety, e.g., a methoxymethyl group (-CH2OCH3). For example, "C2-4 alkoxyalkyl" denotes alkoxyalkyl groups with two to four carbon atoms, such as -CH2OCH3, -CH2CH2OCH3, -CH2OCH2CH3, and -CH2CH2OCH2CH3. The phrase "pharmaceutically acceptable" is used in this document to refer to compounds, materials, compositions and / or dosage forms that, within the scope of good medical judgment, are suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problem or complication, consistent with a reasonable benefit / risk ratio. Compounds of formula (I) can be provided as amorphous solids or crystalline solids. Freeze-drying can be used to provide compounds of formula (I) as amorphous solids. It should also be understood that the solvates (e.g., hydrates) of compounds of formula (I) are also within the scope of the present invention. The term "solvate" means a physical association of a compound of formula (I) with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain cases, the solvate may be isolated, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Examples of solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Methods of solvation are known in the art. Various forms of prodrugs are well known in the technique, which are described in: a) The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996); b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) ; c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Chapter 5, pages 113-191 (Harwood Academic Publishers, 1991) ; and d) Hydrolysis in the metabolism of drugs and prodrugs, Bernard Testa and Joachim M. Mayer, (Wiley-VCH, 2003). Furthermore, the compounds of formula (I), after their preparation, can be isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of a compound of formula (I) ("substantially pure"), which is then used or formulated as described herein. This document also includes such "substantially pure" compounds of formula (I) as part of the present invention. "Stable compound" and "stable structure" are intended to include a compound that is robust enough to survive isolation to a useful degree of purity from a reaction mixture and its formulation into an effective therapeutic agent. The present invention is intended to include stable compounds. "Therapeutically effective quantity" is intended to include a quantity of a compound of the present invention alone, or a quantity of the claimed combination of compounds, or a quantity of a compound of the present invention in combination with other active ingredients effective to act as an inhibitor for TLR7 / 8 / 9, or effective to treat or prevent autoimmune and / or inflammatory pathologies, such as SLE, IBD, multiple sclerosis (MS), Sjögren's syndrome, and rheumatoid arthritis. As used herein, "treat" or "treatment" covers the treatment of a pathological condition in a mammal, particularly a human, and includes: (a) preventing the occurrence of the pathology in a mammal, particularly when such mammal has a predisposition to the pathology but has not yet been diagnosed with it; (b) inhibiting the pathology, i.e., stopping its development; and / or (c) alleviating the pathology, i.e., causing the regression of the pathology. The compounds of the present invention are intended to include all isotopes of the atoms appearing in the present compounds. Isotopes include atoms that have the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium (D) and tritium (T). Isotopes of carbon include 13C and 14C. Generally, the isotopically labeled compounds of the invention can be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using a suitable isotopically labeled reagent instead of an unlabeled reagent. For example, methyl (-CH3) also includes deuterated methyl groups such as -CD3. Utility The human immune system has evolved to defend the body against microorganisms, viruses, and parasites that can cause infection, illness, or death. Complex regulatory mechanisms ensure that the various cellular components of the immune system target foreign substances or organisms without causing permanent or significant damage to the individual. While the initiating events are not well understood at this time, in autoimmune disease states, the immune system directs its inflammatory response to target organs in the affected individual.The different autoimmune diseases are typically characterized by the predominant or initial target organ or tissues affected; such as the joint in the case of rheumatoid arthritis, the thyroid gland in the case of Hashimoto's thyroiditis, the central nervous system in the case of multiple sclerosis, the pancreas in the case of type I diabetes, and the intestine in the case of inflammatory bowel disease. The compounds of the invention inhibit signaling through Toll-like receptor 7, 8, or 9 (TLR7, TLR8, TLR9) or combinations thereof. Therefore, the compounds of formula (I) are useful in the treatment of conditions associated with the inhibition of signaling through one or more of TLR7, TLR8, or TLR9 receptors. Such conditions include diseases associated with the TLR7, TLR8, or TLR9 receptor in which cytokine levels are modulated as a consequence of intracellular signaling. As used herein, the terms "treat" or "treatment" encompass the treatment of a pathology in a mammal, particularly a human, and include: (a) preventing or delaying the onset of the pathology in a mammal, particularly when such mammal has a predisposition to the pathology but has not yet been diagnosed with it; (b) inhibiting the pathology, i.e., stopping its development; and / or (c) achieving a complete or partial reduction of the symptoms or the pathology and / or relieving, improving, reducing, or curing the disease or disorder and / or its symptoms. In view of their activity as selective inhibitors of TLR7, TLR8 or TLR9, the compounds of Formula (I) are useful in the treatment of diseases associated with the TLR7, TLR8 or TLR9 receptor family, but not limited to, inflammatory diseases such as Crohn's disease, ulcerative colitis, asthma, graft-versus-host disease, allograft rejection, chronic obstructive pulmonary disease; autoimmune diseases such as Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, psoriasis; autoinflammatory diseases including Cryopyrin-Associated Periodic Syndromes (CAPS), TNF Receptor-Associated Periodic Syndrome (TRAPS), Familial Mediterranean Fever (FMF), adult-onset idiopathic arthritis, systemic-onset juvenile idiopathic arthritis, gout, gouty arthritis; metabolic diseases including type 2 diabetes, atherosclerosis, myocardial infarction;Destructive bone disorders such as bone resorption disease, osteoarthritis, osteoporosis, multiple myeloma-related bone disorder; proliferative disorders such as acute myeloid leukemia, chronic myeloid leukemia; angiogenic disorders such as angiogenic disorders including solid tumors, ocular neovascularization and infantile hemangiomas; infectious diseases such as sepsis, septic shock and shigellosis; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, cerebral ischemia or neurodegenerative disease caused by traumatic injury, oncological and viral diseases such as metastatic melanoma, Kaposi's sarcoma, multiple myeloma and HIV infection and CMV retinitis, AIDS, respectively. More particularly, the specific conditions or diseases that can be treated with the compounds of the invention include, but are not limited to, pancreatitis (acute or chronic), asthma, allergies, adult respiratory distress syndrome, chronic obstructive pulmonary disease, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, graft-versus-host disease, endotoxin-induced inflammatory reaction, tuberculosis, atherosclerosis, muscular degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis,pancreatic P-cell disease; diseases characterized by massive neutrophil infiltration; rheumatoid spondylitis, gouty arthritis and other arthritic conditions, cerebral malaria, chronic inflammatory lung disease, silicosis, pulmonary sarcoidosis, bone resorption disease, allograft rejection, fever and myalgia due to infection, cachexia secondary to infection, keloid formation, scar tissue formation, ulcerative colitis, fever, influenza, osteoporosis, osteoarthritis, acute myeloid leukemia, chronic myeloid leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, sepsis, septic shock and shigellosis; Alzheimer's disease, Parkinson's disease, cerebral ischemia or neurodegenerative disease caused by traumatic injury; angiogenic disorders including solid tumors,Ocular neovascularization and infantile hemangiomas; viral diseases including acute hepatitis infection (including hepatitis A, hepatitis B, and hepatitis C), HIV infection and CMV retinitis, AIDS, ARC or malignancy, and herpes; stroke, myocardial ischemia, ischemia in stroke-induced heart attacks, organ hypoxia, vascular hyperplasia, cardiac and renal reperfusion injury, thrombosis, cardiac hypertrophy, thrombin-induced platelet aggregation, endotoxemia and / or toxic shock syndrome, conditions associated with prostaglandin endoperoxidase syndase-2, and pemphigus vulgaris. In this embodiment, compounds of the invention are included for use in treatment methods in which the condition is selected from lupus, including lupus nephritis and systemic lupus erythematosus (SLE), Crohn's disease, ulcerative colitis, allograft rejection, rheumatoid arthritis, psoriasis, ankylosing spondylitis,psoriatic arthritis and pemphigus vulgaris. Compounds of the invention are also included for use in treatment methods where the condition is selected from ischemia-reperfusion injury, including cerebral ischemia-reperfusion injury due to stroke and cardiac ischemia-reperfusion injury due to myocardial infarction. The compounds of the invention may also be used in a treatment method where the condition is multiple myeloma. In one embodiment, the compounds of formula (I) are useful in the treatment of cancer, including Waldenstrom macroglobulinemia (WM), diffuse large B-cell lymphoma (DLBCG), chronic lymphocytic leukemia (CLL), cutaneous diffuse large B-cell lymphoma, and primary CNS lymphoma. Furthermore, the TLR7, TLR8, or TLR9 inhibitors of the present invention inhibit the expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxide synthase-2 (PGHS-2), also known as cyclooxygenase-2 (COX-2), IL-1, IL-6, IL-18, and chemokines. Consequently, additional conditions associated with TLR7 / 8 / 9 include edema, analgesia, fever, and pain, such as neuromuscular pain, headache, cancer pain, dental pain, and arthritis pain. The compounds of the invention can also be used to treat veterinary viral infections, such as lentivirus infections, including, but not limited to, equine infectious anemia virus; or retrovirus infections, including feline immunodeficiency virus, bovine immunodeficiency virus, and canine immunodeficiency virus. The present invention provides compounds for use in methods for treating such conditions, comprising administering to a subject in need a therapeutically effective amount of at least one compound of formula (I) or a salt thereof. The phrase "therapeutically effective amount" includes an amount of a compound of the present invention that is effective when administered alone or in combination to inhibit an autoimmune disease or a chronic inflammatory disease. Methods for treating conditions associated with TLR7, TLR8, or TLR9 may include administering compounds of formula (I) alone or in combination with each other and / or other therapeutic agents useful for treating such conditions. Accordingly, "therapeutically effective amount" also includes an amount of the combination of the claimed compounds that is effective in inhibiting TLR7, TLR8, or TLR9 and / or in treating diseases associated with TLR7, TLR8, or TLR9. Examples of such other therapeutic agents include corticosteroids, rolipram, calfostine, cytokine-suppressing anti-inflammatory drugs (CSAIDs), interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as desoxyspergualine (DSG); nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, celecoxib, and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, PROGRAF®); antimalarial drugs such as hydroxychloroquine; and cytotoxic drugs such as azathioprine and cyclophosphamide. TNF-α inhibitors such as tenidap, antibodies directed against TNF or the soluble TNF receptor and rapamycin (sirolimus or RAPAMUNE®) or derivatives thereof. The aforementioned different therapeutic agents, when used in combination with the compounds of the present invention, may be used, for example, in the amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by a person skilled in the art. Such other therapeutic agent(s) may be administered before, during, or after the administration of the inventive compounds. The present invention also provides pharmaceutical compositions capable of treating conditions associated with the TLR7 / 8 / 9 receptor, including diseases mediated by the IL-1 family receptor, as described above. Inventive compositions may contain other therapeutic agents as described above and may be formulated, for example, using conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type suitable for the desired mode of administration (e.g., excipients, binders, preservatives, stabilizers, flavorings, etc.) according to techniques such as those well known in the pharmaceutical formulation art. Accordingly, the present invention further includes compositions comprising one or more compounds of formula (I) and a pharmaceutically acceptable carrier. A "pharmaceutically acceptable carrier" refers to a generally accepted means in the art for administering biologically active agents to animals, particularly mammals. Pharmaceutically acceptable carriers are formulated according to a number of factors well within the scope of those skilled in the art. These include, but are not limited to, the type and nature of the active agent being formulated; the subject to whom the composition containing the agent is to be administered; the intended route of administration of the composition; and the therapeutic indication for which it is intended. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms.Such carriers may include a number of different ingredients and additives in addition to the active agent. These additional ingredients are included in the formulation for a variety of reasons, such as stabilization of the active agent, binding, etc., which are well known to those skilled in the art. Descriptions of suitable pharmaceutically acceptable carriers and the factors involved in their selection can be found in a variety of readily available sources, such as Remington's Pharmaceutical Sciences, 17th edition (1985). Compounds according to formula (I) can be administered by any means suitable for the condition to be treated, which may depend on the need for site-specific treatment or the amount of compound of formula (I) to be administered. Also included within this invention is a class of pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable, non-toxic carriers and / or diluents and / or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of formula (I) can be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such route and in a dose effective for the desired treatment. The compounds and compositions of the present invention can, for example, be administered orally, via mucosal routes, or parenterally, including intravascular, intravenous, intraperitoneal, subcutaneous, intramuscular, and intrasternal routes in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.For example, the carrier may contain a mixture of mannitol or lactose and microcrystalline cellulose. The mixture may contain additional components such as a lubricating agent, for example, magnesium stearate, and a disintegrating agent such as crospovidone. The carrier mixture may be filled into a gelatin capsule or compressed into a tablet. The pharmaceutical composition may be administered as an oral dosage form or as an infusion, for example. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, liquid capsule, suspension, or liquid. The pharmaceutical composition is preferably manufactured as a dosage unit containing a particular amount of the active ingredient. For example, the pharmaceutical composition may be provided as a tablet or capsule comprising an amount of active ingredient in the range of approximately 0.1 to 1000 mg, preferably from approximately 0.25 to 250 mg, and more preferably from approximately 0.5 to 100 mg. An appropriate daily dose for a human or other mammal may vary widely depending on the patient's condition and other factors, but can be determined using routine methods. Any pharmaceutical composition contemplated herein may, for example, be administered orally by any acceptable and suitable oral preparation. Examples of oral preparations include, but are not limited to, tablets, lozenges, suckling pills, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions intended for oral administration. In order to provide pharmaceutically palatable preparations, a pharmaceutical composition according to the invention may contain at least one agent selected from sweetening agents, flavoring agents, coloring agents, demulcents, antioxidants, and preservatives. A tablet may, for example, be prepared by mixing at least one compound of formula (I) with at least one pharmaceutically acceptable, non-toxic excipient suitable for tablet manufacture. Illustrative excipients include, but are not limited to, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating and disintegrating agents such as microcrystalline cellulose, croscarmellose sodium, maize starch, and alginic acid; binding agents such as starch, gelatin, polyvinylpyrrolidone, and gum arabic; and lubricating agents such as magnesium stearate, stearic acid, and talc.Furthermore, a tablet may be uncoated or coated using known techniques to mask the unpleasant taste of a drug or to delay the disintegration and absorption of the active ingredient in the gastrointestinal tract, thereby prolonging the effects of the active ingredient. Examples of water-soluble taste-masking materials include, but are not limited to, hydroxypropyl methylcellulose and hydroxypropyl cellulose. Examples of time-delaying materials include, but are not limited to, ethyl cellulose and cellulose acetate butyrate. Hard gelatin capsules may, for example, be prepared by mixing at least one compound of formula (I) with at least one inert solid diluent, such as, for example, calcium carbonate, calcium phosphate, and kaolin.Soft gelatin capsules can, for example, be prepared by mixing at least one compound of formula (I) with at least one water-soluble carrier, such as, for example, polyethylene glycol, and at least one oily medium, such as, for example, peanut oil, liquid paraffin, and olive oil. An aqueous suspension can be prepared, for example, by mixing at least one compound of formula (I) with at least one excipient suitable for the manufacture of an aqueous suspension. Excipients suitable for the manufacture of an aqueous suspension include, but are not limited to, suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium liginate, alginic acid, polyvinylpyrrolidone, tragacanth gum, and gum arabic; dispersing or wetting agents such as a naturally occurring phosphatide, such as lecithin; condensation products of alkylene oxides with fatty acids, such as polyoxyethylene stearate; and condensation products of ethylene oxide with long-chain aliphatic alcohols, such as heptadecaethylene-oxycetanol.Ethylene oxide condensation products with partial esters derived from fatty acids and hexitol, such as, for example, polyoxyethylene sorbitol monooleate, and ethylene oxide condensation products with partial esters derived from fatty acids and hexitol anhydrides, such as, for example, polyethylene sorbitan monooleate. An aqueous suspension may also contain at least one preservative, such as, for example, ethyl and n-propyl p-hydroxybenzoate; at least one colorant; at least one flavoring agent; and / or at least one sweetening agent, including, but not limited to, for example, sucrose, saccharin, and aspartame. Oil suspensions may, for example, be prepared by suspending at least one compound of formula (I) in either a vegetable oil, such as peanut oil, olive oil, sesame oil, or coconut oil, or in a mineral oil, such as liquid paraffin. An oil suspension may also contain at least one thickening agent, such as beeswax, hard paraffin, or cetyl alcohol. To provide a palatable oil suspension, at least one of the sweetening agents described earlier herein and / or at least one flavoring agent may be added. An oil suspension may further contain at least one preservative, including, but not limited to, an antioxidant, such as butylated hydroxyanisole and alpha-tocopherol. Dispersible powders and granules may, for example, be prepared by mixing at least one compound of formula (I) with at least one dispersing and / or wetting agent; at least one suspending agent; and / or at least one preservative. Suitable dispersing agents, wetting agents, and suspending agents are as described above. Preservatives include, but are not limited to, antioxidants, such as ascorbic acid. In addition, dispersible powders and granules may also contain at least one excipient, including, but not limited to, sweeteners, flavoring agents, and coloring agents. An emulsion of at least one compound of formula (I) may, for example, be prepared as an oil-in-water emulsion. The oil phase of emulsions comprising compounds of formula (I) may be constituted from known ingredients in a known manner. The oil phase may be provided by, but is not limited to, for example, a vegetable oil, such as olive oil and peanut oil; a mineral oil, such as liquid paraffin; and mixtures thereof. Although the phase may comprise simply an emulsifier, it may also comprise a mixture of at least one emulsifier with a fat or an oil, or with both a fat and an oil.Suitable emulsifying agents include, but are not limited to, for example, naturally occurring phosphatides, such as soybean lecithin; esters or partial esters derived from fatty acids and hexitol anhydrides, such as, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, such as, for example, polyoxyethylsorbitan monooleate. Preferably, a hydrophilic emulsifier is included along with a lipophilic emulsifier that acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s), with or without the stabilizer(s), constitute what is known as the emulsifying wax, and the wax, together with the oil and fat, forms what is known as the emulsifying ointment base, which constitutes the dispersed oil phase of cream formulations.An emulsion may also contain a sweetening agent, a flavoring agent, a preservative, and / or an antioxidant. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax or other materials well known in the art. The compounds of formula (I) may, for example, also be administered intravenously, subcutaneously, and / or intramuscularly by any pharmaceutically acceptable and suitable injectable form. Examples of injectable forms include, but are not limited to, sterile aqueous solutions comprising acceptable vehicles and solvents, such as water, Ringer's solution, and isotonic sodium chloride solution; sterile oil-in-water microemulsions; and aqueous or oily suspensions. Parenteral formulations may be in the form of sterile, isotonic, aqueous or non-aqueous solutions or suspensions for injection. These solutions and suspensions may be prepared from sterile powders or granules, using one or more of the carriers or diluents mentioned for use in oral formulations, or using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride solution, tragacanth gum, and / or various buffers. Other adjuvants and modes of administration are well known in pharmaceutical practice.The active ingredient can also be administered by injection in the form of a composition with suitable carriers including saline solution, dextrose or water, or with cyclodextrin (i.e., Captisol), co-solvent solubilization (i.e., propylene glycol) or micellar solubilization (i.e., Tween 80). A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent, for example, a solution in 1,3-butanediol. Acceptable vehicles and solvents include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, non-volatile oils are commonly used as solvents or suspension mediums. Any mild, non-volatile oil, including synthetic mono- or diglycerides, may be used for this purpose. Furthermore, fatty acids, such as oleic acid, are also used in the preparation of injectables. A sterile, injectable oil-in-water microemulsion can, for example, be prepared by 1) dissolving at least one compound of formula (I) in an oily phase, such as, for example, a mixture of soybean seed oil and lecithin; 2) combining the formula (I) containing the oily phase with a mixture of water and glycerol; and 3) processing the combination to form a microemulsion. A sterile aqueous or oily suspension can be prepared according to methods already known in the art. For example, a sterile aqueous solution or suspension can be prepared with a parenterally acceptable, non-toxic diluent or solvent, such as, for example, 1,3-butanediol, and a sterile oily suspension can be prepared with an acceptable, non-toxic, sterile solvent or suspension medium, such as, for example, sterile fixed oils, for example, synthetic mono- or diglycerides and fatty acids, such as, for example, oleic acid. The carriers, adjuvants, and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-alpha-tocopherol succinate polyethylene glycol 1000, surfactants used in pharmaceutical dosage forms such as Tweens, polyethoxylated castor oil such as CREMOPHOR surfactant (BASF), or other similar polymeric delivery matrices, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, mixtures of partial glycerides of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances,Polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, and lanolin. Cyclodextrins such as alpha, beta, and gamma-cyclodextrin or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrins or other solubilized derivatives, can also be advantageously used to enhance the release of compounds from the formulations described herein. The pharmaceutically active compounds of this invention can be processed according to conventional pharmacy methods to produce medicinal agents for administration to patients, including humans and other mammals. The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and / or may contain conventional adjuvants, such as preservatives, stabilizers, emulsifiers, humectants, buffers, etc. Tablets and lozenges can also be prepared with enteric coatings. Such compositions may also include adjuvants such as humectants, sweeteners, flavorings, and perfumes.The amounts of compounds administered and the dosage regimen for treating a disease with the compounds and / or compositions of the present invention depend on a variety of factors, including the subject's age, weight, sex, medical condition, type of disease, severity of the disease, route and frequency of administration, and the particular compound employed. Therefore, the dosage regimen can vary widely but can be routinely determined using standard methods. A daily dose of approximately 0.001 to 100 mg / kg of body weight, preferably between approximately 0.0025 and approximately 50 mg / kg of body weight, and most preferably between approximately 0.005 and 10 mg / kg of body weight, may be appropriate. The daily dose may be administered in one to four doses per day. Other dosage schedules include one dose per week and one dose per two-day cycle. For therapeutic purposes, the active compounds of this invention are normally combined with one or more adjuvants appropriate for the indicated route of administration. If administered orally, the compounds may be mixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, alkyl cellulose esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, gum arabic, sodium alginate, polyvinylpyrrolidone, and / or polyvinyl alcohol, and then compressed or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation, which may be provided in a dispersion of the active compound in hydroxypropyl methylcellulose. The pharmaceutical compositions of this invention comprise at least one compound of formula (I) and, optionally, an additional agent selected from any pharmaceutically acceptable carrier, adjuvant, or carrier. Alternative compositions of this invention comprise a compound of formula (I) described herein, or a prodrug thereof, and a pharmaceutically acceptable excipient, adjuvant, or carrier. A manufactured article is also described. As used herein, the manufactured article is intended to include, but is not limited to, kits and packages. The manufactured article may comprise: (a) a first container; (b) a pharmaceutical composition located within the first container, wherein the composition comprises: a first therapeutic agent, comprising: a compound of the present invention or a pharmaceutically acceptable salt form thereof; and (c) a package insert indicating that the pharmaceutical composition can be used for the treatment of an inflammatory disorder and / or an autoimmune disease (as defined above). Alternatively, the package insert may indicate that the pharmaceutical composition can be used in combination (as defined above) with a second therapeutic agent to treat an inflammatory disorder and / or an autoimmune disease.The manufactured article may further comprise: (d) a second container, wherein components (a) and (b) are located within the second container and component (C) is located either within or outside the second container. Located within the first and second containers means that the respective container holds the article within its boundaries. The first container is a receptacle used to hold a pharmaceutical composition. This container may be for manufacturing, storage, shipping, and / or individual / bulk sale. The first container is intended to cover a bottle, vial, flask, syringe, tube (for example, for a cream preparation), or any other container used to manufacture, hold, store, or distribute a pharmaceutical product. The second container is one used to hold the first container and, optionally, the package insert. Examples of the second container include, but are not limited to, boxes (e.g., cardboard or plastic), crates, cartons, bags (e.g., paper or plastic bags), sachets, and sacks. The package insert may be physically attached to the outside of the first container by tape, glue, staples, or another method of attachment, or it may be inside the second container without any physical means of attachment to the first container. Alternatively, the package insert may be located on the outside of the second container. When located on the outside of the second container, it is preferred that the package insert be physically attached by tape, glue, staples, or another method of attachment. Alternatively, it may be adjacent to or in contact with the outside of the second container without being physically attached. The package insert is a label, tag, marker, etc., that provides information related to the pharmaceutical composition located inside the original container. The information listed will generally be determined by the regulatory agency that governs the area in which the manufactured product will be sold (for example, the U.S. Food and Drug Administration). The package insert may specifically list the indications for which the pharmaceutical composition has been approved. The package insert can be made of any material on which a person can read the information contained within or on it. For example, the package insert is a printable material (e.g., paper, plastic, cardboard, foil, paper or plastic with an adhesive backing, etc.) on which the desired information has been formed (e.g., printed or applied). Preparation methods The compounds of the present invention can be prepared in various ways well known to a person skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, in conjunction with synthetic methods known in the art of synthetic organic chemistry, or variations thereof, as determined by those skilled in the art. Preferred methods include, but are not limited to, those described below. The compounds of this invention can be prepared using the reactions and techniques described in this section. The reactions are carried out in solvents appropriate for the reagents and materials employed and are suitable for the transformations being performed. Furthermore, in the description of the synthetic methods described below, it is understood that all proposed reaction conditions, including the choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment, and preparation procedures, are selected to be standard conditions for that reaction, which should be readily recognizable by a person skilled in the art. A person skilled in the art of organic synthesis will understand that the functionality present in various portions of the molecule should be achievable with the proposed reagents and reactions.Such restrictions on substituents compatible with the reaction conditions will be readily apparent to a person skilled in the art, and alternative methods must then be employed. This will sometimes require an assessment to modify the order of the synthesis steps or to select one particular process scheme over another to obtain a desired compound of the present invention. It will also be recognized that another major consideration when planning any synthetic route in this field is the judicious choice of the protecting group used to shield reactive functional groups present in the compounds described in the present invention. An authoritative reference describing the numerous alternatives to the qualified professional is Greene and Wuts (Protective Groups In Organic Synthesis, third edition, Wiley and Sons, 1999). Examples The preparation of compounds of formula (I), and intermediate products used in the preparation of compounds of formula (I), can be carried out using the procedures shown in the following examples and related procedures. The methods and conditions used in these examples, and the actual compounds prepared, are not intended to be limiting, but are meant to demonstrate how compounds of formula (I) can be prepared. The starting materials and reagents used in these examples, when not prepared by a procedure described herein, are generally commercially available or reported in the chemistry literature, or can be prepared using procedures described in the chemistry literature. Abbreviations Acetyl acyl Acetic acid (AcOH) ACN acetonitrile anhydrous. anhydrous aqueous Bn bencilo Boc-ditertbutyl dicarbonate anhydride Bu butilo Boc ter / -butoxi carb onilo CV Volumes of the column DCE dichloroethane DCM dichloromethane DIPEA diisopropylethylamine DMAP dimethylaminopyridine DMF dimethylformamide DMSO dimethyl sulfoxide EtOAc ethyl acetate And ethyl EtOH ethanol Et3N triethylamine Hor H2 hydrogen h, hoh hour (s) HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate hex hexane i iso HC1 hydrochloric acid HPLC high-pressure liquid chromatography IPA isopropyl alcohol Liquid chromatography (LC) CL-EM liquid chromatography-mass spectroscopy LiA1H4 lithium aluminum hydride molar M millimolar mM I insert myself MeOH methanol MHz megahertz min. minute(s) minutes minute(s) M+1 (M+H) + EM mass spectrometry not normal N NBS n-bromosuccinimide NCS n-chlorosuccinimide NIS n-iodosuccinimide nm nanometer nM nanomolar NMP A-methylpyrrolidinone Pd / C palladium on carbon PdCh (dppf) [1, 1-Z>A (diphenylphosphino)ferrocene]dichioroptodoadium (II) PET petroleum ether Phenyl Propyl PSI pounds per square inch Return time, holding time sat. saturated SFC supercritical fluid chromatography TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran Precatalyst XPhos chloro (2-dicyclohexylphosphino-2',4',6'-triisopropyl-l,l'-biphenyl)[2-(2'-amino-l,l'-biphenyl)]palladium(II) Analytical and preparative conditions for HPLC / MSCL Method A: Column: Acquity UPLC BEH C18, 3.0 x 50 mm, 1.7 µm particles; mobile phase A: 5:95 acetonitrile: water with 5 mM ammonium acetate; mobile phase B: 95:5 acetonitrile: water with 5 mM ammonium acetate; method: % of B: 0 min-20%: l.lmin -90%: 1.7 min-90%; flow: 0.7 ml / min. Method B: Kinetex XB-C18 (75 x 3 mm) 2.6 microns; Solvent A: Ammonium formate 10 mM in water: Acetonitrile (98:2); Mobile phase B: Ammonium formate 10 mM in water: Acetonitrile (2:98); Temperature: 50 °C; Gradient: 0-100% of B for 3 minutes; Flow rate: 1.1 ml / min; Detection: UV at 220 nm. Method C: Waters XBridge BEH C18 XP (50 x 2.1 mm) 2.5 pm; mobile phase A: 5:95 acetonitrile:water with 10 mM NH4OAc; mobile phase B: 95:5 acetonitrile:water with 10 mM NH4OAc; temperature: 50 °C; Gradient: 0-100% of B for 3 minutes; flow: 1.1 ml / min. Method D: Waters XBridge BEH C18 XP (50 x 2.1 mm) 2.5 pm; mobile phase A: 5:95 acetonitrile: water with 0.1% TFA; mobile phase B: 95:5 acetonitrile: water with 0.1% TFA; temperature: 50 °C; Gradient: 0-100% of B for 3 minutes; flow: 1.1 ml / min. Method E: Ascende Express Cl8 (50 x 2, 1 mm) 2, 7 pm; mobile phase A: 5:95 acetonitrile:water with 10 mM TMLOAc; mobile phase B: 95:5 acetonitrile:water with 10 mM NH40Ac; temperature: 50 °C; Gradient: 0-100% of B for 3 minutes; flow: 1, 1 ml / min. Method F: Ascende Express Cl8 (50 x 2, 1 mm) 2, 7 pm; mobile phase A: 5:95 acetonitrile:water with 0.1% TFA; mobile phase B: 95:5 acetonitrile:water with 0.1% TFA; temperature: 50 °C; Gradient: 0-100% of B for 3 minutes; flow: 1.1 ml / min. Method G: Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm), 1.7 micrometers; solvent A = 100% water with 0.05% TFA; solvent B = 100% acetonitrile with 0.05% TFA; gradient = 2-98% B for 1 minute, then a 0.5 minute hold at 98% B; flow rate: 0.8 ml / min; detection: UV at 220 nm. Method H: Column: ZORBAX SB AQ (4.6 x 50) mm, 3.5 microns, solvent A: acetonitrile (98:2); mobile phase B: Ammonium formate 10 mM in water:acetonitrile (2:98); temperature: 50 °C; Gradient: 0-100% of B for 3 minutes; flow rate: 1.1 ml / min; detection: UV at 220 nm. Method AA: Waters XBridge C18, 19 x 150 mm, 5 pm particles; Mobile phase A: Ammonium acetate 10 mM; Mobile phase B: Methanol; Gradient: 10-45% of B for 20 minutes, then a 5-minute hold at 100% of B; Flow: 20 ml / min. Method AB: Waters XBridge C18, 19 x 150 mm, 5 pm particles; mobile phase A: 0.1% trifluoroacetic acid; mobile phase B: acetonitrile; gradient: 5-25% of B for 25 minutes, then a 5-minute maintenance at 100% of B; flow: 15 ml / min. AC Method: Column: Bridge X C18 (250 X19, 5pm), mobile phase A: TFA 0.1% in water, mobile phase B: ACN, isocratic 0 / 10, 10 / 60, flow: 17 ml / min AD Method: Chiral SFC: Column: Lux Cellulose-4 (250 x 4, 6) mm; 5 pm, solvent, ACN (1:1) , co-solvent; NH4OH at 0, 2% in MeOH, 204 g-50.- 100 bar, 30 min, flow 20 ml / min. AF Method: Chiral SFC Conditions: Column: Luxcellulose-4 (250 X 21.5) mm, 5 pm, % CO2: 50%, % co-solvent: 50% NH4OH at 0.2% in MeOH + ACN (1:1), total flow: 70.0 g / min, Back pressure: 100 bar, temperature: 30 °C, UV: 290 nm. Examples 175, 178, 188-189 and 876 are provided for reference purposes only and are not part of the present invention. Example 1 tert-butyl 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamido)piperidine-1-carboxylate Intermediate product 1A: 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate A solution of methyl 4-bromo-1H-pyrazol-3-carboxylate (10.0 g, 48.8 mmol) in THF (150.00 mL) was reacted with NaH (2.341 g, 58.5 mmol) in portions at 0 °C. The reaction mixture was stirred for 30 min, then SEM-C1 (10.38 mL, 58.5 mmol) was added. The reaction mixture was stirred at 0 °C for 5 h. The reaction was stopped with water (30 mL). The reaction mixture was separated into two phases, and the aqueous phase was extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated to produce the crude compound. The crude compound was purified by ISCO using a 120 g silica column. The compound was eluted in 20% hexane EA, and the fractions were collected and concentrated to obtain methyl 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (13.95 g, 41.6 mmol, 85% yield) as an oil. CL-MS retention time: 1.63 min [A], MS (E+) m / z: 337.1 [M+2H]. Intermediate product 1B: 4-(prop-1-en-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-methylpyrazol-3-carboxylate A mixture of methyl 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (13.9 g, 41.5 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (23.38 ml, 124 mmol) and ribasic potassium phosphate (26.4 g, 124 mmol) was degassed in dioxane (150.00 ml) and water (50.0 ml) with nitrogen for 1 min. Then, PdC12 (dppf)-CH2C12 adduct (3.39 g, 4.15 mmol) was added and the reaction mixture was stirred at 90 °C for 16 h. The reaction mixture was cooled to room temperature and separated into two phases. The aqueous phase was extracted with DCM (2 x 50 ml) and the combined organic extracts were dried (Na2SO4) and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted in 15–20% hexane EA. The fractions were collected and concentrated to yield methyl 4-(prop-1-en-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (11.550 g, 39.0 mmol, 94% yield) as an oil. CL-MS retention time: 1.46 min [A], MS (E+) m / z: m / z = 297.5 [M+H]. Intermediate IC: 4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylatemethyl Pd-C (4.15 g, 39.0 mmol) was added to a solution of methyl 4-(prop-1-en-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (11.55 g, 39.0 mmol) in MeOH (120.00 mL) at room temperature. The mixture was stirred at room temperature in a hydrogen bladder for 3 h. The reaction mass was filtered through Celite, the filtrate was collected, concentrated, and vacuum dried to provide methyl 4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (11.5 g, 38.5 mmol, 99% yield) as an oil. CL-EM retention time: 1.56 min [A], EM (E+) m / z = 299.5 [M+H]. Intermediate ID: methyl 4-isopropyl-1H-pyrazole-3-carboxylate 4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (11.50 g, 38.5 mmol) was shaken in 4 M hydrochloric acid in dioxane (50.00 ml, 200 mmol) at 70 °C for 16 h. The reaction mass was concentrated, the residue was dissolved in DCM (50 ml), brought to a basic pH with 0.5 M NaOH, the two phases were separated, the aqueous phase was extracted with DCM (2 x 50 ml), the combined organic extracts were washed with water (50 ml) and brine (10 ml), dried (Na2SO4), and the combined organic extracts were concentrated and vacuum dried to provide methyl 4-isopropyl-1H-pyrazol-3-carboxylate (6.12 g, 36.4 mmol, 94% yield) as a whitish solid. CL-MS retention time: 0.89 min [A], MS (E+) m / z = 169.4 [M+H]. Intermediate product 1E: methyl 5-iodo-4-isopropyl-1H-pyrazole-3-carboxylate To a solution of methyl 4-isopropyl-1H-pyrazol-3-carboxylate (3.75 g, 22.30 mmol) in acetonitrile (150 mL) was added NIS (12.54 g, 55.7 mmol) at room temperature. The reaction mixture was stirred at 70 °C for 2 days. The reaction mass was concentrated, the residue was diluted with DCM, the precipitated solid was filtered and washed with DCM, and the filtrates were collected and concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted in 25% hexane EA, and the fractions were collected and concentrated to obtain methyl 5-iodo-4-isopropyl-1H-pyrazol-3-carboxylate (4.11 g, 13.98 mmol, 63% yield) as a whitish solid. CL-MS retention time: 1.68 min [A], MS (E+) m / z = 293.1 [MH]. Intermediate product F1: methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylate A mixture of methyl 5-iodo-4-isopropyl-1H-pyrazol-3-carboxylate (2.00 g, 6.80 mmol), 8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (2.64 g, 10.20 mmol), and tribasic potassium phosphate (4.33 g, 20.40 mmol) was degassed for 10 min in dioxane (30.0 ml) and water (10.0 ml). Then, PdCh(dppf)-CH2Q2 adduct (0.555 g, 0.680 mmol) was added, and the reaction mixture was degassed again for 2 min. The reaction mixture was stirred at 90 °C for 16 h. The reaction mixture was diluted with DCM (20 ml) and water (10 ml). The two phases were separated, the aqueous layer was extracted with 10% MeOH in DCM (2 x 30 ml), the combined organic extracts were dried (Na₂SO₄) and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 24 g silica column. The compound was eluted in EA, and the fractions were collected and concentrated to obtain methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylate (1.12 g, 3.74 mmol, 55% yield) as a whitish solid. LC-MS retention time: 0.92 min [G], MS (IEN): m / z = 300.5 [M+H]. The following intermediates were prepared according to the general procedure described in intermediate IF. Table 1 Intermediate product 1Q: 4-Isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylic acid A solution of methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylate (1.00 g, 3.34 mmol) in THF (10.00 ml) and MeOH (10.00 ml) was mixed with 1 M NaOH (10.02 ml, 10.02 mmol) at room temperature. The reaction mixture was stirred at 80 °C for 16 h. The reaction mass was concentrated to remove THF and MeOH, acidified using 0.5 M HCl, the precipitated solid was filtered, washed with water, and then vacuum dried to obtain 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylic acid (0.930 g, 3.26 mmol, 98% yield) as a whitish solid. Cl-MS retention time: 0.46 min [G], MS (IEN): m / z = 286.4 [M+H]. Example 1: 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamido) tert-butyl piperidin-1-carboxylate 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylic acid (0.500 g, 1.752 mmol) and tert-butyl 4-aminopiperidin-1-carboxylate (0.526 g, 2.63 mmol) were added to a solution of DCM (20.00 ml), TEA (3.00 ml, 21.52 mmol), and 1-propanephosphonic anhydride (5.00 ml, 8.40 mmol) at room temperature. The mixture was stirred at room temperature for 16 h. The reaction was stopped by adding water (10 ml). The two phases were separated, the aqueous layer was extracted with DCM (2 x 30 ml), the combined organic extracts were dried (Na2SO4) and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 24 g silica column. The compound was eluted in EA, and the fractions were collected and concentrated to yield tert-butyl 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamido)piperidine-1-carboxylate (0.610 g, 1.305 mmol, 74% yield) as a whitish solid. LC-MS retention time: 0.92 min [A], MS (ES): m / z = 468.6 [M+H]; 1H-NMR (400 MHz, CD3OD) ppm 8.72 (s, 1 H), 8.49 (s, 1 H), 7.54 (s, 1 H), 4.18-4.04 (m, 3 H), 3.0.- 2.88 (m, 2 H), 2.68 (s, 3 H), 1.9.- 1.91 (m, 2 H), 1.61-1.50 (m, 3 H), 1.48 (s, 9H), 1.34 (d, J = 7.2 Hz, 6 H). The following examples were prepared according to the general procedure described in example 1. Example 43 4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -N- (piperidin-4-yl) -1H-pyrazol-3-carboxamida A solution of 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamido)piperidin-1-carboxylate of tert-butyl (0.630 g, 1.347 mmol) in dioxane (5.00 mL) was reacted with 4 M hydrochloric acid in dioxane (5.00 mL, 20.00 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 h. The reaction mass was concentrated to provide the crude compound. The crude compound was ground with diethyl ether (2X10 mL) and then vacuum dried to provide 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (0.462 g, 1.257 mmol, 93% yield) as a white solid.CL-EM retention time: 0.92 min [G], EM (ES): m / z = 368.6 [M+H]; 1H NMR (400 MHz, CD3OD) ppm 8, 74 (s, 1 H) , 8, 49 (s, 1 H) , 7, 54 (s, 1 H) , 4, 16-4, 10 (m, 1 H) , 3, 46-3, 38 (m, 2 H) , 3, 37-3, 34 (m, 1 H), 3.15-3.06 (m, 2 H), 2.70 (s, 3 H), 2.23-2.12 (m, 2 H), 1.871.76 (m, 2 H), 1.34 (d, J = 7.2 Hz, 6 H). The following examples were prepared according to the general procedure described in example 43. Table 3 Example 69 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide solution was mixed with HCl (22 mg, 0.054 mmol) in MeOH (2.00 mL), 3,3,3-trifluoropropanal (18.31 mg, 0.163 mmol), and AcOH (0.1 mL, 1.747 mmol) at room temperature. The reaction mixture was stirred at room temperature for 6 h, sodium cyanoborohydride (17.11 mg, 0.272 mmol) was added, and the reaction mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC-MS purification using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to provide 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)-1H-pyrazol-3-carboxamide (17.2 mg, 0.037 mmol, 68% yield) as a pale solid.CL-EM retention time: 1,702 min [E], EM (ES) : m / z= 464, 2 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.75 (s, 1H) , 8.49 (s, 1H) , 7.54 (s, 1H) , 3.97-3.88 (m, 1H) , 2.99 (d, 7=12.0 Hz, 2H) , 2, 77-2, 59 (m, 4H) , 2, 53-2, 36 (m, 2H) , 2, 29 (t, 7=11, 0 Hz, 2H) , 2, 21, 93 (m, 2H) , 1, 78-1, 59 (m, 2H) , 1, 41-1, 20 (m, 6H) . The following examples were prepared according to the general procedure described in example 69. Table 4 Example 171 4-isopropyl-N-(1-(2-methoxyethyl)piperidin-4-yl)-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide To a solution of 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide, HCl (0.015 g, 0.037 mmol) and 1-bromo-2-methoxyethane (10.32 mg, 0.074 mmol) in THF (1.00 ml) and DMF solvent mixture (0.5 ml) DIPEA (0.1 ml, 0.573 mmol) was added at room temperature. The mixture was shaken 10 times at 90 °C for 4 h. The reaction mass was purified by preparative CL-EM purification using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to provide 4-isopropyl-N-(1-(2-methoxyethyl)piperidin-4-yl)-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (0.8 mg, 1.880 mol, 5% yield) as a pale solid.CL-EM retention time: 0.92 min [E], EM (ES): m / z = 426.1 [M+H]; JHNMR (400 MHz, methanol-d4) ppm 8.74 (s, 1H), 8.50 (s, 1H), 7.54 (s, 1H), 4.14 (sa, 1H), 3.81-3.62 (m, 4H), 3.48-3.41 (m, 4H) , 3, 37 (d, J=6, 5 ​​Hz, 2H) , 3, 26-3, 14 (m, 2H) , 2, 78-2, 61 (m, 3H) , 2, 29 (d, J=12, 5 Hz, 2H) , 2, 17 (sa, 1H) , 2, 02-1, 82 (m, 2H), 1, 37-1, 32 (m, 6H) . The following examples were prepared according to the general procedure 10 described in example 171. Table 5 Example 174 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-(1-(methylsulfonyl)propan-2-yl)piperidin-4-yl)-1H-pyrazole-3-carboxamide K2CO3 (0.018 g, 0.134 mmol) was added at room temperature to a solution of 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide, HCl (0.018 g, 0.045 mmol), 2-chloro-1-(methylsulfonyl)propane (0.014 g, 0.089 mmol), and DIPEA (0.1 mL, 0.573 mmol) in dioxane (1.00 mL). The reaction mixture was stirred at 110 °C for 16 h. The reaction mixture was filtered and concentrated to give the crude compound. The crude compound was purified by preparative LC-MS using the AB method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to provide 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-(1-(methylsulfonyl)propan-2-yl)piperidin-4-yl)-1H-pyrazol-3-carboxamide (4.3 mg, 8.53 mol, 19% yield) as a pale solid. LC-MS retention time: 1.515 min [E], MS (ES): m / z = 488.1 [M+H]; 1H-NMR (400 MHz, CD3OD) ppm 8.74 (s, 1 H) , 8.49 (s, 1 H) , 7.54 (s, 1 H) , 3.91-3.84 (m, 1 H) , 3.60-3.52 (m, 1 H) , 3.41-3.38 (m, 1 H) , 2.96 (s, 3 H) , 2.98-2.82 (m, 3 H) , 2.70 (s, 3 H) , 2.61-2.58 (m, l H) , 2.42-2.38 (m, 1 H) , 2.06-1.95 (m, 3 H) , 1.70-1.58 (m, 2 H) , 1.33 (d, J = 6.8 Hz, 6 H) , 1.20 (d, J = 6.8 Hz, 3 H) . Ejemplo 175 (referencia) 4-isopropil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1- (2, 2, 2-trifluoroetil) -N- (1- (2, 2, 2-trifluoroetil) piperidin-4-il) -1H-pirazol-3-carboxamida To a solution of 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (0.021 g, 0.057 mmol) and 2,2,2-trifluoroethyl trifluoromethane sulfonate (0.027 g, 0.114 mmol) in DMF (1.500 ml) were added TEA (0.2 ml, 1.435 mmol) and CS2CO3 (0.037 g, 0.114 mmol) at room temperature. The reaction mixture was stirred at 90 °C for 4 h. The reaction mixture was filtered, the filtrate was purified by preparative CL-EM purification, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to provide 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-(2,2,2-trifluoroethyl)-N-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazol-3-carboxamide (9.6 mg, 0.018 mmol, 31% yield) as a pale solid.Retention time of CL-EM: 1, 873 min [E], EM (ES): m / z= 532, 2 [M+H]; 1H-RMN (400 MHz, methanol-d4) ppm 8, 76 (s, 1H), 8, 53 (s, 1H), 7, 42 (s, 1H), 4, 05-3, 83 (m, 1H), 3, 40-3, 34 (m, 2H), 3, 28-3, 12 (m, 3H) , 2, 80-2, 71 (m, 2H) , 2, 70 (s, 3H) , 2, 03 (d, 7=14, 1 Hz, 2H) , 1, 87-1, 70 (m, 2H) , 1, 35-1, 26 (m, 1H), 1, 21 (d, J=7, 0 Hz, 6H). Example 176 N- (1- (2- (dimetilamino) -2-oxoetil) piperidin-4-il) -4-isopropil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1H-pirazol-3-carboxamida To a solution of 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (0.015 g, 0.041 mmol) in THF (1.00 ml) and DMF solvent mixture (0.50 ml) were added TEA (0.2 ml, 1.435 mmol) and 2-chloro-N,N-dimethylacetamide (9.92 mg, 0.082 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC-MS purification using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to provide N-(1-(2-(dimethylamino)-2-oxoethyl)piperidin-4-yl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (4.8 mg, 10.08 mol, 25% yield) as a pale solid.CL-EM retention time: 0.92 min [E], EM (ES): m / z = 453.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.74 (s, 1H), 8.49 (s, 1H), 7.54 (s, 1H), 4.95 (s, 1H), 4.00-3.85 (m, 1H), 3.81 (s, 1H), 3, 16-3, 09 (m, 3H) , 3, 08-2, 99 (m, 2H) , 2, 97 (s, 3H) , 2, 762, 64 (m, 3H) , 2, 36 (s, 2H) , 2, 00 (d, J=10, 5 Hz, 2H) , 1.85-1.65 (m, 2H), 1, 44-1, 26 (m, 7H) . The following example was prepared in accordance with the general procedure described in example 176. Table 6 Example 178 (reference) N-(1-isopropylpiperidin-4-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide Intermediate product 178A: methyl 4-bromo-5-iodo-1H-pyrazole-3-carboxylate To a stirred solution of methyl 4-bromo-1H-pyrazol-3-carboxylate (1 g, 4.88 mmol) in acetonitrile (50 mL) NBS (5.3 mmol) was added at room temperature. The reaction mixture was stirred at 100 °C for 16 h. The reaction mass was diluted with ethyl acetate and washed with water and brine, dried (Na₂SO₄), and concentrated to obtain the crude mass. The crude mass was purified by ISCO using a 24 g silica column. The compound was eluted in 80% EA in hexanes. The fractions were collected and concentrated to yield methyl 4-bromo-5-iodo-1H-pyrazol-3-carboxylate (360 mg, 1.088 mmol, 22.30% yield) as a whitish solid. Clem retention time 0.98 min [B], EM (E-) m / z 0.332.9 [M+H]. Intermediate product 178B: methyl 4-bromo-5-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate NaH (87 mg, 3.63 mmol) was added to a stirred solution of methyl 4-bromo-5-iodo-1H-pyrazol-3-carboxylate (600 mg, 1.813 mmol) in THF at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h. Then, 2-(trimethylsilyl)ethoxymethyl chloride (363 mg, 2.176 mmol) was added at 0 °C, and the reaction mixture was stirred at room temperature for 3 h. The reaction was stopped with ice water. The reaction mixture was extracted with EtOAc, washed with brine, dried over sodium sulfate, and concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 24 g silica column. The fractions were collected and concentrated to yield methyl 4-bromo-5-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (800 mg, 1,735 mmol, 96% yield) as a whitish solid. Cl-MS retention time: 1.61 min [B], MS (E-) m / z: 463.1 [M+H]. Intermediate product 178C: 4-bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-ethyl pyrazol-3-carboxylate Ethyl 4-bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (800 mg, 1.665 mmol, 79% yield) was prepared according to the general process described for intermediate IF using ethyl 4-bromo-5-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (1 g, 2.104 mmol) as the starting intermediate. CL-EM retention time: 1.92 min [B], EM (E-) m / z: 482.3 [M+H]. Intermediate product 178D: 4-Bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylic acid 4-Bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylic acid (130 mg, 0.287 mmol, 58.3% yield) was prepared according to the general process described in intermediate product IQ using methyl 4-bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (230 mg, 0.493 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-EM retention time 0.91 min [A], EM (E-) m / z: 454.2 [M+H]. Intermediate product 178E: 4-(4-bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H pyrazol-3-carboxamido) tert-butyl piperidin-1-carboxylate 4-(4-bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido) tert-butyl piperidin-1-carboxylate (160 mg, 0.252 mmol, 52% yield) was prepared according to the procedure described in intermediate product 1H using 4-bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylic acid as a starting intermediate. CL-EM retention time 1, 56 min [A], EM (E-) m / z: 636, 4 [M+H]. Intermediate product 178F: 4-(5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido) tert-butyl piperidin-1-carboxylate Pd / C (26.8 mg, 0.252 mmol) was added at room temperature to a stirred solution of 4-(4-bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido)piperidin-1-carboxylate tert-butyl (160 mg, 0.252 mmol) in MeOH (15 ml). The reaction mixture was stirred under hydrogen gas bladder pressure for 16 h. The reaction mass was filtered through a Celite bed, washed with MeOH, and concentrated to yield tert-butyl 4-(5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido)piperidine-1-carboxylate (100 mg, 0.180 mmol, 71% yield) as a brown liquid. CL-EM retention time: 1.94 min [A], EM (E-) m / z: 556.5 [M+H]. Intermediate 178G: 5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide To a stirred solution of tert-butyl 4-(5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido)piperidin-1-carboxylate (120 mg, 0.216 mmol) in DCM (10 ml) TFA (0.017 ml, 0.216 mmol) was added at room temperature. The reaction mixture was stirred at the same temperature for 3 h. The reaction mass was concentrated to obtain the crude compound. The crude compound was purified by preparative LC-MS using the AB method. The fractions containing the compound were collected and dried by centrifugal evaporation to yield 5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (4.6 mg, 0.430 mmol, 12% yield) as a pale solid. LC-MS retention time 0.635 min [D], MS (E^ m / z: 326.1 (M+H) .1H-RMN (400 MHz, DMSO-d6) ppm 9, 19 (s, 1H) , 8, 50 (s, 1H) , 8, 42-8, 28 (m, 1H) , 7, 96 (s, 1H) , 7, 36 (s, 1H) , 3, 97 (d, J=7, 8Hz, 1H), 3, 17 (d, 7= 11, 7Hz, 2H), 2, 85-2, 74 (m, 2H), 2, 61 (s, 3H), 1, 95-1, 83 (m, 3H), 1, 69-1, 55 (m, 2H). Ejemplo 178: N-(1-isopropylpiperidin-4-il)-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il)-1H-pirazol e-3-carboxamida To a stirred solution of 5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (30 mg, 0.092 mmol) in MeOH (3 mL) were added propan-2-one (5.36 mg, 0.092 mmol) and acetic acid (5.28 mL, 0.092 mmol). The reaction mixture was stirred at room temperature for 16 h. Then, NaCNBH3 (5.79 mg, 0.092 mmol) was added and the reaction mixture was stirred at room temperature for 2 h. The reaction mass was concentrated to give the crude compound. The crude compound was purified by preparative LC-MS using the AA method, the fractions containing the compound were collected and dried by centrifugal evaporation to provide N-(1-isopropylpiperidin-4-yl)-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (1.1 mg, 0.252 mmol, 12% yield) as an off-white solid.Retention time of CL-EM 0, 694 min [E], EM (E-) m / z: 368, 2 (M+H) ; 1H RMN (400 MHz, DMSO-d6) ppm 13, 42 (s, 1H) , 8, 90 (s, 1H) , 8, 55 (s, 1H) , 7, 90 (d, J= 8, 1Hz, 1H) , 7, 62 (s, 1H) , 3, 76 (sa, 1H) , 2, 88-2, 73 (m, 4H) , 2, 63 (s, 3H) , 2, 23 (s, 3H) , 2, 09 (d, J=5, 6 Hz, 2H) , 1, 91 (s, 2H) , 1, 83-1, 71 (m, 2H) , 1, 711, 55 (m, 2H), 1, 24 (m, 3H), 1, 11 (t, J= 7, 3Hz, 3H). Example 179 N-(1-isopropylpiperidin-4-il)-4-metil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il)-1H-pirazol-3-carboxamida Producto INTERMEDIO 179A: 4- (4-metil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1- ( (2- (trimetilsil) etoxi) metil) -1H-pirazol-3-carboxamido) piperidin-1-carboxilato de terc-butilo A stirred solution of 4-(4-aomo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido)piperidin-1-carboxylate tert-butyl (100 mg, 0.158 mmol), tribasic potassium phosphate (100 mg, 0.473 mmol) and methylboronic acid (18.86 mg, 0.315 mmol) in THF (50 ml) degassed with N2 for 10 min was added. PdC12 (dppf)-CH2C12 adduct (12.87 mg, 0.016 mmol) was added to the reaction mixture. The reaction mixture was degassed for 10 min. The reaction mixture was stirred at 80 °C for 16 h. The reaction mass was diluted with ice water, extracted with EtOAc, washed with brine, dried over sodium sulfate, and concentrated to provide the crude compound.The crude compound was purified by ISCO using a 12 g silica column, eluted in 65% hexane EA, and the fractions containing the compound were collected and concentrated to give tert-butyl piperidin-1-carboxylate 4-(4-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido) (60 mg, 0.252 mmol, 52% yield) as an oil. CL-EM retention time 2.06 min [B], EM (E-) m / z: 570.6 (M+H). Intermediate 179B: 4-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide 4-Methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (30 mg, 0.252 mmol, 49% yield) was prepared according to the general process described in Example 43 using 4-(4-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamide) tert-butyl piperidin-1-carboxylate (100 mg, 0.176 mmol) as a starting intermediate. CL-EM retention time 0.64 min [E], EM (R) m / z: 340.2 [M+H]; 1HRMN (400 MHz, DMSO-d6) ppm 13.51 (s, 1H) , 8.99 (s, 1H) , 8.24 (d, J=7.8 Hz, 1H) , 7.67 (s, 1H) , 7.14 (s, 1H) , 7.01 (s, 1H) , 4.O7 (s, 1H) , 3.03 (s, 2H) , 2.94 (d, .7=6.8 Hz, 2H) , 2.67-2.55 (m, 3H) , 1.96 (d, J=13.4 Hz, 2H) , 1.79 (d, ^=11.7 Hz, 1H), 1, 24 (s, 1H) , 1, 17 (t, 7=7, 3 Hz, 3H) . Example 179: N-(1-isopropylpiperidin-4-yl)-4-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide N-(1-isopropylpiperidin-4-yl)-4-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (8.2 mg, 0.252 mmol, 22% yield) was prepared according to the general process described in Example 69 using 4-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (30 mg, 0.088 mmol) as the starting intermediate. CL-EM retention time 0.798 min [E], EM (E-) m / z-. 382.2 (M+H) ; 1H-NMR (400 MHz, DMSO-d6) ppm 13.53 (s, 1H) , 9.01 (s, 1H) , 8.57 (s, 1H) , 8.32 (d, J=8, 3 Hz, 1H) , 7.12 (s, 1H) , 6.99 (s, 1H) , 6, 56 (s, 1H) , 4, 06 (s, 3H) , 3, 18-3, 05 (m, 2H) , 2, 99 (s, 1H) , 2, 93 (s, 1H) , 2, 63 (s, 3H) , 2, 11 (d, J=19, 6 Hz, 1H), 2, 02 (s, 2H) , 1.88 (d, J=12.7 Hz, 3H) , 1.35-1.21 (m, 6H) , 1.21-1.09 (m, 2H) . The following example was prepared in accordance with the general procedure described in example 179. Table 7 Example 181 4-ethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)-1H-pyrazole-3-carboxamide Intermediate product 181A: 4-(5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-4-vinyl-1H-pyrazol-3-carboxamido) tert-butyl piperidin-1-carboxylate 4-(5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-4-vinyl-1H-pyrazol-3-carboxamido)piperidin-1-carboxylate of tert-butyl was prepared according to the process described in intermediate 1B, using 4-(4-bromo-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido)piperidin-1-carboxylate of tert-butyl (300 mg, as a starting intermediate. CL-EM retention time 2.07 min [C], EM (E-) m / z: 582, 6 [M+H]. Intermediate product 18IB: 4-(4-ethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido) tert-butyl piperidin-1-carboxylate Pd / C (36.6 mg, 0.344 mmol) was added to a stirred solution of tert-butyl 4-(5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-4-vinyl-1H-pyrazol-3-carboxamido)piperidin-1-carboxylate (200 mg, 0.344 mmol) in MeOH (125 ml) at room temperature. The reaction mixture was stirred in hydrogen under bladder pressure for 16 h. The reaction mass was filtered through a celite bed, washed with MeOH and concentrated to provide 4-(4-ethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido)piperidin-1-tert-butyl carboxylate (160 mg, 0.430 mmol, 68% yield) as an oil. CL-EM retention time 1, 53 min [A], EM (E-) m / z: 467, 5 [M+H]. Intermediate 181C: 4-ethyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide Ethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (13.1 mg, 0.430 mmol, 18% yield) was prepared according to the procedure described in Example 43 using tert-butyl 4-(4-ethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido)piperidin-1-carboxylate (120 mg, 0.206 mmol) as a starting intermediate. CL-EM retention time 0.807 min [A], EM (E-) m / z: 354.2 (M+H) ; 1H-NMR (400 MHz, DMSO-d6) ppm d 13, 46 (s a., 1H) , 8, 92 (s a., 1H) , 8, 32 (s a., 1H) , 8, 25 (d, J=7, 8 Hz, 1H) , 7, 62 (s a., 1H) , 7, 00 (s, 1H) , 4, 07 (dd, J=7, 6, 3, 7 Hz, 1H) , 3, 32 (s a., 3H) , 3, 092, 99 (m, 2H) , 2, 99-2, 89 (m, 1H) , 2, 68-2, 58 (m, 3H) , 1, 97 (d, J= 11.7Hz, 2H), 1.86-1.66 (m, 2H), 1.21-1.03 (m, 3H). Example 181: 4-ethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)-1H-pyrazol-3-carboxamide 4-ethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)-1H-pyrazol-3-carboxamide (11.5 mg, 37% yield) was prepared according to the general procedure described in Example 69 using 4-ethyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazol-3-carboxamide (30 mg, 0, 085 mmol) as an intermediate starting product. CL-EM retention time 0.859 min [C], EM (E-) m / z: 368.2 (M+H) ; 1H-NMR (400 MHz, DMSO-d6) ppm 13.42 (s a., 1H) , 8.90 (s, 1H) , 8.55 (s, 1H) , 7.90 (d, J= 8, 1Hz, 1H) , 7.62 (s, 1H) , 3.76 (s a., 1H) , 2, 88-2, 73 (m, 4H) , 2, 63 (s, 3H) , 2, 23 (s, 3H) , 2, 09 (d, J= 5, 6Hz, 2H) , 1, 91 (s, 2H) , 1, 83-1, 71 (m, 2H) , 1, 71-1, 55 (m, 2H) , 1, 24 (s, 1H) , 1, 11 (t, J= 7, 3Hz, 3H) . The following example was prepared in accordance with the general procedure described in example 181. Table 8 Example 183 2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N- (1-isopropylpiperidin-4-yl) -2-oxoacetamide Intermediate product 183 A: 2-formyl-3-methylbutanenitrile LDA (2 M, 391 mL, 782 mmol) was added dropwise at -78 °C to a solution of 3-methylbutanenitrile (50.0 g, 601 mmol) in THF (1000 mL). The reaction mixture was stirred for 20 min, and then a solution of ethyl formate (66.8 g, 902 mmol) in THF (200 mL) was added. The reaction mixture was stirred for an additional 1 h at the same temperature, then cooled to room temperature and stirred at room temperature for 16 h. The reaction was stopped with saturated NH₄Cl. The mixture was stirred for 10 min, and the volatiles were evaporated. The residue was dissolved with excess EA, washed with water and brine, dried (Na₂SO₄), and concentrated to provide crude 2-formyl-3-methylbutanenitrile (55 g, 495 mmol, 82% yield) as an oil. CL-EM retention time: 0.77 min [A], EM (E-) m / z: 110.2 [MH]. Intermediate 183B: 4-isopropyl-1H-pyrazole-3-amine Hydrazine (38.8 mL, 1237 mmol) and acetic acid (70.8 mL, 1237 mmol) were added to a solution of 2-formyl-3-methylbutanenitrile (55.0 g, 495 mmol) in ethanol (600 mL) at room temperature. The mixture was stirred at 100 °C for 16 h. The reaction mixture was cooled to room temperature. The volatiles were evaporated. The residue was diluted with saturated NaHCO₃ and extracted with chloroform (3 x 500 mL). The combined organic phase was washed with water and brine, dried over sodium sulfate, and concentrated to give crude 4-isopropyl-1H-pyrazol-3-amine (45.0 g, 359 mmol, 72% yield) as a brown semisolid. CL-EM retention time: 0.710 min [B], EM (E+) m / z'.126, 1 [M+H]. Intermediate 183C: 3-bromo-4-isopropyl-1H-pyrazole A mixture of 4-isopropyl-1H-pyrazol-3-amine (15.0 g, 120 mmol) and p-toluenesulfonic acid monohydrate (34.2 g, 180 mmol) in acetonitrile (250 mL) was reacted with isoamyl nitrite (24.20 mL, 180 mmol), copper(II) bromide (26.8 g, 120 mmol), and tetrabutylammonium bromide (77 g, 240 mmol) at 10 °C. The mixture was stirred at room temperature for 2 h. The reaction was stopped with cold water. The reaction mixture was extracted with ethyl acetate (3 x 500 mL), the combined organic phase was washed with water and brine, dried over sodium sulfate, and concentrated. To obtain the raw material, it was purified by ISCO using a silica column. The compound was eluted with 30%–90% ethyl acetate and petroleum ether. The fractions were collected and concentrated to yield 3-bromo-4-isopropyl-1H-pyrazole (14.0 g, 74.1 mmol, 62% yield) as a light brown liquid. CL-MS retention time: 1.10 min [A], MS (E+) m / z: 191.3 [M+2H]. Intermediate 183D: 3-bromo-5-iodo-4-isopropyl-1H-pyrazole To a solution of 3-bromo-4-isopropyl-1H-pyrazole (14.0 g, 74.1 mmol) in acetonitrile (350 mL) was added NIS (33.3 g, 148 mmol) at room temperature. The reaction mixture was stirred at 80 °C for 16 h. The volatiles were evaporated. The residue was diluted with excess DCM, washed with water and brine, dried over sodium sulfate, and concentrated to give the crude compound. The crude compound was purified by ISCO using a 120 g silica column. The compound was eluted with 40–50% ethyl acetate in petroleum ether, the fractions were collected and concentrated to give 3-bromo-5-iodo-4-isopropyl-1H-pyrazole (12.0 g, 38.1 mmol, 51% yield) as a light brown solid. Cl-MS retention time: 1.26 min [A], MS (E+) m / z: 317.2 [M+2H]. Intermediate 183E: 3-bromo-5-iodo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole NaH (7.62 g, 191 mmol) was added to a solution of 3-bromo-5-iodo-4-isopropyl-1H-pyrazole (40.0 g, 127 mmol) in THF (600 mL) at 0 °C. The reaction mixture was stirred for 50 min. SEM-C1 (31.8 g, 191 mmol) was then added, and the reaction mixture was stirred at room temperature for 16 h. The reaction was stopped with saturated NH4Cl. The volatiles were evaporated, and the residue was diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated to give the crude compound. The crude compound was purified by ISCO using a 120 g silica column. The compound was eluted with 25–30% ethyl acetate in petroleum ether. The fractions were collected and concentrated to yield 3-bromo-5-iodo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (30.0 g, 67.4 mmol, 53% yield) as a light brown liquid. CL-MS retention time: 4.30 min [B] MS (E+) m / z: 447.0 [M+2H]. Intermediate 183F: 6-(3-bromo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine 6-(3-bromo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (12.2 g, 27.1 mmol, 86% yield) was prepared according to the general procedure described in the intermediate IF using 3-bromo-5-iodo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (14 g, 31.4 mmol) and 8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (9.78 g, 37.7 mmol) as an intermediate of Starting material to provide the title compound as a gummy solid. CL-EM retention time: 1.72 min [A] EM (E+) m / z: 452.0 [M+2H]. Intermediate 183G: 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-2-oxoacetate of ethyl To a solution of 6-(3-bromo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.070 g, 0.155 mmol) in THF (3.00 mL) 2.5 M nBuLi in hexanes (0.093 mL, 0.233 mmol) was added at -78 °C. The reaction mixture was stirred at the same temperature for 45 min. To a solution of diethyl oxalate (0.066 mL, 0.482 mmol) in THF (3.00 mL) the above reaction mixture was added dropwise at -78 °C, with stirring at the same temperature for 1 h. The reaction was stopped by adding water. The mixture was extracted with EtOAc (2 x 20 ml), the combined organic extracts were dried (Na2SO4) and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 12 g silica column, eluted in 30% hexane EA, and the fractions were collected and concentrated to give ethyl 2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-2-oxoacetate as a gummy solid. Cl-MS retention time: 1.60 min [A], MS (IEN): m / z = 472.6 [M+H]. Intermediate 183H: 2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole To a solution of ethyl 2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-2-oxoacetate (0.060 g, 0.127 mmol) in THF (1.00 mL), a solvent mixture of MeOH (0.500 mL) and water (0.500 mL), LiOH (0.030 g, 1.272 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated by removing MeOH and THF. The residue was diluted with water (5 mL) and washed with EtOAc (1 x 10 mL). The aqueous phase was brought to acidic pH with 5% HCl and extracted with 10% MeOH in DCM (2 x 20 ml). The combined organic extracts were dried (Na2SO4) and concentrated to provide crude 2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-2-oxoacetic acid (0.042 g, 0.095 mmol, 74% yield) as a gummy solid.CL-EM retention time: 0.88 min [A], EM (IEN) : m / z= 444.4 [M+H]. Intermediate 18I: 2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1- ( (2- (trimethylsilyl) ethoxy) methyl) -1H-pyrazol-3-yl) -N-(1-isopropyl-4-yl) -2-oxoacetamide To a solution of 2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-2-oxoacetic acid (0.042 g, 0.095 mmol) and 1-isopropylpiperidin-4-amine (0.013 g, 0.095 mmol) in DMF, TEA (0.013 ml, 0.095 mmol) and HATU (0.036 g, 0.095 mmol) were added at room temperature. The reaction mixture was stirred at the same temperature for 1 h. The reaction was stopped by adding water. The reaction mixture was extracted with 10% MeOH in DCM (2 x 20 mL), the combined organic extracts were dried (Na₂SO₄), and concentrated to obtain crude 2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-N-(1-isopropylpiperidin-4-yl)-2-oxoacetamide (0.045 g, 0.079 mmol, 84% yield) as a gummy solid. CL-MS retention time: 1.27 min [A], MS (IEN): m / z = 568.6 [M+H]. Example 183: 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(1-isopropylpiperidin-4-yl)-2-oxoacetamida To a solution of 2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-N-(1-isopropylpiperidin-4-yl)-2-oxoacetamide (0.039 g, 0.068 mmol) in dioxane (0.500 mL) 4 M hydrochloric acid in dioxane (1.00 mL, 4.00 mmol) was added at room temperature. The reaction mixture was stirred at 70 °C for 16 h. The reaction mass was purified by preparative LC-MS using the AB method. After purification by preparative LC-MS, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(l-isopropylpiperidin-4-yl)-2-oxoacetamide, HCl (0.0027 g, 5.25 mol, 8% yield) as a pale solid. LC-MS retention time: 1.285 min [F], MS (ES): m / z = 438.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.75 (s, 1H), 8.49 (s, 1H), 7.58 (s, 1H), 4.02-3.95 (m, 1H), 3.213.13 (m, 2H), 2.84-2.70 (m, 2H), 2.71 (s, 3H), 2.21-2.10 (m, 2H), 1.84-1.75 (m, 2H), 1.33 (d, J = 7.2 Hz, 6H), 1.24 (d, J = 6.8 Hz, 6H). Example 184 1- (4-isopropil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1H-pirazol-3-il) -N, N-dimetil metanamina Product intermedio 184A: 4-isopropil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il)-1H-pirazol-3-carbaldehído To a solution of methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylate (0.25 g, 0.835 mmol) in THF (10 ml) at -10 °C, LiAlH4 (0.383 ml, 0.919 mmol) was added dropwise, stirred at the same temperature for 30 min, and allowed to stand at room temperature for 15 min. The reaction mass was inactivated with water (5 ml) and extracted with EtOAc (2 x 50 ml). The separated organic layer was dried over sodium sulfate, filtered, and concentrated to obtain the crude product. The crude compound was purified by combiflash using a 24 g silica column, eluting with 2-6% MeOH / CHCh. The fractions were collected and concentrated to obtain 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carbaldehyde (0.1 g, 0.282 mmol, 34% yield) as a yellow solid. Cl-EM 1.69 min [B], EM (E-) m / z: 270, 2 [M+H].Example 184: 1-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethylmethanamine. To a solution of 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carbaldehyde (0.025 g, 0.093 mmol) in MeOH (3 ml) TEA (0.013 ml, 0.093 mmol) was added, followed by dimethylamine (4.19 mg, 0.093 mmol) and then acetic acid (5.31 ul, 0.093 mmol) drop by drop. The resulting light yellow solution was stirred in nitrogen at 25 °C for 12 h. After this, sodium cyanoborohydride (0.018 g, 0.278 mmol) was added and stirring continued at the same temperature for 6 h. The reaction mass was diluted with water (5 ml), extracted with EtOAc (3X10 ml), the separated organic phase was dried over sodium sulfate, filtered and concentrated to obtain the crude compound.The crude sample was purified by preparative LC-MS using method AB. The fractions were collected and concentrated to obtain 1-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethylmethanamine (5.1 mg, 0.017 mmol, 18% yield) as a pale yellow solid. LC-MS 0.97 min [E], MS (E-) m / z: 299.2 [M+H]; 1H-NMR (400 MHz, DMSO-d6) 12.94 (s, 1H) , 8.75 (sa, 1H) , 8.51 (sa, 1H) , 7.55 (sa, 1H) , 4.14-4.06 (m, 1H) , 3.17 (d, J=4.9 Hz, 3H) , 3.03 (dt, J=14, 3.7, 3 Hz, 1H) , 2.60 (s, 3H) , 2.33 (d, J=2.0 Hz, 3H) , 2.17-2.00 (m, 1H) , 1.22 (d, J=7, 1 Hz, 6H). The following examples were prepared according to the general procedure used to prepare example 184. Table 9 Examples 188 and 189 (reference) 4-isopropyl-N-(1-isopropylpiperidin-4-yl)-1-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazolecarboxamide Producto intermedio 188A: 4-isopropyl-1-metil-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-carboxilato de metilo To a solution of methyl 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylate (0.201 g, 0.672 mmol) in a solvent mixture of acetonitrile (12.00 ml) and DMF (1.5 ml) CS2CO3 (2.188 g, 6.72 mmol) and Mel (0.210 ml, 3.36 mmol) were added at room temperature, then the mixture was stirred at the same temperature for 1 h. The reaction mass was filtered through a Celite bed, washed with EtOAc, and the filtrate was concentrated to obtain the crude compound. The raw material was purified by ISCO using a 24 g silica column. The regioisomer compound mixture was eluted in 4% MeOH in CHCh, the fractions were collected and concentrated to obtain methyl 4-isopropyl-1-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylate (0.245 g, 0.782 mmol, 93% yield) as a whitish solid. Cl-MS retention time: 0.98 and 1.14 min [A], MS (IEN): m / z = 314.5 [M+H]. Intermediate product 188B: 4-Isopropyl-1-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylic acid A solution of methyl 4-isopropyl-1-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylate (0.243 g, 0.775 mmol) in THF (2.00 ml) and MeOH (2.00 ml) was given IM NaOH (1.551 ml, 1.551 mmol) at room temperature, then the mixture was stirred at 80 °C for 16 h. The reaction mass was concentrated, the residue was diluted with water (2 ml), then acidified using 0.5 N aqueous HCl, the precipitated solid was filtered, washed with water and dried under vacuum to obtain 4-isopropyl-1-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylic acid (0.114 g, 0.381 mmol, 49% yield) as a whitish solid (mixture of regioisomers). CL-MS retention time: 0.40 min [A], MS (IEN): m / z = 300.4 [M+H]. Examples 188 and 189 To a solution of 4-isopropyl-1-methyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxylic acid (0.120 g, 0.401 mmol) in DMF, TEA (0.168 mL, 1.203 mmol) and HATU (0.229 g, 0.601 mmol) were added at room temperature. The mixture was stirred at the same temperature for 16 h. The reaction mass was purified by preparative LC-MS using the AA method to separate the two isomers. After purification, the fractions containing the products were collected, combined, and dried using a Genevac centrifugal evaporator to provide Examples 188 and 189 Example 188: (0.1055 g, 0.249 mmol, 62% yield) as a blank solid. CL-MS retention time: 0.90 min [A], MS (ES): m / z = 424.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.65 (s, 1H), 8.38 (s, 1H), 7.34 (s, 1H), 4.02-3.98 (m, 1H), 3.63 (s, 3H), 3.51-3.42 (m, 2H) , 3, 18-3, 10 (m, 2H) , 2, 59 (s, 3H) , 2, 26-2, 18 (m, 2H) , 1, 88-1, 79 (m, 2H) , 1, 30 (d, J = 6, 8 Hz, 6H) , 1, 11 (d, J = 7, 2Hz, 6H) . Example 189: (0.0313 g, 0.072 mmol, 18% yield) as a blank solid. CL-MS retention time: 1.098 min [A], MS (ES): m / z = 424.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.67 (s, 1H), 8.46 (s, 1H), 7.63 (s, 1H), 4.22-4.11 (m, 1H), 3.90 (s, 3H), 3.573.50 (m, 2H) , 3.26-3.18 (m, 2H) , 2.66 (s, 3H) , 2.40-2.25 (m, 2H) , 1.91-1.83 (m, 2H) , 1.38 (d, J = 6.8 Hz, 6H) , 1.28 (d, J = 7, 2Hz, 6H) . Example 190 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxamide Intermediate product 190A: 4,4,4-trifluorobutanenitrile To a stirred solution of 4,4,4-trifluorobutanal (4 g, 31.7 mmol) in water (20 ml) was added hydroxylaminosulfonic acid (3.95 g, 34.9 mmol) in water (20 ml) stirred at room temperature for 16 h. The water-diluted reaction mass extracted with DCM was dried over sodium sulfate and concentrated to obtain 4,4,4-trifluorobutanenitrile (2.6 g, 21.12 mmol, 66% yield) as an oil. Intermediate product 190B: methyl 4-bromo-5-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate LDA (21.12 mL, 21.12 mmol) was added to a stirred solution of 4,4,4-trifluorobutanenitrile (2.6 g, 21.12 mmol) in THF (10 mL) at 0 °C, stirred for 5 min, then ethyl formate (1.565 g, 21.12 mmol) was added, and the mixture was stirred at room temperature for 16 h. The reaction mass was inactivated with 1 N HCl, extracted with EtOAc, dried over sodium sulfate, and concentrated to obtain 4,4,4-trifluoro-2-formylbutanenitrile (2.5 g, 16.55 mmol, 78% yield) as a brown oil. Intermediate product 190C: 4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-amine Hydrazine (1.298 mL, 41.4 mmol) and acetic acid (5 mL) were added to a stirred solution of 4,4,4-trifluoro-2-formylbutanenitrile (2.5 g, 16.55 mmol) in EtOH (15 mL), then stirred at 100 °C for 16 h. The reaction mass was concentrated; the residue was diluted with DCM, washed with saturated NaHCO3 solution, and the aqueous phase was extracted with DCM. The combined organic extracts were dried (Na2SO4) and concentrated to obtain 4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-amine (2.2 g, 13.32 mmol, 81% yield) as a brown liquid. CL-EM retention time 0.67 min [A], EM (E-) m / z: 166.2 [M+H]. Intermediate product 190D: 3-bromo-4-(2,2,2-trifluoroethyl)-1H-pyrazole A stirred solution of 4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-amine (2.2 g, 13.32 mmol) in acetonitrile (20 ml) was mixed with p-toluenesulfonic acid monohydrate (3.80 g, 19.99 mmol), isoamyl nitrite (2.93 ml, 19.99 mmol), cupric bromide (2.98 g, 13.32 mmol), and tetrabutylammonium bromide (8.59 g, 26.6 mmol) at room temperature, then stirred at the same temperature for 16 h. The reaction mass was inactivated with EtOAc-extracted water, dried over sodium sulfate, and concentrated to obtain a crude product. The crude mass was purified by ISCO using a silica column (24 g), the fractions were collected and concentrated to obtain 3-bromo-4-(2,2,2-trifluoroethyl)-1H-pyrazole (1.8 g, 7.86 mmol, 59% yield) as a brown liquid. CL-EM retention time 1.30 min [A], EM (E-) m / z: 229.1 [M+H]. Intermediate product 190E: 3-bromo-5-iodo-4-(2,2,2-trifluoroethyl)-1H-pyrazole NIS (6.39 g, 28.4 mmol) was added to a stirred solution of 3-bromo-4-(2,2,2-trifluoroethyl)-1H-pyrazole (1.3 g, 5.68 mmol) in acetonitrile (30 mL) at room temperature, then stirred at 100 °C for 16 h. The reaction mass was concentrated, diluted with water, extracted with EtOAc, dried over sodium sulfate, and concentrated to obtain the crude. The crude mass was purified using an ISCO silica column (24 g), the fractions were collected, and concentrated to obtain 3-bromo-5-iodo-4-(2,2,2-trifluoroethyl)-1H-pyrazole (800 mg, 2.254 mmol, 40% yield) as a brown liquid. CL-EM 1 retention time, 39 min [A], EM (E-) m / z: 355.0 [MH]. Intermediate product 190F: 3-bromo-5-iodo-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole NaH (0.203 g, 5.07 mmol) was added at 0 °C to a stirred solution of 3-bromo-5-iodo-4-(2,2,2-trifluoroethyl)-1H-pyrazole (1.2 g, 3.38 mmol) in THF (40 mL), stirred at the same temperature for 30 min, then (trimethylsilyl)ethoxymethyl chloride (0.752 mL, 4.06 mmol) was added at the same temperature, stirred at room temperature for 3 h. The reaction mass was inactivated with EtOAc-extracted water, dried over sodium sulfate, and concentrated to obtain a crude product. The crude mass was purified by ISCO silica column (24 g) to obtain 3-bromo-5-iodo-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (800 mg, 1,649 mmol, 49% yield) as a brown liquid. CL-EM retention time 2.41 min [A], EM (E-) m / z 485.0 [M+H]. Intermediate 190G: 6-(3-bromo-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine To a stirred solution of 3-bromo-5-iodo-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (1.8 g, 3.71 mmol) in dioxane (100 ml) and water (3 ml) were added 8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (1.442 g, 5.57 mmol) and tribasic potassium phosphate (2.363 g, 11.13 mmol), the mixture was degassed with nitrogen for 10 min, to which PdC12 (dppf)-CH2C12 adduct was then added (0.303 g, 0.371 mmol) and the mixture was stirred at 100 °C for 16 h. The reaction mass was filtered through a celite bed, washed with EtOAc, the filtrates were collected and concentrated to obtain a crude product.The crude mass was purified by ISCO using a silica column (40 g), the fractions were collected and concentrated to obtain 6-(3-bromo-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (1.3 g, 2.65 mmol, 71% yield) as an oil. Clem retention time 2.14 min [A], ME (E-) m / z 508.3 [M+H]. Intermediate 190H: Methyl 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate A stirred solution of 6-(3-bromo-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (600 mg, 1,185 mmol) in DMF (10 ml) and MeOH (10 ml) was given 1,1'bis(diphenylphosphino)ferrocene (131 mg, 0,237 mmol), palladium(ii) acetate (26,6 mg, 0,118 mmol) and TEA (0,413 ml, 2,96 mmol), degassed with nitrogen for 10 min, then stirred at 80 °C in CO2 in an autoclave for 16 h. The reaction mass was brought to room temperature, filtered through Celite, washed with MeOH, the filtrate was collected and concentrated to obtain the crude compound.The crude mass was purified by ISCO using a 24 g silica column, the compound was eluted in 80% hexane EA, the fractions were collected and concentrated to obtain methyl 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate (460 mg, 1.088 mmol, 22% yield) as a brown oil. CL-MS retention time 1.86 min [A], MS (E-) m / z: 486.3 [M+H]. Intermediate 190I: 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylic acid LiOH (74.0 mg, 3.09 mmol) was added to a stirred solution of 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylate methyl (300 mg, 0.618 mmol) in THF (10 ml), water (2 ml) and MeOH solvent mixture (5 ml) at room temperature, and stirred for 16 h. The reaction mass was diluted with EtOAc-extracted water, dried over sodium sulfate, and concentrated to obtain 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylic acid (240 mg, 0.509 mmol, 82% yield) as a whitish solid. CL-MS retention time 0.96 min [A], MS (E-) m / z: 472.0 [M+H]. Intermediate product 190J: 4-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido) tert-butyl piperidin-1-carboxylate 1-Propanephosphonic anhydride (0.062 ml, 0.212 mmol) and EtsN (0.044 ml, 0.318 mmol) were added at room temperature for 16 h to a stirred solution of 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxylic acid (50 mg, 0.106 mmol) in DCM (15 ml). The reaction mass was diluted with cold water, extracted with EtOAc, dried over sodium sulfate and concentrated to obtain the crude compound. The crude mass was purified by ISCO using a 4 g silica column. The compound was eluted in EA. The fractions were collected and concentrated to obtain 4-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido) tert-butyl piperidine-1-carboxylate (50 mg, 0.076 mmol, 72% yield) as a whitish solid. CL-EM retention time 2.04 min [A], EM (E-) m / z: 654.3 [M+H]. Example 190: 5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(piperidin-4-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazole-3-carboxamide To a stirred solution of tert-butyl 4-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-carboxamido)piperidine-1-carboxylate (250 mg, 0.382 mmol) in DCM (2 ml) TFA (0.029 ml, 0.382 mmol) was added at room temperature, and the mixture was stirred for 16 h. The reaction mass was concentrated to obtain the crude compound. The crude compound was purified by preparative LC-MS using the AB method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-carboxamide (160 mg, 0.252 mmol, 52% yield) as a whitish solid. LC-MS retention time: 0.60 min [C], MS (E-) m / z: 424 [M+H]. The following examples were prepared according to the general procedure used to prepare intermediate 190J. Table 10 The following example was prepared in accordance with the general procedure used to prepare example 190. Table 11 Example 195 5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- (1-propylpiperidin-4-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazole-3-carboxamide Propionaldehyde (7.13 mg, 0.123 mmol) and acetic acid (1.082 uL, 0.019 mmol) were added to a stirred solution of 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-carboxamide (40 mg, 0.094 mmol) in MeOH (3 ml) and stirred at room temperature for 16 h, then NaCNBH3 (11.87 mg, 0.189 mmol) was added and stirred for another 2 h. The reaction mass was purified by preparative LC-MS using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-propylpiperidin-4-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-carboxamide (2.3 mg, 7% yield) as a whitish solid.CL-EM retention time 1, 03 min [E], EM (E-) m / z: 446, 2 [M+H]; 1H-NMR (400 MHz, DMSO-d6) = 13.97-13.83 (m, 1H), 9.27-9.09 (m, 1H), 8.93-8.80 (m, 1H), 8.64-8.49 (m, 2H), 7.28-7, 19 (m, 1H) , 4, 213, 95 (m, 2H) , 3, 12-2, 93 (m, 3H) , 2, 90 (s, 1H) , 2, 74 (s, 1H) , 2, 01 (dd a, J=1, 3, 9, 4 Hz, 2H) , 1, 94-1, 78 (m, 3H), 1, 74-1, 59 (m, 3H), 1, 03-0, 80 (m, 6H). The following examples were prepared according to the general procedure used to prepare example 195: Table 12 Example 205 5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- (1- (2- (methylamino) -2-oxoethyl) piperidin-4-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazole-3-carboxamide To a stirred solution of 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-carboxamide (40 mg, 0.094 mmol) in DMF (2 ml) and THF (2 ml) EtsN (0.040 ml, 0.283 mmol) was added at room temperature, stirred for 5 min, then 2-chloro-N-methylacetamide (12.19 mg, 0.113 mmol) was added and stirred for 16 h. The reaction mass was purified by preparative LC-MS using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-(2-(methylamino)-2-oxoethyl)piperidin-4-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-carboxamide (4.3 mg, 7% yield).Retention time of CL-EM 1, 07 min [E], EM (E-) m / z: 495, 2 [M+H]; 1H-RMN (400 MHz, DMSO-d6) ppm 8, 91-8, 78 (m, 1H) , 8, 54 (s, 1H) , 8, 19-8, 00 (m, 1H) , 7, 62 (da, 7=3, 5 Hz, 1H) , 7, 23 (d, 7=1, 0 Hz, 1H) , 4, 20-3, 98 (m, 5H) , 3, 83-3, 70 (m, 1H) , 3, 05-2, 87 (m, 4H) , 2, 84-2, 75 (m, 2H) , 2, 62 (d, 7=4, 5 Hz, 5H) , 2, 242, 10 (m, 2H), 1, 91 (s, 2H), 1, 81-1, 58 (m, 5H), 1, 19-1, 05 (m, 2H). Ejemplo 206 6- (4-isopropil-3- (1-metilpiperidin-4-il) -1H-pirazol-5-il) -8-metil-[1, 2, 4]triazolo[1, 5-a]piridina Producto intermedio 206A: 6-(3-bromo-4-isopropil-1H-pirazol-5-il)-8-metil-[1, 2, 4]triazolo[1, 5-a]piridina The PdCl2 (dppf)-CH2C12 adduct (1.556 g, 1.905 mmol) and K3PO4 (9.95 g, 57.2 mmol) were added to a degassed solution of 3-bromo-5-iodo-4-isopropyl-1H-pyrazole (6.0 g, 19.05 mmol) and solvent mixture of 8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (7.40 g, 28.6 mmol) in dioxane (150 ml) and water (35 ml), then the mixture was stirred at 95 °C for 4 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, the filtrate was washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound. The crude compound was purified by ISCO using an 80 g silica column, the compound was eluted with 65% ethyl acetate in petroleum ether, the fractions were collected and concentrated to obtain 6-(3-bromo-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (3.0 g, 9.37 mmol, 49% yield) as a light brown solid.CL-EM retention time: 1.07 min [A], EM (E+) m / z: 322.4 [M+2H]. Intermediate 206B: tert-butyl 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate Pd2(dba)3 (0.057 g, 0.062 mmol) and S-Phos (0.051 g, 0.125 mmol) were added to a degassed solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1 (2H)-tert-butyl carboxylate (0.579 g, 1.874 mol), K2CO3 (0.518 g, 3.75 mmol) and 6-(3-bromo-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.400 g, 1, 249 mmol) in mixture of Acetonitrile (20 ml) and water (4.0 ml) were added, then the mixture was stirred at 110 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, the filtrate was washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with ethyl acetate, and the fractions were collected and concentrated to obtain 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5,6-dihydropyridine-1(2H)-tert-butyl carboxylate (0.450 g, 1.065 mmol, 85% yield) as a whitish solid. Cl-MS retention time: 1.48 min [A], MS (E+) m / z: 423.6 [M+H]. INTERMEDIATE Product 206C: tert-butyl 4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidine-1-carboxylate Pd / C (0.201 g, 1.893 mmol) was added to a solution of 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5,6-dihydropyridine-1(2H)-tert-butyl carboxylate (0.400 g, 0.947 mmol) in MeOH (25 ml), then the suspension was stirred at room temperature for 36 h in a hydrogen chamber. The reaction mixture was filtered through Celite, washed with methanol, the filtrate was collected and concentrated to obtain tert-butyl 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-carboxylate (0.350 g, 0.824 mmol, 87% yield) as a light brown solid. CL-MS retention time: 1.37 min [A], MS (E+) m / z: 425.6 [M+H]. Intermediate 206D: 6-(4-isopropyl-3-(piperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine A solution of 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-carboxylate tert-butyl (0.350 g, 0.824 mmol) in dioxane (2.0 ml) was reacted with 4 M HCl in dioxane (4.12 ml, 16.49 mmol) at room temperature, then stirred at the same temperature for 2 h. The reaction mass was concentrated and dried under vacuum to obtain 6-(4-isopropyl-3-(piperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine HCl (0.450 g) as a light yellow solid. LCM retention time: 1.1 min [E], MS (E+) m / z: 325.1 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.65 (s, 1H) 8.45 (s, 1H) 7.54 (s, 1H) 3.49 (s, 2H) 3.05-3.25 (m, 4H) 2.67 (s, 3H) 1.86-2.10 (m, 6 H) 1.28 (d, J=7.09 Hz, 6 H) . Example 206: 6-(4-isopropyl-3-(1-methylpiperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine A solution of 6-(4-isopropyl-3-(piperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.040 g, 0.123 mmol), formaldehyde (0.017 ml, 0.616 mmol) and acetic acid (0.706 uL, 0.012 mmol) in MeOH (5.0 ml) was stirred at room temperature for 8 h, then sodium cyanoborohydride (0.012 g, 0.185 mmol) was added at 0 °C and stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AA method. The fractions containing the product were combined and dried by centrifugal evaporation to obtain 6-(4-isopropyl-3-(1-methylpiperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (3.8 mg) as a white solid. LC-MS retention time: 1.25 min [C], MS (E+) m / z: 339.2 [M+H]; 1H NMR (400 MHz, methanol-d4) ppm 8.63 (s, 1H) 8.43 (s, 1H) 7.54 (s, 1H) 3.47 (s, 1H) 2.92-3.19 (m, 4H) 2.66 (s, 3H) 2.43 (s, 4H) 1, 83-2, 07 (m, 4 H) 1, 191, 34 (m, 6 H) . The following example was prepared in accordance with the general procedure used to prepare example 206. Table 13 Example 208 3-(dimethylamino)-1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)propan-1-one Intermediate 208A: tert-butyl (3-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-3-oxopropyl) carbamate To a solution of 6-(4-isopropyl-3-(piperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.200 g, 0.616 mmol) and 3-((tert-butoxycarbonyl)amino)propanoic acid (0.117 g, 0.616 mmol) in a solvent mixture of DMF (5.0 ml) and THF (2.0 ml) TEA (0.430 ml, 3.08 mmol) and HATU (0.234 g, 0.616 mmol) were added at 0 °C, and the mixture was stirred at room temperature for 16 h. The reaction mixture was extracted with DCM, washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 24 g silica column, eluted with 5% MeOH in DCM, and the fractions were collected and concentrated to obtain tert-butyl carbamate (3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-3-oxopropyl) (0.180 g, 0.363 mmol, 59% yield) as an oil.CL-EM retention time: 1. 13 min [A], EM (E+) m / z: 496. 6 [M+H]. Intermediate 208B: 3-amino-1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) piperidin-1-yl) propan-1-one The following examples were prepared according to the general procedure used to prepare Example 208. To a solution of (3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-3-oxopropyl) tert-butyl carbamate (0.250 g, 0.504 mmol) in dioxane (3.0 mL) 4 M HCl in dioxane (3.78 mL, 15.13 mmol) at room temperature was added, and the mixture was stirred for 2 h. The reaction mass was then concentrated to obtain the crude compound. The crude material was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 3-amino-1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)propan-1-one (38 mg) as a whitish solid.Retention time of CL-EM: 0, 92 min [C], EM (E+) m / z: 396, 3 [M+H]; 1HRMN (400 MHz, metanol-d4) ppm 8, 66 (d, 7=1, 0 Hz, 1H) , 8, 46 (s, 1H) , 7, 64-7, 42 (m, 1H) , 4, 78-4, 66 (m, 1H) , 4, 19-3, 92 (m, 1H) , 3, 30-3, 16 (m, 4H) , 3, 09 (quin, 7=7, 2 Hz, 1H) , 2, 94-2, 76 (m, 3H) , 2, 75-2, 61 (m, 3H) , 2, 08-1, 92 (m, 7H) , 1, 90-1, 65 (m, 2H), 1, 31 (d, 7=7, 5Hz, 6H). Ejemplo 208: 3- (dimetilamino)-1- (4- (4-isopropil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1H-pirazol-3-il) piperidin-1-il) propan-1-ona The mixture of 3-amino-1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)propan-1-one (0.040 mg, 0.101 mol), formaldehyde (0.014 L, 0.506 mol) and acetic acid (0.05 ml) in methanol (5.0 ml) was stirred at room temperature for 8 h, then sodium cyanoborohydride (0.013 mg, 0.202 mol) was added at 0 °C, the resulting reaction mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AB method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 3-(dimethylamino)-1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)propan-1-one (20.2 mg) as a white solid.CL-EM retention time: 0.97 min [F], EM (E+) m / z: 424.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.67 (s, 1H), 8.48 (s, 1H), 7.56 (d, 7=1.5 Hz, 1H), 4.79-4.69 (m, 1H), 4.07 (d, 7=13.6 Hz, 1H) , 3, 52-3, 39 (m, 2H) , 3, 31-3, 17 (m, 2H) , 3, 09 (quin, J=12 Hz, 1H) , 3, 04-2, 97 (m, 52H) , 2, 95 (d, J=5, 5 Hz, 6H) , 2, 88-2, 76 (m, 1H), 2, 74-2, 62 (m, 3H), 2, 10-1, 93 (m, 2H), 1, 92-1, 71 (m, 2H), 1, 38-1, 25 (m, 6H). The following example was prepared in accordance with the general procedure used to prepare example 208. Table 14 The following example was prepared in accordance with the general procedure used to prepare example 208. Table 15 Example 211 2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-N-methylacetamide 2-Chloro-N,N-dimethylacetamide (0.022 g, 0.185 mmol) and TEA (0.064 ml, 0.462 mmol) were added to a solvent mixture solution of 6-(4-isopropyl-3-(piperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.030 g, 0.092 mmol) in DMF (1.0 ml) and THF (1.0 ml) at 0 °C, then stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AA method. The fractions containing the product were combined and dried by centrifugal evaporation to obtain 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-N-methylacetamide (9.2 mg) as a whitish solid. LC-MS retention time 1.50 min [C], MS (E+) m / z: 410.2 [M+H]; 1HRMN (400 MHz, methanol-d4) ppm 8.62 (s, 1H) 8.43 (s, 1H) 7.56 (s, 1H) 3.40-3.53 (m, 1H) 3.01-3.17 (m, 6H) 2.89-2.99 (m, 4H) 2, 67 (s, 3 H) 2, 29 (s, 2 H) 1, 81-2, 07 (m, 4 H) 1, 17-1, 32 (m, 7 H) . The following example was prepared in accordance with the general procedure used to prepare example 211. Table 16 Example 213 6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -1, 2, 3, 4-tetrahydroisoquinoline, HC1 Intermediate 213 A: 3-bromo-5-iodo-4-isopropyl-1-(((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole A solution of 3-bromo-5-iodo-4-isopropyl-1H-pyrazole (40.0 g, 127 mmol) in THF (600 ml) was mixed with NaH (7.62 g, 191 mmol) at 0 °C, stirred for 50 min, and SEM-C1 (31.8 g, 191 mmol). The mixture was then stirred at room temperature for 16 h. The reaction mixture was inactivated with saturated NH4Cl, the volatiles were evaporated, and the residue was diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 120 g silica column. The compound was eluted with 25–30% ethyl acetate in petroleum ether. The fractions were collected and concentrated to obtain 3-bromo-5-iodo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (30.0 g, 67.4 mmol, 53% yield) as a light brown liquid. CL-MS retention time: 4.30 min [B] MS (E+) m / z: 447.0 [M+2H]. Intermediate 213B: 6-(3-bromo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine 6-(3-bromo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (12.2 g, 27.1 mmol, 86% yield) was prepared according to the general process described in intermediate 206A using 3-bromo-5-iodo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (14 g, 31.4 mmol) and 8-methyl-6-(4, 4, 5, 5-tetramethyl-1, 3, 2-di oxaborol an-2-yl)-[1, 2, 4]triazolo[1, 5-a]pyridine (9.78 g, 37. 7 mmol) as a starting intermediate to provide the title compound as a gummy solid. CL-EM retention time: 1.72 min [A] EM (E+) m / z: 452.0 [M+2H]. The following intermediate steps were prepared according to the general procedure used to prepare intermediate product 213B. Table 17 Intermediate 213H: 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine Pd2dba3 (0.508 g, 0.555 mmol), tricyclohexylphosphine (0.311 g, 1.110 mmol) and potassium acetate (3.27 g, 33.3 mmol) were added to a degassed solution of BISPIN (3.66 g, 14.43 mmol) and 6-(3-bromo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (5.0 g, 11.10 mmol) in dioxane (100 ml), the mixture was stirred at 110 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, and washed with ethyl acetate. The filtrate was collected and concentrated to obtain the crude compound.The crude compound was purified by ISCO using an 80 g silica column. The compound was eluted with 45% ethyl acetate in petroleum ether. The fractions were collected and concentrated to obtain 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (4.5 g, 9.04 mmol, 81% yield) as a whitish solid. Cl-MS retention time: 1.87 min [A] MS (E+) m / z: 498.4 [M+H]. The following intermediates were prepared according to the general procedure used to prepare intermediate 213H. Table 18 Intermediate 213N: 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline A solution of 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.600 g, 1.206 mmol), 6-bromo-1,2,3,4-tetrahydroisoquinoline (0.512 g, 2.412 mmol) and K2CO3 (0.500 g, 3.62 mmol) in a solvent mixture of acetonitrile (16.00 ml) and water (8.00 ml) for 10 min with nitrogen, to which Pd2 was then added (dba) s (0.055 g, 0.060 mmol) and 2-dicyclohexylphosphine-2', 6'-dimethoxybiphenyl (0.050 g, 0.121 mmol) , was degassed again for 2 min and stirred at 110 °C for 16 h. Both phases were separated, the aqueous phase was extracted with 10% MeOH in DCM (2X30 ml), the combined organic extracts were dried (Na2SO4) and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 24 g silica column. The compound was eluted in 10% MeOH on DCM. The fractions were collected and concentrated to obtain 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline (0.340 g, 0.676 mmol, 56% yield) as a whitish solid. Cl-MS retention time: 1.29 min [A], MS (E+) m / z: 503.7 [M+H]. Example 213: 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-10 3-yl)-1,2,3,4-tetrahydroisoquinoline, HC1 A solution of 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline (0.360 g, 0.716 mmol) in dioxane (3.00 ml) was given 4 M HCl in dioxane (5.00 ml, 20.00 mmol) at room temperature, then the mixture was stirred at 70 °C for 16 h. The reaction mass was concentrated to obtain the crude compound. The crude compound was ground with diethyl ether (2 x 10 mL), then vacuum dried to obtain 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline, HCl (0.270 g, 0.660 mmol, 92% yield) as a white solid. Cl-MS retention time 0.76 min [A], MS (E+) m / z: 0.76 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.64 (s, 1H), 8.36 (s, 1H), 7.58-7.47 (m, 1H), 7.40-7.18 (m, 3H), 4.36 (s, 2H), 3.50-3, 43 (m, 2H), 3, 13 (t, J=6, 3 Hz, 2H), 3, 04-2, 94 (m, 1H), 2, 59 (s, 3H), 1, 07 (d, J= 7, 0Hz, 6H). The following examples were prepared according to the general procedure used to prepare example 213. Table 19 Example 235 6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-methyl-1, 2, 3, 4-tetrahydroisoquinoline To a solution of 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline, HCl (0.017 g, 0.042 mmol) in MeOH (2.00 ml) formaldehyde (0.2 ml, 2.54 mmol) and acetic acid (0.2 ml, 3.49 mmol) were added at room temperature, stirred for 6 h, then sodium cyanoborohydride (7.84 mg, 0.125 mmol) was added and stirred at the same temperature for 16 h. The reaction mass was purified by preparative LC-MS using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-methyl-1,2,3,4-tetrahydroisoquinoline (0.0016 g, 4.02 mol, 10% yield) as a pale solid.CL-EM retention time 0.76 min [E], EM (E+) m / z: 387.2 [M+H]; * H-NMR (400 MHz, methanol-d4) ppm 8.75 (s, 1H), 8.47 (s, 1H), 7.67 (s, 1H), 7.40-7.28 (m, 2H), 7.27-7.18 (m, 1H), 3.90-3, 68 (m, 3H) , 3, 18-3, 02 (m, 4H) , 2, 91 (s, 2H) , 2, 71 (s, 3H) , 2, 57 (s, 3H) , 1, 19 (d, J=7, 0 Hz, 6H) . The following examples were prepared according to the general procedure used to prepare example 235. Table 20 Example 263 6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -2- (2-methoxyethyl) -1, 2, 3, 4-tetrahydroisoquinoline To a solution of 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline, HCl (0.022 g, 0.054 mmol) and 1-bromo-2-methoxyethane (0.015 g, 0.108 mmol) in THF (1.00 ml) and DMF solvent mixture (0.500 ml) DIPEA (0.3 ml, 1.718 mmol) was added at room temperature, then the mixture was stirred at 90 °C for 16 h. The reaction mass was concentrated and purified by preparative LC-MS using the AA method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to provide 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(2-methoxyethyl)-1,2,3,4-tetrahydroisoquinoline (0.0094 g, 0.021 mmol, 39% yield) as a pale solid.CL-EM retention time 1, 473 min [E], EM (E+) m / z: 429, 3 [M+H]; 1H-NMR (400 MHz, methanold4) ppm 8.75 (s, 1H) , 8.47 (s, 1H) , 7.67 (s, 1H) , 7.38-7.27 (m, 2H) , 7.267.16 (m, 1H) , 3.87 (s, 2H) , 3.69 (t, J=5.5 Hz, 2H) , 3.43-3.39 (m, 3H) , 3.17-3.02 (m, 4H) , 3.00-2.93 (m, 2H) , 2.88 (t, J=5.5 Hz, 2H) , 2, 76-2, 67 (m, 3H), 1.96 (s, 5H), 1.19 (d, J=7.0 Hz, 6H). The following examples were prepared according to the general procedure used to prepare example 263. Table 21 Example 268 2-(dimethylamino)-1-(6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one A mixture of 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline, HCl (0.022 g, 0.054 mmol), and dimethylglycine (0.011 g, 0.108 mmol) in DMF (1.00 mL) was mixed with TEA (0.2 mL, 1.435 mmol) and HATU (0.041 g, 0.108 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 16 h. The reaction mass was purified by preparative LC-MS using the AA method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to provide 2-(dimethylamino)-1-(6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (0.0034 g, 7.28 mol, 13% yield) as a pale solid.CL-EM 1 retention time, 145 min [E], EM (E+) m / z: 458, 3 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.76 (s, 1H) , 8.48 (s, 1H) , 7.67 (s, 1H) , 7.49-7.26 (m, 3H) , 4.82 (d, J=10.5 Hz, 2H) , 3. 92-3, 77 (m, 2H) , 3, 59 (d, J=6, 8 Hz, 2H) , 3, 16-2, 93 (m, 3H) , 2, 71 (s, 3H) , 2, 50 (s, 6H) , 1, 20 (d, J=7, 1 Hz, 6H) . The following examples were prepared according to the general procedure used to prepare example 268. Table 22 Example 271 2-(6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)-N,N-dimethylacetamide A solution of 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline, HCl (0.030 g, 0.073 mmol) and 2-chloro-N,N-dimethylacetamide (0.018 g, 0.147 mmol) in THF (1.00 ml) and DMF solvent mixture (0.50 ml) was given TEA (0.2 ml, 1.435 mmol), then the mixture was stirred at the same temperature for 16 h. The reaction mixture was purified by preparative LC-MS using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)-N,N-dimethylacetamide (0.0022 g, 4.71 mol, 6% yield) as a pale solid.Retention of CL-EM 15 time 1.380 min [E], EM (E+) m / z: 458.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8,73(s,1H), 8,46(s,1H), 7,66(s,1H), 7,35-7,23(m,2H), 7, 19(d,J=7,3Hz,1H), 3,35. 85(s,2H),3,52(s,2H),3,19-3,05(m,4H),3,05-2,83(m,7H), 2,69(s,3H), 1,18(d,J=7,1Hz,6H). The following examples were prepared according to the general procedure used to prepare example 271. Table 23 Example 277 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-2-ol Intermediate product 277A: 6-(4-isopropyl-3-(6-methoxypyridin-2-yl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine Se preparó 6- (4-isopropyl-3- (6-methoxypyridin-2-yl) -1H-pirazol-5-yl) -8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine de acuerdo con el proceso general descrito en el intermedio-213N usando 2-bromo-6-methoxypyridin (0, 041 g, 0, 218 mmol) y 6- (4-isopropyl-3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pirazol-yl) -8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (0, 080 g, 0, 218 mmol) como intermedio de partida para proporcionar el composed of the title as a solid blanquecino. CL-EM retention time 1, 62 min [C] EM (E+) m / z: 349, 1 (M+H) ; 1H-RMN (400 MHz, methanol-d4) 8, 76 (s a., 1H) , 8, 48 (s a., 1H) , 7, 78 (s a., 1H) , 7, 66 (s a., 1H) , 7, 31 (s a., 1H) , 6, 81 (d, J=7, 6 Hz, 1H) , 4, 02 (s, 3H) , 3, 623, 45 (m, 1H) , 2, 71 (s, 3H) , 1, 33 (d, J=7, 3 Hz, 6H) . Example 277: 6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-2-ol BBr3 (0.163 uL, 1.722 mol, IM in DCM) was added to a solution of 6-(4-isopropyl-3-(6-methoxypyridine-2-yl)-1H pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.060 mg, 0.172 mol) in DCM (3.0 mL). The resulting reaction mixture was stirred at room temperature for 16 h. The reaction mixture was slowly inactivated with methanol and concentrated to obtain the crude product. The crude compound was purified by preparative LC / MS using the AB method. The fractions containing the product were combined and dried by centrifugal evaporation to obtain 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-2-ol (12 mg) as a whitish solid. LC-MS retention time: 1.01 min [C], MS (E+) m / z: 335.1 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8.80 (sa, 1H) , 8.57-8.43 (m, 1H) , 7.71 (dd, J=92.7.0 Hz, 1H) , 7.61 (sa, 1H) , 6.63 (sa, 2H) , 3, 24-3, 11 (m, 1H) , 2, 77-2, 65 (m, 3H) , 1, 24 (d, 7=7, 1 Hz, 6H) . Example 278 6-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-1,2,3,4-tetrahydro Intermediate product 278A: tert-butyl 6-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate Boc anhydride (4.34 ml, 18.69 mmol) was added to a solution of 6-bromo-1,2,3,4-tetrahydroisoquinoline (3.050 g, 14.38 mmol) and TEA (6.01 ml, 43.1 mmol) in DCM (80.0 ml) at room temperature, and the mixture was stirred for 14 h. The reaction mixture was diluted with DCM, washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude product. The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with 15%–20% ethyl acetate in petroleum ether. The fractions were collected and concentrated to obtain tert-butyl 6-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (3.5 g, 11.21 mmol, 78% yield) as a light brown solid. CL-MS retention time: 1.60 min [A], MS (E+) m / z: 258.3 [M+H-tBu]. Intermediate product 278B: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-tert-butyl carboxylate PdC12 (dppf)-CH2C12 adduct (0.915 g, 1.121 mmol) and potassium acetate (3.30 g, 33.6 mmol) were added to a degassed solution of 6-bromo-3,4-dihydroisoquinoline-2(1H)-tert-butyl carboxylate (3.5 g, 11.21 mmol) and BISPIN (3.70 g, 14.57 mmol) in dioxane (120 mL). The resulting mixture was stirred at 95 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, and washed with excess ethyl acetate. The filtrates were dried over sodium sulfate and concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 40 g silica column, the compound was eluted with 45% ethyl acetate in petroleum ether, the fractions were collected and concentrated to obtain 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-tert-butyl carboxylate (3.5 g, 9.74 mmol, 87% yield) as a light brown solid.LC-MS retention time: 1.74 min [A], MS (E+) m / z: 304.5 [M+H-tBu]. Intermediate 278C: tert-butyl 6-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate. 6-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-3,4-dihydroisoquinoline-2(1H)-tert-butyl carboxylate (85 mg, 0.190 mmol, 56% yield) was prepared according to the general procedure described in intermediate product 213N, using 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-tert-butyl carboxylate (0.122 g, 0.340 mmol) and 4-(3-bromo-4-isopropyl-1H-pyrazol-5-yl)-2,6-dimethylpyridine (0.100 g, 0.340 mmol) as a starting intermediate to provide the title compound as a gummy solid. CL-EM retention time: 1.49 min [A], EM (E+) m / z: 447.3 [M+H]. Example 278: 6-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline 6-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-1,2,3,4-tetrahydroisoquinoline (17 mg) was prepared according to the general process described in Example 213, using 6-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-3,4-dihydroisoquinoline-2(1H)-tert-butyl carboxylate (55 mg, 0.123 mmol) as a starting intermediate to provide the title compound as a whitish solid. Retention time: 0.78 min [E] ME (E+) m / z: 347.6 [M+H]; XHNMR (400 MHz, metanol-d4) 7, 87 (s, 2H) , 7, 50-7, 30 (m, 3H) , 4, 48 (s, 2H) , 3, 59 (t, J=6, 3 Hz, 2H) , 3, 29-3, 15 (m, 3H) , 2, 81 (s, 6H) , 1, 24 (d, J=7, 0Hz, 6H) . Example 279 N-(2, 2-difluoroetil)-4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) cyclohexan-1-amine Intermediate 279A: 6-(4-isopropyl-3-(1, 4-dioxaspiro[4.5]dec-7-en-8-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine Se preparó 6- (4-isopropyl-3- (l, 4-dioxaspiro [4.5]dec-7-en-8-il) -1- ( (2- (trimethylsilyl) ethoxy) metil) -1H-pirazol-5-yl) -8-metil-[1, 2, 4]triazolo[1, 5-a]piridina (1, 1 g, 2, 158 mmol, 72% de rendimiento) de acuerdo con el proceso general descrito en el producto intermedio 213N usando 4, 4, 5, 5-tetrametil-2- (1, 4-dioxaspiro [4.5]dec-7-en-8-il) -l, 3, 2-dioxaborolano (800 mg, 3, 01 mmol) y 6- (3-bromo-4-isopropyl-1- ( (2- (trimethylsilyl) ethoxy) metil) -1H-pirazol-5-yl) -8-metil-[1, 2, 4]triazolo[1, 5-a]piridina (1760 mg, 3, 91 mmol) como intermedios de partida para proporcionar el compuesto del título como un sólido amarillo. Tiempo de retención de CL-EM: 3, 49 min [B], EM (E+) m / z: 510, 4 [M+H]. Intermediate product 279B: 6-(4-isopropyl-3-(1, 4-dioxaspiro[4.5]decan-8-yl)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine Se preparó 6- (4-isopropil-3- (1, 4-dioxaspiro[4.5]decan-8-il) -1- ( (2- (trimetilsilyl) etoxi) metil) -1H-pirazol-5-yl) -8-metil-[1, 2, 4]triazolo[1, 5-a]piridina (700 mg, 1, 368 mmol, rendimiento del 46%) de acuerdo con el proceso general descrito en el producto intermedio 206C, uso 6- (4-isopropil-3- (1, 4-dioxaspiro [4.5]dec-7-en-8-il) -1- ( (2- (trimetilsilyl) etoxi) metil) -1H-pirazol-5-yl) -8-metil-[1, 2, 4]triazolo [1, 5-a]pyridine (1.5 g, 2.94 mmol) as an intermediate to provide the composition of the title as a white solid. CL-EM retention time: 3, 79 min [B], EM (E+) m / z: 512, 7 [M+H]. Intermediate product 279C: 4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexan-1-one To a solution of 6-(4-isopropyl-3-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (500 mg, 0.981 mmol) in DCM (6.0 mL) was added to TFA (1.889 mL, 24.52 mmol) at 0 °C, the mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated and vacuum dried to obtain 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexan-1-one (320 mg, 0.948 mmol, 97% yield) as a gummy solid. CL-MS retention time: 0.92 min [A], MS (E+) m / z: 338.6 [M+H]. Example 279: N-(2,2-difluoroethyl)-4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexan-1-amine A mixture of 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexan-1-one (100 mg, 0.296 mmol), 2,2-difluoroethan-1-amine (120 mg, 1.482 mmol) and acetic acid (3.39 µL, 0.059 mmol) in DMF (3.0 mL) was stirred at room temperature for 8 h. Sodium cyanoborohydride (37.2 mg, 0.593 mmol) was then added at 0 °C, and the mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AA method to separate the two isomers. Isomer 1: The fractions containing the product were combined and dried by centrifugal evaporation to provide isomer 1 as a pale solid. CL-EM retention time: 1.49 min [C], EM (E+) m / z: 403.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8.64 (sa, 1H) , 8.46 (s, 1H) , 7.57 (sa, 1H) , 3, 1.- 2.99 (m, 3H) , 2.93 (sa, 1H) , 2.69 (s, 4H) , 2, 15 (d, 7=11, 0 Hz, 2H), 2, 00 (d, 7=12, 2 Hz, 2H), 1, 79-1, 65 (m, 2H), 1, 39-1, 22 (m, 9H). Isomer 2: The fractions containing the product were combined and dried by centrifugal evaporation to provide isomer 1 as a pale solid. CL-MS retention time: 1.76 min [C], MS (E+) m / z: 403.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8.65 (s, 1H) , 8.46 (s, 1H) , 7.57 (s, 1H) , 3.12-2.85 (m, 4H) , 2.69 (s, 3H) , 2.14-1.85 (m, 4H) , 1.72 (s, 3H) , 1.29 (d, 7=7, 1 Hz, 6H) . The following examples were prepared according to the general procedure used to prepare example 279. Table 24 Example 296 2-(dimethylamino)-N-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N-methylacetamide HATU (21.57 mg, 0.057 mmol), TEA (0.040 ml, 0.284 mmol) and dimethylglycine (8.78 mg, 0.085 mmol) at room temperature, stirred for 12 h. The reaction mass was purified by preparative LC / MS using the AB method. The fractions containing the product were combined and dried by centrifugal evaporation to yield the title compound (12.0 mg) as a whitish solid. LC-MS retention time: 1.23 min [E], MS (E+) m / z: 438.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8.55 (sa, 1H), 8.45 (s, 1H), 7.85 (s, 1H), 7.21 (sa, 1H), 4.13 (s, 3H), 3.25-3.19 (m, 1H), 3, 08 (d, J=11, 5 Hz, 2H) , 2, 41 (s, 3H) , 2, 34 (t, 7=11, 7 Hz, 2H) , 2, 24 (d, J=12, 2 Hz, 2H) , 2, 03-1, 89 (m, 2H) , 1, 28 (d, J= 7, 1Hz, 6H) . The following example was prepared in accordance with the general procedure used to prepare example 296. Table 25 Example 298 2- ((4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)(methyl)amino)-N,N-dimethylacetamide TEA (0.040 ml, 0.284 mmol) was added to a mixture of 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methylcyclohexan-1-amine (20.0 mg, 0.057 mmol) and 2-chloro-N,N-dimethylacetamide (10.35 mg, 0.085 mmol) in DMF (2.0 ml), then stirred at room temperature for 12 h. The reaction mass was purified by preparative LC / MS using the AA method; the collection of the fraction was triggered by MS signals. The fractions containing the product were combined and dried by centrifugal evaporation to obtain 2-((4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)(methyl)amino)N,N-dimethylacetamide (9.1 mg) as a pale solid.CL-EM retention time: 1.15 min [E], EM (E+) m / z: 438.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8.65 (s, 1H), 8.46 (s, 1H), 7.57 (s, 1H), 3.61 (s, 2H), 3.13 (s, 3H), 3.11-2.97 (m, 5H), 2, 97-2, 77 (m, 3H) , 2, 69 (s, 3H) , 2, 51 (s, 3H) , 2, 19-1, 95 (m, 4H) , 1, 81-1, 67 (m, 2H) , 1, 65-1, 46 (m, 2H) , 1, 29 (d, J=7, 3 Hz, 6H) . The following examples were prepared according to the general procedure used to prepare example 298. Table 26 Example 300 N-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N,l-dimethylazetidine-3-carboxamide Intermediate 300A: tert-butyl 3-((4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)(methyl)carbamoyl)azetidine-1-carboxylate 3-((4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)(methyl)carbamoyl) tert-butyl azetidine-1-carboxylate (150.0 mg, 0.280 mmol, 82% yield) was prepared according to the general process described in intermediate 296 using 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methylcyclohexan-1-amine (120 mg, 0.340 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-EM retention time: 1.20 min [A], EM (E+) m / z: 536.6 [M+H]. Intermediate product 300B: N-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-Nm ethylazetidin-3-carboxamide N-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N-methylazetidin-3-carboxamide (31 mg) was prepared according to the general procedure described in intermediate 279C, using 3-((4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)(methyl)carbamoyl)azetidin-1-carboxylate (150 mg, 0.280 mmol) as the starting intermediate, providing the title compound as a white solid. CL-EM retention time: 1, 12min [E], EM (E+) m / z: 436, 3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8,738.60 (m, 1H) , 8.52-8.40 (m, 1H) , 7.57 (s, 1H) , 4.52 (d, 7=5.4 Hz, 1H) , 4.37-4.22 (m, 3H) , 4, 17-4, 00 (m, 1H) , 3, 07 (quin, >7, 0 Hz, 2H) , 2, 95 (s, 2H) , 2, 88 (s, 2H) , 2, 69 (s, 3H) , 2, 07 (d, J=11, 7 Hz, 2H) , 1, 96-1, 79 (m, 4H), 1.76 (s, 1H), 1.38-1.20 (m, 7H), 0.91 (d, >9.8 Hz, 1H). Example 300: N-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N,1-dimethylazetidine-3-carboxamide-2-(dimethylamino)-N-(4-(4-isopropyl-5-) was prepared (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) cyclohexyl) -N-methylacetamide according to the general procedure described 923 mg) in example - 307, using N- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl) -N-methylazetidin-3-carboxamide (40.0 mg, 0.092 mmol) as a starting intermediate providing the title compound as a white solid.CL-EM retention time: 1.13 min [E], EM (E+) m / z: 450.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 71-8, 58 (m, 1H) , 8, 51-8, 37 (m, 1H) , 7, 57 (s, 1H) , 4, 51 (s, 1H) , 4, 05-3, 89 (m, 2H) , 3, 82 (s, 2H) , 3, 76 (s, 1H) , 3, 50 (s, 1H) , 3, 14-3, 00 (m, 2H) , 3, 00-2, 76 (m, 4H) , 2, 72-2, 52 (m, 5H) , 2, 37 (d, J=7, 8Hz, 1H), 2, 05 (d, J= 5, 6Hz, 2H) , 2, 00-1, 93 (m, 2H) , 1, 88 (d, J=12, 2 Hz, 2H) , 1, 84-1, 66 (m, 4H) , 1, 40-1, 14 (m, 7H) . The following example was prepared in accordance with the general procedure used to prepare example 300. Table 27 The following examples were prepared according to the general procedure used to prepare example 300. Table 28 Example 307 6- (4-isopropyl-3- (4- (1-isopropylpiperidin-4-yl) phenyl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine INTERMEDIATE Product 307A: 4-(4-bromophenyl)-3, 6-dihidropindimethyl (2H)-tert-butyl carboxylate PdCl2 (dppf)-CH2C12 adduct (0.289 g, 0.353 mmol) and K3PO4 (1.847 g, 10.60 mmol) were added to a degassed solution of l-bromo-4-iodobenzene (1.0 g, 3.53 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1-(2H)-tert-butyl carboxylate (0.656 g, 2.21 mmol) in a mixture of dioxane (20.0 ml) and water (4.0 ml). The resulting reaction mixture was stirred at 95 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, and washed with excess ethyl acetate. The combined organic phases were washed with water and brine, then dried over sodium sulfate and evaporated to obtain the crude material.The raw material was purified by ISCO using a 40 g silica column. The compound was eluted with 30–55% ethyl acetate and petroleum ether to obtain tert-butyl 4-(4-bromophenyl)-3,6-dihydropyridine-1(2H)-carboxylate (850 mg, 2.51 mmol, 71% yield) as a light brown semisolid. Cl-MS retention time: Ulmin [A], MS (E+) m / z: 284.3 [M-tBu]. Intermediate 307B: tert-butyl 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-carboxylate Pd2(dba)3 (54 mg, 0.059 mmol) and SPhos (48.5 mg, 0.118 mmol) were added to a degassed solution of tert-butyl 4-(4-bromophenyl)-3,6-dihydropyridin-1(2H)-carboxylate (400 mg, 1.183 mmol). K2CO3 (490 mg, 3.55 mmol) and 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1, 5-a]pyridine (765 mg, 1, 537 mmol) in a mixture of acetonitrile (20.0 mL) and water (4.0 mL). The resulting reaction mixture was stirred at 110 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, and washed with excess ethyl acetate. The combined organic phases were washed with water and brine, then dried over sodium sulfate and evaporated to obtain a crude compound.The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with 55–85% ethyl acetate and petroleum ether to obtain 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-tert-butyl carboxylate (520 mg, 0.827 mmol, 70% yield) as a light yellow solid. Cl-MS retention time: 4.48 min [B], MS (E+) m / z: 629.9 [M+H]. Intermediate 307C: tert-butyl 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)piperidine-1-carboxylate To a solution of 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate (480 mg, 0.763 mmol) in methanol (20.0 mL) at 26 °C, Pd-C (244 mg, 2.290 mmol) was added. The reaction mixture was stirred at room temperature for 12 h in a hydrogen bladder. The reaction mixture was filtered and washed with excess methanol and THF. The combined organic phases were evaporated to obtain tert-butyl 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)piperidin-1-carboxylate (330 mg, 0.523 mmol, 68% yield) as a light brown solid. CL-EM retention time 4.36 min [B], EM (E+) m / z: 631.4 (M+H). Intermediate 307D: 6-(4-isopropyl-3-(4-(piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine TFA (0.946 ml, 12.28 mmol) was added to a solution of 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)piperidin-1-carboxylate tert-butyl (310 mg, 0.491 mmol) in DCM (5.0 ml) at 0 °C. The reaction mixture was stirred for 12 hours at room temperature. The volatiles were evaporated and dried under high vacuum to obtain 6-(4-isopropyl-3-(4-(piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (270 mg) as a whitish solid. CL-MS retention time: 1.68 min [B], MS (E+) m / z: 401.4 [M+H]. Example 307: 6-(4-isopropyl-3-(4-(1-isopropylpiperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine A solution of 6-(4-isopropyl-3-(4-(piperidin-4-yl)) was stirred at room temperature for 8 h. phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.045 g, 0.112 mmol), acetone (0.082 mL, 1.124 mmol) and acetic acid (0.643 uL, 0.011 mmol) in MeOH (2.0 ml), then sodium cyanoborohydride (10, 59 mg, 0.169 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 6-(4-isopropyl-3-(4-(1-isopropylpiperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (2.8 mg) as a pale solid.CL-EM retention time: 1.32 min [E], EM (E+) m / z: 443.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 76 (s, 1H) , 8, 48 (s, 1H) , 7, 717, 63 (m, 1H) , 7, 60-7, 49 (m, 7=8, 5 Hz, 2H) , 7, 49-7, 37 (m, 7=8, 0 Hz, 2H) , 3, 70-3, 56 (m, 3H) , 3, 30-3, 23 (m, 1H) , 3, 16-2, 98 (m, 2H) , 2, 78-2, 66 (m, 3H) , 2, 26 (d, 7=14, 1 Hz, 2H), 2, 12-1.98 (m, 2H), 1.44 (d, J=7.0 Hz, 6H), 1.19 (d, 7=7.0 Hz, 6H). The following example was prepared in accordance with the general procedure used to prepare intermediate product 307D. Table 29 The following examples were prepared according to the general procedure used to prepare Example 307. Table 30 Example 318 6-(4-isopropyl-3-(4-(1-(2-methoxyethyl)piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine TEA (0.134 mL, 0.960 mmol) was added to a solution of 6-(4-isopropyl-3-(4-(piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (40.0 mg, 0.096 mmol) and 1-bromo-2-methoxyethane (66.7 mg, 0.480 mmol) in DMF (2.0 mL). The reaction mixture was stirred at 70 °C for 2 h. The volatiles were evaporated and dried under high vacuum to obtain a residue. The crude material was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 6-(4-isopropyl-3-(4-(1-(2-methoxyethyl)piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine as a white solid.Adjustment time for CL-EM: 1, 65 min [E], EM (E+) m / z: 475, 4 [M+H]; 1H RMN (400 MHz, metanol-d4) 8, 42 (s, 1H) , 8, 33 (s, 1H) , 7, 42 (d, 7=7, 8 Hz, 2H) , 7, 34 (d, 7=8, 1 Hz, 2H) , 7, 13 (s, 1H) , 4, 02 (s, 3H) , 3, 71-3, 61 (m, 4H) , 3, 36 (s, 3H) , 3, 32-3, 28 (m, 2H) , 3, 143, 02 (m, 3H) , 2, 95-2, 88 (m, 1H) , 2, 60 (s, 1H) , 2, 10 (d, 7=13, 9 Hz, 2H), 2, 03-1, 94 (m, 2H), 1, 19 (s, 2H), 1, 10 (d, 7=7, 1 Hz, 6H). Those who come to the site will start with the general procedure used to prepare the site 318. Table 31 Example 321 2- (4- (4- (4-isopropil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1H-pirazol-3-il)fenil) piperidin-1-il) -N, N-dimetilacetamida To a solution of 6-(4-isopropyl-3-(4-(piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.025 g, 0.062 mmol) in DMF solvent (2 ml) were added TEA (0.026 ml, 0.187 mmol) and 2-chloro-N,N-dimethylacetamide (10.93 µL, 0.106 mmol) at room temperature. The resulting solution was stirred at room temperature for 12 h. The reaction mass was diluted with water (10 ml) and extracted with ethyl acetate (3 x 10 ml). The separated organic phase was dried over sodium sulfate, filtered, and dried. The crude sample was purified by preparative LC-MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 2-(4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)piperidin-1-yl)-N,N-dimethylacetamide (2.14 mg, 4.10 mol, 6.57% yield) as a pale yellow solid.CL-EM 1 retention time, 35 min [E], EM (E-) m / z: 486, 2 [M+H]; 1H NMR (400 MHz, DMSO-d6) 13.04 (s, 1H) , 8.78 (s, 1H) , 8.51 (s, 1H) , 7.63 (s, 1H) , 7.55-7.38 (m, 3H) , 7.35 (s, 1H) , 3, 21-3, 12 (m, 2H) , 3, 09-3, 01 (m, 4H) , 2, 96 (d, J=11, 5 Hz, 2H) , 2, 88 (s, 1H) , 2, 83 (s, 3H) , 2, 62 (s, 3H) , 2, 18 (t, 7=10, 4 Hz, 2H), 1.86-1.75 (m, 2H), 1.75-1.61 (m, 2H), 1.12 (d, J=7.1 Hz, 6H). The following example was prepared in accordance with the general procedure used to prepare example 321. Table 32 Example 323 2-(dimethylamino)-1-(4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)piperidin-1-yl)ethan-1-one TEA (0.061 ml, 0.436 mmol) was added, followed by HATU (166 mg, 0.436 mmol), to a solution of 6-(4-isopropyl-3-(4-(piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (175 mg, 0.436 mmol) and dimethylglycine (45 mg, 0.436 mmol) in DMF (1 ml). The resulting reaction mixture was stirred at room temperature for 3 h. The reaction mass was diluted with water (5 ml) and extracted with ethyl acetate (3 x 10 ml). The separated organic phase was dried over sodium sulfate, filtered, and dried. The crude sample was purified by preparative LC-MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 2-(dimethylamino)-1-(4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)piperidin-1-yl)ethan-1-one (5 mg, 10.09 mol) as a pale yellow solid.Retention time for CL-EM 1, 27 min [E], EM (E-) m / z: 486, 2 [M+H]; 1H-RMN (400 MHz, DMSO-d6) 13, 05 (s a., 1H), 8, 76 (s, 1H), 8, 50 (s, 1H), 7, 62 (s a., 1H), 7, 49-7, 22 (m, 4H), 4, 51 (s a., 1H) , 4, 14 (d, J=5, 4 Hz, 2H) , 3, 25 (d, J=12, 7 Hz, 1H) , 3, 11-2, 91 (m, 2H) , 2, 86 (s a., 2H) , 2, 61 (s, 3H) , 2, 25 (s, 6H), 1, 91-1, 77 (m, 2H), 1, 62 (d, J=9, 5 Hz, 1H), 1, 49 (s, 1H), 1, 12 (d, J=7, 1 Hz, 6H). Example 324 6- (4-isopropil-3- (4- (l-metilazetidin-3-il)fenil) -1H-pirazol-5-il) -8-metil-[1, 2, 4]triazolo [1, 5-a]piridina Product intermedio 324A: 3-(4-bromofenil) azetidina-1-carboxilato de terc-butilo Sodium bis(trimethylsilyl)amide (3.53 ml, 7.06 mmol) was added to a degassed solution of tert-butyl 3-iodoazetidin-1-carboxylate (1.0 g, 3.53 mmol), 2-(4-bromophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.0 g, 3.53 mmol), nickel(ii) iodide (0.110 g, 0.353 mmol) and trans-2-aminocyclohexanol hydrochloride (0.054 g, 0.353 mmol) in 2-propanol (14.0 ml). The reaction mixture was stirred at room temperature for 30 min and then microwaved at 80 °C for 1 h. The reaction mixture was diluted with ethyl acetate, filtered and washed with excess ethyl acetate, the filtrate was washed with water, brine, dried over sodium sulfate and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with 25–35% ethyl acetate in petroleum ether. The fractions were collected and concentrated to obtain tert-butyl 3-(4-bromophenyl)azetidine-1-carboxylate (650 mg, 2.082 mmol, 59% yield) as a light brown solid. Cl-MS retention time: 1.55 min [A], MS (E+) m / z: 256 [M-tBu]. Intermediate product 324B: 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidine-1-carboxylate tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) tert-butyl azetidine-1-carboxylate (650 mg, 1.809 mmol, 87% yield) was prepared according to the general procedure described for intermediate 278B using 3-(4-bromophenyl) tert-butyl azetidine-1-carboxylate (650 mg, 2.082 mmol) as the starting intermediate to provide the title compound as a whitish solid. Cl-MS retention time: 1.67 min [A], MS (E+) m / z: 304.0 [M+H-tBu]. Intermediate 324C: tert-butyl 3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)azetidine-1-carboxylate 3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethyl-1-silyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl) tert-butyl azetidine-1-carboxylate (450 mg, 0.746 mmol, 56% yield) was prepared according to the general procedure described in intermediate product 307B, using 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) tert-butyl azetidine-1-carboxylate (0.622 g, 1.732 mmol) and 6-(3-bromo-4-isopropyl-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.600 g, 1.332 mmol) as starting intermediates to provide the title compound as a gummy solid. CL-MS retention time: 1.91 min [A], MS (E+) m / z: 603.5 [M+H]. Intermediate 324D: 6-(3-(4-(azetidin-3-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine 6-(3-(4-(azetidin-3-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (2.6 mg) was prepared according to the general procedure described in intermediate 307D using tert-butyl 3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)azetidine-1-carboxylate (450 mg, 0.746 mmol) as a starting intermediate to provide the title compound as a whitish solid. LC-MS retention time: 1.07 min [E], MS (E+) m / z: 373.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8, 77 (s, 1H), 8, 49 (s, 1H), 7, 67 (s, 1H), 7, 63-7, 44 (m, 4H), 4, 43-4, 23 (m, 3H), 3, 17-3, 07 (m, 1H) , 2.71 (s, 3H) , 1.99-1.88 (m, 2H) , 1.31 (s, 1H) , 1.2O (d, J=7.1 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 324D. Table 33 Example 324: 6- (4-isopropyl-3- (4- (l-methylazetidin-3-yl) phenyl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine If prepared 6- (4-isopropyl-3- (4- (l-methylazetidin-3-yl) phenyl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (13.6) performed with the general procedure described in example 307 using 6- (3- (4- (azetidin-3-yl) phenyl) -4-isopropyl-1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (30.0 mg, 0.081 mmol) as an intermediate product to provide the composition of the title as a white solid. CL-EM retention time: 1, 13 min [E], EM (E+) m / z: 387, 3 [M+H]; 1H-RMN (400 MHz, methanol-d4) 8, 77 (s, 1H) , 8, 49 (s, 1H) , 7, 66 (s, 1H) , 7, 65-7, 48 (m, 4H) , 4, 67 (s, 2H) , 4, 58 (s, 1H) , 4, 41 (s, 2H) , 4, 29 (s, 2H) , 3, 18-2, 99 (m, 5H) , 2, 71 (s, 3H) , 1, 40-1, 26 (m, 1H) , 1, 20 (d, J=7, 1 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 324. Table 34 Example 334 2-(dimethylamino)-1-(3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)azetidin-1-yl)ethan-1-one 2-(dimethylamino)-1-(3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)azetidin-1-yl)ethan-1-one (28.2 mg) was prepared according to the general procedure described in Example 323 using 6-(3-(4-(azetidin-3-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (40.010 mg, 0.107 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-EM retention time: 1.32 min [E], EM (E+) m / z: 458.3 [M+H]; 1H NMR (400 MHz, methanol-d4) 8, 77 (s, 1H) , 8, 49 (s, 1H) , 7, 67 (s, 1H) , 7, 62-7, 48 (m, 4H) , 4, 69 (t, 7=8, 6 Hz, 1H) , 4, 62-4, 55 (m, 1H) , 4, 39-4, 32 (m, 1H) , 4, 23-4, 11 (m, 2H) , 4, 09 (s, 2H) , 3, 13 (dt, J=14, 2, 7, 1 Hz, 1H) , 3, 04-2, 93 (m, 6H), 2, 71 (s, 3H) , 1, 32 (d, J=3, 7 Hz, 151H) , 1, 20 (d, J=7, 1 Hz, 6H) . The following example was prepared in accordance with the general procedure used to prepare example 334. Table 35 Example 336 1-(3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)azetidin-1-yl)-2-methylpropan-2-ol TEA (0.056 mL, 0.403 mmol) was added to a solution of 6-(3-(4-(azetidin-3-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (30.0 mg, 0.081 mmol) and 1-chloro-2-methylpropan-2-ol (17.49 mg, 0.161 mmol) in DMF (2.0 mL) at room temperature. The reaction mixture was stirred at 90 °C for 16 h. The reaction mass was purified by preparative LC / MS using the AA method. The fractions containing the product were combined and dried by centrifugal evaporation to obtain 1-(3-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)azetidin-1-yl)-2-methylpropan-2-ol (4.6 mg) as a white solid. LC-MS retention time: Ulmin [E], MS (E+) m / z: 445.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 76 (s, 1H) , 8, 48 (s, 1H) , 7, 67 (s, 1H) , 7, 60-7, 40 (m, 4H) , 4, 16 (d, J=T6 Hz, 2H) , 4, 083, 95 (m, 1H) , 3, 73 (sa, 2H) , 3, 12 (dt, 7=14, 4, 7, 1 Hz, 1H) , 2, 93-2, 78 (m, 2H) , 2, 762, 65 (m, 3H) , 1, 95 (s, 2H) , 1, 31 (sa, 1H) , 1, 29-1, 22 (m, 6H), 1, 20 (d, J=7, 1 Hz, 6H). The following examples were prepared in accordance with the general procedure used to prepare example 336. Table 36 Example 339 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine Intermediate product 339A: 6-bromo-3', 6'-dihydro-[3, 4'-bipyridine]-1' (21H)-tert-butyl carboxylate 6-bromo-3',6'-dihydro-[3,4'-bipyridin]-1'(21H)-tert-butyl carboxylate (1.4 g, 4.1310 mmol, 85% yield) was prepared according to the general procedure described in intermediate product 307A, using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridin-1(2H)-tert-butyl carboxylate (1.5 g, 4.85 mmol) and 2-bromo-5-iodopyridine (2.066 g, 7.28 mmol) as starting intermediates to provide the title compound as a light brown semisolid. LC-MS retention time: 1.80 min [A], MS (E+) m / z: 341.0 [M+2H]. Intermediate 339B: 6-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-3',6'-dihydro-[3,4'-bipyridin]-1'(21H) tert-butyl carboxylate 6-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-3',6'-dihydro-[3,4'-bipyridin]-1'(21H)-tert-butyl carboxylate (700 mg, 1.084 mmol, 52.5% yield) was prepared according to the general procedure described in intermediate product 307B using 6-bromo-3',6'-dihydro-[3,4'-bipyridin]-1'(21H)-tert-butyl carboxylate (0.700 g, 2.063 mmol) and 6-(4-isopropyl-3-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (1.695 g, 3.30 mmol) to produce the title compound as a light brown semisolid. LC-MS retention time: 1.75 min [A], MS (E+) m / z: 646.6 [M+H]. Intermediate 339C: 4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidine-1-carboxylate tert-butyl tert-butyl 4-(6-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidine-1-carboxylate (420 mg, 0.648) was prepared mmol, 59% yield) according to the general procedure described in intermediate 307C using 6-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-3',6'-dihydro-[3,4 '-bipyridin]-l' (21H) tert-butyl carboxylate (0.700 g, 1.084 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-MS retention time: 1.67 min [A], MS (E+) m / z: 648.6 [M+H]. Example 339: 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridin6-(4-isopropyl-3-(5-(piperidin-4-yl)pyridin-2-yl) -1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridin (25 mg) was prepared according to the general procedure described in intermediate 307D using 4-(6-(4-isopropyl-5-(8-methoxy-iazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy) methyl)-1H-pyrazol-3-yl) pyridin-3-yl) tert-butyl piperidin-1-carboxylate (500 mg, 0.772 mmol) as a starting intermediate to produce the title compound as a whitish solid.CL-EM retention time: 0.97 min [E], EM (E+) m / z: 418.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 65 (s, 1H) , 8, 54 (s, 1H) , 8, 45 (s, 1H) , 7, 86 (d, J= 6, 5Hz, 1H) , 7, 74 (d, 7=8, 0 Hz, 1H) , 7, 23 (s, 1H) , 4, 14 (s, 3H) , 3, 55-3, 45 (m, 2H) , 3, 40 (d, J=6, 0Hz, 1H) , 3, 17-3, 02 (m, 3H) , 2, 15 (d, 7=13, 6 Hz, 2H) , 2, 02-1, 87 (m, 4H), 1, 39-1, 13 (m, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 339. Table 37 Example 347 6-(3-(5-(1-ethylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine A mixture of 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (35 mg, 0.084 mmol), acetaldehyde (0.024 ml, 0.419 mmol) was stirred. mmol) and acetic acid (0.960 uL, 0.017 mmol) in MeOH (5.0 mL) at room temperature for 8 h. Sodium cyanoborohydride (10.54 mg, 0.168 mmol) was added at 0 °C and the reaction mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 6-(3-(5-(1-ethylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (2.5 mg) as a whitish solid.CL-EM retention time: 1.11 min [E], EM (E+) m / z: 446.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8.63 (sa, 1H) , 8.54 (s, 1H) , 8.44 (s, 1H) , 7.85 (sa, 1H) , 7.70 (d, 7=8.8 Hz, 1H) , 7.24 (s, 1H) , 4, 19-4, 07 (m, 3H) , 3, 27 (d, 7=11, 5 Hz, 2H) , 2, 82 (sa, 1H) , 2, 67 (d, 7=7, 1 Hz, 2H) , 2, 43-2, 29 (m, 2H) , 2, 09-1, 98 (m, 2H) , 1, 98-1, 85 (m, 6H), 1, 39-1, 10 (m, 11H). The following examples were prepared in accordance with the general procedure used to prepare Example 347. Table 38 Example 389 2-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidin-1-yl)-N, N-dimethylacetamide 2- (4- (6- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridine-3-yl) piperidin-1-yl) -N mg. el acuceda proceda (N-dimethyl conethylace general) was prepared in Example 321 , using 6- (4-isopropyl-3- (5- (piperidin-4-yl) pyridine-2-yl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazole[1, 5-a]pyridine intermediate (30) providing mm8 medium 0 compound of the title as a pale solid. Retention time of CL-EM 1, 28 min [C], EM (E+) m / z: 503, 3 [M+H]; 1H-RMN (400 MHz, methanol-d4) 8, 68 (s, 1H) , 8, 55 (s, 1H) , 8, 46 (s, 1H) , 7, 89 (d, J=8, 1 Hz, 1H) , 1, 7, H 7, 7,8 (d 23 (s, 1H) , 4, 31 (s, 2H) , 4, 14 (s, 3H) , 3, 81 (d, J= 12, 0 Hz, 2H) , 3, 47-3, 39 (m, 1H) , , 3, 17-3) ( (s, 1H) , 3, 12-2, 89 (m, 7H) , 2, 24 (s, 3H) , 2, 18 (s, 1H) , 1, 38-1, 19 (m, 7H) . The following examples were prepared in accordance with the general procedure used to prepare example 389. Table 39 Example 402 2-(dimethylamino)-1-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidin-1-yl)ethan-1-one 2-(dimethylamino)-1-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidin-1-yl)ethan-1-one (32 mg) was prepared according to the general procedure described in example 323, using 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (35 mg, 0.084 mmol) as a starting intermediate to provide the title compound as an off-white solid. CL-EM 1 retention time, 16 min [C], EM (E+) m / z: 503, 3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 64 (s, 1H) , 8, 55 (s, 1H) , 8, 45 (s, 1H) , 7, 86 (d, J= 7, 6Hz, 1H) , 7, 71 (d, 7= 8, 6Hz, 1H) , 7, 24 (s, 1H) , 4, 74 (d, 7= 10, 5Hz, 1H) , 4, 42-4, 27 (m, 2H) , 4, 14 (s, 3H) , 3, 85 (d, 7= 11, 7Hz, 1H) , 3, 39 (d, 7= 7, 1Hz, 2H), 3, 122.96 (m, 16h) , 2.96-2.85 (m, 1H) , 2.72 (s, 3H) , 2.04 (d, 7= 11.2Hz, 2H) , 1.89-1.70 (m, 2H) , 1.38-1.21 (m, 6H). The following examples were prepared in accordance with the general procedure used to prepare example 402. Table 40 Example 405 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-ylphenyl)-N,N-dimethylazetidin-3-amine Intermediate product 405A: (1-(4-bromophenyl)azetidin-3-yl) tert-butyl carbamate Xantphos (0.139 g, 0.240 mmol), Pd2(dba)s (0.219 g, 0.240 mmol), and CS2CO3 (2.342 g, 7.19 mmol) were added to a degassed solution of tert-butyl azetidine-3-ylcarbamate hydrochloride (0.500 g, 2.396 mmol) and ibromo-4-iodobenzene (1.356 g, 4.79 mmol) in dioxane (10.0 ml). The reaction mixture was stirred at 100 °C for 15 h. The reaction mixture was diluted with ethyl acetate, filtered, and washed with excess ethyl acetate. The combined organic phases were washed with water and brine, dried over sodium sulfate, and concentrated to yield the crude compound. The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with 30% ethyl acetate in petroleum ether. The fractions were collected and concentrated to obtain tert-butyl (1-(4-bromophenyl)azetidin-3-yl)carbamate (500 mg, 1,528 mmol, 64% e yield) as a light yellow solid.Retention time of CL-EM 1.52 min [A], EM (E+) m / z: 273.1 [M-tBu+H]. Intermediate product 405B: (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1- ( (2- (trimethylsilyl) ethoxy) methyl) -1H-pyrazol-3-yl) phenyl-3-dezetyl-carbatoyl) el (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1- ((2- (trimethyl silyl) ethoxy) methyl) -1H-pyrazol-3-yl) phenyl) azetidin-3-yl) terc-butyl carbamate (260 mg, 0.421 mmol, 34% yield) was carefully prepared with the general process described in the intermediate product 307B, using (1- (4-bromophenyl) azetidin-3-yl) tertbutyl carbamate (0.400 g, 1.222 mmol) and 6- (4-isopropyl-3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1- ( (2- (trimetilsilyl) etoxi) m ethyl) -1H-pirazol-5-yl) -8-metil-[1, 2, 4]triazolo[1, 5-a]piridina (0.791 g, 1.589 mmol) como producto intermedio de partida para proporcionar el compuesto del título como un sólido gmoso. Tiempo de retención de CL-EM: 1, 80 min [A], EM (E+) m / z: 618, 5 [M+H]. Intermediate product 405C: 1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) phenyl) azetidine-3-amine 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)azetidin-3-amine (1.2 mg) was prepared according to the general procedure described in intermediate 307D using (1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)azetidin-3-yl) tert-butyl carbamate (250 mg, 0.405 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-EM retention time: 1.21 min [E], EM (E+) m / z: 388.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 62 (s, 1H) , 8, 36 (s, 1H) , 7, 54 (s, 1H) , 7, 31-7, 22 (m, 7=8, 6 Hz, 2H) , 6, 61-6, 46 (m, 7=8, 6 Hz, 2H) , 4, 21-4, 11 (m, 2H) , 4, 07-4, 00 (m, 1H) , 3, 76 (dd, J=8, 6, 4, 6 Hz, 2H) , 3, 27-3, 24 (m, 1H) , 2, 97 (dt, 7=14, 6, 7, 5Hz, 1H) , 2, 59 (s, 3H), 1, 94 (s, 1H), 1, 26-1, 16 (m, 2H), 1, 11-1, 03 (m, 6H). Example 405: 1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) -N, N-dimethylazeti din-3-amine 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylazetidin-3-amine (0.9 mg) was prepared according to the general procedure described in Example 307, using 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)azetidin-3-amine (30 mg, 0.077 mmol) as a starting intermediate to provide the title compound as a white solid. LC-MS retention time: 1.58 min [E], MS (E+) m / z: 416.3 [M+H]; 1H NMR (400 MHz, DMSO-d6) 7.92 (s, 1H) , 7.66 (s, 1H) , 6.86 (s, 1H) , 6.54 (d, 7=8, 3 Hz, 2H) , 5.83 (d, 7=8, 1 Hz, 2H) , 3.29 (t, 7=7, 3 Hz, 2H) , 2.95 (t, 7=6, 7 Hz, 2H) , 2.62-2.57 (m, 1H) , 2.56 (s, 2H) , 2.32-2.23 (m, 1H) , 1.94-1.83 (m, 4H) , 1, 51 (s, 6H) , 1.25 (s, 1H) , 1.18 (s, 1H) , 0.50 (s, 2H) , 0.45 (s, 1H) , 0.37 (d, 7=7, 1 Hz, 7H) , 0.27 (s, 1H) , 0.09 (s, 1H). The following examples were prepared in accordance with the general procedure used to prepare example 405C. Table 41 The following examples were prepared in accordance with the general procedure used to prepare example 405. Table 42 Example 417 6-(4-isopropyl-3-(4-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine 1-Chloro-2-(methylsulfonyl)ethane (0.053 g, 0.374 mmol) and DIPEA (0.065 ml, 0.374 mmol) were added to a solution of 6-(4-isopropyl-3-(4-(piperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.030 g, 0.075 mmol) in DMF (1.0 ml) and THF (1.0 ml) at 0 °C. The reaction mixture was stirred at 90 °C for 16 h. The reaction mass was purified by preparative LC-MS using the AB method, the fractions were collected and dried by centrifugal evaporation to obtain 6-(4-isopropyl-3-(4-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (2.6 mg) as a whitish solid. LC-MS retention time: 1.03 min [D], MS (E+) m / z: 508.3 [M+H]; 1H NMR (400 MHz, methanol-d4) 8, 73 (sa, 1H), 8, 48 (d, 7=1, 5 Hz, 1H), 7, 66 (sa, 1H), 7, 55-7, 37 (m, 2H), 7, 17 (d, J=6, 5 ​​Hz, 2H), 3, 76-3, 70 (m, 2H), 3, 69-3, 64 (m, 2H), 3, 57 (sa, 4H), 3, 48 (sa, 5H) , 3, 18-3, 13 (m, 3H) , 3, 07 (d, J=9, 5 Hz, 2H) , 2, 70 (sa, 3H) , 1, 38 (sa, 1H) , 1, 35-1, 27 (m, 3H) , 1, 20-1, 12 (m, 7H) , 1.08 (sa, 1H) , 0.89 (sa, 1H) . The following examples were prepared in accordance with the general procedure used to prepare example 417. Table 43 Example 420 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-4-methylpiperazin-2-one Intermediate product 420A: tert-butyl 4-(4-bromophenyl)-3-oxopiperazine-1-carboxylate, Copper(I) iodide (0.135 g, 0.707 mmol), N,N'-dimethylethylenediamine (0.062 g, 0.707 mmol), and K3PO4 (2.155 g, 12.37 mmol) were added to a degassed solution of 1-bromo-4-iodobenzene (1.0 g, 3.53 mmol) and tert-butyl 3-oxopiperazine-1-carboxylate (0.708 g, 3.53 mmol) in DMF (20.0 mL). The mixture was stirred at 100 °C for 14 h in a sealed tube. The reaction mixture was extracted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 40 g silica column, eluted with 45% ethyl acetate in petroleum ether, and the fractions were collected and concentrated to obtain tert-butyl 4-(4-bromophenyl)-3-oxopiperazine-1-carboxylate (420 mg, 1.182 mmol, 33% yield) as a light brown semisolid. CL-MS retention time: 1.21 min [A], MS (E+) m / z: 357.4 [M+2H]. INTERMEDIATE PRODUCT 420B: 4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-yl) phenyl)-3-oxopiperazine-1-carboxylate de tert-butyl 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)-3-oxopiperazine-1-carboxylate tert-butyl (220 mg, 0.341 mmol, 34% yield) was prepared according to the general procedure described in intermediate 307B using 4-(4-bromophenyl)-3-oxopiperazine-1-carboxylate tert-butyl (0.357 g, 1.005 mmol) and 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.500 g, 1.005 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-MS retention time: 1.58 min [A], MS (E+) m / z: 646.4 [M+H]. Intermediate 420C: 1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)piperazin-2-one 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)piperazin-2-one (5.4 mg) was prepared according to the general procedure described in intermediate 307D using tert-butyl 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)-3-oxopiperazine-1-carboxylate (0.210 g, 0.325 mmol) as a starting intermediate to provide the title compound as a gummy solid. LC-MS retention time: 1.063 min [E], MS (E+) m / z: 416.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 77 (s a., 1H) , 8, 48 (s, 1H) , 7, 75-7, 56 (m, 3H) , 7, 50 (d, J=8, 3 Hz, 2H) , 3, 89-3, 72 (m, 2H) , 3, 67 (s, 2H), 3, 18-3, 06 (m, 1H), 2, 71 (s, 3H), 1, 21 (d, J=7, 1 Hz, 6H). Example 420: 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-il)-1H-pirazol-3-il)phenyl)-4-methylpiperazin-2-ona Prepare 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pirazol-3-yl)phenyl)-4-methylpiperazin-2-ona (2,3 mg) according to the general procedure described in Example 307, using 1-(4-(4-isopropyl-5-(8-methyl-[1, 2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pirazol-3-yl)phenyl)piperazin-2-ona (30 mg, 0,072 mmol) as starting intermediate providing the title compound as a solid blanco. CL-EM retention time: 1, 21 min [E], EM (E+) m / z: 430, 2 [M+H]; * H-RMN (400 MHz, methanol-d4) 8, 77 (s, 1H) , 8, 49 (s, 1H) , 7, 77-7, 59 (m, 3H) , 7, 54 (d, 7=8, 5 Hz, 2H) , 4, 24-3, 98 (m, 4H) , 3, 76 (t, J=5, 3 Hz, 2H) , 3, 18-3, 05 (m, 4H) , 3, 01 (s, 1H) , 2, 80-2, 64 (m, 4H) , 1, 21 (d, J= 7, 0Hz, 7H) . The following examples were prepared in accordance with the general procedure used to prepare example 420. Table 44 Example 423 6-(3-(5-(4-cyclobutylpiperazin-1-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine Intermediate product 423A: tert-butyl 4-(pyridin-3-yl)piperazin-1-carboxylate Pd2(dba)5 (0.869 g, 0.949 mmol) and Xantphos (1.099 g, 1.899 mmol) were added to a degassed solution of 3-bromopyridine (3.0 g, 18.99 mmol), tert-butyl piperazine-1-carboxylate (3.54 g, 18.99 mmol), and sodium tert-butoxide (5.47 g, 57.0 mmol) in dioxane (75 mL). The mixture was stirred at 10 °C for 16 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated to give the crude compound. The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with 50–65% ethyl acetate and petroleum ether. The fractions were collected and concentrated to give tert-butyl 4-(pyridin-3-yl)piperazin-1-carboxylate (3.5 g, 13.29 mmol, 70% yield) as a light brown solid. Cl-MS retention time: 1.28 min [A], MS (E+) m / z: 264.4 [M+2H]. Intermediate product 423B: tert-butyl 4-(6-bromopyridin-3-yl)piperazin-1-carboxylate NBS (1.487 g, 8.35 mmol) was added to a solution of tert-butyl 4-(pyridin-3-yl)piperazine-1-carboxylate (2.2 g, 8.35 mmol) in acetonitrile (50 mL) at 0 °C. The mixture was stirred at the same temperature for 1 h. The reaction mixture was slowly inactivated with 5% aqueous NaOH solution, extracted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated to give the crude compound. The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with 25-30% ethyl acetate in petroleum ether. The fractions were collected and concentrated to yield tert-butyl 4-(6-bromopyridin-3-yl)piperazin-1-carboxylate (1.6 g, 4.68 mmol, 56.0% yield) as a pale brown solid. Cl-MS retention time: 1.66 min [A], MS (E+) m / z: 344.4 [M+2H]. Intermediate product 423C: 4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-yl) pyridin-3-yl) piperazin-1-carboxylate de tert-butyl if prepared 4- (6- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1- ((2- (trimethylsilyl) ethoxi) methyl) -1H-pyrazol-3-yl) pyridin-3-yl) piperazin-1-carboxylate of terc-butyl (620 mg, 0.955 mmol, 47% yield) prepared with the general procedure described in the intermediate product 307B, using 4-(6-bromopyridin-3-yl) piperazine-1-carboxylate of tert-butylene (0.700 g, 2.045 mmol) and 6-(4-isopropyl-3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1- ((2- (trimethylsilyl) ethoxy) methyl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1, 681 g, 3, 27 mmol) as intermediate products to be produced the composition of the title as a solid blanquecino. CL-EM retention time: 1, 46 min [A], EM (E+) m / z: 649, 6 [M+H]. Intermediate product 423D: 6- (4-isopropyl-3- (5- (piperazin-1-yl) pyridin-2-yl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazole[1, 5-a]pyridine Se preparó 6- (4-isopropil-3- (5- (piperazin-1-il) piridin-2-il) -1H-pirazol-5-il) -8-methoxy-[1, 2, 4]triazolo [1, 5-a]piridina (18, 7 mg) de acuerdo con el procedimiento general descrito en el producto intermedio 307 B usando 4- (6- (4-isopropil-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1- ( (2- (trimetilsilyl) etoxi) metil) -1H-pirazol-3-il) piridin-3-il) piperazin-1-carboxylato de terc-butilo (730 mg, 1, 125 mmol) como producto intermediate part to present the composition of the title as a solid white. CL-EM retention time: 0, 96min [C] EM (E+) m / z: 419, 3 [M+H]; 1H-RMN (400 MHz, methanol-d4) = 8, 53 (s, 1H) , 8, 49 (da, 7=1, 2 Hz, 1H) , 8, 44 (s, 1H) , 7, 71-7, 62 (m, 1H) , 7, 61-7, 51 (m, 1H) , 7, 30-7, 17 (m, 1H) , 4, 14 (s, 3H) , 3, 64-3, 54 (m, 4H) , 3, 49-3, 40 (m, 4H) , 3, 39-3, 34 (m, 1H) , 1, 27 (d, 7=7, 3 Hz, 6H). Ejemplo 423: 6- (3- (5- (4-cyclobutilpiperazin-1-il) piridin-2-il) -4-isopropil-1H-pirazol-5-il) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]piridin-6- (3- (5- (4-cyclobutilpiperazin-1-il) piridin-2-il) -4-isopropil-1H-pirazol-5-il) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]piridine (12, 3 mg) se preparó de acuerdo con el procedimiento general descrito en el ejemplo 307 usando 6- (4-isopropil-3- (5- (piperazin-1-il) piridin-2-il) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazole [1, 5-a]pyridine (25.0 mg, 0.060 mmol) and cyclobutanone (12.56 mg, 0.179 mmol) as intermediates to produce the title compound as a white solid.CL-EM retention time: 1.65 min [C], EM (E+) m / z: 473.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 52 (s, 1H), 8, 46-8, 34 (m, 2H), 7, 617, 54 (m, 1H), 7, 53-7, 45 (m, 1H), 7, 24 (s, 1H), 4, 14 (s, 3H) , 3, 44-3, 38 (m, 4H) , 3, 31-3, 26 (m, 1H) , 2, 99-2, 90 (m, 1H) , 2, 70-2, 59 (m, 4H) , 2, 23-2, 11 (m, 2H) , 2, 08-1, 96 (m, 2H), 1.88-1.75 (m, 2H), 1.26 (d, 7=7.1 Hz, 6H). The following example was prepared in accordance with the general procedure used to prepare example 423D. Table 45 The following examples were prepared in accordance with the general procedure used to prepare example 423. Table 46 Example 451 2-(dimethylamino)-1-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)piperazin-1-yl)ethan-1-one Se preparó 2- (dimetilamino) -1- (4- (6- (4-isopropil-5- (8-metoxi-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1H-pirazol-3-il) piridin-3-il) piperazin-1-il) etan-1-ona (19, 4 mg) de acuerdo con el procedimiento general descrito en el ejemplo 323, utilizzare 6- (4-isopropil-3- (5- (piperazin-1-il) piridin-2-il) -1H-pirazol-5-il) -8-metoxi-[1, 2, 4]triazolo[1, 5-a]piridina (25, 0 mg, 0, 060 mmol) como producto intermedio de partida para obtener el composed of the title as a solid blanquecino. CL-EM retention time: 1, 15 min [F], EM (E+) m / z: 504, 3 [M+H]; 1H-RMN (400 MHz, methanol-d4) 8, 56 (d, 7=1, 2 Hz, 1H) , 8, 46 (s, 1H) , 8, 42 (d, 7=2, 0 Hz, 1H) , 7, 90-7, 78 (m, 2H) , 7, 21 (d, 7=1, 0 Hz, 1H) , 4, 36 (s, 2H) , 4, 14 (s, 3H) , 3, 91-3, 85 (m, 2H) , 3, 70-3, 66 (m, 2H) , 3, 58-3, 49 (m, 4H) , 3, 30 (d, 7=6, 8Hz, 1H) , 3, 00 (s, 6H) , 1, 28 (d, 7=7, 1 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 451. Table 47 Example 454 6-(4-isopropyl-3-(5-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine To a solution of 6-(4-isopropyl-3-(5-(piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (25.0 mg, 0.060 mmol), 1-chi oro-2-(methylsulfonyl)ethane (12. 78 mg, 0.090 mmol) in DMF (1.0 mL) and THF (1.0 mL) was added to TEA (0.042 mL, 0.299 mmol) at room temperature. The reaction mixture was stirred for 16 h. The reaction mass was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 6-(4-isopropyl-3-(5-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (17.6 mg) as a white solid.CL-EM retention time: 1.29 min [E], EM (E+) m / z: 525.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 52 (s, 1H) , 8, 43 (s, 1H) , 8, 41 (da, J=2, 1 Hz, 1H) , 7, 617, 54 (m, 1H) , 7, 52-7, 46 (m, 1H) , 7, 24 (s, 1H) , 4, 14 (s, 3H) , 3, 44-3, 36 (m, 6H) , 3, 29 (sa, 1H) , 3, 11 (s, 3H) , 2, 97 (t, J=6, 7 Hz, 2H) , 2, 82-2, 71 (m, 4H), 2, 68 (s, 1H) , 1, 31 (s, 1H) , 1, 26 (d, J= 7, 1Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 454. Table 48 Example 459 2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-4-methylmorpholine Intermediate product 459A: 2-(4-nitrophenyl)oxirane A solution of 2-bromo-1-(4-nitrophenyl)ethanone (10.503 g, 43.0 mmol) in MeOH (100 ml) (compound not completely dissolved) was given NaBH4 (2.035 g, 53.8 mmol) in portions at 0 °C (gas evolution was observed and then it became a clear solution). The reaction mixture was stirred at the same temperature for 5 min. After stirring at room temperature for 2 h, K2CO3 (6.54 g, 47.3 mmol) was added in portions. The suspension was stirred at room temperature for 6 h. The reaction mass was concentrated, the residue was diluted with water (100 ml), extracted with DCM (2 x 150 ml), the combined organic extracts (Na2SO4) were dried and concentrated to obtain 2-(4-nitrophenyl)oxirane (6.63 g, 40.1 mmol, 93% yield) as a pale yellow solid. 1H-NMR (300 MHz, CDCh) ppm 8.23 ​​(d, J = 9 Hz, 1 H), 7.46 (d, J = 9 Hz, 1 H), 3.99-3.97 (m, 1 H), 3.25-3.21 (m, 1 H), 2.79-2.76 (m, 1H). Intermediate product 459B: 2-((2-hydroxyethyl)amino)-1-(4-nitrophenyl)ethanol 2-(4-Nitrophenyl)oxirane (6.256 g, 37.9 mmol) was stirred in ethanolamine (100.00 mL) at 40 °C for 2 h. TLC showed no trace of the starting material and the formation of a new polar spot. The reaction mixture was diluted with water (100 mL) and EtOAc (100 mL). The two phases were separated. The aqueous phase was extracted with EtOAc (2 x 100 mL), the combined organic extracts were washed with water (100 mL) and brine (20 mL), dried with Na₂SO₄, and concentrated to obtain the crude compound. The crude compound was ground with acetonitrile (3 x 20 mL) to obtain 2-((2-hydroxyethyl)amino)-1-(4-nitrophenyl)ethanol (4.65 g, 20.55 mmol, 54.3% yield) as a white solid. CL-MS retention time 0.48 min [G], MS (E-) m / z: 227.3 [M+H]. Intermediate product 459C: (2-hydroxy-2-(4-nitrophenyl)ethyl) (2-hydroxyethyl) tert-butyl carbamate To a solution of 2-((2-hydroxyethyl)amino)-1-(4-nitrophenyl)ethanol (4.62 g, 20.42 mmol) in DCM (60.00 mL) was added TEA (3.42 mL, 24.51 mmol). The reaction mixture was stirred for 5 min. Then, BOc₂O (5.22 mL, 22.46 mmol) was added and dissolved in DCM (5 mL) dropwise at room temperature. The reaction mixture was stirred at the same temperature. Initially, the compound did not dissolve completely. After the addition of BOC₂O, the compound dissolved completely. The reaction mixture was stirred at room temperature for 2 h. The reaction was stopped by adding water. The reaction mixture was extracted with DCM, the organic phase was dried (Na2SO4) and concentrated to obtain the crude compound.The crude compound was purified by ISCO using an 80 g silica column. The compound was eluted in 4% MeOH in CHCh, and the fractions were collected and concentrated to obtain tert-butyl (2-hydroxy-2-(4-nitrophenyl)ethyl)(2-hydroxyethyl)carbamate (6.6 g, 20.22 mmol, 99% yield) as a white solid. CL-MS retention time: 1.00 min [G], MS (E-) m / z: 327.3 [M + H]. Intermediate product 459D: 2-(4-nitrophenyl)morpholine-4-carboxylate tert-butyl TEA (7.33 mL, 52.6 mmol) was added to a solution of tert-butyl (2-hydroxy-2-(4-nitrophenyl)ethyl)(2-hydroxyethyl)carbamate (6.6 g, 20.22 mmol) and triphenylphosphine (6.37 g, 24.27 mmol) in toluene (120.00 mL) at 0 °C. The reaction mixture was stirred for 5 min. Then, di-tert-butyl azodicarboxylate (5.59 g, 24.27 mmol) dissolved in toluene (20 mL) was added dropwise at the same temperature. The reaction mixture was stirred at room temperature for 16 h. The reaction was stopped with water (50 mL). The phases were separated, the aqueous phase was extracted with EtOAc (2 x 50 ml), the combined organic extracts were dried (Na2SO4) and concentrated to obtain the crude compound. The crude compound was purified by ISCO using an 80 g silica column; the compound was 25% EA in hexane. The fraction was collected and concentrated to obtain the compound as a gummy solid.The gummy solid compound was ground with hexane (2 x 20 mL) and then the solid was vacuum dried to obtain 2-(4-nitrophenyl)morpholin-4-tert-butyl carboxylate (4.2 g, 13.62 mmol, 67% yield) as a white solid. (The product and reagent come in the same solvent system during column purification and cannot be removed from the hexane grinding as well). CL-EM retention time 2.804 min [H], EM (E-) m / z: 253.2 [M+H-tBu]. Intermediate product 459E: 2-(4-aminophenyl)morpholine-4-carboxylate tert-butyl Pd / C (1.450 g, 13.62 mmol) was added to a solution of 2-(4-nitrophenyl)morpholin-4-tert-butyl carboxylate (4.2 g, 13.62 mmol) in MeOH (75 mL). The reaction mixture was stirred at room temperature in a hydrogen bladder for 3 h. The reaction mixture was filtered through Celite and concentrated to obtain the crude compound. The crude compound was purified by ISCO using an 80 g silica column. The compound was eluted in 35% hexane EA, and the fractions were collected and concentrated to obtain 2-(4-aminophenyl)morpholin-4-tert-butyl carboxylate (2.25 g, 8.08 mmol, 59% yield) as a white solid. CL-EM retention time 1, 588 min [H], EM (E-) m / z: 223, 0 [M+H-tBu], Intermediate product 459F: 2-(4-bromophenyl)morpholine-4-carboxylate tert-butyl To a solution of copper(II) bromide (0.241 g, 1.078 mmol) in acetonitrile (5 ml) were added tert-butyl nitrite (0.148 g, 1.437 mmol) and tert-butyl 2-(4-aminophenyl)morpholin-4-carboxylate (0.2 g, 0.719 mmol) at 0 °C. The resulting solution was stirred at room temperature for 12 h. The reaction mass was filtered through Celite, washed with EtOAc (50 ml) and the filtrate was concentrated to obtain the crude product. The crude compound was purified by ISCO using a 24 g silica column, eluting with 9% EtOAc / petroleum ether. The fractions were collected and concentrated to obtain 2-(4-bromophenyl)morpholin-4-tert-butyl carboxylate (125 mg, 0.365 mmol, 50.8% yield) as a white oil. CL-EM retention time 3.52 min [D], EM (E-) m / z'.243.2 [M+H-Boc]. Intermediate product 459G: 2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-yl) phenyl) tert-butyl morpholine-4-carboxylate A mixture of 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine was degassed (0.872 g, 1.753 mmol), tert-butyl 2-(4-bromophenyl)morpholine-4-carboxylate (0.500 g, 1.461 mmol) and K2CO3 (0.606 g, 4.38 mmol) in acetonitrile (32.00 mL) and water (8.00 mL) for 10 min with nitrogen. Next, Pd2(dba)s (0.067 g, 0.073 mmol) and 2-dicyclohexylphosphine-2',6'-dimethoxybiphenyl (0.060 g, 0.146 mmol) were added, and the reaction mixture was stirred for 5 min. The reaction mixture was stirred at 110 °C for 16 h. The two phases were separated, the aqueous phase was extracted with DCM (2 x 30 mL), the combined organic extracts (Na2SO4) were dried, and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 24 g silica column. The compound was eluted in 50% hexane EA, and the fractions were collected and concentrated to obtain 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl) morpholin-4-carboxylate tert-butyl (0.627 g, 0.991 mmol, 68% yield) as a gummy solid. CL-MS retention time 1.93 min [A], MS (E-) m / z: 633.8 [M+H]. Intermediate 459H: 2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholine. To a solution of 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1Hpyrazol-3-yl)phenyl)morpholin-4-carboxylate tert-butyl (0.900 g, 1.422 mmol) in dioxane (5.00 ml) 4 M hydrochloric acid in dioxane (5.00 ml, 20.00 mmol) was added at room temperature. The reaction mixture was stirred at 70 °C for 16 h. The reaction mass was concentrated, ground with diethyl ether (2 x 10 ml), then vacuum dried to obtain the crude compound. The crude compound was purified by preparative HPLC using the AC method, the fractions contained in the compound were collected and concentrated to obtain 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholine (0.480 g, 1.193 mmol, 84% yield) as a white solid. Racemic 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholine was subjected to SFC for enantiomer separation. After purification of chiral SFC using the AD method, the fractions were collected, concentrated, and lyophilized to obtain: Enantiomer 1, chiral SFC Tr-6.92: (0.150 g, 0.373 mmol, 31% yield) and Enantiomer 2, chiral SFC Tr-9.69: (0.135 g, 0.335 mmol, 28% yield) as a white solid. CL-EM retention time 0.77 min [A], EM (E-) m / z: 403.6 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8, 76 (s, 1H) , 8, 48 (s, 1H) , 7, 67 (s, 1H) , 7, 53 (s, 4H) , 4, 64 (dd, J=10, 8, 2, 3 Hz, 1H) , 4, 15-4, 05 (m, 1H) , 3, 86 (td, J=11, 3, 3, 5 Hz, 1H) , 3, 21-3, 06 (m, 2H) , 3, 05-2, 94 (m, 2H) , 2, 87-2, 76 (m, 1H) , 2, 71 (s, 3H), 1, 96 (s, 1H) , 1, 19 (d, J=7, 0 Hz, 6H) . Example 459: 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-4-methylmorpholine Formaldehyde in water (0.2 ml, 2.178 mmol) and acetic acid (0.1 ml, 1.747 mmol) were added to a solution of 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholine (0.012 g, 0.030 mmol) in MeOH (1.5 ml) at room temperature. The mixture was stirred at the same temperature for 6 h. Sodium cyanoborohydride (9.37 mg, 0.149 mmol) was added to the reaction mixture at room temperature. The reaction mixture was stirred at the same temperature for 16 h.The reaction mass was purified by preparative LC-MS using the AA method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-4-methylmorpholine (7.2 mg, 0.016 mmol, 55% yield) as a pale solid. LC-MS retention time 1.48 min [E], MS (E-) m / z: 403.6 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8, 76 (s, 1H) , 8, 48 (s, 1H) , 7, 67 (s, 1H) , 7, 54 (s, 4H) , 4, 65 (dd, 7=10, 5, 2, 5 Hz, 1H) , 4, 10 (dd, 7=11, 5, 2, 0 Hz, 1H) , 3, 93-3, 83 (m, 1H) , 3, 15-3, 01 (m, 2H) , 2, 89 (d, 7=13, 6 Hz, 1H) , 2, 71 (s, 3H) , 2, 47-2, 26 (m, 4H), 2, 19 (t, 7=11, 0 Hz, 1H) , 1, 19 (d, 7=7, 5 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 459. Table 49 Example 466 2- (2- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl)phenyl) morpholino) -N, N-dimethylacetamide To a solution of 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholine (0.008 g, 0.020 mmol) in a solvent mixture of THF (1.00 ml) and DMF (0.50 ml) were added TEA (0.15 ml, 1.076 mmol) and 2-chloro-N,N-dimethylacetamide (4.83 mg, 0.040 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 16 h. The reaction mass was purified by preparative LC-MS using the AA method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholino)-N,N-dimethylacetamide (8.1 mg, 0.016 mmol, 82% yield) as a pale solid. LC-MS retention time 1.451 min [E], MS (E-) m / z: 488.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.75 (s a., 1H), 8. 47 (s, 1H), 7. 68 (s a., 1H) , 7.52 (s, 4H) , 4.74-4.67 (m, 1H) , 4.05 (dd, 7=11.5, 2.0 Hz, 1H) , 3.91 (td, 7=11.5, 2.5 Hz, 1H) , 3.37 (s, 1H), 3, 21-3, 03 (m, 5H), 2, 98 (s, 3H), 2, 89 (d, 7=12, 5 Hz, 1H), 2, 71 (s, 3H), 2, 43 (td, 7=11, 5, 3, 5 Hz, 1H), 2, 24 (t, 7=10, 8 Hz, 1H) . The following examples were prepared in accordance with the general procedure used to prepare example 466. Table 50 Example 469 2-(dimethylamino)-1-(2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholino)ethan-1-one To a solution of 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholine (0.008 g, 0.020 mmol) in DMF (1.00 ml) were added TEA (0.15 ml, 1.076 mmol), dimethylglycine (4.10 mg, 0.040 mmol) and HATU (0.015 g, 0.040 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 16 h. The reaction mass was purified by preparative LC-MS using the AA method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(dimethylamino)-1-(2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholino)ethan-1-one (3.1 mg, 6.36 mol, 32% yield) as a pale solid. LC-MS retention time 1.302 min [E], MS (E-) m / z: 488.3[M+H]; 1H NMR (400 MHz, methanol-d4) ppm 8.77 (s, 1H), 8.48 (s, 1H), 7.67 (s, 1H), 7.63-7.48 (m, 4H), 4.63 (s a., 1H) , 4, 44 (d, J=13, 6 Hz, 1H) , 4, 22-4, 05 (m, 2H) , 3, 97 (d, J=13, 1 Hz, 1H) , 3, 84-3, 67 (m, 1H) , 3, 65-3, 48 (m, 1H) , 3, 45-3, 35 (m, 2H) , 3, 283, 06 (m, 2H) , 3, 04-2, 93 (m, 1H) , 2, 83 (dd, J=13, 6, 11, 0 Hz, 1H) , 2, 71 (s, 3H) , 2, 46 (s, 6H) , 1, 95 (s, 1H), 1, 20 (d, J=7, 0 Hz, 6H) . The following example was prepared in accordance with the general procedure used to prepare example 469. Table 51 Example 471 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-ylphenyl)-N-methylcyclohexan-1-amine Intermediate product 471 A: 8-(4-bromophenyl)-1,4-dioxaspiro[4.5]dec-7-ene The PdCl2 (dppf)-CH2C12 adduct (0.767 g, 0.939 mmol) and K3PO4 (4.91 g, 28.2 mmol) were added to a degassed mixture of 1-bromo-4-iodobenzene (3.99 g, 14.09 mmol) and 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4,5]dec-7en-8-yl)-1,3,2-dioxaborolane (2.5 g, 9.39 mmol) in dioxane (60.0 mL) and water (10.0 mL). The mixture was stirred at 100 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, and washed with excess ethyl acetate. The combined organic phases were washed with water and brine, dried over sodium sulfate, and evaporated to give the crude product. The crude product was purified by ISCO using a 40 g silica column, the compound was eluted with 35–45% ethyl acetate in petroleum ether, the fractions were collected, and concentrated to give 8-(4-bromophenyl)-1,4-dioxaspiro[4,5]dec-7-ene (2.5 g, 8.47 mmol, 90% yield) as a light yellow semisolid.CL-EM retention time: 3.13 min [B], EM (E+) m / z: 297.2 [M+2H]. Intermediate 471B: 2- (4- (1, 4-dioxaspiro[4.5]dec-7-en-8-yl) phenyl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane PdC12(dppf)-CH22 adduct (0.830 g, 1.016 mmol) and potassium acetate (2.99 g, 30.5 mmol) were added to a degassed solution of BISPIN (3.36 g, 13.21 mmol) and 8-(4-bromophenyl)-1,4-dioxaspiro[4,5]dec-7-ene (3.0 g, 10.16 mmol) in dioxane (80.0 mL). The reaction mixture was stirred at 100 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, and washed with excess ethyl acetate. The filtrate was dried over sodium sulfate and evaporated to obtain the crude compound. The crude compound was purified by ISCO using a 40 g silica column, the compound was eluted with 2545% ethyl acetate in petroleum ether, the fractions were collected and concentrated to obtain 2-(4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.2 g, 9.35 mmol, 92% yield) as a light brown semisolid.CL-EM retention time 2, 48 min [B], EM (E+) m / z: 343, 2 [M+2H]. Intermediate product 471C:6- (3- (4- (1, 4-dioxaespiro[4.5]dec-7-en-8-yl) phenyl) -4-isopropyl-1- ((2- (trimethylsilyl) ethoxy) methyl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine Se preparó 6- (3- (4- (1, 4-dioxaspiro[4.5]dec-7-en-8-yl) phenyl) -4-isopropyl-1- ( (2- (trimethylsilyl) ethoxy) methyl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (3, 5 g, 5, 97 mmol, 90 % de rendimiento) de acuerdo con el procedimiento general descrito en el producto intermedio 307B, uso 6- (3-bromo-4-isopropyl-1- ( (2- (trimethylsilyl) ethoxy) methyl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (3, 0 g, 6, 66 mmol) and 2- (4- (1, 4-dioxaspiro [4.5]dec-7-en-8-yl) phenyl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (2, 74 g, 7, 99 mmol) as intermediate products to provide the composition of the title as a chewy solid. CL-EM retention time: 1, 80 min [B], EM (E+) m / z: 586, 4 [M+H]. Intermediate product 471D: 6- (3- (4- (1, 4-dioxaspiro[4.5]decan-8-yl)phenyl) -4-isopropyl-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine Se preparó 6- (3- (4- (1, 4-dioxaspiro [4.5]decan-8-yl) fenil) -4-isopropyl-1- ( (2- (trimetilsilyl) etoxi) metil) -1H-pirazol-5-yl) -8-metil-[1, 2, 4]triazolo[1, 5-a]piridina (2. 0 g, 3. 40 mmol, rendimiento del 57%) de acuerdo con el proceso general descrito en el producto intermedio 307C, uso 6- (3- (4- (1, 4-dioxaspiro [4.5]dec-7-en-8-yl) fenil) -4-isopropyl-1- ( (2- (trimetilsilyl) etoxi) metil) -1H-pirazol-5-yl) -8-metil-[1, 2, 4]triazole[1, 5-a]pyridine (3, 5 g, 5, 97 mmol) as an intermediate product to provide the composition of the title as a white solid. CL-EM retention time: 4, 53 min [B], EM (E+) m / z: 588, 2 [M+H]. Intermediate product 471E: 4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) phenyl) cyclohexan-1-one To a solution of 6-(3-(4-(1,4-dioxaspiro[4.5]decan-8-yl)phenyl)-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (2.2 g, 3.74 mmol) in DCM (25.0 ml) was added to TFA (7.21 ml, 94 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 12 h. The reaction mass was concentrated, ground with diethyl ether, and vacuum dried to provide 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)cyclohexan-1-one (1.6 g, 3.87 mmol) as a whitish solid. CL-MS retention time: 1.18 min [A], MS (E+) m / z: 414.4 [M+H]. Example 471: 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylcyclohexan-1-amine A mixture of 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)cyclohexan-1-one (1.6 g, 3.87 mmol), methylamine hydrochloride (2.61 g, 38.7 mmol) and acetic acid (0.044 ml, 0.774 mmol) was stirred in DMF (20.0 ml) at room temperature for 8 h. Sodium cyanoborohydride (0.486 g, 7.74 mmol) was added at 0 °C and the reaction mixture was stirred at room temperature for 16 h. The reaction mass was concentrated to obtain the crude compound, which was then purified by preparative LC-MS using the AA method to separate the isomers. The fractions were collected, concentrated, and lyophilized to yield two isomers. Product intermedio 471 A: Isómero 1, como un solido blanco. Retention time for CL-EM: 1, 20 min [E], EM (E+) m / z: 429, 3 [M+H]; 1H-RMN (400 MHz, metanol-d4) 8, 75 (s a., 1H) , 8, 48 (s, 1H) , 7, 67 (s, 1H) , 7, 52-7, 44 (m, 7=8, 3 Hz, 2H) , 7, 44-7, 34 (m, J=8, 1 Hz, 2H) , 15-3, 80 (s, 1H) , 3, 13-2, 99 (m, 2H) , 2, 77-2, 65 (m, 5H) , 2, 28 (d, J=9, 5 Hz, 2H) , 2, 11 (d, J=13, 2 Hz, 2H) , 1, 93 (s, (2H) , 1, 77-1, 65 (m, 2H) , 1, 60-1, 50 (m, 2H) , 1, 31 (s, 4H) , 1, 19 (d, J=7, 1 Hz, 5H) , 0, 91 (d, J=7, 3 Hz, 2H) ; y Intermediate product 471B: Isomer 2, as a white solid. CL-MS retention time: 1.19 min [E], MS (E+) m / z: 429.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 75 (s, 1H) , 8, 48 (s, 1H) , 7, 67 (s, 1H) , 7, 54-7, 45 (m, 2H) , 7, 44-7, 32 (m, 2H) , 3, 18-2, 94 (m, 3H) , 2, 79-2, 61 (m, 7H) , 2, 28 (d, J=10, 8 Hz, 2H) , 2, 10 (d, J=12, 5 Hz, 2H) , 1, 92 (s, 3H) , 1, 71 (qd, 7=12, 9, 3, 1Hz, 2H), 1, 62-1, 47 (m, 2H), 1, 31 (s, 1H), 1, 19 (d, J=7, 1 Hz, 6H). The following examples were prepared in accordance with the general procedure used to prepare example 471A / B. Table 52 Example 510 4- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N, N-dimethylcyclohexane-1-amine A solution of 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylcyclohexan-1-amine (20.0 mg, 0.047 mmol), formaldehyde (6.43 µl, 0.233 mmol) and acetic acid (0.534 µl, 9.33 mmol) in MeOH (2.0 ml) was stirred at room temperature for 8 h. Sodium cyanoborohydride (5.87 mg, 0.093 mmol) was added at 0 °C and the reaction mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylcyclohexan-1-amine (4.3 mg) as a pale solid.CL-EM retention time: 1.25 min [E], EM (E+) m / z: 443.3 [M+H]; 1HRMN (400 MHz, methanol-d4) 8.76 (s, 1H) , 8.53-8.41 (m, 1H) , 7.67 (s, 1H) , 7.51-7.44 (m, J=8.2 Hz, 2H) , 7.44-7.36 (m, 7=8, 1 Hz, 2H) , 3, 12 (dt, 7=14, 2, 7, 1 Hz, 2H) , 2, 77 (s, 5H) , 2, 74-2, 56 (m, 5H) , 2, 29-2, 17 (m, 2H) , 2, 13 (d, J=10, 1Hz, 2H), 1, 94 (s, 2H), 1, 80-1, 55 (m, 4H), 1, 39-1, 28 (m, 1H), 1, 19 (d, J=T2 Hz, 6H). The following examples were prepared in accordance with the general procedure used to prepare example 510. Table 53 Example 518 2-(dimethylamino)-N-(4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)cyclohexyl)-N-methyl acetamide 2-(dimethylamino)-N-(4-(4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)cyclohexyl)-N-methylacetamide (3.4 mg) was prepared according to the general procedure described in Example 469, using 4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylcyclohexan-1-amine (20.0 mg, 0.047 mmol) as a starting intermediate, to provide the title compound as a whitish solid. CL-EM retention time: 1.45 min [E], EM (E+) m / z: 514.3 [M+H]; 1HRMN (400 MHz, methanold4) 8.76 (s, 1H) , 8.48 (s, 1H) , 7.67 (s, 1H) , 7.59-7.32 (m, 4H) , 4.50 (d, J=T6 Hz, 1H) , 3.62 (sa, 1H) , 3, 60-3, 51 (m, 1H) , 3, 203, 02 (m, 1H) , 3, 0.- 2, 83 (m, 3H) , 2, 76-2, 60 (m, 4H) , 2, 55 (d, J=3, 5 Hz, 6H) , 2, 14-1, 9815 (m, 2H), 1, 98-1, 84 (m, 2H), 1, 84-1, 62 (m, 4H), 1, 39-1, 27 (m, 1H), 1, 20 (d, J=7, 1 Hz, 6H). The following example was prepared in accordance with the general procedure used to prepare example 518. Table 54 Example 520 2- ((4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)cyclohexyl)(methyl)amino)-N,N-dimethylacetamide 2-((4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)cyclohexyl)(methyl)amino)-N,N-dimethylacetamide (12.6 mg) was prepared according to the general procedure described in Example 466, using 4-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylcyclohexan-1-amine (20.0 mg, 0.047 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-EM retention time: 1.37 min [F], EM (E+) m / z: 514.4 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 75 (s, 1H) , 8, 48 (s, 1H) , 7, 68 (s, 1H) , 7, 5.- 7, 27 (m, 4H) , 3, 59-3, 39 (m, 2H) , 3, 22-3, 05 (m, 4H) , 2.98 (s, 3H) , 2.71 (s, 4H) , 2.62 (t, J= 11.7Hz, 1H) , 2.41 (s, 3H) , 2.14-1.94 (m, 4H) , 1.71-1.45 (m, 4H), 1, 31 (s, 1H) , 1, 19 (d, J=7, 2Hz, 6H) , 0, 91 (d, J=7, 1 Hz, 1H) . The following examples were prepared in accordance with the general procedure used to prepare example 520. Table 55 Example 524 2-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)propan-2-amine, TFA Intermediate product 524A: (2-(4-bromophenyl)propan-2-yl) tert-butyl carbamate A solution of 2-(4-bromophenyl)propan-2-amine (1.00 g, 4.67 mmol) in DCM (15.0 mL) was reacted with TEA (1.302 mL, 9.34 mmol) and Boc-anhydride (1.627 mL, 7.01 mmol) at 0 °C. The reaction mass was concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted in 10% EA in hexane, and the fractions were collected and concentrated to obtain tert-butyl (2-(4-bromophenyl)propan-2-yl)carbamate (1.24 g, 3.95 mmol, 84% yield) as a white solid. LC-MS retention time: 1.54 min [A], MS (E+) m / z: 260.3 [M+2H-tBu], Intermediate 524B: tert-butyl (2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)carbamate A mixture of (2-(4-bromophenyl)propan-2-yl) tert-butyl carbamate (600 mg, 1.909 mmol), BISPIN (727 mg, 2.86 mmol), and potassium acetate (562 mg, 5.73 mmol) in dioxane (18 mL) was degassed with nitrogen for 5 min. PdCl₂(dppf)-CH₂Cl₂ (156 mg, 0.191 mmol) adduct was then added, and the reaction mixture was degassed for another 2 min. The reaction mixture was stirred at 100 °C for 16 h. The reaction mass was diluted with EtOAc (20 mL), the solids were filtered through Celite, and the filtrate was collected and concentrated to obtain the crude compound. The crude compound was purified by ISCO, using a 40 g silica column, the compound was eluted in 15% EA in hexanes, the fractions were collected and concentrated to obtain (2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl) tert-butyl carbamate (600 mg, 1,661 mmol, 87% yield) as a white solid.CL-EM retention time: 1, 65 min [A], EM (E+) m / z: 362, 6 [M+H]. Intermediate product 524C: (2-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1-((2-(trimethylsilyl) ethoxy) methyl)-1H-pyrazol-3-yl) phenyl) propan-2-yl) tert-butyl carbamate A solution of 6-(3-bromo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (320 mg, 0.686 mmol), (2-(4-(4, 4, 5, tert-butyl 5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)carbamate (372 mg, 1,029 mmol) and K2CO3 (284 mg, 2,058 mmol) in a solvent mixture of acetonitrile (16.00 mL) and water (4.00 mL) for 10 min with nitrogen. Next, Pd2(dba)3 (31.4 mg, 0.034 mmol) and 2-dicyclohexylphosphine-2',6'-dimethoxybiphenyl (28.2 mg, 0.069 mmol) were added. The reaction mixture was degassed for 2 min and stirred at 110 °C for 16 h. The reaction mixture was brought to room temperature, the two phases were separated, the aqueous phase was extracted with DCM (2 x 20 mL), the combined organic extracts (Na2SO4) were dried and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 24 g silica column. The compound was eluted in 50% hexane EA. The fractions were collected and concentrated to obtain tert-butyl (2-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)propan-2-yl)carbamate (200 mg, 0.322 mmol, 47.0% yield) as a whitish solid. CL-MS retention time: 1.87 min [A], MS (E+) m / z: 621.6 [M+H]. Intermediate 524: 2-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)propan-2-amine, TFA A solution of (2-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)propan-2-yl) tert-butyl carbamate (0.200 g, 0.322 mmol) in DCM (3.00 ml) was given TFA (1.500 ml, 19.47 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. The reaction mass was concentrated, then ground with diethyl ether (2 x 10 mL) and vacuum dried to obtain 2-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)propan-2-amine, TFA (0.150 g, 0.297 mmol, 92% e yield) as a whitish solid. CL-MS retention time: 0.74 min [A], MS (E+) m / z: 389.4 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 43 (d, J=1, 2 Hz, 1H) , 8, 33 (s, 1H) , 7, 65-7, 47 (m, 4H) , 7, 18-7, 10 (m, 1H) , 4, 02 (s, 3H) , 3, 07-2, 93 (m, 2H) , 1, 71 (s, 6H) , 1, 24-1, 14 (m, 3H) , 1, 11 (d, J=7, 3 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 524. Table 56 Example 532 2-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylpropan-2-amine Formaldehyde (0.2 mL, 2.178 mmol) and acetic acid (0.2 mL, 3.49 mmol) were added to a solution of 2-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)propan-2-amine, TFA (18 mg, 0.036 mmol) in MeOH (1.5 mL) at room temperature. The reaction mixture was stirred at the same temperature for 6 h. Then, sodium cyanoborohydride (11.21 mg, 0.178 mmol) was added at room temperature and the reaction mixture was stirred for 16 h. The reaction mass was purified by preparative CL-EM purification using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylpropan-2-amine (5.1 mg, 0.012 mmol, 33% yield) as a pale solid.CL-EM retention time: 1,289 min [E], EM (E+) m / z: 419, 3 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8, 43 (s, 1H) , 8, 33 (s, 1H) , 7, 69-7, 53 (m, 7=8, 3 Hz, 2H) , 7, 527, 30 (m, J=8, 1 Hz, 2H) , 7, 14 (s, 1H) , 4.02 (s, 3H) , 3.05 (quin, J=7, 2 Hz, 1H) , 2.29 (s, 6H) , 1.84 (s, 1H) , 1.52 (s, 6H) , 1.19 (s, 1H) , 1.12 (d, J=7, 1Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare Example 532. Table 57 Example 570 (S) -N-ethyl-1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylethane-1-amine Intermediate product 570A: (S) - (1- (4-bromophenyl) ethyl) tert-butyl carbamate To a solution of (S)-1-(4-bromophenyl)ethan-1-amine (1.5 g, 7.50 mmol) in dichloromethane (30.0 ml) at 0 °C, TEA (3.13 ml, 22.49 mmol) and Boc-anhydride (2.089 ml, 9.00 mmol) were added. The reaction mixture was stirred at room temperature for 12 h. The reaction mass was concentrated, purified by ISCO using a 40 g silica column, and the compound was eluted with 35–40% ethyl acetate in petroleum ether. The fractions were collected and concentrated to obtain (S)-(1-(4-bromophenyl)ethyl) tert-butyl carbamate (2.0 g, 6.66 mmol, 89% yield) as a whitish solid. CL-MS retention time: 1.46 min [A], MS (E+) m / z: 246.1 [M-tBu+2H]. Intermediate product 570B: (S) - (1- (4-bromophenyl) ethyl) (methyl) tert-butyl carbamate NaH (0.853 g, 21.32 mmol) was added to a solution of (S)-(1-(4-bromophenyl)ethyl) tert-butyl carbamate (3.2 g, 10.66 mmol) in THF (60.0 mL) at 0 °C. The reaction mixture was stirred for 30 min at room temperature, and Mel (3.33 mL, 53.3 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 12 h. The reaction was stopped with saturated NH4Cl solution, extracted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with 25–30% ethyl acetate in petroleum ether. The fractions were collected and concentrated to obtain tert-butyl (S)-(1-(4-bromophenyl)ethyl)(methyl)carbamate (3.0 g, 9.55 mmol, 90% yield) as an oil. CL-MS retention time: 1.72 min [A], MS (E+) m / z: 260.1 [M-tBu+2H]. Intermediate product 570C: (S)-methyl (1- (4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl) tert-butyl carbamate (S)-methyl (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl) tert-butyl carbamate (3.8 g, 10.52 mmol) was prepared according to the general process described for intermediate 524B, using (S)-(1-(4-bromophenyl)ethyl)(methyl)carbamate (3.2 g, 10.18 mmol) as the starting intermediate to provide the title compound as a whitish solid. Cl-MS retention time: 1.86 min [A], MS (E+) m / z: 306.3 [M-tBu]. Intermediate 570D: (S)-(1-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)(methyl)tert-butyl carbamate (570D) (S)-(1-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-y)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)(methyl) tert-butyl carbamate (850 mg, 1,369 mmol, 80% yield) was prepared according to the general process described in intermediate product 524C, using (S)-methyl(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl) 6-(2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methoxy-[1,2, 4]triazolo[1,5-a]pyridine (800 mg, 1,715 mmol) and (S)-methyl(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)tert-butyl carbamate (744 mg, 2,058 mmol) as starting intermediates to provide the title compound as a pale brown solid. Cl-MS retention time: 4.30 min [B], MS (E+) m / z: 621.4 [M+H]. Intermediate 570E: (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylethan-1-amine (S)-1-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylethan-1-amine (500 mg, 1,280 mmol, 94% yield) was prepared according to the general process described in Example 524, using (S)-(1-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)(methyl) tert-butyl carbamate (850 mg, 1,369 mmol) as a starting intermediate to provide the title compound as a white solid. CL-EM retention time: 0.72 min [A], EM (E+) m / z: 391.4 [M+H]; 1H-NMR (400 MHz, DMSO-d6) ppm 7.74 (d, J=1.0 Hz, 1H) , 7.63 (s, 1H) , 6.96-6.77 (m, 4H) , 6.43 (s, 1H) , 3.68-3.56 (m, 1H) , 3.33 (s, 3H) , 2.35 (dt, J=14, 1.7, 2 Hz, 1H) , 1.85 (s, 3H) , 0.94 (d, J=6, 8 Hz, 3H) , 0.51 (sa, 1H) , 0.42 (d, J=7, 1 Hz, 6H). Example 570: (S) -N-ethyl-1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylethane-1-amine A mixture of (S)-1-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylethan-1-amine (40.0 mg, 0.102 mmol), acetaldehyde (0.029 ml, 0.512 mmol) and AcOH (1.173 uL, 0.020 mmol) in MeOH (3.0 ml) was stirred at room temperature for 8 h, and sodium cyanoborohydride (12.87 mg, 0.205 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AB method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain (S) -N-ethyl-1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylethan-1-amine (12.4 mg) as a whitish solid.CL-EM retention time: 1.24 min [F], EM (E+) m / z: 419.3 [M+H]; 1H NMR (400 MHz, methanol-d4) 8.54 (d, 7=1.0 Hz, 1H) , 8.44 (s, 1H) , 7.76-7.62 (m, 4H) , 7.22 (d, 7=1.0 Hz, 1H) , 4.73-4.65 (m, 2H) , 4, 12 (s, 3H) , 3, 41 (s, 1H) , 3, 20-3, 08 (m, 2H) , 3, 05-2, 97 (m, 1H) , 2, 93-2, 85 (m, 2H) , 2, 74 (s, 2H) , 1, 80 (dd, 7=11, 0, 7, 0 Hz, 3H), 1, 46-1, 29 (m, 4H), 1, 22 (d, 7=7, 0 Hz, 6H). The following example was prepared in accordance with the general procedure used to prepare intermediate product 570E. Table 58 The following examples were prepared in accordance with the general procedure used to prepare example 570. Table 59 Example 581 2- (dimethylamino) -N- (2- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) propane-2-yl) acetamide To a solution of 2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)propan-2-amine, TFA (0.014 g, 0.029 mmol) in DMF (1.00 ml) were added TEA (0.1 ml, 0.717 mmol), dimethylglycine (5.91 mg, 0.057 mmol) and HATU (0.229 g, 0.602 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 2 h. The reaction mass was purified by preparative CL-EM purification using the AB method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(dimethylamino)-N-(2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)propan-2-yl)acetamide (6.0 mg, 0.013 mmol, 46% yield) as a pale solid.CL-EM retention time: 1,723 min [E], EM (E+) m / z: 460, 4 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8, 65 (s, 1H) , 8, 37 (s, 1H) , 7, 56 (s, 1H) , 7, 49-7, 41 (m, 7=8, 1 Hz, 2H) , 7, 41-7, 31 (m, 7=8, 3 Hz, 2H) , 3.04-2.93 (m, 3H) , 2.60 (s, 3H) , 2.30 (s, 6H) , 1.63 (s, 6H) , 1.08 (d, J=7, 1 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 581. Table 60 Example 584 10 2- (2- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) pyrrolidin-1-yl) -N, N-dimethylacetamide 2-(2-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)pyrrolidine-1-yl)-N,N-dimethylacetamide (21.5 mg) was prepared according to the general procedure described in Example 466, using 6-(4-isopropyl-3-(4-(pyrrolidine-2-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (20 mg, 0.052 mmol) as a starting intermediate, providing the title compound as a white solid. CL-EM retention time: 1,626 min [E], EM (E+) m / z: 472, 3 [M+H]; 1H-NMR (400 MHz, DMSO-d6) 13.09 (sa, 1H) , 8.81 (sa, 1H) , 8.53 (s, 1H) , 7.63 (s, 1H) , 7.46 (s, 4H) , 3.91 (s, 2H) , 3.54 (sa, 1H) , 3, 32 (sa, 1H) , 3, 24 (sa, 1H) , 3, 05 (dt, 7=14, 3, 7, 0 Hz, 1H) , 2, 93 (d, 7=11, 7 Hz, 1H) , 2, 82 (s, 3H) , 2, 71 (s, 3H), 2, 63 (s, 3H) , 2, 44 (d, 7=8, 1 Hz, 1H) , 2, 21 (sa, 1H) , 1, 92 (s, 1H) , 1, 85 (sa, 1H) , 1, 67 (sa, 1H) , 1, 13 (d, 7=7, 1, 3, 2Hz, 6H). The following example was prepared in accordance with the general procedure used to prepare example 584. Table 61 Example 585 (S)-N- ((S)-1-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-N, 1-dimethylazetidine-2-carboxamide Intermediate 585A: tert-butyl (S)-2-((S)-1-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)(methyl)carbamoyl)azetidine-1-carboxylate TEA (0.214 ml, 1.537 mmol) and HATU (140 mg, 0.369 mmol) were added to a solution of (S)-1-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl) -N-methylethane-1-amine (120.0 mg, 0.307 mmol) and (S)-1-(tert-butoxycarbonyl)azetidine-2-carboxylic acid (61.8 mg, 0.307 mmol) in DMF (5.0 mL). The mixture was stirred at room temperature for 16 h. The reaction mass was diluted with water, extracted with 5% MeOH in DCM (2 x 50 ml), the combined organic phase was washed with brine, dried (Na2SO4), and concentrated to obtain tert-butyl (S)-2-((S)-1-(4-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)(methyl)carbamoyl)azetidine-1-carboxylate (155 mg, 0.270 mmol, 88% yield) as a gummy solid. CL-MS retention time: 1.14 min [A], MS (E+) m / z: 574.6 [M+H]. Intermediate 585B: (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylazetidine-2-carboxamide (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylazetidin-2-carboxamide (2 mg) was prepared according to the general process described in Example 524, using (S) -2- ( ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) (methyl) carbamoyl) tert-butyl azetidin-1-carboxylate (200 mg, 0.349 mmol) as a starting intermediate to provide the title compound as a white solid. CL-EM retention time: 1.19 min [E], EM (E+) m / z: 474.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 54 (s a., 1H) , 8, 44 (s, 1H) , 7, 67-7, 37 (m, 4H) , 7, 25 (s a., 1H) , 6, 02 (d, J=6, 6 Hz, 1H) , 4, 71 (d, J= 7, 6Hz, 1H) , 4, 14 (s, 3H) , 4, 11-4, 00 (m, 1H) , 3, 81 (s, 1H) , 3, 73-3, 62 (m, 1H) , 3, 58 (s a., 1H) , 3, 16 (t, J=6, 5Hz, 2H) , 2, 88 (s a., 2H), 2, 80 (s, 1H), 2, 74-2, 56 (m, 2H), 2, 45 (s a., 1H), 2, 37 (s a., 1H) , 1, 92 (s, 3H) , 1, 70 (d, J=6, 6 Hz, 1H) , 1, 66-1, 53 (m, 2H) , 1, 31 (s, 2H) , 1, 22 (d, 7, 1 Hz, 6H) . Ejemplo 585: (S)-N- ( (S)-1- (4- (4-isopropil-5- (8-metoxi-[1, 2, 4]triazolo[1, 5-a]piridin-6-5 il) -1H-pirazol-3-il)fenil)etil) -N, 1-dimetilazetidin-2-carboxamida Se preparó (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]piridin-6-yl) -1H-pirazol-3-yl) phenyl) ethyl) -N, 1-dimetilazetidin-2-carboxamida (25 mg) de acuerdo con el proceso general descrito en el Ejemplo 510, utilizzare (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]piridin-6-yl) -1H-pirazol-3-yl) phenyl) ethyl) -N-metilazetidin-2-carboxamida (40, 0 mg, 0, 084 mmol) as an intermediate product of the part to proportion the content of the title as a white solid. CL-EM retention time: 1, 22 min [E], EM (E+) m / z: 488, 3 [M+H]; 1HRMN (400 MHz, methanol-d4) 8, 61-8, 50 (m, 1H) , 8, 44 (s, 1H) , 7, 62-7, 33 (m, 4H) , 7, 25 (s, 1H) , 5, 99 (d, J=7, 1 Hz, 1H) , 4, 60 (d, J=18, 1 Hz, 1H) , 4, 20-4, 08 (m, 3H) , 3, 76 (sa, 1H) , 3, 59-3, 45 (m, 1H) , 3, 21-2, 97 (m, 2H) , 2, 94-2, 80 (m, 2H) , 2, 78-2, 60 (m, 4H) , 2, 53-2, 31 (m, 2H) , 2, 20-2, 00 (m, 2H) , 1, 99-1, 92 (m, 3H) , 1, 76-1, 56 (m, 3H) , 1, 54 (s, 2H) , 1, 3.- 1, 26 (m, 1H), 1, 26-1, 15 (m, 6H), 1, 11 (sa, 1H). The following examples were prepared according to the general procedure used to prepare the 585A intermediate. Table 62 The following examples were prepared in accordance with the general procedure used to prepare example 585B. Table 63 The following examples were prepared in accordance with the general procedure used to prepare example 585. Table 64 Example 616 (S) -2- ( (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) (methyl) amino) -N, N-dimethylacetamide (S)-2-((1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)(methyl)amino)-N,N-dimethylacetamide was prepared according to the general process described in Example 466 using (S)-1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylethan-1-amine (40.0 mg, 0.107 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-EM retention time: 1.48 min.[C], EM (E+) m / z: 460.4 [M+H]; 1H NMR (400 MHz, methanol4) 8.76 (s, 1H) , 8.48 (s, 1H) , 7.68 (s, 1H) , 7.53 (s, 4H) , 3.89 (q, J=6.6 Hz, 1H) , 3.20-3.08 (m, 1H) , 3, 08-3, 00 (m, 3H) , 2, 98-2, 88 (m, 3H) , 2, 71 (s, 3H) , 2, 33 (s, 3H) , 2, 06 (s, 2H) , 1, 97 (s, 1H) , 1, 49 (d, J=6, 6Hz, 3H) , 1, 31 (a.s, 1H), 1, 20 (d, J=7, 1 Hz, 6H). The following example was prepared in accordance with the general procedure used to prepare example 616. Table 65 Example 618 (S)-2-(dimethylamino)-N-(1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-N-(oxetan-3-yl)acetamide (S)-2-(dimethylamino)-N-(1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-N-(oxetan-3-yl)acetamide (11 mg) was prepared according to the general process described in Example 323 using (S)-N-(1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)oxetan-3-amine (30.0 mg, 0.072 mmol) as a starting intermediate to provide the title compound as a white solid.CL-EM retention time: 1, 12 min [F], EM (E+) m / z: 502, 3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8.77 (sa, 1H) , 8.49 (s, 1H) , 7.79-7.51 (m, 5H) , 5.53 (d, 7=6.8 Hz, 2H) , 4.58 (sa, 1H) , 4.33 (sa, 1H) , 4, 01 (dd, 7=12, 8, 6, 0 Hz, 1H) , 3, 94-3, 74 (m, 3H) , 3, 70-3, 61 (m, 1H) , 3, 36 (d, J=5, 9 Hz, 3H) , 3, 28 (s, 2H) , 3, 23 (s, 2H) , 3, 13 (dd, 7= 13, 0, 7, 1 Hz, 1H) , 2, 71 (s, 3H) , 2, 01-1, 88 (m, 3H) , 1, 85 (d, 7=7, 1 Hz, 2H) , 1, 31 (s, 2H) , 1, 26-1, 07 (m, 6H), 0, 92 (sa, 1H) . The following example was prepared in accordance with the general procedure used to prepare example 618. Table 66 Example 620 (S) -2- (ethyl (methyl) amino) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylacetamide TEA (0.039 ml, 0.277 mmol) and N-methylethanamine (16.38 mg, 0.277 mmol) were added to a solution of (S)-2-chloro-N-(1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-N-methylacetamide (25.0 mg, 0.055 mmol) in a solvent mixture of DMF (1.5 ml) and THF (1.0 ml) at 0 °C. The mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain (S) -2- (ethyl (methyl) amino) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylacetamide (12.3 mg) as a white solid.CL-EM retention time: 1.36 min [E], EM (E+) m / z: 474.3 [M+H]; JHNMR (400 MHz, methanol-d4) 8.77 (s, 1H) , 8.49 (s, 1H) , 7.67 (s, 1H) , 7.62-7.41 (m, 4H) , 6.03 (d, J=7.3 Hz, 1H) , 3.98-3, 80 (m, 2H) , 3, 11 (d, J=7, 1 Hz, 1H) , 3, 01 (d, J=6, 6 Hz, 2H) , 2, 88 (d, J=5, 6 Hz, 1H) , 2, 82 (s, 2H) , 2, 79-2, 66 (m, 6H) , 2, 61 (s, 1H), 1.97 (s, 3H), 1.73 (d, J=6.6 Hz, 1H), 1.63 (d, J=7.3 Hz, 2H), 1.36-1.09 (m, 10H). The following examples were prepared in accordance with the general procedure used to prepare example 620. Table 67 Example 624 (S) -1- (2-fluoro-5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N, N-dimethylethane-1-amine Intermediate 624A: N-((S)-1-(2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide PdC12 (dppf)-CH2C12 adduct (0.152 g, 0.186 mmol) and potassium acetate (0.548 g, 5.59 mmol) were added to a degassed solution of BISPIN (0.615 g, 2.421 mmol) and N-((S)-1-(5-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (0.600 g, 1.862 mmol) in dioxane (25 mL). The reaction mixture was stirred at 100 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, and washed with excess ethyl acetate. The filtrates were collected, dried over sodium sulfate, and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 40 g silica column. The compound was eluted with 45–50% ethyl acetate in petroleum ether. The fractions were collected and concentrated to obtain N-((S)-1-(2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (680 mg, 1,841 mmol, 99% yield) as a light yellow solid. Cl-MS retention time: 1.45 min [A], MS (E+) m / z: 370.3 [M+H]. Intermediate 624B: N-((S)-1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide Pd2(dba)s (61.0 mg, 0.067 mmol) and S-Phos (54.6 mg, 0.133 mmol) were added to a degassed solution of 6-(3-bromo-4-isopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1. 2,4]triazolo[1,5-a]pyridine (600 mg, 1,332 mmol), K2CO3 (552 mg, 4,00 mmol) and N-((S)-1-(2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) solvent mixture ethyl)-2-ethylpropane-2-sulfinamide (590 mg, 1,598 mmol) in acetonitrile (25 ml) and water (5 ml). The reaction mixture was stirred at 110 °C for 14 h in a sealed tube. The reaction mixture was extracted with ethyl acetate, washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 40 g silica column, eluted with 65–75% ethyl acetate in petroleum ether, and the fractions were collected and concentrated to obtain N-((S)-1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (550 mg, 0.897 mmol, 67% yield) as a light brown semisolid. Cl-MS retention time: 1.75 min [A], MS (E+) m / z: 613.3 [M+H]. Intermediate 624C: (S)-1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethane-1-amine To a solution of N-((S)-1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (500 mg, 0.816 mmol) in DCM (5.0 ml) TFA (1.571 ml, 20.40 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 12 h. The reaction mass was concentrated and dried under high vacuum to obtain the crude compound. The crude compound was purified by preparative LC / MS using the AA method. The fractions containing the product were combined and dried by centrifugal evaporation to obtain (S)-1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethan-1-amine (8.5 mg). LC-MS retention time: 1.29 min [E], MS (E+) m / z: 379.2 [M+H]; 1HRMN (400 MHz, methanol-d4) 8.66 (s, 1H) , 8.38 (s, 1H) , 7.61-7.48 (m, 2H) , 7.4.- 7, 41 (m, 1H), 7, 28-7, 15 (m, 1H), 4, 57 (q, J=6, 6 Hz, 1H), 3, 00 (dt, 7=14, 1, 7, 0 Hz, 1H), 2, 6. 1. 83 (s, 3H) Ejemplo 624: (S) -1- (2-fluoro-5- (4-isopropil-5- (8-metil-[1, 2, 4]triazolo[1, 5-a]piridin-6-il) -1H-pirazol-3-il)fenil) -N, N-dimetiletan-1-amina Formaldehyde (10.92 µL, 0.396 mmol) and acetic acid (0.908 µL, 0.016 mmol) were added to a solution of (S)-1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethan-1-amine (30.0 mg, 0.079 mmol) in MeOH (5.0 mL) at room temperature. The reaction mixture was stirred for 8 h. Sodium cyanoborohydride (9.96 mg, 0.159 mmol) was then added at 0 °C. The reaction mixture was stirred at room temperature for 16 h. The reaction mass was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain (S) -1- (2-fluoro-5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N,N-dimethylethan-1-amine 10.5 mg as a whitish solid.CL-EM retention time: 1.55 min [E], EM (E+) m / z: 407.3 [M+H]; 1H-NMR (400 MHz, methanol-d4) 8, 65 (s, 1H) , 8, 37 (s, 1H) , 7, 55 (s, 1H) , 7, 50 (dd, 7= 6, 8, 1, 8 Hz, 1H) , 7, 39 (td, 7=5, 4, 2, 4 Hz, 1H) , 7, 26-7, 11 (m, 1H) , 3, 95 (sa, 1H) , 2, 99 (dt, 7= 14, 2, 7, 2 Hz, 1H) , 2, 68-2, 51 (m, 3H) , 2, 27 (s, 6H) , 1, 90-1, 76 (m, 1H) , 1, 42 (d, 7=6, 7 Hz, 3H) , 1, 08 (t, 7=7, 8 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 624. Table 68 Example 629 (S)-2-(dimethylamino)-N-(1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)acetamide (S) -2- (dimethylamine) -N- (1- (2-fluoro-5- (4-isopropyl-5-) (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) acerdote (mg5) acetamide (mg5) ethyl (mg5) acerdote process was prepared general described in Example 469, using (S) -1- (2-fluoro-5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl (7,0-1) phenyl (7,0-1) phenyl as a starting intermediate product to provide the title compound as a pale solid. Retention time of CL-EM: 1.52 min [E], EM (E+) m / z: 464.3 [M+H]; 1H-RMN (400 MHz, methanol-d4) 8, 65 (s, 1H) , 8, 39 (s, 1H) , 7, 54 (s, 1H) , 7, 41 (dd, J= 7, 1, 1, 7Hz, 1H, 29) 3 9 , 7 7, 15 (dd, J=10, 1, 8, 6 Hz, 1H), 5, 26 (q, J=7, 0 Hz, 1H) , 3, 9.- 3, 75 (m, 2H) , 2, 98 (dt, 72, 1,74, H 2, Hz 89-2, 79 (m, 5H) , 2, 76 (sa, 1H) , 2, 60 (s, 3H) , 1, 46 (d, J=7, 0 Hz, 3H) , 1, 28-1, 14 (m, 1H = 0, 6 , 1, t The following example was prepared in accordance with the general procedure used to prepare example 629. Table 69 Example 631 N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl)phenyl)ethyl)propan-2-amine Intermediate 631A: 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethan-1-one prepared (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethan-1-one (350 mg, 0.715 mmol, 71% yield) according to the general process described in intermediate 307B, using 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3, 2-dioxaborolan-2-yl)-1- ((2-(trimethylsilyl) ethoxy) methyl) -1H-pyrazol-5-yl) -8-methyl-[1,2,4]triazolo[1,5-a]pyridine (0.500 g, 1.005 mmol) as a starting intermediate to obtain the title compound as a pale yellow solid. Cl-MS retention time: 1.61 min [A], MS (E+) m / z: 490.6 [M+H]. Intermediate 631B: N-(1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)propan-2-amine N-(1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)propan-2-amine was prepared according to the general process described in Example 279, using 1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethan-1-one (0.040 g, 0.082 mmol) and propan-2-amine (0.024 g, 0.408 mmol) as intermediates of Starting to provide the title compound as a pale yellow solid. CL-MS retention time: 1.62 min [A], MS (E+) m / z: 533.7 [M+H]. Example 631: N-(1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)propan-2-amine TFA (0.145 mL, 1.877 mmol) was added to a solution of N-(1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)phenyl)ethyl)propan-2-amine (0.040 g, 0.075 mmol) in CH2CI2 (2.0 mL) at 0 °C. The reaction mixture was stirred at room temperature for 12 h. The reaction mass was concentrated to obtain the crude compound. The crude compound was purified by preparative LC / MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain N-(1-(4-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)propan-2-amine (28 mg) as a white solid.CL-EM retention time: 1.18 min [E], EM (E+) m / z: 403.3 [M+H]; * H-NMR (400 MHz, methanol-d4) 8, 76 (s, 1H) , 8, 48 (s, 1H) , 7, 67 (s, 1H) , 7, 61-7, 49 (m, 4H) , 4, 29 (d, J=6, 5 ​​Hz, 1H) , 3, 13 (quin, / =7, 0 Hz, 1H) , 2, 99-2, 82 (m, 1H) , 2, 71 (s, 3H) , 1, 99-1, 86 (m, 1H) , 1, 57 (d, .7=7, 0 Hz, 3H) , 1, 26-1, 14 (m, 13H) . The following examples were prepared in accordance with the general procedure used to prepare Example 631. Table 70 Example 672 2-(dimethylamino)-N-(1-(6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)ethyl)-N-methylacetamide 2- (dimethylamine) -N- (1- (6- (4-isopropyl-5-) (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridine-3-yl) general process ethyl.acute 3 tam conida) -N-methyl was prepared described in Example 469, using 1- (6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridine-3-yl) -0 -comomine (mg2 mmol, 1,0-a starting intermediate to obtain the title compound as a white solid. Retention time of CL-EM: 1.21min [E], EM (E+) m / z: 461.3 [M+H]; 1H-RMN (400 MHz, methanol-d4) 8, 66 (s, 1H) , 8, 61-8, 51 (m, 1H) , 8, 37 (s, 1H) , 7, 78 (d, J=9, 0 Hz, 1.7, H) 6 , 6 , (s, 1H) , 5, 92 (q, J=7, 1 Hz, 1H) , 3, 643, 43 (m, 2H) , 3, 26 (d, J=9, 0 Hz, 1H) , 2, 82-2, 69 (m-2, 3, 6) . , 2, 48 (s, 5H) , 2, 39 (s, 2H) , 1, 84 (s, 2H) , 1, 63 (d, 7=6, 8 Hz, 1H) , 1, 54 (d, J=7, 1 Hz, 2, H 0 2) ( The following examples were prepared in accordance with the general procedure used to prepare example 672. Table 71 Example 676 2- ((1- (2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl)thiazol-5-yl)ethyl) (methyl)amino) -N, N-dimethylacetamide DIPEA (0.021 ml, 0.118 mmol) was added to a stirred solution of 1-(2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-N-methylethan-1-amine (15 mg, 0.039 mmol) in DMF (2 ml). The reaction mixture was stirred at room temperature for 5 min and 2-chloro-N,N-dimethylacetamide (5.74 mg, 0.047 mmol) was added. The reaction mixture was stirred for 16 h. The reaction mass was purified by preparative LC-MS using the AA method, the fractions containing the product were combined and dried by centrifugal evaporation to obtain 2-((1-(2-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)ethyl)(methyl)amino)-N,N-dimethylacetamide (1.5 mg) as a pale solid.CL-EM retention time: 1,519 min [E], EM (E+) m / z: 467, 3 [M+H]; 1H-NMR (400 MHz, DMSO-d6) 8.94 (s, 1H) , 8.56 (s, 1H) , 7.71 (s, 1H) , 7.56 (s, 1H) , 4.22 (sa, 1H) , 3.35 (sa, 3H) , 3.05 (s, 3H) , 2, 83 (s, 3H) , 2, 65-2, 60 (m, 3H) , 2, 16 (s, 3H) , 1, 86 (s, 18H) , 1, 76 (s, 1H) , 1, 41 (d, 7=6, 7 Hz, 3H) , 1, 341, 16 (m, 7H) . The following examples were prepared in accordance with the general procedure used to prepare example 676. Table 72 Example 679 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine Intermediate product 679A: 6-bromo-N-methyl-1,2,3,4-tetrahydronaphthalene-2-amine Methanamine (44.4 mL, 89 mmol) and AcOH (5.10 mL) were added to a stirred solution of 6-bromo-3,4-dihydronaphthalen-2(1H)-one (2 g, 8.89 mmol) in MeOH (100 mL). The reaction mixture was stirred at room temperature for 16 h and NaCNBH3 (1.675 g, 26.7 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. The reaction was stopped with water. The mixture was extracted with EtOAc, washed with water and brine, dried over sodium sulfate, and concentrated to obtain 6-bromo-N-methyl-1,2,3,4-tetrahydronaphthalene-2-amine (1.3 g, 0.376 mmol, 63% yield) as a whitish solid. CL-MS retention time: 0.84 [A], MS (E+) m / z: 240.4 [M+H]. Intermediate product 679B: (6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl) (methyl) tert-butyl carbamate To a stirred solution of 6-bromo-N-methyl-1,2,3,4-tetrahydronaphthalene-2-amine (2 g, 8.33 mmol) in THF (50 mL) were added Boc anhydride (1.934 mL, 8.33 mmol), TEA (1.161 mL, 8.33 mmol), and DMAP (1.017 g, 8.33 mmol) at room temperature. The reaction mixture was stirred for 3 h. The reaction mixture was extracted with EtOAc, washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound. The crude compound was purified by ISCO using a 24 g silica column, the fractions were collected and concentrated to obtain 6-bromo-N-methyl-1,2,3,4-tetrahydronaphthalene-2-amine (1.3 g, 0.376 mmol, 63% yield) as a whitish solid. Cl-MS retention time: 1.76 [A], MS (E-) m / z: 337.2 [M+H]. Intermediate 679C: (6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)(methyl)carbamate tert-butyl tert-butyl (6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)(methyl)carbamate (280 mg, 0.444 mmol, 88% yield) was prepared according to the general process described. The intermediate product 307B was prepared using 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (500 mg, 1.005 mmol) as a starting intermediate to give the title compound as a brown liquid. Cl-MS retention time: 2.13 [B], MS (E-) m / z: 631.8 [M+H]. Intermediate product 679D: 6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine (8.3 mg, 0.126 mmol, 9% yield) was prepared according to the general process described in intermediate product 307D, using (6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)(methyl) tert-butyl carbamate (230 mg, 0, 365 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-MS retention time: 1.16 [E], MS (E-) m / z: 401.3 [M+H]; 1H-NMR (400 MHz, DMSO-d) ppm 8.78 (s, 1H) , 8.51 (s, 1H) , 7.60 (s, 1H) , 7.24-7.16 (m, 3H) , 3.17 (s, 2H) , 3.12-2.97 (m, 3H), 2, 97-2, 80 (m, 3H), 2, 61 (s, 3H), 2, 44 (s, 3H), 2, 05 (s, 2H), 1, 80 (s, 2H), 1, 16-1, 05 (m, 6H). Example 679: 6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalene-2-amine (4.0 mg, 0.126 mmol, 8.57% yield) was prepared according to the general process described in intermediate product 279 using 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-1,2,3,4-tetrahydronaphthalene-2-amine (30 mg, 0.075 mmol) as a starting intermediate to provide the title compound as a solid whitish. CL-EM retention time: 1.25[E], EM (E-) m / z: 415.3 [M+H]; 1H-NMR (400 MHz, DMSO-d6) 13, 03 (s a., 1H) , 8, 79 (s a., 1H) , 8, 52 (s, 1H) , 7, 61 (s, 1H) , 7, 22 (d, J=6, 8 Hz, 3H) , 3, 90 (s, 2H) , 3, 08-2, 87 (m, 4H) , 2, 872, 74 (m, 3H) , 2, 61 (s, 3H) , 2, 41 (s a., 5H) , 2, 33 (d, J= 1, 7Hz, 1H) , 2, 09 (d, J=11, 5Hz, 1H), 1, 67 (s a., 1H), 1, 12 (d, J=7, 1 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare Example 679D. Table 73 The following examples were prepared in accordance with the general procedure used to prepare example 679. Table 74 Example 690 2- (dimethylamino) -N- (6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -1, 2, 3, 4-tetrahydronaphthalen-2-yl) -Nm ethyl acetamide To a solution of 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine (30 mg, 0.075 mmol) in DMF (2 ml) was added dimethylglycine (7.72 mg, 0.075 mmol), HATU (28.5 mg, 0.075 mmol) and DIPEA (0.013 ml, 0.075 mmol) at room temperature were stirred for 16 h. The reaction mass was purified by preparative LC-MS using the AA method. The fractions containing the product were combined and dried by centrifugal evaporation to obtain 2-(dimethylamino)-N-(6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide as a pale solid. LC-MS retention time: 1.37 min [E], MS (E+) m / z: 486.3 [M+H]; 1H-NMR (400 MHz, DMSO-d6) 13.05 (s a., 1H) , 8.79 (s a., 1H) , 8.52 (s, 1H) , 7.61 (s, 1H) , 7.24 (d, J=4, 2 Hz, 3H) , 4.65 (s a., 1H), 3, 90 (s, 2H), 3, 26 (s a., 2H), 3, 17 (s a., 1H) , 3, 1.- 2, 93 (m, 5H) , 2, 93-2, 84 (m, 1H) , 2, 80 (s, 1H) , 2, 72 (dd, J=11, 4, 5, 0 Hz, 1H) , 2, 61 (s, 3H) , 2, 402, 16 (m, 6H), 2, 04-1, 93 (m, 1H), 1, 91 (s, 1H), 1, 81 (s a., 1H), 1, 13 (d, J=7, 1 Hz, 6H). The following examples were prepared in accordance with the general procedure used to prepare example 690. Table 75 Example 692 2- ((6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)(methyl)amino)-N,N-dimethylacetamide 2-((6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)(methyl)amino)-N,N-dimethylacetamide was prepared according to the general process described in Example 466, using 6-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine (30 mg, 0.075 mmol) as a starting intermediate to provide the title compound as a whitish solid. CL-EM retention time: 1.46 min [E], EM (E+) m / z: 486.2 [M+H]; 1H-NMR (400 MHz, DMSO-d6) 13, 02 (s a., 1H) , 8, 77 (s a., 1H) , 8, 51 (s a., 1H) , 7, 62 (s a., 1H) , 7, 20 (d, J=8, 1 Hz, 3H) , 3, 12-2, 98 (m, 4H) , 2, 982, 75 (m, 8H) , 2, 61 (s, 3H) , 2, 29 (s a., 3H) , 2, 01 (d, J=11, 5 Hz, 1H) , 1, 66 (dd, J=11, 5, 4, 9 Hz, 1H), 1, 12 (d, J=7, 1 Hz, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 692. Table 76 Example 694 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine Intermediate product 694A: (3-bromo-4-oxocyclohexyl) tert-butyl carbamate Aluminum chloride (0.125 g, 0.938 mmol) was added at 0 °C to a solution of tert-butyl (4-oxocyclohexyl)carbamate (5.00 g, 23.44 mmol) in THF (40 mL) and diethyl ether (40 mL). The reaction mixture was stirred for 5 min, and bromine (1.208 mL, 23.44 mmol) was added dropwise at the same temperature. The reaction mixture was stirred for 6 h. Decolorization occurred, and the formation of solids was observed. The reaction mass was filtered, washed with diethyl ether, the filtrate was collected, and concentrated to yield the crude compound. The crude compound was ground with diethyl ether (3 x 30 mL), the ether was collected and concentrated, and vacuum dried to give tert-butyl (3-bromo-4-oxocyclohexyl)carbamate (5.1 g, 17.46 mmol, 75% yield) as an orange solid. Cl-MS retention time: 1.14 min [A], MS (E+) m / z: 238.4 [M+2H-tBu]. Intermediate product 694B: tert-butyl (2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)carbamate To a solution of (3-bromo-4-oxocyclohexyl) tert-butyl carbamate (5.1 g, 17.46 mmol) in acetonitrile (120 ml) were added DIPEA (6.10 ml, 34.9 mmol) and thiourea (1.462 g, 19.20 mmol) at room temperature. The reaction mixture was stirred at 90 °C for 2 h. The reaction mass was brought to room temperature and concentrated to give (2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl) tert-butyl carbamate (4.6 g, 17.08 mmol, 98% yield) as a gummy solid. CL-EM retention time: 1.06 min [A], EM (E+) m / z: 270.2 [M+H]. Intermediate product 694C: (2-bromo-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl) tert-butyl carbamate Copper(II) bromide (4.20 g, 18.79 mmol) and isoamyl nitrite (3.44 ml, 25.6 mmol) were added to a solution of (2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl) tert-butyl carbamate (4.6 g, 17.08 mmol) in acetonitrile (100.00 ml) at 0 °C. The reaction was continued at the same temperature for 1.5 h. The reaction was stopped with water (100 ml). The reaction mixture was stirred for 10 min, the solids were filtered, the filtrates were extracted with DCM (2 x 200 ml), the combined organic phases were collected, dried (Na2SO4), and concentrated under vacuum to provide the crude compound. The crude compound was purified by ISCO using an 80 g column, the compound was eluted in 20% EA in hexanes, the fractions were collected and concentrated to provide tert-butyl (2-bromo-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)carbamate (2.3 g, 6.90 mmol, 40.4% yield) as a white solid.Tiempo de retención de CL-EM: 1, 73 min [A], EM (E+) m / z: 333, 0 [M], Producto intermedio 694D: (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]piridin-6-yl) -1- ( (2- (trimetilsilil) etoxi) metil) -1H-pirazol-3-yl) -4, 5, 6, 7-tetrahidrobenzo[d]tiazol-6-yl) carbamato de terc-butilo. A solution of 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine was degassed (1,15 g, 1.120 mmol), (2-bromo-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl) tert-butyl carbamate (0.410 g, 1.232 mmol) and K2CO3 solvent mixture (0.464 g, 3.36 mmol) in acetonitrile (16.00 ml) and water (4.00 ml) for The solution was degassed for 10 min under nitrogen. Pd2(dba)s (0.051 g, 0.056 mmol) and 2-dicyclohexylphosphine-2',6'-dimethoxybiphenyl (0.046 g, 0.112 mmol) were added to the solution. The mixture was degassed again for 2 min. The reaction mixture was stirred at 110 °C for 16 h. The reaction mixture was brought to room temperature, the two phases were separated, the aqueous phase was extracted with DCM (2 x 10 mL), the combined organic extracts (Na2SO4) were dried and concentrated to provide the crude compound.The crude compound was purified by ISCO using a 24 g silica column. The compound was eluted in 50% hexane EA. The fractions were collected and concentrated to yield tert-butyl carbamate (2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl) (750 mg, 0.586 mmol, 52.3% yield) as a whitish solid. CL-MS retention time: 1.48 min [A], MS (E+) m / z: 640.5 [M+H]. Intermediate 694E: 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine To a solution of (2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl) tert-butyl carbamate (0.750 g, 0.586 mmol) in DCM (5.00 ml) TFA (3.00 ml, 38.9 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated to provide the crude compound. The crude compound was purified by the preparative AC HPLC method, the fractions containing the product were combined, concentrated and lyophilized to provide 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine (210 mg, 0.503 mmol, 86% yield) as a white solid.The 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amineracemic (210 mg, 0.513 mmol) was purified by SFC using the AF method to separate both enantiomers. The fractions containing the products were collected, concentrated, and lyophilized to provide two isomers. Intermediate product 694E (isomer 1): (72 mg, 0.176 mmol, 34% yield) (peak 1, chiral SFC Tr-9, 88) as a blank solid. CL-EM retention time: 0.990 min [E], EM (E+) m / z: 410.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.43 (d, J = 0.8 Hz, 1H), 8.35 (s, 1H), 7.06 (s, 1H), 4.02 (s, 3H), 3.66-3.62 (m, 1H), 3. 48-3, 39 (m, 1H), 3, 28-3, 20 (m, 1H), 2, 96-2, 81 (m, 2H), 2, 25-2, 19 (m, 1H), 2, 01-1, 95 (m, 2H), 1, 24 (d, J = 6, 8 Hz, 6H) ; and the intermediate product 694E (isomer 2): (93 mg, 0.227 mmol, 44% yield) (peak 2, chiral SFC Tr-13.17) as a blank solid. CL-EM retention time: 1.07 min [E], EM (E+) m / z: 410.1 [M+H]; 1HRMN (400 MHz, methanol-d4) ppm 8.43 (d, J = 0.8 Hz, 1H), 8.35 (s, 1H), 7.06 (s, 1H), 4.02 (s, 3H), 3.66-3.62 (m, 1H), 3. 48-3, 39 (m, 1H), 3, 28-3, 20 (m, 1H), 2, 96-2, 81 (m, 2H), 2, 25-2, 19 (m, 1H), 2, 01-1, 95 (m, 2H), 1, 24 (d, J = 6, 8 Hz, 6H). Example 694: 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine (21 mg, 0.051 mmol) in MeOH (2.00 mL), formaldehyde (0.2 mL, 2.178 mmol), and AcOH (0.1 mL, 1.747 mmol) were added to a solution at room temperature. The mixture was stirred at the same temperature for 6 h, then sodium cyanoborohydride (16.11 mg, 0.256 mmol) was added at room temperature. The reaction mixture was stirred at the same temperature for 16 h. The reaction mass purified by reparative CL-EM using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine (6.3 mg, 0.014 mmol, 27% yield) as a pale solid.CL-EM retention time: 1,023 min [F], EM (E+) m / z: 438, 2 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.54 (s, 1H) , 8.45 (s, 1H) , 7.18 (s, 1H) , 4.13 (s, 3H) , 3.81 (s, 1H) , 3.50 (sa, 1H) , 3. 24-3, 13 (m, 2H) , 3, 10 (d, 7=14, 9 Hz, 1H) , 3, 01-2, 78 (m, 2H) , 2, 63 (s, 6H) , 2, 31 (sa, 1H) , 2, 05-1, 87 (m, 2H) , 1, 43-1, 21 (m, 7H) . The following examples were prepared in accordance with the general procedure used to prepare example 694E. Table 77 The following examples were prepared in accordance with the general procedure used to prepare example 694. Table 78 Example 718 2-(dimethylamino)-N-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) acetamide To a solution of 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine (15 mg, 0.037 mmol) and dimethylglycine (5.67 mg, 0.055 mmol) in DMF (1.00 ml) were added TEA (0.1 ml, 0.717 mmol) and HATU (27.9 mg, 0.073 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 2 h. The reaction mass was purified by preparative CL-EM using the AB method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(dimethylamino)-N-(2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)acetamide (3.0 mg, 5.75 mol, 15.70% yield) as a pale solid.CL-EM retention time: 1, 117 min [F], EM (E+) m / z: 495, 3 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.55 (s, 1H) , 8.45 (s, 1H) , 7.17 (s, 1H) , 4.34 (d, 7=9, 3 Hz, 1H) , 4.13 (s, 3H) , 3.55 (d, 7=7, 1 Hz, 1H) , 3, 27-3, 11 (m, 3H) , 3, 05-2, 95 (m, 2H) , 2, 95-2, 74 (m, 2H) , 2, 40 (s, 5H) , 2, 14 (s, 1H) , 2, 08-1, 91 (m, 2H), 1, 39-1, 17 (m, 6H) . The following examples were prepared in accordance with the general procedure used to prepare example 718. Table 79 Example 722 N-ethyl-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine Intermediate product 722A: (2-bromo-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(methyl) tert-butyl carbamate N-ethyl-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4,5,6,7- tert-butyl (2-bromo-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)carbamate solution (1.2 g, 3.60 mmol) in THF (50.00 ml) was mixed with NaH (0.432 g, 10.80 mmol) at 0 °C. The reaction mixture was stirred for 1 h, and then cooled. Mel (0.675 ml, 10.80 mmol) was added. The reaction mixture was stirred at the same temperature for 5 h. The reaction was stopped with ice at 0 °C. The mixture was extracted with EtOAc, washed with brine, and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 24 g silica column. The compound was eluted in 18% EtOAc in hexane. The fractions were collected and concentrated to obtain (2-tetrahydrobenzo[d]thiazol-6-amine bromo-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(methyl) tert-butyl carbamate (1.15 g, 3.31 mmol, 92% yield) as a white solid. Cl-MS retention time: 1.99 in [A], MS (E+) m / z: 349.2 [M + 2H]. Intermediate 722B: (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1- ( (2- (trimethylsilyl) ethoxy) methyl) -1H-pyrazol-3-yl) -4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) (methyl) tert-butyl carbamate A solution of 6-(4-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine was degassed (2.90 g, 2.82 mmol), tert-butyl (2-bromo-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) (methyl) carbamate (0.817 g, 2.353 mmol) and K2CO3 (0.976 g, 7.06 mmol) in a solvent mixture of acetonitrile (40. 00 ml) and water (10, 00 ml) for 10 min with nitrogen. Then, Pd2(dba)3 (0.108 g, 0.118 mmol) and 2-dicyclohexylphosphine-2',6'-dimethoxybiphenyl (0.097 g, 0.235 mmol) were added. The reaction mixture was degassed for 2 min and stirred at 110 °C for 16 h. The reaction mixture was brought to room temperature, the two phases were separated, the aqueous phase was extracted with DCM (2 x 20 ml), the combined organic extracts (Na2SO4) were dried and concentrated to obtain the crude compound.The crude compound was purified by ISCO using a 24 g silica column. The compound was eluted in 50% hexane EA. The fractions were collected and concentrated to obtain tert-butyl (2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(methyl)carbamate (2.75 g, 1.262 mmol, 54% yield) as a whitish solid. Cl-MS retention time: 1.85 min [A], MS (E+) m / z: 654.6 [M+H]. Intermediate 722C: 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine A solution of (2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(methyl)tert-butyl carbamate (2.75 g, 1.262 mmol) in DCM (5.00 ml) was given TFA (3.00 ml, 38.9 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h. The reaction mass was concentrated to obtain the crude compound, the crude compound was purified by preparative HPLC using the AC method, the fractions containing the compound were collected, concentrated and lyophilized to obtain 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine, TFA (670 mg, 1,197 mmol, 95% yield) as a whitish solid. The racemic compound was purified by SFC using the AD method to separate both enantiomers, the desired fractions were collected, concentrated and lyophilized to give: Example 722Ca: Isomer 1 (270 mg, 0.631 mmol, 39.9% yield) (peak 1, chiral SFC Tr-11, 82) as a blank solid. CL-MS retention time: 1.557 min [B], MS (E+) m / z: 424.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8.54 (d, J = 1.2 Hz, 1H), 8.46 (s, 1H), 7.17 (s, 1H), 4.13 (s, 3 H), 3.88-3.64 (m, 1H), 3.51- 3.32 (m, 2H), 3.10-2.95 (m, 3 H), 2.86 (s, 3H), 2.41-2.38 (m, 1H), 2.13-2.05 (m, 1H), 1.34 (d, J = 6.8 Hz, 6 H) ; and Example 722Cb: Isomer 2 (330 mg, 0.756 mmol, 47.8% yield) (peak 2, chiral SFC Tr-19, 44) as a blank solid. CL-EM retention time: 1.539 min [B], EM (E+) m / z: 424.2 [M+H]; 1H-NMR (400 MHz, methanold4) ppm 8.54 (d, J = 1.2 Hz, 1H), 8.45 (s, 1H), 7.17 (s, 1H), 4.13 (s, 3H), 3.74-3.68 (m, 1H), 3. 53-3, 40 (m, 2 H), 3, 08-2, 94 (m, 3 H), 2, 85 (s, 3 H), 2, 42-2, 35 (m, 1H), 2, 12-2, 04 (m, 1H), 1, 33 (d, J = 6, 8 Hz, 6 H) . Example 722: N-ethyl-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine AcOH (0.1 ml, 1.747 mmol) was added at room temperature to a solution of 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine (19 mg, 0.045 mmol) and acetaldehyde (9.88 mg, 0.224 mmol) in MeOH (2.00 ml). The reaction mixture was stirred at the same temperature for 6 h, and sodium cyanoborohydride (8.46 mg, 0.135 mmol) was added. The reaction mixture was stirred at the same temperature for 16 h. The reaction mass 5 was purified by preparative LC-MS using the AA method, the fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain N-ethyl-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine (4, 1 mg, 8, 44 mol, 19% yield) as a pale solid. CL-EM retention time: 0.853 min [F], EM (E+) m / z: 452.3 [M+H]; 1H NMR (400 MHz, methanol-d4) ppm 8.54 (d, .7=1.0 Hz, 1H), 8.49-8.43 (m, 1H), 7.17 (s, 1H), 4.13 (s, 3H), 3.97-3.86 (m, 1H), 3, 60-3, 42 (m, 3H) , 3, 37 (s, 2H) , 3, 24-3, 12 (m, 2H) , 3, 09-3, 00 (m, 1H) , 2, 98 (s, 3H) , 2, 41 (s, 2H) , 2, 20 (s, 2H), 1, 44 (t, 7=7, 2 Hz, 4H) , 1, 40-1, 26 (m, 7H) , 1, 23 (s, 1H) . The following examples were prepared in accordance with the general procedure used to prepare example 722. Table 80 Example 734 2- (dimethylamino) -N- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) -N-methylacetamide To a solution of 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine (11 mg, 0.026 mmol) and dimethylglycine (4.02 mg, 0.039 mmol) in DMF (1.00 ml) were added DIPEA (0.1 ml, 0.573 mmol) and HATU (19.75 mg, 0.052 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 2 h. The reaction mass was purified by preparative LC-MS purification using the AB method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-(dimethylamino)-N-(2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-N-methylacetamide (10.8 mg, 0.021 mmol, 80% yield) as a pale solid. LC-MS retention time: 0.925 min [F], MS (E+) m / z: 509.2 [M+H]; 1H-NMR (400 MHz, methanol-d4) ppm 8, 55 (s, 1H), 8, 46 (s, 1H), 7, 18 (s, 1H), 4, 31 (s, 1H), 4, 13 (s, 3H), 3, 70 (s, 2H), 3, 59-3, 49 (m, 1H) , 3, 20-2, 92 (m, 8H) , 2, 62 (s, 3H) , 2, 56 (s, 3H) , 2, 32-2, 16 (m, 1H) , 2, 12 (s, 1H) , 2, 09-1, 99 (m, 1H) , 1.96 (s, 2H), 1, 41-1, 25 (m, 8H), 0, 98-0, 83 (m, 1H) . The following examples were prepared in accordance with the general procedure used to prepare example 734. Table 81 Example 736 2- ((2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) (methyl)amino) -N, N-dimethylacetamide To a solution of 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-6-amine (12 mg, 0.028 mmol) and 2-chloro-N,N-dimethylacetamide (5.17 mg, 0.042 mmol) in a solvent mixture of DMF (0.50 mL) and THF (1.50 mL) was added DIPEA (0.1 mL, 0.573 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 16 h. The reaction mass was purified by preparative LC-MS using the AA method. The fractions containing the product were combined and dried using a Genevac centrifugal evaporator to obtain 2-((2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(methyl)amino)-N,N-dimethylacetamide (3.6 mg, 6.68 mol, 23% yield) as a pale solid. LC-MS retention time: 1.335 min [E], MS (E+) m / z: 509.3 [M+H]; JHNMR (400 MHz, methanol-d4) ppm 8.55 (s, 1H), 8.45 (s, 1H), 7.17 (s, 1H), 4.20-4.10 (m, 3H), 3.80 (s, 1H), 3.63-3.44 (m, 2H) , 3.37 (s, 1H) , 3.19 (s, 1H) , 3.16-3.03 (m, 4H) , 3.00-2.91 (m, 3H) , 2.88 (d, J= 4.6Hz, 1H) , 2.65-2.36 (m, 3H), 2, 24 (d, J=6, 6 Hz, 1H) , 1, 96-1, 85 (m, 1H) , 1, 37-1, 23 (m, 5H) . The following examples were prepared in accordance with the general procedure used to prepare example 736. Table 82 Example 742 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(piperidin-4-yl)thiazole Intermediate product 742A: 4-(thiazol-5-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate Intermediate product 742A: 4-(thiazol-5-yl)-3,6-dihydropyridine-1-(2H)-tert-butyl carboxylate XPhos Pd G2 (2.399 g, 3.05 mmol) and K3PO4 (15.93 g, 91 mmol) were added to a degassed solution of 5-bromothiazole (5.0 g, 30.5 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate (11.31 g, 36.6 mmol) in a solvent mixture of THF (150 mL) and water (30.0 mL). The reaction mixture was stirred at 80 °C for 14 h in a sealed tube. The reaction mixture was diluted with ethyl acetate, filtered, the filtrate was washed with water and brine, dried over sodium sulfate, and concentrated to obtain the crude compound. The crude compound was purified by ISCO using an 80 g silica column. The compound was eluted with 45–65% ethyl acetate in petroleum ether, and the fractions were collected and concentrated to obtain tert-butyl 4-(thiazol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate (6.2 g, 23.28 mmol, 76% yield) as a light brown solid.CL-EM retention time: 2.49 min [B], EM (E+) m / z: 267.2 [M+H]. Intermediate product 742B: tert-butyl 4-(thiazol-5-yl)piperidin-1-carboxylate To a solution of tert-butyl 4-(thiazol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate (6.2 g, 23.28 mmol) in methanol (250 mL) Pd-C (2.477 g, 23.28 mmol) was added at room temperature. The reaction mixture was stirred at room temperature in a hydrogen bladder for 12 h. The reaction mixture was filtered and washed with excess methanol and THF; the filtrates were collected and concentrated to obtain the crude compound. The crude compound was purified by ISCO using an 80 g silica column, eluted with 20–35% ethyl acetate in petroleum ether, and the fractions were...

Claims

1. Compound of Formula (I), the N-oxide, or a salt thereof, wherein: G is: R1 is -CH3, -CH2CH3, -CH(CH3)2, -CF3 or -CH2CF3; each R2 is independently -CN, -CH3 or -OCH3; R2a is C1-6 alkyl, C1-3 fluoroalkyl, C1-6 hydroxyalkyl, C1-3 aminoalkyl, -(CH2)O-40 (C1-3 alkyl), C3-6 cycloalkyl, -(CH2)1-3C(O)NRyRy, -CH2 (C3-6 cycloalkyl), -CH2 (phenyl), tetrahydrofuranyl, tetrahydropyranyl or phenyl; each R2b is independently hydrogen, halo, -CN, -NRXRX, C1-6 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 fluoroalkoxy, -(CH2)O-20 (C1-3 alkyl), -(CH2)O-3C(O)NRxRx, -(CH2)I-3 (C3-6 cycloalkyl), -C(O)O (C1-3 alkyl), -C(O)NRX (C1-3 alkyl), -CrX=CRXRX, or -Crx=CH (C3-6 cycloalkyl); A is: (i) -CH2N(CH3)RX, -C(O)NRXRX, -C(O)N(CH3)(CH2CH2CN), -C(O)N(CH2CH3)(CH2CH2CN), or -C(O)N(CH3)(CH2CH2CH2N(CH3)2); (ii) -C (O) A1, -C (0) NRX (CRXRX) O-2A1,-CH2NHA1 or -C(O)C(O)NHA1; (iii) zero-to-1 substituted cyclohexyl R3b; (iv) zero to 1 substituted piperidinyl R3c; (v) phenyl substituted with zero to 1 R3a and zero to 1 R3e; (vi) pyridinyl substituted with zero to 1 R3f and zero to 1 R3g; (vii) pyrazinyl or pyrimidinyl, each substituted with zero to 1 R3f; (viii) thiazolyl substituted with R3h and from zero to 1 R3i (ix) diazabicyclo[2.2.1]heptanyl or diazaspiro[3.3]heptanyl, each substituted with zero to 1 Rsj; or (x) benzo[d]thiazolyl, dihydroisoquinolinyl, tetrahydronaphthyridinyl, tetrahydrobenzo[d]thiazolyl, tetrahydroimidazo[1, 2-a]pyrazinyl, tetrahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydronaphthalenyl, etrahydropyrazolo[1, 2]. 5-a]pyrazinyl, tetrahydropyrido[4, 3-d]pyrimidinyl, tetrahydrothiazolo[4, 5-C]pyridinyl or tetrahydrothiazolo[5, 4-C]pyridinyl, each substituted with zero to 1 Rsk; A1 is azetidinyl, cyclohexyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, pyridinyl,diazepanyl, hexahydropyrrolo[3, 4-C]pyrrolyl, each substituted with zero to 1 R3a; R3a is -OH, -CH3, -CH2CH3, -CH2CH2CH3, -CH (CH3) 2, -CH2CH (CH3) 2, -CH (CH3) (CH2CH3) , -CH2C (CH3) 3, -CH2CH2CH (CH3) 2, -CH (CH3) CH (CH3) 2, -CH2CH2C (CH3) 3, -CH2C (CH2CH3) 2, -CH2CF3, -CH2CH2CF3, -CH2CH 3 2CH2CF3, -CH2CH2CN, -CH2C (CH3) 2OH, -CH2CH2 OCH 3, -CH2CH2S (O) 2CH3, -CH (CH3) CH2S (O) 2CH3, -CH2NH2, -CH2CH2N (CH3) 2, -CH2C(O)NH(CH3), -CH2C(O)N(CH3)2, -NRyRy, -N(CH3)(CH2CH2OCH3), -NH(CH2CH2CH2CF3), -NHCH(CH3)(CH2OCH3), -C(O)NH2, -C(O)OC(CH3)3, -CH2(cyclopropyl), -CH2(methyloxetanyl), -CH2 (tetrahydrofuranyl), -CH2 (tetrahydropyranyl), -CH2 (dimethylisoxazolyl), -CH2 (methyltriazolyl), -CH2 (methoxypyrimidinyl), -NH (oxetanyl), -NH (methyloxetanyl), -NH (tetrahydropyranyl), -NH (dimethyltetrahydropyranyl), -N(cyclopropyl)2, -NHCH2(cyclopentyl), -NHCH2 (dimethylisoxazolyl), -NHCH2 (methyloxetanyl), -NHCH2 (pyridinyl),-NHCH2 (pyrimidinyl) , -NHCH2 (methylpyrimidinyl) , -NHCH2 (methoxypyrimidinyl) , -NHCH2 (tetrahydropyranyl) , cyclobutyl, oxetanyl, isopropypiperidinyl, tetrahydropyranyl, dimethylpyranyl ether; R3b is -NH (CH3) , -NH (CH2CH2) , -N (CH3) (CH2CH3) , -NH (CH2CH2N (CH3) 2) , -N (CH3) C (O) CH2N (CH3) 2, -N (CH3) 2, CH2C (CH2C) (isopropylpiperidinyl) , -N (CH3) C (O) (azetidynyl) , -N (CH3) C (O) (isopropylazethidinyl) , -N (CH3) C (O) (ethyl azetidinyl) , -N (CH3) C (O) (methyl azetidynyl) -methylhethinylH2 (CH2) methylpiperazinyl or dimethylaminopiperidinyl R3C is alkyl C1-3, -CH2C (O) N (CH3) 2, -C (O) CH2CH2N (CH3) 2 or -dC (O) 2:CH2 (CH3NH) ; CRxRxNRxRx, -CrxRxNRx (alkyl C2-5) , -CH (CH3) N (CH3) (CH2CF3) , -CH2CH2S (O) 2CH3, -CH (CH3) N (CH3) CH2C (O) N (CH3) (CH3C2) CH2C3) -CH 2, -CrxRxNRxC (O) CHRxNRxRy, -CH (CH3) N (CH3) C (O) CH2NRX (C3-4 fluoroalkyl) , -NRXRX,-NH (CH (CH3) 2) , -C (O) NH2, -CrXRXQ1.- CrXRXNRXQ1.- CrXRXNRXCH2Q1.- CrXRXNRXC (O) Q1.- CRXRXNRXC (O) CRXRxRxQI (O) CRXRxRxQI, -CrXRXQI, -CrXRXQ1. -CH (CH3) N (oxetanyl) (C (O) CH2N (alkyl C1-2) 2) ; (b) zero to 1-substituted azetidinyl substituents selected between alkyl C1–3, −CH2C(CH3)2OH, −C(O)CH2N(CH3)2, −N(CH3)2, −NHCH(CH3)2, oxetanyl and tetrahydropyranyl; (c) cyclopropyl or cyclohexyl, each substituted with -NRXRX, NRx (alkyl C2-4) , -NH (oxetanyl) , -N (CH3) CH2CH2 OCH, -N (CH3) CH2C (O) N (CH3) 2, CCH -N (O) (CH3) (CH3) CH2 (ethylhethanyl) ; or (d) morpholinyl, piperazinonyl, piperazinyl, piperidinyl, or pyrrolidinyl, each substituted with zero to 1 substituent selected between alkyl C1-5.- CH2CF3, -CH2C (CH3) (CH3) 2, oxetanyl, methyloxetanyl and tetrahydropyranyl; Q1 is azetidinyl, cyclopropyl, morpholynyl, oxetanyl, tetrahydropyranyl, triazolyl, oxaazaspiro[3.3]heptanyl,piperazinonyl, difluoropiperidinyl or pyrrolidinyl, each substituted with zero to 2 substituents independently selected from F, -CH3, -CH2CH3.- CH2OH and oxethanyl; R3e is F; R3f is: (a) -OH, -NH2, -N (CH3) 2, -NH (CH (CH3) 2) , -NHCH2C (CH3) 2OCH3.- CH2NH (CH3) , -CH2N (CH3) 2.- CH2NH (CH (CH3) 2) , -CH (CH3) N (CH3) 2 or -CH (CH3) N (CH3) C (O) CH2N (CH3) 2; (b) cyclohexyl substituted with -NH2.- N (CH3) 2.- NRX (CH2CH2OCH3) , -NH (cyclobutyl) , -NH (methyloxethanyl) , -NHCH2 (methylsulfonylcyclopropyl) , morpholinyl, methoxyazetidinyl, piperazinonyl, difluoropiperidinyl, methoxypiperidinyl, oxaazaspiro[3.3]heptanyl or oxaazaspiro[3.5]nonanyl; (c) diazaspiro[3.3]heptanyl substituted with zero to one substituent selected from C1-4 alkyl, -CH2CH2OCH3.- CH2CH2S (O) 2CH3, -CH2 (C3-4 cycloalkyl) , -CH2 (tetrahydropyranyl) , cyclobutyl, oxethanyl and tetrahydropyranyl; (d) piperazinyl substituted with zero to one substituent selected from C1-6 alkyl,-CH2CH2CF3.- CH2CH2OCH3, -CH2CH2S (O) 2CH3.- CH2 (C3-4 cycloalkyl), -CH2 (ethyloxetanyl), -CH2C (O) NH (CH3), -CH2C (O) N (CH3) 2, -C (O) CH2N (CH3) 2, -C (O) CH2N (CH2CH3) 2.- CH2 (tetrahydropyranyl), cyclobutyl, xetanyl, tetrahydropyranyl and dioxothiotetrahydropyranyl; or (e) piperidinyl substituted with zero to one substituent selected from C1-6 alkyl.- CH2CN, -CH2CH2F, -CH2CH2CH2F, -CH2CH2CF3.- CH2C (CH3) 2OH, -CH2CH2OCH3.- CH2CH2S (O) 2CH3.- CH2C (O) NRXRX, -C (O) CH2N (CH3) 2.- C (O) CH2N (CH2CH3) 2.- CH2 (C3-4 cycloalkyl) , -CH2 (tetrahydrofuranyl) , -CH2 (tetrahydropyranyl) , -CH2 (methyltriazolyl) , cyclobutyl, ethoxycyclobutyl, oxethanyl, tetrahydrofuranyl and tetrahydropyranyl; R3g is F, -CH3 or -CF3; R3h is: (a) -CH (CH3) N (CH3) RX, -CH (CH3) N (CH3) (C2-3 alkyl), -CH (CH3) N (CH 3) CH2C (O) N (CH3) 2.- CH (CH3) N (CH 3) C (O) CH2N (CH3) 2 or -CH (CH 3) N (CH 3) (tetrahydropyranyl) (b) cyclohex substituted with -N(CH3)RX, -N(CH3)(CH(CH3)3),-N(CH3)(CH2CH2CF3), -NRX(CH2CH2OCH3), -NH(CH2C(CH3)2OCH3), -N(CH3)C(O)CH2N(CH3)2, -NH(cyclobutyl), -NRx(oxetanyl), -NH(methyl oxetanyl), -NH(tetrahydropyranyl) , -NHCH2 (methylsulfonylcyclopropyl), NHCH2 (methyloxetanyl), methoxyazetidinyl, (trifluoromethyl)hydroxyazetidinyl, morpholinyl, pyrrolidinyl, piperazinonyl, methylsulfonylpiperazinyl, oxazepanyl, oxaazaspiro [3, 3]heptanyl, oxaazaspiro [3, 5]nonanyl or dioxothiazaspiro[3, 3]heptanyl; (c) piperazinyl substituted with zero to two -CH3; and zero or one substituent selected from C1-5 alkyl.- CH2CN, -CH2CH2F, -CH2CH2CH2F, -CH2C (CH3) 2OH, -CH2CH2 OCH 3, -CH2CH2S (O) 2CH3, -CH2C (O) N (CH3) RX, -NHC (O) CH2N (CH3) 2.- NHC (O) CH2N (CH2CH3) 2.- C (O) CH2N (CH3) 2.- C (O) CH2N (CH2CH3) 2.- CH2 (C3-4 cycloalkyl) , -CH2 (tetrahydropyranyl) , -C (O) CH2 (morpholinyl) , cyclobutyl,oxetanilo and tetrahidropyranilo; or (d) piperidinyl replaced with wax or a -CH3 and wax or 1 substitute selected between alquilo C1-6.- CH2CN, -CH2CH2F, -CH2CH2CH2F, -CH2CH2CF3, -CH2C (CH3) 2OH, -CH 2 CH 2 OCH 3, -CH2CH2OC (CH3) 3, -CH2CH 2 S (O) 2 CH3, -CH2C (O) NH2.- CH2C (O) N (CH3) 2.- CH 2C (O) N (CH3) 2) , -C (O) CH2N (CH3) 2.- C (O) CH2N (CH2CH3) 2.- C (O) CH2N (CH3) (CH2CH2 OCH 3) , -NH2, -NH (CH2CH2CH3) , -NH (CH(CH3)2) , -NHCH2CH(CH3)2.- N(CH3)2, -N(CH3)(CH2CH3) , -NH(CH2C(CH3)2OCH3) , -CH2 (C3-6 cycloalkyl) , -CH2 (methylsulfonylcyclopropyl) , -CH2 (oxetanil) , -CH2 (methyloxetanil) , -CH2 (ethyloxetanil) , -CH2 (tetrahydrofuranyl) , -CH2 (tetrahydropyranyl) , -CH2 (methyltriazolyl) , -CH2C(O) (oxetanil) , -CH2C(O) (morpholinil) , -CH2C(O) (oxaazaspiro[3.3]heptanil) , -C(O)CH2 (methoxyazetidinyl) , -C (O) CH2 (morpholinil) , -C (O) CH2 (oxaazaspiro[3.5]nonanilo) , -C (O) CH2 (piperidinonyl) ,-N (CH2 (cyclopropyl) ) 2.- N (CH2 (tetrahydropyranyl) ) 2.- NH (methyloxethanyl) , -NH (tetrahydropyranyl) , -NHC (O) CH2 (morpholinyl) , -NHCH2 (cyclopropyl) , cyclobutyl, ethoxycyclobutyl, ethoxycyclobutyl, oxethanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxotetrahydrothiophenyl and (oxanilamino) piperidinyl; R3i is -CH3 or -CF3; R3j is C1-6 alkyl.- CH2CH2 OCH 3, -CH2CH2S (O) 2CH3, -C (O) CH2N (CH3) 2, -CH2 (C3-4 cycloalkyl) , -CH2 (tetrahydropyranyl) , -CH (CH3) (cyclopropyl) , cyclobutyl, oxethanyl, tetrahydropyranyl or isopropylpiperidinyl; R3k is C1-4 alkyl.- CH2C (CH3) 2OH, -CH2CH2 OCH 3, -CH2C (O) NRXRX, -C (O) CH3, -C (O) CH2CH (CH3) OH, -C (O) CH2N (CH3) 2, -NRX (C1-3 ALKYL), -NRx (C3-4 fluoroalkyl), -NRX (CH2CH2 OCH 3) , -N (CH3) (CH2CH2S (O) 2CH3) , -N (CH3) (CH2C (O) N (CH3) 2) , -NRX (C (O) CH2N (CH3) 2) , -N (CH2CH2CH2CF3) 2.- NRx (oxetanyl) , -N (CH3) (methyloxetanyl), -N (CH3) (tetrahydropyranyl), -NH (ethoxycyclobutyl),oxethanyl or isopropylpiperidinyl; and R3 is hydrogen; each Rx is independently H or -CH3; each Ry is independently H or C1-6 alkyl; and p is zero, 1 or 2.

2. Compound according to claim 1, N-oxide or a salt thereof, wherein A is: (i) -CH2N(CH3)RX, -C(O)NRXRX, -C(O)N(CH3)(CH2CH2CN), -C(O)N(CH2CH3)(CH2CH2CN) or -C(O)N(CH3)(CH2CH2CH2N(CH3)2); or (ii) -C(O)A1.-C(O)NRX(CRXRX)O-2A1.-CH2NHA1 or -C(O)C(O)NHA1.

3. Compound according to claim 1, N-oxide or a salt thereof, wherein A is: (i) cyclohexyl substituted at 0 to 1 R3b; (ii) piperidinyl substituted at 0 to 1 R3c; (iii) phenyl substituted at 0 to 1 R3d and 0 to 1 R3e; (iv) pyridinyl substituted at 0 to 1 R3f and 0 to 1 R3g; (v) pyrazinyl or pyrimidinyl, each substituted at 0 to 1 R3f; (vi) thiazolyl substituted at R3h and 0 to 1 R3i; (vii) diazabicyclo[2.2.1]heptanyl or diazaspiro[3.3]heptanyl,each substituted with zero to 1 R3j; or (viii) benzo[d]thiazolyl, dihydroisoquinolinyl, tetrahydronaphthiridinyl, tetrahydrobenzo[d]thiazolyl, tetrahydroimidazo[1,2-a]pyrazinyl, tetrahydroisoquinolinonyl, tetrahydroisoquinolinyl, tetrahydronaphthalenyl, tetrahydropyrazolo[1,5-a]pyrazinyl, tetrahydropyrido[4,3-d]pyrimidinyl, tetrahydrothiazolo[4,5-C]pyridinyl or tetrahydrothiazolo[5,4-C]pyridinyl, each substituted with zero to 1 R3k.

4. Compound according to claim 1 or a salt thereof, wherein R1 is -CH(CH3)2; each R2 is independently -CH3 or -OCH3; yp is 1 or 2.

5. A compound according to claim 4 or a salt thereof, wherein A is: (i) cyclohexyl substituted at 0 to 1 R3b; (ii) phenyl substituted at 0 to 1 R3d and 0 to 1 R3e; (iii) pyridinyl substituted at 0 to 1 R3f and 0 to 1 R3g; and (iv) thiazolyl substituted at R3h and 0 to 1 R3i.

6. A compound according to claim 4 or a salt thereof,wherein: A is -C (0) NRx (CRxRx) o-2A1; and A1 is azetidinyl, cyclohexyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, pyridinyl, diazepanyl, hexahydropyrrolo[3, 4-C]pyrrolyl, each substituted with zero to 1 R3a.

7. Compound according to claim 1, N-oxide or salt thereof, wherein said compound is: tert-butyl piperidin-1-carboxylate (1) 4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamido) 4-isopropyl-N-(1-isopropylpiperidin-4-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (2) ; 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(2-morpholinoethyl)-1H-pyrazole-3-carboxamide (3); 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(2-(pyridin-2-yl)ethyl)-1H-pyrazole-3-carboxamide (4) ; 4-isopropyl-N- (2-methyl-2-morpholinopropyl) -5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (5) ; 4-isopropyl-N-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-methylpiperidin-4-yl) -1H-pyrazole-3-carboxamide (6) ; N-(4-(dimethylamino)cyclohexyl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (7) 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-methylpiperidin-4-yl) -1H-pyrazole-3-carboxamide (8) ; 4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-methyl-N-(1-methylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (9) ; (4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) (4-methyl-1, 4-diazepan-1-yl) methanone (10) ; 4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (11) ; 4-isopropyl-N-(1-isopropylpiperidin-4-yl)-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (12) ; (4- (dimethylamino) piperidin-1-yl) (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) methanone (13) ; (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) (4- (pyridin-4-yl) piperazin-1-yl) methanone (14) ; 1- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carbonyl) piperidin-4-carboxamide (15) ; N-(2-cyanoethyl)-4-isopropyl-N-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (16) ; 4-isopropyl-N-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(pyridin-3-ylmethyl)-1H-pyrazole-3-carboxamide (17) ; (R)-(3-(dimethylamino)pyrrolidin-1-yl) (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)methanone (18) ; 3-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carbonyl)piperazin-1-yl)propanenitrile (19) ; 4-isopropyl-5-(8-methoxy-[1, 2,4]triazolo[1,5-a]pyridin-6-yl)-N-methyl-N-(1-methylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (20); (3-(dimethylamino)azetidin-1-yl)(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)methanone (21) ; (S)-(3-(dimethylamino)pyrrolidin-1-yl)(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)methanone (22) ; (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) (4-methyl-1, 4-diazepan-1-yl) methanone (23) ; N-(3-(dimethylamino)propil)-4-isopropyl-N-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (24) ; 4-isopropyl-N-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-methylpyrrolidin-3-yl)-1H-pyrazol-3-carboxamide (25) ; 4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(2-methyl-2-morpholinopropyl)-1H-pyrazole-3-carboxamide (26) ; 4-isopropyl-N-methyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamide (27) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- (tetrahydro-2H-pyran-4-yl) -1H-pyrazol-3-carboxamide (28) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamide (29) ; (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) (morpholino) methanone (30) ; 4-isopropyl-N, N-dimethyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (31) ; N-(4-hydroxycyclohexyl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (32) ; 5-(7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-isopropyl-N-(1-isopropylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (33) ; 5-(3, 4-dimethoxyphenyl)-4-isopropyl-N-(1-isopropylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (34) ; 4-isopropyl-N-(1-isopropylpiperidin-4-yl)-5-(1H-pyrazolo[3, 4-b]pyridin-4-yl)-1H-pyrazole-3-carboxamide (35); 5-(2,6-dimethylpyridin-4-yl) -4-isopropyl-N-(1-isopropylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (36) ; 4-isopropyl-N-(1-isopropylpiperidin-4-yl)-5-(8-methylimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (37) ; 4-isopropyl-N-(1-isopropylpiperidin-4-yl)-5-(2-methylpyridin-4-yl)-1H-pyrazole-3-carboxamide (38) ; 5-(l, 5-dimethyl-6-oxo-1, 6-dihydropyridin-3-yl)-4-isopropyl-N-(1-isopropylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (39) ; 5-(8-cyanoquinolin-5-yl)-4-isopropyl-N-(1-isopropylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (40) ; 4-isopropyl-5-(1-methyl-1H-pyrrolo[2, 3-b]pyridin-3-yl)-N-(1-methylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (41) ; 4-isopropyl-N-(1-isopropylpiperidin-4-yl)-5-(1-methyl-1H-pyrrolo[2, 3-b]pyridin-3-yl)-1H-pyrazole-3-carboxamide (42) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide (43) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -N-(piperidin-4-ylmethyl) -1H-pyrazole-3-carboxamide (45) ; N-((1r,4r)-4-aminocyclohexyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (46) ; N-(((1r,4r)-4-aminocyclohexyl) methyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (47) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(morpholin-2-ylmethyl)-1H-pyrazole-3-carboxamide (48) ; N-(azetidin-3-ylmethyl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (49) ; (R)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(pyrrolidin-3-yl)-1H-pyrazole-3-carboxamide (50) ; (S)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(pyrrolidin-2-ylmethyl)-1H-pyrazole-3-carboxamide (51) ; (R)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -N-(piperidin-3-yl) -1H-pyrazole-3-carboxamide (52) ; (S) - (3-aminopyrrolidin-1-yl) (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) methanone (53) ; (S) -4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(piperidin-3-yl) -1H-pyrazole-3-carboxamide (54) ; (4-aminopiperidin-1-yl) (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) methanone (55) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(piperidin-2-ylmethyl)-1H-pyrazole-3-carboxamide (56) ; (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) (piperazin-1-yl)methanone (57) ; N-(azetidin-3-yl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (58) ; (hexahydropyrrolo[3, 4-C]pyrrol-2 (1H) -yl) (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) methanone (59) ; 4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -N-(piperidin-4-yl) -1H-pyrazole-3-carboxamide (60) ; (4-(aminomethyl)piperidin-1-yl) (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) methanone (61) ; 4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(piperidin-4-ylmethyl) -1H-pyrazole-3-carboxamide (62) ; N-((1s,4s)-4-aminocyclohexyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (63) ; 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(morpholin-2-ylmethyl)-1H-pyrazole-3-carboxamide (64) ; 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(morpholin-2-ylmethyl)-1H-pyrazole-3-carboxamide (65) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(piperidin-3-yl)-1H-pyrazole-3-carboxamide (66) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(piperidin-3-yl)-1H-pyrazole-3-carboxamide (67) ; 4-isopropyl-5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl) -N-(piperidin-4-yl) -1H-pyrazole-3-carboxamide (68) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-(3, 3, 3-trifluoropropyl)piperidin-4-yl) -1H-pyrazole-3-carboxamide (69) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-(oxetan-3-yl)piperidin-4-yl) -1H-pyrazole-3-carboxamide (70) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-(4, 4, 4-trifluorobutyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (71) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-((tetrahydrofuran-3-yl)methyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (72) ; N-(1-(cyclopropylmethyl)piperidin-4-yl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (73) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-neopentylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (74) ; N-(1-(3, 3-dimethylbutyl)piperidin-4-yl)-4-isopropyl-5-(8-methyl-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (75) ; N-(1-isopentylpiperidin-4-yl) -4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (76) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-((tetrahydro-2H-pyran-4-yl) methyl) piperidin-4-yl) -1H-pyrazole-3-carboxamide (77) ; N-(1-((3,5-dimethylisoxazol-4-yl)methyl)piperidin-4-yl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (78) ; N-(1-(2-ethylbutyl)piperidin-4-yl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (79) ; 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-((1r,4r)-4-(oxetan-3-ylamino)cyclohexyl)-1H-pyrazole-3-carboxamide (80) ; 4-isopropyl-N-((1r,4r)-4-(isopropylamino)cyclohexyl)-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (81) ; N- ( (1r,4r) -4- (dimethylamino) cyclohexyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (82) ; N- (1- (2- (dimethylamino) ethyl) piperidin-4-yl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (83) ; N- ( (1s, 4s) -4- (dimethylamino) cyclohexyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (84) ; 4-isopropyl-N-((1s,4s)-4-(isopropylamino)cyclohexyl)-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (85) ; 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-((1s,4s)-4-(oxetan-3-ylamino)cyclohexyl)-1H-pyrazole-3-carboxamide (86) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-( (1s, 4s) -4-( ( (tetrahydrofuran-3-yl) metil) amino) cyclohexyl) -1H-pyrazol-3-carboxamide (87) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-( (1s, 4s) -4-( (4, 4,4-trifluorobutyl) amino) cyclohexyl) -1H-pyrazole-3-carboxamide (88) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- ( (1s, 4s) -4- (neopentylamino) cyclohexyl) -1H-pyrazole-3-carboxamide (89) ; N- ( (1s, 4s) -4- (bis (3, 3-dimethylbutyl) amino) cyclohexyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (90) ; N-((1s,4s)-4-(diisopentylamino)cyclohexyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (91) ; 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-((1s,4s)-4-((tetrahydro-2H-pyran-4-yl)methyl)amino)cyclohexyl)-1H-pyrazole-3-carboxamide (92) ; N-( (1s, 4s) -4-( (3, 5-dimethylisoxazol-4-yl) methyl) amino) cyclohexyl) -4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamide (93) ; N-( (1s, 4s) -4-( (ciclopentilmetil) amino) cyclohexyl) -4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (94) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- ( (1s, 4s) -4- ( (pyridin-3-ylmethyl) amino) cyclohexyl) -1H-pyrazole-3-carboxamide (95) ; 4-isopropyl-N- ( (1s, 4s) -4- ( ( (2-methoxypyrimidin-5-yl) methyl) amino) cyclohexyl) -5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (96) ; N-((1s,4s)-4-((2,2-dimethyltetrahydro-2H-pyran-4-yl)amino)cyclohexyl)-4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (97) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-( (1s, 4s) -4-( (tetrahydro-2H-pyran-4-yl) amino) cyclohexyl) -1H-pyrazol-3-carboxamide (98) ; il)amino)cyclohexyl)-1H-pyrazole-3-carboxamide (99) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((1s, 4s)-4-(pentan-3-ylamino)cyclohexyl)-1H-pyrazole-3-carboxamide (100) ; N-((1s, 4s)-4-((2-ethylbutyl)amino)cyclohexyl)-4-isopropyl-5-(8-methyl-[1,2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamida (101) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- ( (1s, 4s) -4- ((pyrimidin-5-ylmethyl) amino)cyclohexyl) 1H-pyrazol-3-carboxamida (102) ; N- ((1r, 4r) -4- (bis (cyclopropylmethyl) amino) cyclohexyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamida (103) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((1r, 4r)-4-(((2-methylpyrimidin-5-yl) methyl) amino) cyclohexyl)-1H-pyrazol-3-carboxamida (104) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((1r, 4r)-4-(((tetrahydrofuran-3-yl) methyl) amino) cyclohexyl)-1H-pyrazol-3-carboxamida (105) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((1r, 4r)-4-(neopentylamino)cyclohexyl)-1H-pyrazole-3-carboxamida N-((1r, 4r)-4-(bis(3, 3-dimethylbutyl)amino)cyclohexyl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamida (107) ; N- ((1r, 4r) -4- (diisopentylamino)cyclohexyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamida (108) ; N- ((1r, 4r) -4- ((cyclopentylmethyl)amino)cyclohexyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamida (109) ; N-((1r, 4r)-4-((2-ethylbutyl)amino)cyclohexyl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamida (110) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((1r, 4r)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)cyclohexyl)-1H-pyrazol-3-carboxamida (111) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((1r, 4r)-4-((pyridin-3-ylmethyl)amino)cyclohexyl)-1H-pyrazol-3-carboxamida (112) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((1r,4r) -4- ( (pyrimidin-5-ylmethyl) amino) cyclohexyl) -1H-pyrazole-3-carboxamide (113) ; 4-isopropyl-N- ( (1r, 4r) -4- ( ( (2-methoxypyrimidin-5-yl) methyl) amino) cyclohexyl) -5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (114) ; N- ( (1r, 4r) -4- ( (2, 2-dimethyltetrahydro-2H-pyran-4-yl) amino) cyclohexyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (115) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-( (1r, 4r) -4-( (tetrahydro-2H-pyran-4-yl) amino) cyclohexyl) -1H-pyrazol-3-carboxamide (116) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-( (1r, 4r) -4-( (3-metilbutan-2-yl) amino) cyclohexyl) -1H-pyrazol-3-carboxamide (118) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((1r,4r)-4-(pentan-3-ylamino)cyclohexyl)-1H-pyrazol-3-carboxamide (119) ; N-((1r,4r)-4-((4,4-dimethylpentan-2-yl)amino)cyclohexyl)-4-isopropyl-5-(8-metil-[1,2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (120) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- (4- ( (3-methyloxetan-3-yl) amino) cyclohexyl) -1H-pyrazole-3-carboxamide (123-124) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- (1-(3-methylbutan-2-yl) piperidin-4-yl) -1H-pyrazole-3-carboxamide (125) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(4-(neopentylamino)cyclohexyl)-1H-pyrazole-3-carboxamide (126 and 131) ; 4-isopropyl-N-(4-(isopropyl (methyl) amino)cyclohexyl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (127 and 132) ; 4-isopropyl-N-(4-((2-methoxyethyl) (methyl) amino)cyclohexyl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1Hpyrazole-3-carboxamide (128) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(4-(methylamino)cyclohexyl)-1H-pyrazole-3-carboxamide (129-130) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -N- (1- ( (3-methyloxetan-3-yl) methyl) piperidin-4-yl) -1H-pyrazole-3-carboxamide (133) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- ( (4-methylmorpholin-2-yl) methyl) -1H-pyrazole-3-carboxamide 4-isopropyl-N- ( (4-isopropylmorpholin-2-yl) methyl) -5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (135) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((4-(oxetan-3-yl)morpholin-2-yl)methyl)-1H-pyrazole-3-carboxamide (136 and 142) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-((4-((3-methyloxetan-3-yl)methyl)morpholin-2-yl)methyl)-1H-pyrazole-3-carboxamide (137) ; N-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (138) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -N- ( (4-methylmorpholin-2-yl) methyl) -1H-pyrazole-3-carboxamide (139) ; N- ( (4-ethylmorpholin-2-yl) methyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (140) ; 4-isopropyl-N- ( (4-isopropylmorpholin-2-yl) methyl) -5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (141) ; N- ( (4- (2-hydroxy-2-methylpropyl) morpholin-2-yl) methyl) -4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (143) ; 4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- ( (4-neopentylmorpholin-2-yl) methyl) -1H-pyrazole-3-carboxamide (144-145) ; 4-isopropyl-N- ( (1r, 4r) -4- ( (l-methoxypropan-2-yl) amino) cyclohexyl) -5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (146) ; 4-isopropyl-N-( (1s, 4s) -4-( (l-methoxypropan-2-yl) amino) cyclohexyl) -5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-carboxamide (147) ; N- ( (1r, 4r) -4- ( (3,3-dimethylbutan-2-yl)amino)cyclohexyl)-4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (148) ; 4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-( (1r, 4r) -4-( ( (3-methyloxetan-3-yl) metil) amino) cyclohexyl) -1H-pyrazol-3-carboxamide (149) ; N-((1s,4s)-4-((3,3-dimethylbutan-2-yl)amino)cyclohexyl)-4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (150) ; 4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-((1s,4s)-4-((3-methyloxetan-3-yl)methyl)amino)cyclohexyl)-1H-pyrazole-3-carboxamide (151) ; N-(1-(sec-butyl)piperidin-4-yl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (152) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (153) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-α]pyridin-6-yl)-N-(1-((3-methyloxetan-3-yl)methyl)azetidin-3-yl)-1H-pyrazole-3-carboxamide (154) ; 4-isopropyl-N-(1-isopropylazetidin-3-yl)-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-carboxamide (155); 4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(1-metilazetidin-3-yl)-1H-pyrazol-3-carboxamide (156) ; 4-isopropyl-N-(1-((2-methoxypyrimidin-5-yl)methyl)piperidin-4-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (157) ; 4-isopropyl-N-(1-((1-methyl-1H-1, 2, 4-triazol-3-yl)methyl)piperidin-4-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (158) ; 4-isopropyl-N-(1-((1-methyl-1H-1, 2, 4-triazol-3-yl)methyl)azetidin-3-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (159) ; (R)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -N-(1-methylpiperidin-3-yl) -1H-pyrazole-3-carboxamide (160) ; (R) -4-isopropyl-N-(1-isopropylpiperidin-3-yl) -5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazole-3-carboxamide (161) ; (S) -4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-methylpiperidin-3-yl) -1H-pyrazole-3-carboxamide (162) ; (S) -4-isopropyl-N-(1-isopropylpiperidin-3-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (163) ; (S) -N-(1-ethylpiperidin-3-yl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (164) ; 4-isopropyl-N-((3S)-1-((3-methyl-3H-1, 2, 4-triazol-5-yl)methyl)piperidin-3-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (165) ; (S)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-(oxetan-3-yl)piperidin-3-yl)-1H-pyrazole-3-carboxamide (166) ; 4-isopropyl-5-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl) -N-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (167) ; 4-isopropyl-5-(1-methyl-1H-pyrrolo[2, 3-b]pyridin-3-yl) -N-(1-neopentylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (168) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-(3, 3, 3-trifluoropropil)piperidin-4-yl)-1H-pyrazole-3-carboxamide (169) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-(2-(methylamino)ethyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (170) ; 4-isopropyl-N-(1-(2-methoxyethyl)piperidin-4-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (171) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (172) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-(2, 2, 2-trifluoroethyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (173) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -N-(1-(1-(methylsulfonyl)propan-2-yl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (174) ; N-(1-(2-(dimethylamino)-2-oxoethyl)piperidin-4-yl)-4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (176) ; 4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-(2-(methylamino)-2-oxoethyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide (177) ; N-(1-isopropylpiperidin-4-yl)-4-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (179) ; 4-methyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (180) ; 4-ethyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)-1H-pyrazole-3-carboxamide (181) ; 4-ethyl-N-(1-isopropylpiperidin-4-yl)-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazole-3-carboxamide (182) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N-(1-isopropylpiperidin-4-yl) -2-oxoacetamide (183) ; 1-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N, N-dimethylmethanamina (184) ; 1-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N-methylmethanamina (185) ; 1-isopropyl-N- ( (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) methyl) piperidin-4-amine (186) ; N- ( (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) methyl) piperidin-4-amine (187) ; 5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N- (piperidin-4-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazole-3-carboxamide (190) ; N-(1-isopropylpiperidin-4-yl)-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazole-3-carboxamide (191) ; 5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazole-3-carboxamide (191)2-trifluoroethyl)-1H-pyrazole-3-carboxamide (192) ; N-(1-isopropylpiperidin-4-yl)-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxamide (193); 5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(piperidin-4-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxamide (194); 5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-propylpiperidin-4-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazole-3-carboxamide (195) ; 5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-neopentylpiperidin-4-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazole-3-carboxamide (196) ; 5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazole-3-carboxamide (197) ; N-(l'-isopropyl-[1, 4'-bipiperidin]-4-yl)-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazole-3-carboxamide (199) ; 5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -N-(1-(oxetan-3-yl)piperidin-4-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazole-3-carboxamide (200) ; 5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazole-3-carboxamide (201) ; N-(l-isobutylpiperidin-4-yl) -5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazole-3-carboxamide (202) ; N-(1-ciclobutilpiperidin-4-yl)-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxamide (203); 5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -N-(1-( (tetrahydro-2H-piran-4-yl) metil) piperidin-4-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazole-3-carboxamide (204) ; 5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-N-(1-(2-(methylamino)-2-oxoethyl)piperidin-4-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazole-3-carboxamide (205); 6-(4-isopropyl-3-(1-methylpiperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1,5-a]pyridine (206) ; 6-(4-isopropyl-3-(1-isopropylpiperidin-4-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 5]triazolo[1, 5-a]pyridine (207) ; 3-(dimethylamino)-1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)propan-1-one (208) ; 2-(dimethylamino)-1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)ethan-1-one (209) ; 1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-3-(isopropylamino)propan-1-one (210) ; 2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-N-methylacetamide (211) ; 2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)piperidin-1-yl)-N,N-dimethylacetamide (212) ; 6-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydroisoquinolina,HC1 (213) ; 6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) isoquinoline (214) ; 6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -3, 4-dihidroisoquinolin-1 (2H) -ona (215) ; 6-(3-(6, 7-dihydro-5H-pyrrolo[3, 4-d]pyrimidin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (216) ; 6-(4-isopropyl-3-(4, 5, 6, 7-tetrahydropyrazolo[1, 5-a]pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (217) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahidrothiazolo[5, 4-C]pyridine (218) ; 6-(4-isopropyl-3-(5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (219) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4, 5, 6, 7-tetrahidrothiazole[5, 4-C]pyridine (220) ; 2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4, 5, 6, 7-tetrahydrothiazolo[4, 5-C]pyridine (221) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5, 6, 7, 8-tetrahydropirido[4, 3-d]pyrimidine (222) ; 6-(4-isopropyl-3-(pyridin-4-yl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (223) ; 6-(4-isopropyl-3-(pyridin-3-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (224) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyridin-3-amine (225) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyrazin-2-amine (226) ; 5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyridin-2-amine (227) ; 5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyrimidin-2-amine (228) ; 4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) benzamide (229) ; 3- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5, 6, 7, 8-tetrahydro-1, 6-naphthyridin (230) ; 7- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -1, 2, 3, 4-tetrahydroisoquinoline (231) ; 3- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) aniline (232) ; 4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) aniline (233) ; 6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydroisoquinoline (234) ; 6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-methyl-1, 2, 3, 4-tetrahydroisoquinoline (235) ; 5-(4-isopropyl-5-(8-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethylpyrazin-2-amine (236) ; 5-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethylpyridin-2-amine (237) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethylpyridin-3-amine (238) ; N-isopropyl-5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyridin-3-amine (239) ; N-isopropyl-5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyridin-2-amine (240) ; N-isopropyl-5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyrazin-2-amine (241) ; N-isopropyl-3-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) aniline (242) ; 4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethylaniline (243) ; N-isopropyl-4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) aniline (244) ; 3-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N,N-dimethylaniline (245) ; 2-isopropyl-6-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydroisoquinolina (246) ; 6-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(oxetan-3-yl)-1, 2, 3, 4-tetrahydroisoquinolina (247) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-6-methyl-5, 6, 7, 8-tetrahydropyrido[4, 3-d]pyrimidine (248) ; 6-ethyl-2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5, 6, 7, 8-tetrahydropyrido[4, 3-d]pyrimidine (249) ; 6-isopropyl-2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5, 6, 7, 8-tetrahydropyrido[4, 3-d]pyrimidine (250) ; 2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -6- (oxetan-3-yl) -5, 6, 7, 8-tetrahydropyrido[4, 3-d]pyrimidine (251) ; 5-isopropyl-2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (252) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(oxetan-3-yl)-4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (253) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-isopropylpiperidin-4-yl)-4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (254) ; 5-isobutyl-2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (255) ; 2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-methyl-4, 5, 6, 7-tetrahidrothiazole[5, 4-C]pyridine (256) ; N-ethyl-2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) benzo[d]thiazol-6-amine (257) ; N-isopropyl-2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) benzo[d]thiazol-6-amine (258) ; 5-isopropyl-2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (259) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-propyl-4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (260) ; 5-ethyl-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (261) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-methyl-4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (262) ; 6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(2-methoxyethyl)-1, 2, 3, 4-tetrahydroisoquinoline (263) ; 1-(6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-3, 4-dihydroisoquinolin-2(1H)-yl)-2-methylpropan-2-ol (264) ; 1-(2-(4-isopropyl-5-(8-methyl-[1,2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -6, 7-dihydrothiazolo[5, 4-C]pyridin-5 (4H) -yl) -2-methylpropan-2-ol (265) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(2-methoxyethyl) -4, 5, 6, 7-tetrahydrothiazolo[5, 4-C]pyridine (266) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(2-methoxyethyl)benzo[d]thiazol-6-amine (267) ; 2-(dimethylamino)-1-(6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-3, 4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (268) ; (S)-3-hydroxy-1-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-6, 7-dihydrothiazolo[5, 4-C]pyridin-5(4H)-yl)butan-1-one (269) ; 2-(dimethylamino)-1-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-6, 7-dihydrothiazolo[5, 4-C]pyridin-5(4H)-yl)ethan-1-one (270) ; 2-(6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridine-6-yl) -1H-pyrazol-3-yl) -3, 4-dihydroisoquinolin-2 (1H) -yl) -N, N-dimethylacetamide (271) ; 2- (6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -3, 4-dihydroisoquinolin-2 (1H) -yl) acetamide (272) ; 2- (6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -3, 4-dihydroisoquinolin-2 (1H) -yl) -N-methyl acetamide) ; 2- (2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -6, 7-dihydrothiazolo[5, 4-C]pyridine-5 (4)-N) (27-methyl) -yl 2- (2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -6, 7-dihydrothiazolo[5, 4-C]pyrithyladine-5 (dimethyl ida) ;n-tamyl) 1- (2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -6, 7-dihydrothiazolo[5, 4-C]pyridine-5 (4H-1) -yl 6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-2-ol (277) ; 6-(5-(2, 6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydroisoquinoline (278) ; N-(2, 2-difluoroethyl)-4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) cycloohexan-1-amine (279) ; 4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N- ((3-methyloxethan-3-yl) methyl) cyclohexan-1-amine (280-281) ; N-ethyl-4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N-methylcyclohexan-1-amine (282-283) ; N1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N2, N2-dimethylethane-1, 2-diamine (284-285) ; 6-(4-isopropyl-3-(4-(4-methylpiperazin-1-yl)cyclohexyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (286-287) ; l-isopropyl-N-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) cyclohexyl) piperidin-4-amine (288-289) ; 4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) cyclohexyl) morpholine (290-291) ; 1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) cyclohexyl) -N, N-dimethylpiperidin-4-amine (292-293) ; 4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methylcyclohexan-1-amine (294-295) ; 2-(dimethylamino)-N-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N-methylacetamide (296-297) ; 2-((4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl) (methyl)amino)-N, N-dimethylacetamide (298-299) ; N-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N, 1-dimethylazetidine-3-carboxamide (300 and 302) ; N-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N, 1-dimethylazetidine-3-carboxamide (300 and 302) ;5-α]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N-methylazetidin-3-carboxamide (300B y 301) ; l-isopropyl-N-(4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N-metilazetidin-3-carboxamide (303-304) ; l-ethyl-N-(4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)cyclohexyl)-N-metilazetidin-3-carboxamide (305-306) ; 6-(4-isopropyl-3-(4-(1-isopropylpiperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 6]iazolo[1, 5-a]pyridine (307) ; 6-(4-isopropyl-3-(4-(piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 7]iazolo[1, 5-a]pyridine (308) ; 6-(4-isopropyl-3-(4-(1-methylpiperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 8]iazolo[1, 5-a]pyridine (309) ; 6-(3-(4-(1-ethylpiperidin-4-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1, 2, 9]triazolo[1, 5-a]pyridine (310) ; 6-(4-isopropyl-3-(4-(1-(oxetan-3-yl)piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1,5-a]pyridine (311) ; 6-(4-isopropyl-3-(4-(1-((3-methyloxetan-3-yl)methyl)piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (312) ; 6-(4-isopropyl-3-(4-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (313) ; 6-(4-isopropyl-3-(4-(1-methylpiperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 10]iazolo[1, 5-a]pyridine (314) ; 6-(4-isopropyl-3-(4-(1-methylpiperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 11]iazolo[1, 5-a]pyridine (315) ; 6-(4-isopropyl-3-(4-(1-isopropylpiperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 12]iazolo[1, 5-a]pyridine (316) ; 6-(4-isopropyl-3-(4-(l-neopentylpiperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 13]triazolo[1, 5-a]pyridine (317) ; 6-(4-isopropyl-3-(4-(1-(2-methoxyethyl)piperidin-4-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (318) ; 1-(4-(4-(4-isopropyl-5-(8-methoxy-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) piperidin-1-yl) -2-methylpropan-2-ol (319) ; 6-(4-isopropyl-3-(4-(1-(2, 2, 2-trifluoroethyl) piperidin-4-yl) phenyl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (320) ; 2-(4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) piperidin-1-yl) -N, N-dimethylacetamide (321) ; 2-(4-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)piperidin-1-yl)acetamida (322) ; 2-(dimethylamino)-1-(4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)piperidin-1-yl)ethan-1-one (323) ; 6-(4-isopropyl-3-(4-(l-methylazetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1, 5-a]pyridine (324) ; 6-(3-(4-(azetidin-3-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-azolo[1, 5-a]pyridine (324E) ; 6-(3-(4-(1-ethylazetidin-3-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-azolo[1, 5-a]pyridine (324E)5-α]pyridine (325) ; 6-(4-isopropyl-3-(4-(1-propylazetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (326) ; 6-(4-isopropyl-3-(4-(1-isopropylazetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (327) ; 6-(4-isopropyl-3-(4-(1-methylazetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-iazolo[1,5-a]pyridine (328); 6-(3-(4-(1-ethylazetidin-3-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-azolo[1, 5-a]pyridine (329) ; 6-(4-isopropyl-3-(4-(l-propylazetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-iazolo[1, 5-a]pyridine (330) ; 6-(4-isopropyl-3-(4-(l-isopropylazetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-iazolo[1, 5-a]pyridine (331) ; 6-(4-isopropyl-3-(4-(1-(oxetan-3-yl)azetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[6-(4-isopropyl-3-(4-(1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (333); 2-(dimethylamino)-1-(3-(4-(4-isopropyl-5-(8-methyl-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) azetidin-1-yl) ethan-1-one (334) ; 2-(dimethylamino) -1-(3-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) azetidin-1-yl) ethan-1-one (335) ; 1-(3-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) azetidin-1-yl) -2-methylpropan-2-ol (336) ; 1-(3-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)azetidin-1-yl)-2-methylpropan-2-ol (337) ; 6-(4-isopropyl-3-(4-(1-(2-(methylsulfonyl)ethyl)azetidin-3-yl)phenyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (338) ; 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (339) ; 6-(4-isopropyl-3-(6-(piperidin-4-yl)pyridin-3-yl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-α]pyridine (340) ; 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyrimidin-2-yl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (341) ; 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (342) ; 6-(4-isopropyl-3-(2-(piperidin-4-yl)pyrimidin-5-yl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (343) ; 6-(4-isopropyl-3-(6-(piperidin-4-yl)pyridazin-3-yl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1, 5-a]pyridine (344) ; 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-iazolo[1, 5-a]pyridine (345) ; 6-(4-isopropyl-3-(5-(piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-7-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (346) ; 6-(3-(5-(1-ethylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (347) ; 6-(4-isopropyl-3-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (347)5-a]pyridine (348) ; 6-(4-isopropyl-3-(5-(1-propylpiperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (349) ; 6-(4-isopropyl-3-(5-(1-isopropylpiperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (350) ; 6-(4-isopropyl-3-(5-(l-neopentylpiperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (351) ; 6-(4-isopropyl-3-(5-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (352) ; 6-(4-isopropyl-3-(5-(1-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (353) ; 6-(3-(5-(1-(3-ethoxycyclobutyl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (354) ; 6-(3-(5-(1-(3-ethoxycyclobutyl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-1,2, 4]triazolo[1, 5-a]pyridine (355) ; 6-(4-isopropyl-3-(5-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (356) ; 6-(4-isopropyl-3-(6-(1-methylpiperidin-4-yl)pyridazin-3-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (357) ; 6-(4-isopropyl-3-(6-(1-isopropylpiperidin-4-yl)pyridazin-3-yl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (358) ; 6-(4-isopropyl-3-(6-(1-metilpiperidin-4-yl)pyridin-3-yl)-1H-pyrazol-5-yl)-8-metil-[1,2,4]triazolo[1,5-a]pyridine (359) ; 6-(3-(6-(1-ethylpiperidin-4-yl)pyridin-3-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (360) ; 6-(4-isopropyl-3-(6-(1-isopropylpiperidin-4-yl)pyridin-3-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (361) ; 6-(4-isopropyl-3-(6-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-3-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (361)5-a]pyridine (362) ; 6- (4-isopropyl-3- (2- (1-isopropylpiperidin-4-yl) pyrimidin-5-yl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (363) ; 6- (4-isopropyl-3- (2- (l-neopentylpiperidin-4-yl) pyrimidin-5-yl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (364) ; 6- (4-isopropyl-3- (5- (1-methylpiperidin-4-yl) pyridin-2-yl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (365) ; 6- (3- (5- (1-ethylpiperidin-4-yl) pyridin-2-yl) -4-isopropyl-1H-pyrazol-5-yl) -8-methyl-iazole[1, 5-a]pyridine (366) ; 6- (4-isopropyl-3- (5- (1-isopropylpiperidin-4-yl) pyridin-2-yl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (367) ; 6- (4-isopropyl-3- (5- (1-methylpiperidin-4-yl) pyrimidin-2-yl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (368) ; 6- (3- (5- (1-ethylpiperidin-4-yl) pyrimidin-2-yl) -4-isopropyl-1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1,5-a]pyridine (369) ; 6- (4-isopropyl-3- (5- (1-isopropylpiperidin-4-yl) pyrimidin-2-yl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (370) ; 6- (4-isopropyl-3- (5- (l-neopentylpiperidin-4-yl) pyrimidin-2-yl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (371) ; 6-(4-isopropyl-3-(5-(1-(3-methylbutan-2-yl) piperidin-4-yl) pyrimidin-2-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (372) ; 6-(4-isopropyl-3-(5-(l-neopentylpiperidin-4-yl) pyridine-2-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (373) ; 6- (3- (5- (1- (cyclopropylmethyl) piperidin-4-yl) pyridin-2-yl) -4-isopropyl-1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazole[1, 5-a]pyridine (374) ; 6- (4-isopropyl-3- (5- (1- ((tetrahydro-2H-pyran-4-yl) methyl) piperidin-4-yl) pyridin-2-yl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazole[1,5-a]pyridine (375) ; 6-(4-isopropyl-3-(5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (376) ; 6-(3-(5-(1-(cyclobutylmethyl)piperidin-4-yl)pyrazin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (377) ; 6-(3-(5-(1-(cyclopropylmethyl)piperidin-4-yl)pyrazin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (378) ; 6-(3-(5-(l-isobutylpiperidin-4-yl)pyrazin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (379) ; 6-(4-isopropyl-3-(5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (380) ; 6-(4-isopropyl-3-(5-(1-methylpiperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (381) ; 6-(3-(5-(1-ethylpiperidin-4-yl)pyrazin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (381)4]triazolo[1, 5-a]pyridine (3 82) ; 6-(4-isopropyl-3-(5-(1-propylpiperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (383) ; 6-(4-isopropyl-3-(5-(1-isopropylpiperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (384) ; 6-(4-isopropyl-3-(5-(1-(oxetan-3-yl)piperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (385) ; 6-(4-isopropyl-3-(5-(1-(pentan-3-yl)piperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (386) ; 6-(3-(5-(l-cyclobutylpiperidin-4-yl)pyrazin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (387) ; 6-(4-isopropyl-3-(5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-7-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (388) ; 2-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) piperidin-1-yl) -N, N-dimethylacetamide (389) ; 1-(4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyrimidin-5-yl) piperidin-1-yl) -2-methylpropan-2-ol (390) ; 1-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) piperidin-1-yl) -2-methylpropan-2-ol (391) ; 6-(4-isopropyl-3-(5-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (392) ; 2-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidin-1-yl)acetamida (393) ; 2-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyridin-3-yl) piperidin-1-yl) acetonitrile (394) ; 6-(4-isopropyl-3-(5-(1-(2-methoxyethyl) piperidin-4-yl) pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridine (395) ; 6-(4-isopropyl-3-(5-(1-(2-methoxyethyl)piperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (396) ; 6-(4-isopropyl-3-(5-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)pyrazin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (397) ; 6-(3-(5-(1-(2-fluoroethyl)piperidin-4-yl)pyrazin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (398) ; 6-(3-(5-(1-(3-fluoropropyl)piperidin-4-yl)pyrazin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (399) ; 2-(4-(5-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyrazin-2-yl)piperidin-1-yl)-N-methylacetamide (400) ; 2-(4-(5-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyrazin-2-yl)piperidin-1-yl)-N, N-dimethylacetamide (401) ; 2-(dimethylamino)-1-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) piperidin-1-yl) ethan-1-one (402) ; 2- (dimethylamino) -1- (4- (5- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyrazin-2-yl) piperidin-1-yl) ethan-1-one (403) ; 2- (diethylamino) -1- (4- (5- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyrazin-2-yl) piperidin-1-yl) ethan-1-one (404) ; 1-(4-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylazetidin-3-amine (405) ; 6-(4-isopropyl-3-(4-(piperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (406); 6-(4-isopropyl-3-(2-(piperazin-1-yl)pyrimidin-5-yl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (407); 6-(4-isopropyl-3-(4-(4-neopentylpiperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-triazolo[1, 5-a]pyridine (408); N-isopropyl-1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-α]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)azetidin-3-amine (409); 6-(4-isopropyl-3-(2-(4-metilpiperazin-1-yl)pyrimidin-5-yl)-1H-pyrazol-5-yl)-8-metil-[1,2,4]triazolo[1,5-a]pyridine (410) ; 6-(4-isopropyl-3-(4-(4-isopropylpiperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-azolo[1,5-a]pyridine (411) ; 6-(4-isopropyl-3-(4-(4-metilpiperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (412) ; 6-(3-(4-(4-ethylpiperazin-1-yl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-iazolo[1,5-a]pyridine (413) ; 6-(4-isopropyl-3-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-metil-[1,2,4]triazolo[1,5-a]pyridine (414) ; 6-(4-isopropyl-3-(2-(4-isopropylpiperazin-1-yl)pyrimidin-5-yl)-1H-pyrazol-5-yl)-8-metil-[1, 2, 4]triazolo[1, 5-a]pyridine (415) ; 6-(4-isopropyl-3-(2-(4-(oxetan-3-yl)piperazin-1-yl)pyrimidin-5-yl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1,5-α]pyridine (416) ; 6-(4-isopropyl-3-(4-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (417) ; 1-(4-(4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) fenil) piperazin-1-yl)-2-metilpropan-2-ol (418) ; 6-(4-isopropyl-3-(5-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (419) ; 1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-4-methylpiperazin-2-one (420) ; 4-isopropyl-1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)piperazin-2-one (421) ; 1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-4-(oxetan-3-yl)piperazin-2-one (422) ; 6-(3-(5-(4-cyclobutylpiperazin-1-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (423) ; 6-(3-(5-(2,6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl) -4-isopropyl-1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (424) ; 1, 1-dioxide of 4-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) piperazin-1-yl) tetrahydro-2H-thiopyran (425) ; 6-(3-(5-(4-(cyclopropylmethyl)piperazin-1-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (426) ; 6-(3-(5-(4-ethylpiperazin-1-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (427) ; 6-(4-isopropyl-3-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (428) ; 6-(4-isopropyl-3-(5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (429) ; 6-(3-(5-(4-isobutylpiperazin-1-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (429)5-a]pyridine (430) ; 6-(4-isopropyl-3-(5-(4-propylpiperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (431) ; 6-(4-isopropyl-3-(5-(4-((tetrahydro-2H-pyran-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (432) ; 6-(4-isopropyl-3-(5-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (433) ; 6-(3-(5-(4-(cyclobutylmethyl)piperazin-1-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5a]pyridine (434) ; 6-(4-isopropyl-3-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (435) ; 6-(4-isopropyl-3-(5-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (435)5-a]pyridine (436) ; 6-(4-isopropyl-3-(5-(4-(pentan-3-yl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (437) ; 6-(3-(5-(4-(2-ethylbutyl)piperazin-1-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (438) ; 6-(3-(5-(4-((3-ethyl oxetan-3-yl) methyl) piperazin-1-yl) pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (439) ; 6-(4-isopropyl-3-(5-(6-((tetrahydro-2H-pyran-4-yl) methyl)-2, 6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (440) ; 6-(3-(5-(6-(cyclobutylmethyl)-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (441) ; 6-(3-(5-(6-isobutyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (441)5-a]pyridine (442) ; 6-(4-isopropyl-3-(5-(6-(tetrahydro-2H-pyran-4-yl)-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (443) ; 6-(3-(5-(6-cyclobutyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (444) ; 6-(4-isopropyl-3-(5-(6-methyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (445) ; 6-(3-(5-(6-ethyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (446) ; 6-(4-isopropyl-3-(5-(6-propyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (447) ; 6-(4-isopropyl-3-(5-(6-isopropyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (448) ; 6-(4-isopropyl-3-(5-(6-(oxetan-3-yl)-2,6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (449) ; 6- (3- (5- (6- (cyclopropylmethyl) -2, 6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl) -4-isopropyl-1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (450) ; 2-(dimethylamino)-1-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyridin-3-yl) piperazin-1-yl) ethan-1-one (451) ; 2-(diethylamino)-1-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) pyridin-3-yl) piperazin-1-yl) ethan-1-one (452) ; 2-(dimethylamino)-1-(6-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)-2, 6-diazaspiro[3.3]heptan-2-yl)ethan-1-one (453) ; 6-(4-isopropyl-3-(5-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (454) ; 2-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) piperazin-1-yl) -N, N-dimethylacetamide (455) ; 2- (4- (6- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) piperazin-1-yl) N-methylacetamide (456) ; 6- (4-isopropyl-3- (5- (6- (2- (methylsulfonyl) ethyl) -2, 6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (457) ; 6-(4-isopropyl-3-(5-(6-(2-methoxyethyl)-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (458) ; 2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-4-methylmorpholine (459-460) ; 4-ethyl-2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)morpholine (461) ; 4-isopropyl-2- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) morpholine (462-463) ; 2- (4- (4-isopropyl-5- (8-methyl-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -4-neopentylmorpholine (464-465) ; 2-(2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) morpholino) -N, N-dimethylacetamide (466-468) ; 2-(dimethylamino) -1-(2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) morpholino) ethan-1-one (469-470) ; 4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylcyclohexan-1-amine (471) ; 4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N, N-dimethylcyclohexan-1-amine (472) ; N-cyclobutyl-4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)cyclohexan-1-amine (473-474) ; 2- (4- (6- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)cyclohexyl)-7-oxa-2-azaspiro[3.5]nonano (475-476) ; 6-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)cyclohexyl)-2-oxa-6-azaspiro[3.3]heptane (477-478) ; 6-(4-isopropyl-3-(5-(4-(3-methoxyazetidin-1-yl)cyclohexyl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (479-480) ; 4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)-N-(2-methoxy-2-methylpropyl)cyclohexan-1-amine (481-482) ; 4-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)cyclohexyl)piperazin-2-one (483-484) ; 4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)-N-((1-(methylsulfonyl)cyclopropyl)methyl)cyclohexan-1-amine (485486) ; 7-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) cyclohexyl) -2-oxa-7-azaspiro[3.5]nonane (487-488) ; 4- (6- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) -N- (2-methoxyethyl) -N-methylcyclohexan-1-amine (490-491) ; N- (4- (6- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) cyclohexyl) -3-methyloxetan-3-amine (492-493) ; 4-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)cyclohexyl)morpholine (494-495) ; 6-(4-isopropyl-3-(5-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-4-methylpyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (496) ; 4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylpyridin-3-yl)-N-((1-(methylsulfonyl)cyclopropyl)methyl)cyclohexan-1-amine (497-498) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylpyridin-3-yl) -N- (2-methoxyethyl) cyclohexan-1-amine (499-500) ; 7- (4- (6- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylpyridin-3-yl) cyclohexyl) -2-oxa-7-azaspiro[3.5]nonano (501) ; 6-(3-(5-(4-(4,4-difluoropiperidin-1-yl)cyclohexyl)-4-methylpyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (502-503) ; 6-(4-isopropyl-3-(5-(4-(4-methoxypiperidin-1-yl)cyclohexyl)-4-methylpyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (504-505) ; 4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylpyridin-3-yl)-N, N-dimethylcyclohexan-1-amine (506-507) ; 4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylpyridin-3-yl)cyclohexan-1-amine (508-509) ; 4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylcyclohexan-1-amine (510 and 513) ; N- (4- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) cyclohexyl) -N-methyloxetan-3-amine (511 and 514) ; N- ( (3-ethyloxetan-3-yl) methyl) -4- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylcyclohexan-1-amine (512 and 515) ; N-ethyl-4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methylcyclohexan-1-amine (516-517) ; 2-(dimethylamino)-N-(4-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)cyclohexyl)-N-methylacetamide (518-519) ; 2- ( (4- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) cyclohexyl) (methyl) amino) -N, N-dimethylacetamide (520-521) ; 4- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-(2-methoxyethyl) -N-methylcyclohexan-1-amine (522-523) ; 2-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-amine, TFA (524) ; 2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-amine (525) ; 1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)cyclopropan-1-amine (526) ; (S)-1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethan-1-amine (527) ; (S)-1-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethan-1-amine (528) ; (R) -1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethan-1-amine (529) ; 6-(4-isopropyl-3-(4-(pyrrolidin-2-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-triazolo[1, 5-a]pyridine (530-531) ; 2-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N, N-dimethylpropan-2-amine (532) ; N-isopropyl-2- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-amine (533) ; N-ethyl-2- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-amine (534) ; N, N-diethyl-2- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-amine (535) ; N-ethyl-2- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-amine (536) ; N- (2- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-yl) tetrahydro-2H-pyran-4-amine (537) ; 2-(4-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylpropan-2-amine (538) ; N,N-diethyl-2-(4-(4-isopropyl-5-(8-metil-[1, 2, 4)triazolo[1,5-a]pyridine-6-yl) -1H-pyrazol-3-yl)phenyl)propan-2-amine (539) ; N- (2- (4- (4-(4-isopropyl-5-) (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-yl) tetrahydro-2H-pyran-4-amine (540) ; N- (2- (4- (4-(4-isopropyl-5-) (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-yl) -2, 2-dimethylpropan-1-amine (544) ; 2- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N- ( (3-methyloxethane-3-yl) methyl) propan-2) ;(54-amine N-isopropyl-2- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-amine (543) ; 2- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N- ( (1-methyl-1H-1, 2, 4-propan5-24methyl-a)mine N- (2- (4- (4-(4-isopropyl-5-) (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) propan-2-yl) oxetan-3-amine (545) ; 1- (4- (4-isopropyl-5- (8-methyl-[1, 2,4]triazole[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl)phenyl) -N, N-dimethylcyclopropane-1-amine (546) ; N-isopropyl-1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) cyclopropan-1-amine (547) ; 1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-neopentylcyclopropane-1-amine (548) ; (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) -N, N-dimethylethane-1-amine (549) ; (S) -N-ethyl-1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethane-1-amine (550) ; (S) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) propan-2-amine (551) ; N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -3-methylbutan-2-amine (553) ;552-5 (S) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -2, 2-dimethylpropan-1-amine (554) ; (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N, N-dimethylethan-1-amine (555) ; (S) -N- (1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) propan-2-amine (556) ; (R)-1-(4-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylethan-1-amine (557) ; (R)-N-(1-(4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) fenil) ethyl) propan-2-amine (558) ; (R) -1-(4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) fenil) -N-( (3-methyloxetan-3-yl) metil) etan-1-amine (559) ; (R)-N-(1-(4-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)fenil)ethyl)-2,2-dimethylpropan-1-amine (560) ; N-((R)-1-(4-(4-isopropyl-5-(8-metil-[1,2,4)triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -3 -methylbutan-2-amine (561) ; N- ( (R) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -3-methylbutan-2-amine (562) ; 6- (4-isopropyl-3- (4- (1-methylpyrrolidin-2-yl) phenyl) -1H-pyrazol-5-yl) -8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (563 and 566) ; 6-(4-isopropyl-3-(4-(l-isopropylpyrrolidin-2-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (564 and 567) ; 6-(4-isopropyl-3-(4-(1-(oxetan-3-yl)pyrrolidin-2-yl)phenyl)-1H-pyrazol-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (565 and 568) ; (S)-N-(1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)oxetan-3-amine (569) ; (S) -N-ethyl-1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methyl ethan-1-amine (570) ; (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methyl ethan-1-amine (570) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylethan-1-amine (571) ; (S) -N- (1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropan-2-amine (572) ; (S) -N- (1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -Nm ethyl ox ethan-3-amine (573) ; (S) -1-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methyl-N-((3-methyloxetan-3-yl)methyl)ethan-1-amine (574) ; (S) -2, 2, 2-trifluoro-N-(1-(4-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-N-methylethan-1-amine (575) ; (S)-2, 2, 2-trifluoro-N-(1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-N-methylethan-1-amine (576) ; (S)-N-ethyl-1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-N-methylethan-1-amine (576) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylethan-1-amine (577) ; (S) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropan-2-amine (578) ; (S) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyloxetan-3-amine (579) ; (S) -1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N-methyl-N-((3-methyl oxetan-3-yl)methyl)ethan-1-amine (580) ; 2-(dimethylamino)-N-(2-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)propan-2-yl)acetamida (581) ; 2-(dimethylamino)-1-(2-(4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) fenil) pyrrolidin-1-yl) ethan-1-one (582-583) ; 2-(2-(4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)fenil)pyrrolidin-1-yl)-N,N-dimethylacetamide (584-585) ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N, 1-dimethylazetidine-2-carboxamide (585) ; (S) -2- (dimethylamino) -N- (1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylacetamide (586) ; (S) -2- (diethylamino) -N- (1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylacetamide (587) ; (S) -2- (dimethylamino) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropanamide (588) ; (R) -2- (dimethylamino) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropanamide (589) ; (S) -2- (dimethylamino) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropanamide (589) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylacetamide (590) ; (S) -2- (diethylamino) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylacetamide (591) ; (R) -2- (dimethylamino) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropanamide (592) ; (S) -2- (dimethylamino) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropanamide (593) ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methylamino) propanamide (594) ; (R) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methylamino) propanamide (595) ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methylamino) propanamide (595) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylazetidine-2-carboxamide (596) ; (R) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methylamino) propanamide (597) ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methylamino) propanamide (598) ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpyrrolidine-2-carboxamide (599) ; (R) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpyrrolidine-2-carboxamide (600) ; (S) -1-ethyl-N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylazetidine-2-carboxamide (601) ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylazetidine-2-carboxamide (601) ;5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N, 1-dimethylazetidine-2-carboxamide (602) ; (S) -1-ethyl-N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -amide (60-methylboxetidine) ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylze-1ti3-amida-260-acarboxane- ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N, 1-dimethyl-(260-pyrroboxyl) (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl)phenyl) ethyl) -N-methyl-carrol-1- (amida-ylobox)2pyr-ethyl (606) ; (R) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N, 1-dimethyl-(260-pyrroboxyl) (R) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-1-(oxetan-3-yl) pyrrolidine-2-carboxamide (608) ; (S) -2- (ethyl (methyl) amino) -N- ( (S) -1-(4- (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropanamide (609) ; (R) -2- (ethyl (methyl) amino) -N- ( (S) -1-(4- (4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropanamide (610) ; (S) -2- (ethyl (methyl) amino) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methylpropanamide (6H) ; (R) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methyl (oxetan-3-yl) amino) propanamide (612) ; (S) -2- (ethyl (methyl) amino) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1,5-[(5-[(6-[(1H-pyridin-6-yl)-1H-pyrazol-3-yl)phenyl]ethyl]-N-methylpropanamide (613); (R) -N- ( ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methyl (oxetan-3-yl) amino) propanamide (614) ; (S) -N- ( (S) -1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methyl (oxetan-3-yl) amino) propanamide (615) ; (S) -2- ( (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) (methyl) amino) -N, N-dimethylacetamide (616) ; (S) -2- ( (1- (4- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) (methyl) amino) -N, N-dimethylacetamide (617) ; (S) -2- (dimethylamino) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N- (oxetan-3-yl) acetamide (618) ; (S) -2- (diethylamino) -N- (1- (4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1,5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N- (oxetan-3-yl) acetamide (619) ; (S) -2- (ethyl (methyl) amino) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -tam(N-methyl) (S) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-methyl-2- (methylpropyl pro3-triamine) 3, (621) ; (S) -2- (3-fluoroazetidin-1-yl) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-222 pyrazol-3-yl) phenyl-N-methyl) ethyl (S) -2- ( (2-fluoro-2-methylpropyl) amino) -N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3)nyl -methyl) -1H ; (S) -1- (2-fluoro-5- (4-isopropyl-5- (8-methyl-[1, 2, 4]tnazolo[1, 5-a]pyndine-6-yl) -1H-pyrazol-3-yl) phenyl) -N, N-dimethylethane-1-amine (624) ; (S) -N, N -diethyl-1- (2-fluoro-5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethan-1-amine (625) ; (S) -N- (1- (2-fluoro-5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) propan-1-amine (626) ; (S) -N- (1- (2-fluoro-5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -N-propilpropan-1-amine (627) ; (S) -N-(1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)propan-2-amine (628) ; (S) -2-(dimethylamino) -N-(1-(2-fluoro-5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)acetamida (629) ; (S) -2- (diethylamino) -N- (1- (2-fluoro-5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) acetamide (630) ; N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) propan-2-amine (631) ; 1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylethan-1-amine (632) ; N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) oxetan-3 -amine (633) ; N- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -3-methyl ox etan-3-amine (634) ; 1-(4-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)-N,N-dimethylethan-1-amine (635) ; 6-(3-(4-(1-(4,4-difluoropiperidin-1-yl)ethyl)phenyl)-4-isopropyl-1H-pyrazol-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (636) ; 4-(1-(4-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) fenil) ethyl) morpholina (637) ; 6-(1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-2-oxa-6-azaspiro[3.3]heptano (638) ; 4-(1-(4-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)phenyl)ethyl)-2-oxa-6-azaspiro[3.3]heptano (638) ;5-a]pyridine-6-yl) -1H-pyrazol-3-yl)phenyl)ethyl)piperazine-2-ona (639) ; 6- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]tnazolo[1, 5-a]pyndm-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) -2-oxa-6-azaspiro[4 (3.64]heptano 4- (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) ethyl) morpholine (642-643) ; 1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine-6-yl) -1H-pyrazol-3-yl) phenyl) -N-methylmethanamine (644) ; 1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) phenyl) -N, N-dimethylmethanamine (645 y 652) ; N- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) benzyl) propan-2-amine (646) ; N- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) benzyl) cyclopropanamine (647) ; (1- (4- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) benzyl) azetidine-3,3-diyl) dimethanol (648) ; N-(4-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)benzyl)-2,2-dimethylpropan-1-amine (649) ; 6-(3-(4-(azetidin-1-ylmetil)fenil)-4-isopropyl-1H-pyrazol-5-yl)-8-metil-[1,2,4]triazolo[1,5-a]pyridine (650) ; N-(4-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)benzyl)-N-methylethanamina (651) ; N- ( (6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) methyl) propan-2-amine (653) ; 1- (6- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) -N-methylmethanamine (654) ; N- ( (5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-2-yl) methyl) propan-2-amine (655) ; 1-(5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-2-yl)-N, N-dimethylmethanamine (656) ; 1-(5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-2-yl)-N, N-dimethylmethanamine (656) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-2-yl) -N-methylmethanamina (657) ; 1-(6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) -N, N-dimethylethan-1-amina (658-659) ; 1-(5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-2-yl) -N-methylethan-1-amina (660-662) ; 1-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-N-methylethan-1-amine (663-664) ; 1-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-N, N-dimethylethan-1-amine (665 and 670) ; N-ethyl-1- (2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) -N-methylethan-1-amine (666 and 669) ; N- (1- (2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) ethyl) -N-methylpropan-2-amine (677-678) ; N- (1- (2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) ethyl) -N-methyltetrahydro-2H-pyran-4-amine (671) ; 2-(dimethylamino) -N- (1-(6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) pyridin-3-yl) ethyl) -N-methylacetamide (672-673) 2-(dimethylamino) -N- (1-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) ethyl) -N-methylacetamide (674-675) ; 2-((1-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)ethyl) (methyl)amino)-N, N-dimethylacetamide (676) ; 2-((1-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)ethyl) (methyl)amino)-N, N-dimethylacetamide (677-678) ; 6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine (679 and 682) ; 6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-1, 2, 3,4-tetrahydronaphthalen-2-amine (680-681) ; 6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine (682) ; N-isopropyl-6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine (683) ; N-(6-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydronaphthalen-2-yl)-N-metiltetrahydro-2H-pyran-4-amine (684-685) ; N-(6-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydronaphthalen-2-yl)-N-methyloxetan-3-amine (686-687) ; 6-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-N-((3-methyloxetan-3-yl)methyl)-1, 2, 3, 4-tetrahydronaphthalen-2-amine (688) ; 6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethyl-1, 2, 3,4-tetrahydronaphthalen-2-amine (689) ; 2-(dimethylamino)-N-(6-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydronaphthalen-2-yl)-N-methylacetamida (690-691) ; 2-( (6-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydronaphthalen-2-yl) (metil) amino)-N, N-dimethylacetamida (692-693) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (694 and 703) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (695-697) ; N-isopropyl-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (698 and 704) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(4, 4, 4-trifluorobutyl)-4, 5, 6,7-tetrahydrobenzo[d]thiazol-6-amine (699) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-bis(4, 4, 4-trifluorobutyl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (700) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(tetrahydro-2H-pyran-4-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (701 and 706) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(3, 3, 3-trifluoropropyl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (702 and 705) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N, N-dimethyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (707 and 712) ; N-isopropyl-2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (708 and 713) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(oxetan-3-yl)-4, 5, 6,7-tetrahydrobenzo[d]thiazol-6-amine (709 and 715) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(tetrahydro-2H-pyran-4-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (710 and 717) ; N-(3-ethoxycyclobutyl)-2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (711-716) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(3, 3, 3-trifluoropropyl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amina (714) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(oxetan-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amina (715) ; 2-(dimethylamino)-N-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl)acetamida (718-719) ; 2-(dimethylamino)-N-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4,5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) acetamide (720-721) ; N-ethyl-2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N-methyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (722 and 728) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N-methyl-N-propyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (723 and 729) ; N-isopropyl-2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N-methyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (724 and 730) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N-methyl-N- (oxetan-3-yl) -4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (725 and 731) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-N-(3, 3, 3-trifluoropropyl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (726 and 732); 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -N-methyl-N-(tetrahydro-2H-pyran-4-yl) -4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amina (727733) ; 2-(dimethylamino) -N-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) -N-methylacetamide (734) ; 2-(dimethylamino)-N-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl)-N-methylacetamide (735) ; 2-((2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) (methyl)amino)-N, N-dimethylacetamide (736) ; 2-((2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-yl) (methyl)amino)-N, N-dimethylacetamide (737) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-(2-methoxyethyl)-N-methyl-4, 5, 6,7-tetrahydrobenzo[d]thiazol-6-amine (738-739) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-N-methyl-N-(2-(methylsulfonyl)ethyl)-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (740-741) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(piperidin-4-yl)thiazol (742) ; 2-(4-isopropyl-5-(8-methylimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(piperidin-4-yl) thiazole (743) ; 2-(4-isopropyl-5-(8-methoxyimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(piperidin-4-yl) thiazole (744) ; 2-(5-(3, 4-dimethoxyphenyl)-4-isopropyl-1H-pyrazol-3-yl)-5-(piperidin-4-yl) thiazole (745) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(piperidin-4-yl)thiazole (746) ; 2-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(piperidin-4-yl)thiazole (747) ; 5-(4-isopropyl-3-(5-(piperidin-4-yl)thiazol-2-yl)-1H-pyrazol-5-yl)-1,3,4-trimethylpyridin-2 (1H) -one (748) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(piperidin-4-yl)thiazole (749) ; 2-(5-(7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-4-methyl-5-(piperidin-4-yl)thiazole (750) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(piperidin-4-yl)-4-(trifluoromethyl)thiazole (751) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)thiazole (752) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-methylpiperidin-4-yl)thiazole (753) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(3, 3, 3-trifluoropropyl)piperidin-4-yl)thiazole (754) ; 5-(1-ethylpiperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (755) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(1-propylpiperidin-4-yl) thiazole (756) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(1-isopropylpiperidin-4-yl) thiazole (757) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)thiazole (758) ; 5-(1-(3-ethoxycyclobutyl)piperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (759) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(oxetan-3-yl)piperidin-4-yl)thiazole (760) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-neopentylpiperidin-4-yl)thiazole (761) ; 5-(l-isopentylpiperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (762) ; 5- (1- ( (3-ethyloxetan-3-yl) methyl) piperidin-4-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (763) ; 1, 1-dióxido de 3- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) tetrahydrothiophene (764) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(pentan-3-yl)piperidin-4-yl)thiazole (765 (; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)thiazole (766) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)thiazole (767) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-((tetrahydrofuran-3-yl)methyl)piperidin-4-yl)thiazole (786) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1- ( (tetrahydrofuran-3-yl) methyl) piperidin-4-yl) thiazole (769) ; 2-(4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1- (tetrahydro-2H-pyran-3-yl) piperidin-4-yl) thiazole (770) ; 2-(4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1- (tetrahydro-2H-pyran-3-yl) piperidin-4-yl) thiazole (771) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-methylpiperidin-4-yl) thiazole (772) ; 5-(1-ethylpiperidin-4-yl)-2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (773) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-isopropylpiperidin-4-yl) thiazole (774) ; 2-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1-propilpiperidin-4-yl) thiazole (775) ; 5- (1- ( (3-ethyloxetan-3-yl) methyl) piperidin-4-yl) -2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (776) ; 2- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1- (tetrahydro-2H-pyran-4-yl) piperidin-4-yl) thiazole (777) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(oxetan-3-yl)piperidin-4-yl)thiazole (778) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(1-methylpiperidin-4-yl)thiazole (779) ; 5-(1-ethylpiperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4 methylthiazole (780) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5- (1- (tetrahydro-2H-pyran-4-yl) piperidin-4-yl) thiazole (781) ; 5- (1- (3-ethoxycyclobutyl) piperidin-4-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazole (782) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5- (1-propylpiperidin-4-yl) thiazole (783) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-isopropylpiperidin-4-yl)-4-methylthiazole (784) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)thiazole (785) ; 5-(1-(3-ethoxycyclobutyl)piperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (786) ; 5-(1-(cyclopropylmethyl)piperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (786) ;5- (1- (cyclopropylmethyl) piperidin-4-yl) -2- (4-isopropyl-5- (8-methoxy[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (788) 5- (l-isobutylpiperidin-4-yl) -2- (4-isopropyl-5- (8-methoxy[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (789) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-((1-methyl-1H-1, 2, 4-triazol-3-yl) methyl)piperidin-4-yl)thiazole (790) ; 5-(1-(cyclobutylmethyl)piperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (791) ; 5-(1-(cyclobutylmethyl)piperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (792) ; 5-(l-isobutylpiperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (793) ; 2-(5-(3,4-dimethoxyphenyl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-methylpiperidin-4-yl) thiazole (794) ; 2-(5-(3, 4-dimethoxyphenyl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-ethylpiperidin-4-yl) thiazole (795) ; 2-(5-(3, 4-dimethoxyphenyl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-propylpiperidin-4-yl) thiazole (796) ; 5-(1-(cyclopropylmethyl)piperidin-4-yl) -2-(5-(3, 4-dimethoxyphenyl) -4-isopropyl-1H-pyrazol-3-yl) thiazole (797) ; 2-(5-(3,4-dimethoxyphenyl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-isopropylpiperidin-4-yl) thiazole (798) ; 2-(5-(3,4-dimethoxyphenyl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl) thiazole (799) ; 2-(5-(3,4-dimethoxyphenyl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-((3-ethyloxetan-3-yl)methyl)piperidin-4-yl) thiazole (800) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-methylpiperidin-4-yl)thiazole (801) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-methylpiperidin-4-yl)thiazole (801) ;5-a]pyridin-6-yl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-ethylpiperidin-4-yl) thiazole (802) ; 2- (5- (7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-propylpiperidin-4-yl) thiazole (803) ; 2- (5- (7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-isopropylpiperidin-4-yl) thiazole (804) ; 5-(1-(ciclopropylmetil)piperidin-4-yl)-2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)thiazole (805) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)thiazole (806) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-(3-ethoxycyclobutyl)piperidin-4-yl)thiazole (807) ; 2-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-methylpiperidin-4-yl)thiazole (808) ; 2-(5-(2,6-dimethylpyridin-4-yl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-propylpiperidin-4-yl) thiazole (809) ; 2-(5-(2, 6-dimethylpyridin-4-yl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-isopropylpiperidin-4-yl) thiazole (810) ; 2-(5-(2, 6-dimethylpyridin-4-yl) -4-isopropyl-1H-pyrazol-3-yl) -5- (1-(tetrahydro-2H-pyran-4-yl) piperidin-4-yl) thiazole (811) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-4-methyl-5-(1-methylpiperidin-4-yl) thiazole (812) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-isopropylpiperidin-4-yl)-4-methylthiazole (813) ; 5-(1-(cyclopropylmethyl)piperidin-4-yl)-2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-4-methylthiazole (814) ; 5-(3-(5-(1-ethylpiperidin-4-yl)thiazol-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-1, 3, 4-trimethylpyridin-2(1H)-one (815) ; 5-(4-isopropyl-3-(5-(1-methylpiperidin-4-yl)thiazol-2-yl)-1H-pyrazol-5-yl)-1, 3,4-trimethylpyridin-2 ( 1 H) -one (816) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)thiazole (817) ; 5-(4-isopropyl-3-(5-(1-propylpiperidin-4-yl)thiazol-2-yl)-1H-pyrazol-5-yl)-1,3,4-trimethylpyridin-2 (1H) -one (818) ; 5-(3-(5-(1-(cyclopropylmethyl)piperidin-4-yl)thiazol-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-1, 3, 4-trimethylpyridin-2(1H)-one (819) ; 5-(1-(2-ethylbutyl)piperidin-4-yl)-2-(4-isopropyl-5-(8-methoxyimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (820) ; 5-(l-isobutylpiperidin-4-yl)-2-(4-isopropyl-5-(8-methoxyimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (821) ; 2-(4-isopropyl-5-(8-methoxyimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-propylpiperidin-4-yl)thiazole (822) ; 2-(4-isopropyl-5-(8-methoxyimidazo[1,2-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1- (tetrahydro-2H-pyran-4-yl) piperidin-4-yl) thiazole (823) ; 2- (4-isopropyl-5- (8-methoxyimidazo[1, 2-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1- (3, 3, 3-trifluoropropyl) piperidin-4-yl) thiazole (824) ; 5- (l-cyclobutylpiperidin-4-yl) -2- (4-isopropyl-5- (8-methoxyimidazo[1, 2-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (825) ; 2-(4-isopropyl-5-(8-methoxyimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(oxetan-3-yl)piperidin-4-yl)thiazole (826) ; 2-(4-isopropyl-5-(8-methoxyimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(pentan-3-yl)piperidin-4-yl)thiazole (827) ; 2-(4-isopropyl-5-(8-methoxyimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-isopropylpiperidin-4-yl)thiazole (828) ; 2-(4-isopropyl-5-(8-methoxyimidazo[1, 2-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-methylpiperidin-4-yl)thiazole (829) ; 2-(4-isopropyl-5-(8-methoxyimidazo[1,2-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1-neopentylpiperidin-4-yl) thiazole (830) ; 5- (1-ethylpiperidin-4-yl) -2- (4-isopropyl-5- (8-methoxyimidazo[1, 2-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (831) ; 5- (1- (cyclopropylmethyl)piperidin-4-yl) -2- (4-isopropyl-5- (8-methoxyimidazo[1, 2-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (832) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-4-methyl-5-(1-propylpiperidin-4-yl) thiazole (833) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-4-methyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl) thiazole (834) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-4-methyl-5-(1-(oxetan-3-yl)piperidin-4-yl)thiazole (835) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-4-methyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)thiazole (836) ; 2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(1-(oxetan-3-yl)piperidin-4-yl) -4-(trifluoromethyl)thiazole (837) ; 5-(1-(cyclopropylmethyl)piperidin-4-yl) -2-(4-isopropyl-5-(8-methoxy-1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-(trifluoromethyl)thiazole (838) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(1-isopropylpiperidin-4-yl) -4-(trifluoromethyl)thiazole (839) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)-4-(trifluoromethyl)thiazole (840) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-methylpiperidin-4-yl)-4-(trifluoromethyl)thiazole (841) ; 5-(1-ethylpiperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-(trifluoromethyl)thiazole (842) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1-propylpiperidin-4-yl) -4- (trifluoromethyl) thiazole (843) ; 1- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -2-morpholinoethan-1-one (844) ; 2- (dimethylamino) -1- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) ethan-1-one (845) ; 2-(dimethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperidin-1-yl)ethan-1-one (846) ; 2-(diethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)ethan-1-one (847) ; 2-(diethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperidin-1-yl)ethan-1-one (848) ; 2-(dimethylamino)-1-(4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperidin-1-yl)ethan-1-one (848) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) ethan-1-one (849) ; 1-(4-(2-(5-(7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-isopropyl-1H-pyrazol-3-yl) -4-methylthiazol-5-yl) piperidin-1-yl) -2-(dimethylamino) ethan-1-one (850) ; 1-(4-(2-(5-(7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-isopropyl-1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -2-(dimethylamino) ethan-1-one (851) ; 2-(dimethylamino)-1-(4-(2-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)ethan-1-one (852) ; 1-(4-(2-(5-(3,4-dimethoxyphenyl)-4-isopropyl-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-2-(dimethylamino)ethan-1-one (853) ; 2-(dimethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-(trifluoromethyl)thiazol-5-yl)piperidin-1-yl)ethan-1-one (854) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (1- (2- (methylsulfonyl) ethyl) piperidin-4-yl) thiazole (855) ; 2- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -N, N-dimethylacetamide (856) ; 2- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) acetamide (857) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(2-methoxyethyl)piperidin-4-yl)thiazole (858) ; 2-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)acetonitrile (859) ; 1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-2-methylpropan-2-ol (860) ; 2-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperidin-1-yl)-N,N-dimethylacetamide (861) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(2-methoxyethyl)piperidin-4-yl)-4-methylthiazole (862) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)thiazole (863) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-((1-(methylsulfonyl)cyclopropyl)methyl)piperidin-4-yl)thiazole (864) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)thiazole (865) ; 2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(2-methoxyethyl)piperidin-4-yl)thiazole (866) ; 1-(4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-2-methylpropan-2-ol (867) ; 2-(4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) acetonitrile (868) ; 2-(4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -N, N-dimethylacetamide (869) ; 2-(4-(2-(5-(7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-isopropyl-1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -N, N-dimethylacetamide (870) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-(2-methoxyethyl)piperidin-4-yl)thiazole (871) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-(2-methoxyethyl)piperidin-4-yl)-4-methylthiazole (872) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-isopropyl-1H-pyrazol-3-yl)-4-methyl-5-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)thiazole (873) ; 2-(5-(2,6-dimethylpyridin-4-yl)-4-isopropyl-1H-pyrazol-3-yl)-5-(1-(2-methoxyethyl)piperidin-4-yl)thiazole (874) ; 2-(4-(2-(5-(2,6-dimethylpyridin-4-yl) -4-isopropyl-1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -N, N-dimethylacetamide (875) ; 2-(5-(3, 4-dimethoxyphenyl) -4-isopropyl-1H-pyrazol-3-yl) -5-(1-(2-methoxyethyl) piperidin-4-yl) thiazole (877) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(1-(2-(methylsulfonyl) ethyl) piperidin-4-yl) -4-(trifluoromethyl) thiazole (878) ; 2-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-(trifluoromethyl)thiazol-5-yl)piperidin-1-yl)-N,N-dimethylacetamide (879) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(1-(2-methoxyethyl)piperidin-4-yl)-4-(trifluoromethyl)thiazol (880) ; 5-(1-(3-fluoropropyl)piperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (881) ; 5-(1-(2-fluoroethyl)piperidin-4-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (881) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol (882) ; 4- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) cyclohexyl) morpholine (883) ; 4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) -N- (2-methoxyethyl) cyclohexan-1-amine (884-885) ; N-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)oxethan-3-amine (886-887) ; 4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-N-(2-methoxyethyl)-N-methylcyclohexan-1-amine (888-889) ; 6-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)-2-oxa-6-azaspiro[3.3]heptano (890-891) ; 4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)-2-oxa-6-azaspiro[3.3]heptano (890-891) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) -N- ( (1- (methylsulfonyl) cyclopropyl) methyl) cyclohexan-1-amine (892-893) ; 6- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) cyclohexyl) -2-thia-6-azaspiro[3.3]heptano 2, 2-dióxido (894-895) ; N-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)tetrahydro-2H-pyran-4-amine (896-897) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(4-(pyrrolidin-1-yl)cyclohexyl)thiazole (898) ; N-cyclobutyl-4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) cyclohexan-1-amine (891B and 892B) ; 4- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) cyclohexyl) piperazin-2-one (893B and 894B) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5- (4- (4- (methylsulfonyl) piperazin-1-yl) cyclohexyl) thiazole (895B and 896B) ; 4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) -N- (2-methoxy-2-methylpropyl) cyclohexan-1-amine (897B and 898B) ; 4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-N-((3-methyloxetan-3-yl)methyl)cyclohexan-1-amine (899B and 900) ; 2-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)-7-oxa-2-azaspiro[3.5]nonano (901-902) ; 4-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)-1, 4-oxazepane (903-904) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-4-methylthiazol (905-906) ; 7-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) cyclohexyl) -2-oxa-7-azaspiro[3.5]nonane (907-908) ; 1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) cyclohexyl) -3-(trifluoromethyl)azetidin-3-ol (909-910) ; 4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-N-methylcyclohexan-1-amine (911-912) ; 4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-N, N-dimethylcyclohexan-1-amine (913-914) ; N- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) cyclohexyl) -3 -methyl oxetan-3-amine (915-916) ; 4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) -N- (2-methoxy-2-methylpropyl) cyclohexan-1-amine (916-917) ; N-cyclobutyl-4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) cyclohexan-1-amine (918-919) ; N- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) cyclohexyl) oxetan-3-amine (920-921) ; 4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) -N- (3, 3, 3-trifluoropropyl) cyclohexan-1-amine (922-923) ; 6-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)cyclohexyl)-2-oxa-6-azaspiro[3.3]heptano (924) ; 2-(dimethylamino)-N-(4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)cyclohexyl)-N-methylacetamide (926-927) ; 4-(2-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-N-methyl-N-(3, 3, 3-trifluoropropyl)cyclohexan-1-amine (928-929) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (piperazin-1-yl) thiazole (930) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(2, 6-diazaspiro[3.3]heptan-2-yl) thiazole (931) ; 1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) piperidin-4-amine (932) ; (S)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(2-methylpiperazin-1-yl)thiazole (933) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(piperazin-1-yl)thiazole (934) ; 5-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (935) ; 5-((2R,5S)-2,5-dimethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (936) ; (R)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (936)5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5-(2-methylpiperazin-1-yl) thiazole (937) ; (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(2-methylpiperazin-1-yl) thiazole (938) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(4-methyl piperazin-1-yl) thiazole (939) ; 5-(4-ethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (940) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(4-propylpiperazin-1-yl) thiazole (941) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(4-isopropylpiperazin-1-yl) thiazole (942) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(4-(oxetan-3-yl)piperazin-1-yl)thiazole (943) ; 5-(4-isobutylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (944) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(4-(tetrahydro-2H-pyran-4-yl) piperazin-1-yl) thiazole (945) ; 5-(4-(cyclopropylmethyl) piperazin-1-yl) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (946) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(4-((tetrahydro-2H-pyran-4-yl)methyl)piperazin-1-yl)thiazole (947) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(6-isopropyl-2, 6-diazaspiro[3.3]heptan-2-yl)thiazole (948) ; N-isopropyl-1- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) piperidin-4-amine (949) ; 1- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) -N- (oxetan-3-yl) piperidin-4-amine (950) ; (S) -5- (4- (cyclopropylmethyl) -2-methylpiperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (951) ; (S) -5- (2, 4-dimethylpiperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (952) ; (S) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(2-methyl-4-propylpiperazin-1-yl) thiazole (953) ; (S) -5-(4-isopropyl-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (954) ; (S) -5-(4-ethyl-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (955) ; (S) -5-(4-isobutyl-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (956) ; N-isobutyl-1- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) piperidin-4-amine (957) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5- (4-methylpiperazin-1-yl) thiazole (958) ; 5-(4-(cyclopropylmethyl)piperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol (959) ; 5-(4-ethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol (960) ; 5-(4-isobutylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol (961) ; N-(cyclopropylmethyl)-1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperidin-4-amine (962) ; 1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperidin-4-amine (962) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) -N-(tetrahydro-2H-pyran-4-yl) piperidin-4-amine (963) ; 1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) -N-propylpiperidin-4-amine (964) ; 1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) -N, N-bis((tetrahydro-2H-pyran-4-yl) methyl) piperidin-4-amine (965) ; N, N-bis (cyclopropylmethyl) -1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl) piperidin-4-amine (966) ; 1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-N, N-dimethylpiperidin-4-amine (967) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(4-propylpiperazin-1-yl)thiazole (968) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5- (4- ( (tetrahydro-2H-pyran-4-yl) methyl) piperazin-1-yl) thiazole (969) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5- (4- (oxetan-3-yl) piperazin-1-yl) thiazole (970) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (4-isopropylpiperazin-1-yl) -4-methylthiazole (971) ; 5-(4-(cyclobutylmethyl)piperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (972) ; (S)-5-(4-(cyclobutylmethyl)-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (973) ; 5-((1S,4S)-5-isobutyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (974) ; 5-((1R,4R)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (974) ;5- ( (1S, 4S) -5-cyclobutyl-2, 5-diazabicyclo[2.2.1]heptan-2-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (976) ; 2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- ( (1S, 4S) -5-isopropyl-2, 5-diazabicyclo[2.2.1]heptan-2-yl) thiazole (977) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-((1R, 4R)-5-propyl-2, 5-diazabicyclo[2.2.1]heptan-2-yl)thiazole (978) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-((1S, 4S)-5-(oxetan-3-yl)-2, 5-diazabicyclo[2.2.1]heptan-2-yl)thiazole (979) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-((1S, 4S)-5-(tetrahydro-2H-pyran-4-yl)-2, 5-diazabicyclo[2.2.1]heptan-2-yl)thiazole (980) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-((1S,4S)-5-((tetrahydro-2H-pyran-4-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)thiazole (981); 5-( (1S, 4S) -5-(ciclobutilmetil) -2, 5-diazabiciclo[2.2.1]heptan-2-yl) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (982) ; 5-((2R,5S)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (983) ; 5-((2R,5S)-4-(cyclobutylmethyl)-2,5-dimethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (984) ; 5-((2R,5S)-4-isobutyl-2,5-dimethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (985) ; 5-((2R,5S)-4-(cyclopropylmethyl)-2,5-dimethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (986) ; 5-((2R,5S)-4-cyclobutyl-2,5-dimethylpiperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (987) ; 5- ( (2R, 5S) -2, 5-dimethyl-4- (tetrahydro-2H-pyran-4-yl) piperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (988) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-((2R, 5S)-2, 4, 5-trimethylpiperazin-1-yl)thiazole (989) ; 5-((2R, 5S)-4-ethyl-2, 5-dimethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (990) ; 5-((2R,5S)-2,5-dimethyl-4-propylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (991) ; 5-((2R,5S)-4-isopropyl-2,5-dimethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (992) ; (R)-2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-α]pyridin-6-yl)-1H-pyrazol-3-yl)-4-metil-5-(2-metil-4-( (tetrahydro-2H-pyran-4-yl) metil) piperazin-1-yl) thiazole (993); (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-metil-5-(2-metil-4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)thiazole (994); (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)thiazole (995) ; (R) -5-(4-cyclobutyl-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (996) ; (R) -5-(4-(cyclobutylmethyl)-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (997) ; (R) -5-(4-isobutyl-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (997) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol (998) ; (R) -5- (4- (cyclopropylmethyl) -2-methylpiperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol (999) ; (R) -5- (2, 4-dimethylpiperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol (1000) ; (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(2-methyl-4-propylpiperazin-1-yl)thiazole (1001) ; (S) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(2-methyl-4-(pentan-3-yl)piperazin-1-yl)thiazole (1002) ; (R) -5-(4-isopropyl-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (1003) ; (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (1003) ;5-α]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(2-methyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazin-1-yl)thiazole (1004); (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(2-metil-4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)thiazole (1005); (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)thiazole (1006) ; (R) -5-(4-cyclobutyl-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (1007) ; (R) -5-(4-(cyclobutylmethyl)-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (1008) ; (R) -5-(4-(cyclopropylmethyl)-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (1009) ; (R) -5-(2, 4-dimethylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (1010) ; (R) -5- (4-isobutyl-2-methylpiperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (1011) ; (R) -5- (4-isopropyl-2-methylpiperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (1012) ; (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(2-methyl-4-(pentan-3-yl)piperazin-1-yl)thiazole (1013) ; (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(2-methyl-4-propylpiperazin-1-yl)thiazole (1014) ; 2-(dimethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)piperazin-1-yl)ethan-1-one (1015); 1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)piperazin-1-yl)ethan-1-one (1015);5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperazin-1-yl) -2-morpholinoethan-1-one (1016) ; (S) -2- (dimethylamino) -1- (4- (2- (4-isopropyl-5 - (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) -3-methylpiperazin-1-yl) ethan-1-one (1017) ; (R)-2-(diethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-3-methylpiperazin-1-yl)ethan-1-one (1018); 2-(diethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperazin-1-yl)ethan-1-one (1018B) 2-(dimethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperazin-1-yl)ethan-1-one (1019) ; 2-(diethylamino)-N-(1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) piperidin-4-yl) acetamide (1020) ; 2- (dimethylamino) -N- (1- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) piperidin-4-yl) acetamide (1021) ; N- (1- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) piperidin-4-yl) -2-morpholinoacetamide (1022) ; 2-(diethylamino)-1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)piperazin-1-yl)ethan-1-one (1023) ; 2-(diethylamino)-1-((2S, 5R)-4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-2, 5-dimethylpiperazin-1-yl)ethan-1-one (1024) ; 2-(dimethylamino)-1-((2S,5R)-4-(2-(4-isopropyl-5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-2,5-dimethylpiperazin-1-yl) ethan-1-one (1025) ; (R) -2- (dimethylamino) -1- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) -3-methylpiperazin-1-yl) ethan-1-one (1026) ; (R) -2- (dimethylamino) -1- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) -3-methylpiperazin-1-yl) ethan-1-one (1027) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(4-(2-methoxyethyl)piperazin-1-yl)thiazole (1028) ; 2-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)piperazin-1-yl)-N, N-dimethylacetamide (1029) ; (S)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(4-(2-methoxyethyl)-2-methylpiperazin-1-yl)thiazole (1030); 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (4- (2- (methylsulfonyl) ethyl) piperazin-1-yl) thiazole (1031) ; 2- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) piperazin-1-yl) -N, N-dimethylacetamide (1032) ; (S) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (2-methyl-4- (2- (methylsulfonyl) ethyl) piperazin-1-yl) thiazole (1033) ; 1-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)piperazin-1-yl)-2-methylpropan-2-ol (1034) ; 5-((2R, 5S)-2, 5-dimethyl-4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazole (1035) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-((2R, 5S)-4-(2-methoxyethyl)-2, 5-dimethylpiperazin-1-yl)thiazole (1036) ; (R)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5-(2-methyl-4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)thiazole (1037) ; (R) -5-(4-(2-fluoroethyl) -2-methylpiperazin-1-yl) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazole (1038) ; (R) -5-(4-(3-fluoropropyl) -2-methylpiperazin-1-yl) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazole (1039) ; (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(4-(2-methoxyethyl)-2-methylpiperazin-1-yl)-4-methylthiazol (1040) ; (R) -2-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-3-methylpiperazin-1-yl)-N, N-dimethylacetamide (1041) ; (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(2-methyl-4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)thiazole (1042) ; (R) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5- (4- (2-methoxyethyl) -2-methylpiperazin-1-yl) thiazole (1043) ; (R) -2- (4- (2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) -3-methylpiperazin-1-yl) -N, N-dimethylacetamide (1044) ; (R) -5- (4- (2-fluoroethyl) -2-methylpiperazin-1-yl) -2- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazole (1045) ; (R) -5-(4-(3-fluoropropyl)-2-methylpiperazin-1-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (1046) ; (R) -2-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazol-5-yl)-3-methylpiperazin-1-yl)-N-methylacetamide (1047) ; (R)-2-(4-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5 -a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-3-methylpiperazin-1-yl)acetonitrile (1048) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5 -a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-3-methylpiperazin-1-yl)acetonitrile (1048) ;5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5-(6-propyl-2, 6 diazaspiro[3.3]heptan-2-yl) thiazole (1049) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5-(6-methyl-2, 6-diazaspiro[3.3]heptan-2-yl) thiazole (1050) ; 5-(6-ethyl-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (1051) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-5-(6-isopropyl-2, 6-diazaspiro[3.3]heptan-2-yl)-4-methylthiazole (1052) ; 5-(6-(cyclopropylmethyl)-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (1053) ; 5-(6-isobutyl-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazole (1054) ; 5-(6-(2-ethylbutyl)-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(4-isopropyl-5-(8-methoxy-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazole (1055) ; 5-(6-cyclobutyl-2, 6-diazaspiro[3.3]heptan-2-yl) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazole (1056) ; 5-(6-(cyclobutylmethyl) -2, 6-diazaspiro[3.3]heptan-2-yl) -2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methylthiazole (1057) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(6-(tetrahydro-2H-pyran-4-yl)-2, 6-diazaspiro[3.3]heptan-2-yl) thiazole (1058) ; 2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methyl-5-(6-((tetrahydro-2H-pyran-4-yl)methyl)-2, 6-diazaspiro[3.3]heptan-2-yl) thiazole (1059) ; 2-(dimethylamino)-1-(6-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)-2, 6-diazaspiro[3.3]heptan-2-yl)ethan-1-one (1060); 2-(4-isopropyl-5-(8-methoxy-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -4-methyl-5- (6- (2- (methylsulfonyl) ethyl) -2, 6-diazaspiro[3.3]heptan-2-yl) thiazole (1061) ; 2-(4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -5-(6-(2-methoxyethyl) -2, 6-diazaspiro[3.3]heptan-2-yl) -4-methylthiazole (1062) ; 5-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(1-isopropylpiperidin-4-yl) thiazole (1063) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(piperidin-4-yl) thiazole (1064) ; 5-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(1-methylpiperidin-4-yl) thiazole (1065) ; 2-(1-ethylpiperidin-4-yl)-5-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (1066) ; 5-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(1-propylpiperidin-4-yl) thiazole (1067) ; 5-(4-isopropyl-5-(8-methyl-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -2- (l-propylpiperidin-4-yl) thiazole (1068) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -2- (1-(tetrahydro-2H-pyran-4-yl) piperidin-4-yl) thiazole (1069) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -2- (1-methylpiperidin-4-yl) thiazole (1070) ; 2-(1-ethylpiperidin-4-yl)-5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazole (1071) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(1-isopropylpiperidin-4-yl) thiazole (1072) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(1-(oxetan-3-yl)piperidin-4-yl) thiazole (1073) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(1-((3-methyloxetan-3-yl)methyl)piperidin-4-yl)thiazole (1074) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -2- (1-neopentylpiperidin-4-yl) thiazole (1075) ; 2- (4- (5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-2-yl) piperidin-1-yl) -N, N-dimethylacetamide (1076) ; 2- (4- (5- (4-isopropyl-5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-2-yl) piperidin-1-yl) acetamide (1077) ; 2-(4-(5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-2-yl)piperidin-1-yl)acetonitrile (1078) ; 1-(4-(5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-2-yl)piperidin-1-yl)-2-methylpropan-2-ol (1079) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-2-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)thiazole (1080) ; 5-(4-isopropyl-5-(8-methyl-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -1H-pyrazol-3-yl) -2- (1- (2-methoxyethyl) piperidin-4-yl) thiazole (1081) ; 2- (dimethylamino) -1- (4- (5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-2-yl) piperidin-1-yl) ethan-1-one (1082) ; 4- (5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-2-yl) -N-methylcyclohexan-1-amine (1083) ; 4-(5-(4-isopropyl-5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-2-yl)-N,N-dimethylciclohexan-1-amine (1084-1085) ; 4-(5-(4-isopropyl-5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-2-yl)-N,N-dimethylciclohexan-1-amine (1085) ; N- (4- (5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-2-yl) cyclohexyl) -N-methyloxetan-3-amine (1086-1087) ; N-isopropyl-4- (5- (4-isopropyl-5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-2-yl) cyclohexyl) -N-methyloxetan-3-amine (1086-1087) ;5-α]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-2-yl)-N-methylciclohexan-1-amine (1088-1089) ; 6-(4-isopropyl-1'-(1-metilpiperidin-4-yl)-1H,11H-[3,4'-bipyrazol]-5-yl)-8-metil-[1,2,4]triazolo[1,5-a]pyridine (1090) ; 6-(4-isopropyl-1-(1-isopropylpiperidin-4-yl)-1H,11H-[3,4-bipyrazol]-5-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (1091) ; 6-(4-isopropyl-l-(1-(oxetan-3-yl)piperidin-4-yl)-1H, 1 1H-[3, 4-bipyrazol]-5-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (1092) ; 6-(4-isopropyl-3-(4-methyl-5-(1-propylpiperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1093) ; 6-(4-isopropyl-3-(3-methyl-5-(piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1094) ; 6-(3-(3-fluoro-5-(piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1095) ; 6-(3-(6-fluoro-5-(piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1095)4]triazolo[1, 5-a]pyridine (1096) ; 6-(4-isopropyl-3-(4-methyl-5-(1-methylpiperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1097) ; 6-(4-isopropyl-3-(5-(1-isopropylpiperidin-4-yl)-4-methylpyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1098) ; 6-(3-(6-fluoro-5-(1-methylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1099) ; 6-(3-(6-fluoro-5-(1-propylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1100) ; 6-(3-(6-fluoro-5-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1101) ; 6-(3-(5-(1-ethylpiperidin-4-yl)-4-methylpyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1101)5-a]pyridine (1102) ; 6-(3-(5-(1-isobutylpiperidin-4-yl)-4-methylpyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1103) ; 6-(3-(5-(1-cyclobutylpiperidin-4-yl)-4-methylpyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1104) ; 6-(3-(5-(1-(cyclobutylmethyl)piperidin-4-yl)-4-methylpyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1105) ; 6-(4-isopropyl-3-(4-methyl-5-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1106) ; 6-(4-isopropyl-3-(4-methyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1107) ; 6-(4-isopropyl-3-(4-methyl-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1107)5-a]pyridine (1108) ; 6-(4-isopropyl-3-(4-methyl-5-(1-((tetrahydrofuran-3-yl)methyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1109) ; 6-(3-(5-(1-(cyclobutylmethyl)piperidin-4-yl)-3-fluoropyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1110) ; 6-(3-(3-fluoro-5-(1-methylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1111) ; 6-(3-(5-(1-ethylpiperidin-4-yl)-3-fluoropyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1112) ; 6-(3-(3-fluoro-5-(1-propylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1113) ; 6-(3-(3-fluoro-5-(1-isopropylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridine (1114) ; 6-(3-(5-(1-(cyclopropylmethyl)piperidin-4-yl)-3-fluoropyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1115) ; 6-(3-(3-fluoro-5-(1-isobutylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1116) ; 6-(3-(3-fluoro-5-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1117) ; 6-(3-(3-fluoro-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1118) ; 6-(3-(3-fluoro-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1119) ; 6-(3-(3-fluoro-5-(1-(pentan-3-yl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1119)5-a]pyridine (1120) ; 6-(3-(5-(1-(2-ethylbutyl)piperidin-4-yl)-3-fluoropyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1121) ; 6-(3-(3-fluoro-5-(1-neopentylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1123) ; 6-(4-isopropyl-3-(3-methyl-5-(1-methylpiperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1124) ; 6-(3-(5-(1-ethylpiperidin-4-yl)-3-methylpyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1125) ; 6-(4-isopropyl-3-(3-methyl-5-(1-propylpiperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1126) ; 6-(4-isopropyl-3-(5-(1-isopropylpiperidin-4-yl)-3-methylpyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridine (1127) ; 6-(3-(5-(1-(cyclopropylmethyl)piperidin-4-yl)-3-methylpyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1128) ; 6-(4-isopropyl-3-(3-methyl-5-(1-(tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1129) ; 6-(3-(5-(1-ethylpiperidin-4-yl)-6-fluoropyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1130) ; 6-(3-(6-fluoro-5-(1-isopropylpiperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1131) ; 6-(3-(5-(l-cyclobutylpiperidin-4-yl)-6-fluoropyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1132) ; 6-(3-(6-fluoro-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridine (1133) ; 2-(dimethylamino) -1-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylpyridin-3-yl)piperidin-1-yl)ethan-1-one (1134) ; 2-(dimethylamino) -1-(4-(5-fluoro-6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidin-1-yl)ethan-1-one (1135) ; 2-(4-(6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)-4-methylpyridin-3-yl)piperidin-1-yl)-N, N-dimethylacetamide (1136) ; 2-(4-(5-fluoro-6-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidin-1-yl)-N, N-dimethylacetamide (1137) ; 6-(3-(3-fluoro-5-(1-(2-methoxyethyl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1138) ; 6-(3-(3-fluoro-5-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)pyridin-2-yl)-4-isopropyl-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1138)5-a]pyridine (1139) ; 6-(4-isopropyl-3-(4-methyl-5-(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)pyridin-2-yl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1140) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(1-methylpiperidin-4-yl)thiazole (1141) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(piperidin-4-yl)thiazole (1142) ; 2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(piperidin-4-yl)thiazole (1143) ; 4-methyl-2- (5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (piperidin-4-yl) thiazole (1144) ; 2- (5- (7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methyl-5- (piperidin-4-yl) thiazole (1145) ; 2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2,2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methyl-5- (1-propylpiperidin-4-yl) thiazole (1146) ; 5- (1-ethylpiperidin-4-yl) -2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methylthiazole (1147) ; 5- (1-isopropylpiperidin-4-yl) -2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methylthiazole (1148) ; 5-(1-(cyclopropylmethyl)piperidin-4-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1149) ; 5-(l-isobutylpiperidin-4-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1150) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)thiazole (1151) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2,2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methyl-5- (1- (tetrahydro-2H-pyran-4-yl) piperidin-4-yl) thiazole (1152) ; 2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methyl-5- (1- (oxetan-3-yl) piperidin-4-yl) thiazole (1153) ; 2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1-methylpiperidin-4-yl) thiazole (1154) ; 5-(1-ethylpiperidin-4-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl) thiazole (1155) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(1-propylpiperidin-4-yl) thiazole (1156) ; 5-(1-isopropylpiperidin-4-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazole (1157); 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazole (1157);2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1- (tetrahydro-2H-pyran-4-yl) piperidin-4-yl) thiazole (1158) ; 5- (1- (cyclopropylmethyl) piperidin-4-yl) -2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazole (1159) ; 2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1- (oxetan-3-yl) piperidin-4-yl) thiazole (1160) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)thiazole (1161) ; 5-(l-isobutylpiperidin-4-yl)-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazole (1162) ; 2-(5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)thiazole (1163); 5-(1-ethylpiperidin-4-yl)-2-(5-(8-metil-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol (1164) ; 5- (1-isopropylpiperidin-4-yl) -2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol (1165) ; 2- (5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4- (2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5- (1- ( (tetrahydro-2H-pyran-4-yl) methyl) piperidin-4-yl) thiazol (1166) ; 2- (5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4- (2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5- (1- (oxetan-3-yl) piperidin-4-yl) thiazol (1167) ; 2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1-propylpiperidin-4-yl)thiazol (1168) ; 2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1- (3, 3, 3-trifluoropropyl) piperidin-4-yl) thiazol (1169) ; 5- (1- (cyclopropylmethyl) piperidin-4-yl) -2- (5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2,2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol (1170) ; 5- (1- (cyclobutylmethyl) piperidin-4-yl) -2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol (1171) ; 2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-tri fluoroethyl) -1H-pyrazol-3-yl) -5- (1-methylpiperidin-4-yl)thiazol (1172) ; 2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-tri fluoroethyl) -1H-pyrazol-3-yl) -5- (1-neopentylpiperidin-4-yl)thiazol (1173) ; 5- (1-ethylpiperidin-4-yl) -4-methyl-2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol (1174) ; 4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(1-(3, 3, 3-trifluoropropyl) piperidin-4-yl) thiazol (1175) ; 5-(1-isopropylpiperidin-4-yl)-4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2,2-trifluoroethyl)-1H-pyrazol-3-yl) thiazol (1176) ; 5-(1-(cyclohexylmethyl) piperidin-4-yl)-4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl) thiazol (1177) ; 5-(1-(cyclopropylmethyl) piperidin-4-yl)-4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl) thiazol (1179) ; 4-methyl-2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1-(oxetan-3-yl) piperidin-4-yl)thiazol (1180) ; 5- (l-isobutylpiperidin-4-yl) -4-methyl-2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol (1181) ; 4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(1-methylpiperidin-4-yl)thiazol (1182) ; 4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2,2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1-propylpiperidin-4-yl) thiazol (1183) ; 4-methyl-2- (5- (8-methyl-[1, 2, 4]triazole[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1- (tetrahydro-2H-pyran-4-yl) piperidin-4-yl)thiazol (1184) ; 4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)thiazol (1185) ; 2-(5-(7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)thiazol (1186) ; 2- (5- (7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1-isopropylpiperidin-4-yl) -4-methylthiazol (1187) ; 5- (1- (cyclopropylmethyl) piperidin-4-yl) -2- (5- (7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methylthiazol (1188) ; 2- (5- (7, 8-dimethyl-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methyl-5-(1-methylpiperidin-4-yl) thiazole (1189) ; 2-(5-(7, 8-dimethyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5-(1-ethylpiperidin-4-yl) -4-methylthiazole (1190) ; 2-(5-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(1-propylpiperidin-4-yl)thiazole (1191) ; 2-(dimethylamino)-1-(4-(2-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)ethan-1-one (1192) ; 2-(dimethylamino)-1-(4-(2-(5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)ethan-1-one (1193); 1-(4-(2-(5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2,2- (diethylamino) -1- (4- (2- (5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) ethan-1-one (1195) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(1-(2-methoxyethyl)piperidin-4-yl)thiazole (1196) ; 5-(1-(2-methoxyethyl)piperidin-4-yl)-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazole (1197) ; 2-m ethyl-1-(4-(2-(5 - (8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) propan-2-ol 1198) ; 2-metil-1-(4-(4-metil-2-(5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) propan-2-ol (1199); 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2,2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (1- (2- (methylsulfonyl) ethyl) piperidin-4-yl) thiazole (1200) ; 2- (4- (2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -N, N-dimethylacetamide (1201) ; 5-(1-(2-(tert-butoxy)ethyl)piperidin-4-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazole (1202) ; 2-(4-(2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-1-morpholinoethan-1-one (1203) ; N,N-dimethyl-2-(4-(2-(5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)acetamide (1204); 5-(1-(2-fluoroethyl)piperidin-4-yl)-2-(5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)thiazole (1205) ; 5-(1-(3-fluoropropyl) piperidin-4-yl)-2-(5-(8-metil-[1, 2,4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazole (1206) ; 2-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -1-(2-oxa-6-azaspiro[3.3]heptan-6-yl) ethan-1-one (1207) ; N-isopropyl-2-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-N-methylacetamide (1208) ; 1-(azetidin-1-yl)-2-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)ethan-1-one (1209) ; 1-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-2-morpholinoethan-1-one (1210) ; 1-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-2-morpholinoethan-1-one (1210) ;2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -2- (7-oxa-2-azaspiro[3.5]nonan-2-yl) ethan-1-one (1211) ; 4- (2- (4- (2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol-5-yl) piperidin-1-yl) -2-oxoethyl) piperazin-2-one (1212) ; 1-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-2-(3-methoxyazetidin-1-yl)ethan-1-one (1213) ; 1-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)piperidin-1-yl)-2-((2-methoxyethyl) (methyl)amino)ethan-1-one (1214) ; 4-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)morpholine (1215); N-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)morpholine (1215);2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) cyclohexyl) oxetan-3-amine (1216-1217) ; 6-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methylthiazol-5-yl) cyclohexyl) -2-oxa-6-azaspiro[3.3]heptano (12181219) ; 2-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)-7-oxa-2-azaspiro[3.5]nonane (12201221) ; 4-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazol-5-yl)cyclohexyl)piperazin-2-one (1222-1223) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(4-(3-methoxyazetidin-1-yl)cyclohexyl)thiazole (1224-1225) ; 2-(4-(2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2,2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol-5-yl) cyclohexyl) -7-oxa-2-azaspiro[3.5]nonane (1226-1227) ; 4- (4- (2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazol-5-yl) cyclohexyl) piperazin-2-one (1228-1229) ; 4-(4-(2-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)thiazol-5-yl)cyclohexyl)morpholine (1230-1231) ; 2-(5-(8-methoxy-[1, 2, 4]tri azol de 1, 5-a]pyridin-6-il) -4-(2, 2, 2-tri fluoroetil) -1H-pyrazol-3-yl) -4-metil-5-( (1S, 4S) -5-metil-2, 5-diazabiciclo[2.2.1]heptan-2-yl) thiazol (1232) 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(piperazin-1-yl)thiazole (1233) ; 4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(piperazin-1-yl)thiazole (1234) ; 5-((2R, 5S)-2, 5-dimethylpiperazin-1-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazole (1235) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methyl-5-(2, 6-diazaspiro[3.3]heptan-2-yl) thiazole (1236) ; 5-((1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1237); 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-((1R, 4R)-5-propyl-2, 5-diazabicyclo[2.2.1]heptan-2-yl)thiazole 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-((1S, 4S)-5-(oxetan-3-yl)-2, 5-diazabicyclo[2.2.1]heptan-2-yl)thiazole (1239) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-((1S, 4S)-5-((tetrahydro-2H-pyran-4-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl) thiazole (1240) ; 5-( (1S, 4S) -5-isopropyl-2, 5-diazabiciclo[2.2.1]heptan-2-yl) -2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methylthiazol (1241) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroetil)-1H-pyrazol-3-yl)-4-metil-5-( (1S, 4S)-5-(tetrahydro-2H-pyran-4-yl)-2, 5-diazabiciclo [2.2.1]heptan-2-yl ) thiazole (1242) ; 5-((1S,4S)-5-isobutyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1243) ; 2-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(4-methylpiperazin-1-yl)thiazole (1244) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2,2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methyl-5- (4- ( (tetrahydro-2H-pyran-4-yl) methyl ) piperazin-1-yl) thiazole (1245) ; 2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methyl-5- (4-propylpiperazin-1-yl) thiazole (1246) ; 5- (4-ethylpiperazin-1-yl) -2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methylthiazole (1247) ; 5-(4-isobutylpiperazin-1-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1248) ; 4-methyl-2-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(4-(oxetan-3-yl)piperazin-1-yl)thiazole (1249) ; 4-metil-2-(5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(4-metilpiperazin-1-yl) thiazole (1250) ; 5-(4-etilpiperazin-1-yl)-4-metil-2-(5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2,2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazole (1251) ; 4-methyl-2- (5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (4-propilpiperazin-1-yl) thiazole (1252) ; 4-methyl-2- (5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -5- (4- ( (tetrahydro-2H-pyran-4-yl) metil) piperazin-1-yl) thiazole (1253) ; 4-metil-2-(5-(8-metil-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)thiazole (1254); 5-(4-(ciclopropylmetil)piperazin-1-yl)-4-metil-2-(5-(8-metil-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroetil)-1H-pyrazol-3-yl)thiazole (1256) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-5-((2R, 5S)-2, 4, 5-trimethylpiperazin-1-yl)thiazole (1257) ; 5-((2R, 5S)-4-ethyl-2, 5-dimethylpiperazin-1-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1,5- ( (2R, 5S) -2, 5-dimethyl-4-propylpiperazin-1-yl) -2- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) thiazole (1259) ; 5-((2R,5S)-4-isopropyl-2,5-dimethylpiperazin-1-yl)-2-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl) thiazole (1260) ; 2-(5-(8-methoxy-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl) thiazole (1261) ; 5-(6-isobutyl-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1262) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(6-(tetrahydro-2H-pyran-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl) thiazole (1263) ; 5-(6-(cyclopropylmethyl)-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1264) ; 5-(6-(1-isopropylpiperidin-4-yl)-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1265) ; 5-(6-isopropyl-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1266) ; 5-(6-(l-cyclopropylethyl)-2, 6-diazaspiro[3.3]heptan-2-yl)-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylthiazole (1267) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methyl-5-(6-(pentan-3-yl)-2,6-diazaspiro[3.3]heptan-2-yl) thiazole (1268) ; 1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl) thiazol-5-yl) -N-(3-methyloxetan-3-yl) piperidin-4-amine (1269) ; 1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -1H-pyrazol-3-yl) thiazol-5-yl) -N-(2-methoxy-2-methylpropyl) piperidin-4-amine (1270) ; N-ethyl-1-(2-(4-isopropyl-5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-1H-pyrazol-3-yl)thiazol-5-yl)-N-methylpiperidin-4-amine (1271) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-N, N-dimethyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (1272) ; N-isopropyl-2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-N-methyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazol-6-amine (1273) ; 2-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-N, N-dimethyl-4, 5, 6,7-tetrahydrobenzo[d]thiazol-6-amine (1274) ; 8-methoxy-6- (3- (4-methyl-5- (1-methylpiperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1275) ; 8-methoxy-6- (3- (5- (piperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1276) ; 6-(3-(5-(1-ethylpiperidin-4-yl)-4-methylpyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1277) ; 8-methoxy-6-(3-(4-methyl-5-(1-propylpiperidin-4-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-[1, 2, 4]triazolo[1, 5-a]pyridine (1278) ; 8-methoxy-6- (3- (5- (1- (oxethan-3-yl) piperidin-4-yl) -4- (trifluoromethyl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1279) ; 8-methoxy-6- (3- (4-methyl-5- (1- (tetrahydro-2H-pyran-4-yl) piperidin-4-yl) pyridin-2 -yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1279) ;5-a]pyridine (1280) ; 8-methoxy-6- (3- (4-methyl-5- (1- ( (tetrahydro-2H-pyran-4-yl) methyl) piperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1281) ; 6- (3- (5- (1-isopropylpiperidin-4-yl) -4-methylpyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1282) ; 6-(3-(5-(1-(2-ethylbutyl)piperidin-4-yl)-4-methylpyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1283) ; 6-(3-(5-(l-isobutylpiperidin-4-yl)-4-methylpyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1284) ; 6-(3-(5-(1-(cyclobutylmethyl)piperidin-4-yl)-4-methylpyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1285) ; 6-(3-(5-(1-ethylpiperidin-4-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridine (1286) ; 8-methoxy-6- (3- (5- (1-methylpiperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1287) ; 6- (3- (5- (l-isobutylpiperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1288) ; 6-(3-(5-(l-cyclobutylpiperidin-4-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1289) ; 6-(3-(5-(1-isopropylpiperidin-4-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1290) ; 8-methoxy-6- (3- (5- (1-propylpiperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1291) ; 8-methoxy-6- (3- (5- (1- (oxetan-3-yl) piperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1,5-a]pyridine (1292) ; 8-methoxy-6- (3- (5- (1- (tetrahydro-2H-pyran-4-yl) piperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1293) ; 8-methoxy-6- (3- (5- (1- ( (tetrahydro-2H-pyran-4-yl) methyl) piperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1294) ; 6-(3-(5-(1-(cyclobutylmethyl)piperidin-4-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1295) ; 2-(dimethylamino)-1-(4-(6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylpyridin-3-yl)piperidin-1-yl)ethan-1-one (1296) ; 2-(dimethylamino)-1-(4-(6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidin-1-yl)ethan-1-one (1297) ; 2-(diethylamino)-1-(4-(6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)pyridin-3-yl)piperidin-1-yl)ethan-1-one (1297) ;2-trifluoroethyl) -1H-pyrazol-3-yl) pyridin-3-yl) piperidin-1-yl) ethan-1-one (1298) ; 2- (4- (6- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -4-methylpyridin-3-yl) piperidin-1-yl) -N, N-dimethylacetamide (1299) ; 2-(4-(6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-4-methylpyridin-3-yl)piperidin-1-yl)-N-methylacetamide (1300) ; 8-methoxy-6-(3-(5-(1-(2-methoxyethyl)piperidin-4-yl)-4-methylpyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-[1, 2, 4]triazolo[1, 5-a]pyridine (1301) ; 8-methoxy-6- (3- (4-methyl-5- (1- (2- (methylsulfonyl) ethyl) piperidin-4-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1302) ; N- (2- (4- (5- (8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) phenyl) propan-2-yl) tetrahydro-2H-pyran-4-amine (1303) ; (S) -1- (4- (5- (8-methoxy-[1, 2, 4]triazolo[1,5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) phenyl) -N-methyl ethan-1-amine (1304B) ; 6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -N-methyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine (1305B) ; 6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-N-methyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine (1306B) ; 6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-N-methyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine (1307B) ; N, N-dimethyl-2-(4-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)phenyl)propan-2-amine (1308) ; (S)-1-(4-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)phenyl)-N, N-dimethylethan-1-amine (1309) ; 6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-N, N-dimethyl-1,2, 3, 4-tetrahydronaphthalen-2-amine (1310) ; N-isopropyl-6- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -N-methyl-1, 2, 3, 4-tetrahydronaphthalen-2-amine (1311) ; N- (6- (5- (8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-3-yl) -1, 2, 3, 4-tetrahydronaphthalen-2-yl) -N-methyloxetan-3-amine (1312) ; 2-(dimethylamino)-N-(2-(4-(5-(8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)phenyl)propan-2-yl)acetamida (1313) ; (S)-2-(dimethylamino)-N-(1-(4-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)phenyl)ethyl)-N-methylacetamida (1314) ; 2-(dimethylamino)-N-(6-(5-(8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-3-yl)-1, 2, 3, 4-tetrahydronaphthalen-2-yl)-N-methylacetamide (1315) ; 8-methoxy-6-(3-(5-(6-((tetrahydro-2H-pyran-4-yl)methyl)-2,6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1316) ; 8-methoxy-6-(3-(5-(6-(oxetan-3-yl) -2, 6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl) -4-(2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1317) ; 6-(3-(5-(6-isopropyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1318) ; 8-methoxy-6-(3-(5-(6-propyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-[1, 2, 4]triazolo[1, 5-a]pyridine (1319) ; 6-(3-(5-(6-ethyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1320) ; 8-methoxy-6-(3-(5-(6-methyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-[1, 2, 4]triazolo[1,5-a]pyridine (1321) ; 6-(3-(5-(6-cyclobutyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1322) ; 6-(3-(5-(6-isobutyl-2, 6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-4-(2, 2, 2-trifluoroethyl)-1H-pyrazol-5-yl)-8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1323) ; 8-methoxy-6- (3- (5- (6- (tetrahydro-2H-pyran-4-yl) -2, 6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1, 5-a]pyridine (1324) ; 6- (3- (5- (6- (cyclobutylmethyl) -2, 6-diazaspiro[3.3]heptan-2-yl) pyridin-2-yl) -4- (2, 2, 2-trifluoroethyl) -1H-pyrazol-5-yl) -8-methoxy-[1, 2, 4]triazolo[1, 5-a]pyridine (1325) ; 8-methoxy-6- (3- (5- (1- ( (tetrahydro-2H-pyran-4-yl) methyl) piperidin-4-yl) pyridin-2-yl) -4- (trifluoromethyl) -1H-pyrazol-5-yl) -[1, 2, 4]triazolo[1,5-a]pyridine (1326) ; 6- (3- (5- (l-cyclobutylpiperidin-4-yl)pyridin-2-yl) -4- (trifluoromethyl) -1H-pyrazol-5-yl) -8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (1327) ; or 6- (3- (5- (1- (cyclobutylmethyl)piperidin-4-yl)pyridin-2-yl) -4- (trifluoromethyl) -1H-pyrazol-5-yl) -8-methoxy-[1,2,4]triazolo[1,5-a]pyridine (1328) .

8. Pharmaceutical composition comprising a compound according to any one of claims 1-7 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

9. A compound according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 8, for use in therapy.

10. A compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition for use according to claim 9.for use in the treatment of autoimmune diseases or chronic inflammatory diseases.

11. A compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition for use according to claim 10, wherein said autoimmune disease or inflammatory disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis (MS), and Sjögren's syndrome.